Previous Chapter: 7 Immune-System Disorders
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

8


Cancer

Chapter Overview

Based on new evidence and a review of prior studies, the committee for did not find any new significant associations between the relevant exposures and particular types of cancer. Current evidence supports the findings of earlier studies that

•   There is sufficient evidence of an association with the chemicals of interest and soft tissue sarcomas and B-cell lymphomas (Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, hairy cell leukemia).

•   There is limited or suggestive evidence of an association between the chemicals of interest and laryngeal cancer; cancer of the lung, bronchus, or trachea; prostate cancer; multiple myeloma, and AL amyloidosis.

•   There is inadequate or insufficient evidence to determine whether there is an association between the chemicals of interest and any other specific type of cancer.

Cancer is the second-leading cause of death in the United States. Among men 55–69 years old, the group that includes most Vietnam veterans (see Table 8-1), however, the risk of dying from cancer exceeds the risk of dying from heart disease, the leading cause of death in the United States, and does not fall to second place until after the age of 75 years (Heron et al., 2009). About 577,000 Americans of all ages were expected to die from cancer in 2010—more than 1,500 per day. In the United States, one-fourth of all deaths are from cancer (Siegel et al., 2012).

This chapter summarizes and presents conclusions about the strength of the

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-1 Age Distribution of Vietnam-Era and Vietnam-Theater Male Veterans, 2009–2010 (Numbers in Thousands)

Age Group (Years)Vietnam EraVietnam Theater
n(%)n(%)
All ages7,8053,816
≤ 54133(1.8)32(0.9)
55–591,109(15.1)369(10.4)
60–643,031(41.3)1,676(47.0)
65–692,301(31.3)1,090(30.6)
70–74675(9.2)280(7.9)
75–84511(6.9)322(9.0)
≥ 85178(2.4)83(2.4)

SOURCE: IOM, 1994, Table 3-3, updated by 20 years.

evidence from epidemiologic studies regarding associations between exposure to the chemicals of interest (COIs)—2,4-dichlorophenoxyacetic acid (2,4-D), 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and its contaminant 2,3,7,8-tetrachlo-rodibenzo-p-dioxin (TCDD), picloram, and cacodylic acid—and various types of cancer. The committee also considers studies of exposure to polychlorinated biphenyls (PCBs) and other dioxin-like chemicals (DLCs) informative if their results were reported in terms of TCDD toxic equivalents (TEQs) or concentrations of specific congeners of DLCs. However, studies that report TEQs based only on mono-ortho PCBs (which are PCBs 105, 114, 118, 123, 156, 157, 167, and 189) were given very limited consideration since mono-ortho PCBs typically contribute less than 10% to total TEQs, based on the WHO revised TEFs of 2005 (La Rocca et al., 2008; Van den Berg et al., 2006). If a new study reported on only a single type of cancer and did not revisit a previously studied population, its design information is summarized here with its results; design information on all other new studies can be found in Chapter 6.

The objective of this chapter is assessment of whether the occurrence of various cancers in Vietnam veterans themselves may be associated with exposure they may have received during military service. Therefore, studies of childhood cancers in relation to parental exposure to the COIs are discussed in Chapter 10, which addresses possible adverse effects in the veterans’ offspring. Studies that consider only childhood exposure are not considered relevant to the committee’s charge.

In an evaluation of a possible connection between herbicide exposure and risk of cancer, the approach used to assess the exposure of study subjects is of critical importance in determining the overall relevance and usefulness of find-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

ings. As noted in Chapters 3 and 6, there is great variety in detail and accuracy of exposure assessment among studies. A few studies used biologic markers of exposure, such as the presence of a chemical in serum or tissues; some developed an index of exposure from employment or activity records; and some used other surrogate measures of exposure, such as presence in a locale when herbicides were used. As noted in Chapter 2, inaccurate assessment of exposure, a form of measurement error, can obscure the relationship between exposure and disease.

Each section on a type of cancer opens with background information, including data on its incidence in the general US population and known or suspected risk factors. Cancer-incidence data on the general US population are included in the background material to provide a context for consideration of cancer risk in Vietnam veterans; the figures presented are estimates of incidence in the entire US population, not predictions for the Vietnam-veteran cohort. The data reported are for 2004–2008 and are from the most recent dataset available (NCI, 2010). Incidence data are given for all races combined and separately for blacks and whites. The age range of 55–69 years now includes about 80% of Vietnam-era veterans, and incidences are presented for three 5-year age groups: 55–59 years, 60–64 years, and 65–69 years. The data were collected for the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and are categorized by sex, age, and race, all of which can have profound effects on risk. For example, the incidence of prostate cancer is about 2.6 times as high in men who are 65–69 years old as in men 55–59 years old and almost twice as high in blacks 55–64 years old as in whites in the same age group (NCI, 2010). Many other factors can influence cancer incidence, including screening methods, tobacco and alcohol use, diet, genetic predisposition, and medical history. Those factors can make someone more or less likely than the average to contract a given kind of cancer; they also need to be taken into account in epidemiologic studies of the possible contributions of the COIs.

Each section of this chapter pertaining to a specific type of cancer includes a summary of the findings described in the previous Agent Orange reports: Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam, hereafter referred to as VAO (IOM, 1994); Veterans and Agent Orange: Update 1996, referred to as Update 1996 (IOM, 1996); Update 1998 (IOM, 1999); Update 2000 (IOM, 2001); Update 2002 (IOM, 2003); Update 2004 (IOM, 2005); Update 2006 (IOM, 2007); Update 2008 (IOM, 2009); and Update 2010 (IOM, 2011). That is followed by a discussion of the most recent scientific literature, a discussion of biologic plausibility, and a synthesis of the material reviewed. When it is appropriate, the literature is discussed by exposure type (service in Vietnam, occupational exposure, or environmental exposure). Each section ends with the committee’s conclusion regarding the strength of the evidence from epidemiologic studies. The categories of association and the committee’s approach to categorizing the health outcomes are discussed in Chapters 1 and 2.

Biologic plausibility corresponds to the third element of the committee’s

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

congressionally mandated statement of task. In fact, the degree of biologic plausibility itself influences whether the committee perceives positive findings to be indicative of an association or the product of statistical fluctuations (chance) or bias.

Information on biologic mechanisms by which exposure to TCDD could contribute to the generic (rather than tissue-specific or organ-specific) carcinogenic potential of the COIs is summarized in Chapter 4. It distills toxicologic information concerning the mechanisms by which TCDD affects the basic process of carcinogenesis; such information, of course, applies to all the cancer sites discussed individually in this chapter. When biologic plausibility is discussed in this chapter’s sections on particular cancer types, the generic information is implicit, and only experimental data peculiar to carcinogenesis at the site in question are presented. A large literature indicates that carcinogenesis is a process that involves not only genetic changes but also epigenetic changes, which modify DNA and its expression without altering its sequence of bases (Johnstone and Baylin, 2010). There is increasing evidence that TCDD and the COIs may disturb cellular processes by epigenetic mechanisms (see Chapter 4), and reference to this evidence, as it applies to cancers is included where it exists, by cancer site.

Considerable uncertainty remains about the magnitude of risk posed by exposure to the COIs. Many of the veteran, occupational, and environmental studies reviewed by the committee did not control fully for important confounders. There is not enough information about the exposure experience of individual Vietnam veterans to permit combining exposure estimates for them with any potency estimates that might be derived from scientific research studies to quantify risk. The committee therefore cannot accurately estimate the risk to Vietnam veterans that is attributable to exposure to the COIs. The (at least currently) insurmountable problems in deriving useful quantitative estimates of the risks of various health outcomes in Vietnam veterans are explained in Chapter 1 and the summary of this report, but the point is not reiterated for every health outcome addressed.

ORGANIZATION OF CANCER GROUPS

For Update 2006, a system for addressing cancer types was described to clarify how specific cancer diagnoses were grouped for evaluation by the committee and to ensure that the full array of cancer types would be considered. The organization of cancer groups follows major and minor categories of cause of death related to cancer sites established by the National Institute for Occupational Safety and Health (NIOSH). The NIOSH groups map the full range of International Classification of Diseases, Ninth Revision (ICD-9) codes for malignant neoplasms (140–208). The ICD system is used by physicians and researchers to group related diseases and procedures in a standard form for statistical evaluation. Revision 10 (ICD-10) came into use in 1999 and constitutes a marked change from the previous four revisions that evolved into ICD-9. ICD-9 was in effect

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

from 1979 to 1998; because ICD-9 is the version most prominent in the research reviewed in this series, it is used when codes are given for a specific health outcome. Appendix C describes the correspondence between the NIOSH cause-of-death groupings and ICD-9 codes (see Table C-1); the groupings for mortality are largely congruent with those of the SEER program for cancer incidence (see Table C-2, which presents equivalences between the ICD-9 and ICD-10 systems). For the present update, the committee gave more attention to the World Health Organization’s classification of lymphohematopoietic neoplasms (WHO, 2008), which stresses partitioning of the disorders first according to the lymphoid or myeloid lineage of the transformed cells rather than into lymphomas and leukemias.

The system of organization used by the committee simplifies the process for locating a particular cancer for readers and facilitated the committee’s identification of ICD codes for malignancies that had not been explicitly addressed in previous updates. VAO reports’ default category for any health outcome on which no epidemiologic research findings have been recovered has always been “inadequate evidence” of association with exposure to the COIs, which in principle is applicable to specific cancers. Failure to review a specific cancer or other condition separately reflects the paucity of information, so there is indeed inadequate or insufficient information to categorize an association with such a disease outcome.

BIOLOGIC PLAUSIBILITY

The studies considered with respect to the biologic plausibility of associations between exposure to the COIs and human cancers have been performed primarily in laboratory animals (rats, mice, hamsters, and monkeys) or cultured cells. Collectively, the evidence obtained from studies of TCDD indicates that a connection between human exposure to this chemical and cancers is biologically plausible, as will be discussed more fully in a generic sense below and more specifically in the biologic-plausibility sections on individual cancers. Recent reviews have affirmed the well-established mechanistic roles of the aryl hydrocarbon receptor (AHR) in cancer (Androutsopoulos et al., 2009; Barouki and Coumoul, 2010; Dietrich and Kaina, 2010; Ray and Swanson, 2009), and the data have firmly established the biologic plausibility of an association between TCDD exposure and cancer. Recently, Hernández et al. (2009) have reviewed the mechanisms of action of nongenotoxic carcinogens, including TCDD in this category.

With respect to 2,4-D, 2,4,5-T, and picloram, several studies have been performed in laboratory animals. In general, the results were negative, although some would not meet current standards of cancer bioassays; for instance, there is some question as to whether the highest doses (generally 30–50 mg/kg) in some of the studies reached a maximum tolerated dose. It is not possible to have absolute confidence that these chemicals have no carcinogenic potential. Further evidence of a lack of carcinogenic potential is provided, however, by negative

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

findings on genotoxic effects in assays conducted primarily in vitro. The evidence indicates that 2,4-D and 2,4,5-T are genotoxic only at very high concentrations.

There is some evidence that cacodylic acid is carcinogenic. Studies performed in laboratory animals have shown that it can induce neoplasms of the kidney (Yamamoto et al., 1995) and bladder (Arnold et al., 2006; Wei et al., 2002). Treatment with cacodylic acid induced formation of neoplasms of the lung when administered to mouse strains that are genetically susceptible to them (Hayashi et al., 1998). Other studies have used the two-stage model of carcinogenesis in which animals are exposed first to a known genotoxic agent and then to a suspected tumor-promoting agent; with this model, cacodylic acid has been shown to act as a tumor-promoter with respect to lung cancer (Yamanaka et al., 1996).

Studies in laboratory animals in which only TCDD has been administered have reported that it can increase the incidence of a number of neoplasms, most notably of the liver, lungs, thyroid, and oral mucosa (Kociba et al., 1978; NTP, 2006). Some studies have used the two-stage model of carcinogenesis and shown that TCDD can act as a tumor-promoter and increase the incidence of ovarian cancer (Davis et al., 2000), liver cancer (Beebe et al., 1995), and skin cancers (Wyde et al., 2004). In exerting its carcinogenic effects, TCDD is thought to act primarily as a tumor-promoter. In many of the animal studies reviewed, treatment with TCDD has resulted in hyperplasia or metaplasia of epithelial tissues. In addition, in both laboratory animals and cultured cells, TCDD has been shown to exhibit a wide array of effects on growth regulation, hormone systems, and other factors associated with the regulation of cellular processes that involve growth, maturation, and differentiation. Thus, it may be that TCDD increases the incidence or progression of human cancers through an interplay of multiple cellular factors. Tissue-specific protective cellular mechanisms may also affect the response to TCDD and complicate our understanding of its site-specific carcinogenic effects.

As shown with long-term bioassays in both sexes of several strains of rats, mice, hamsters, and fish, there is adequate evidence that TCDD is a carcinogen in laboratory animals, increasing the incidence of tumors at sites distant from the site of treatment at doses well below the maximum tolerated. On the basis of animal studies, TCDD has been characterized as a nongenotoxic carcinogen because it does not have obvious DNA-damaging potential, but it has been known for many years that it is a potent tumor-promoter and a weak initiator in two-stage initiation–promotion models for liver, skin, and lung. Early studies demonstrated that TCDD is 2 orders of magnitude more potent than the “classic” promoter tetradecanoyl phorbol acetate and that its skin-tumor promotion depends on the AHR. Recent evidence has shown that AHR activation by TCDD in human breast and endocervical cell lines induces sustained high concentrations of the interleukin-6 cytokine, which has tumor-promoting effects in numerous tissues—including breast, prostate, ovary, and malignant cholangiocytes—and opens up the possibility that TCDD would promote carcinogenesis in these and possibly

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

other tissues (Hollingshead et al., 2008). In rat liver, TCDD downregulates reduced folate carrier (Rfc1) mRNA and protein, whose normal levels are essential in maintaining folate homeostasis (Halwachs et al., 2010). Reduced Rfc1 activity and a functional folate deficiency may contribute to the risk of carcinogenesis posed by TCDD exposure.

Mechanisms by which TCDD induces G1 arrest in hepatic cells (Mitchell et al., 2006; Weiss et al., 2008) and decreases viability of endometrial endothelial cells (Bredhult et al., 2007), insulin-secreting beta cells (Piaggi et al., 2007), peripheral T cells (Singh et al., 2008), and neuronal cells (Bredhult et al., 2007) have been identified, and the results suggest possible carcinogenic mechanisms. TCDD may contribute to tumor progression by inhibiting p53 regulation (phosphorylation and acetylation) triggered by genotoxicants through the increased expression of the metastasis marker AGR2 (Ambolet-Camoit et al., 2010) and through a functional interaction between the AHR and FHL2—"four and a half LIM protein 2,” in which the LIM domain is a highly conserved protein structure (Kollara and Brown, 2009). Borlak and Jenke (2008) demonstrated that the AHR is a major regulator of c-raf and proposed that there is cross-talk between the AHR and the mitogen-activated protein kinase signaling pathway in chemically induced hepatocarcinogenesis. TCDD inhibits ultraviolet-C radiation-induced apoptosis in primary rat hepatocytes and Huh-7 human hepatoma cells, and this supports the hypothesis that TCDD acts as a tumor-promoter by preventing initiated cells from undergoing apoptosis (Chopra et al., 2009). Additional in vitro work with mouse hepatoma cells has shown that activation of the AHR results in increased concentrations of 8-hydroxy-2’-deoxyguanosine (8-OHdG), a product of DNA-base oxidation and later excision repair and a marker of DNA damage. Induction of cytochrome P4501A1 (CYP1A1) by TCDD or indolo(3,2-b) carbazole is associated with oxidative DNA damage (Park et al., 1996). In vivo experiments in mice corroborated those findings by showing that TCDD caused a sustained oxidative stress, as determined by measurements of urinary 8-OHdG (Shertzer et al., 2002) involving AHR-dependent uncoupling of mitochondrial respiration (Senft et al., 2002). Mitochondrial reactive-oxygen production depends on the AHR. Other than the occasional observation of 8-OHdG, there is little evidence that TCDD is genotoxic, and it appears likely that some of these mechanisms of action may be induced by epigenetic modifications (events that affect gene function but do not involve a change in gene coding sequence) of the genome.

Electronics-dismantling workers who experienced complex exposures, including exposure to polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDDs and PCDFs), had increased concentrations of urinary 8-OHdG indicative of oxidative stress and genotoxicity; this cannot, however, be ascribed directly to the DLCs (Wen et al., 2008). Clastogenic genetic disturbances arising as a consequence of confirmed exposure to Agent Orange were determined by analyzing sister-chromatid exchanges (SCEs) in lymphocytes from a group of 24 New Zea-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

land Vietnam War veterans and 23 control volunteers (Rowland et al., 2007). The results showed a highly significant difference (p < 0.001) in mean SCE frequency between the experimental group and the control group. The Vietnam War veterans also had a much higher proportion of cells with SCE frequencies above the 95th percentile than did the controls (11.0% and 0.07%, respectively).

The weight of evidence that TCDD and dioxin-like PCBs make up a group of chemicals with carcinogenic potential includes unequivocal animal carcinogenesis and biologic plausibility based on mode-of-action data. Although the specific mechanisms by which dioxin causes cancer remain to be established, the intracellular factors and mechanistic pathways involved in dioxin’s cancer-promoting activity all have parallels in animals and humans. No qualitative differences have been reported to indicate that humans should be considered as fundamentally different from the multiple animal species in which bioassays have demonstrated dioxin-induced neoplasia.

Thus, the toxicologic evidence indicates that a connection of TCDD and perhaps cacodylic acid with cancer in humans is, in general, biologically plausible, but (as discussed in The Committee’s View of “General” Human Carcinogens below) it must be determined case by case whether such potential contributes to each individual type of cancer. Experiments with 2,4-D, 2,4,5-T, and picloram in animals and cells have not provided a strong biologic basis for either the presence or the absence of carcinogenic effects.

THE COMMITTEE’S VIEW OF “GENERAL” HUMAN CARCINOGENS

To address its charge, the committee weighed the scientific evidence linking the COIs to specific individual cancer sites. That was appropriate given the different susceptibilities of various tissues and organs to cancer and the various genetic and environmental factors that can influence the occurrence of a particular type of cancer. Before considering each site in turn, however, it is important to address the concept that cancers share some characteristics among organ sites and to clarify the committee’s view regarding the implications of a chemical’s being a “general” human carcinogen. All cancers share phenotypic characteristics: uncontrolled cell proliferation, increased cell survival, invasion outside normal tissue boundaries, and eventually metastasis. The current understanding of cancer development holds that a cell or group of cells must acquire a series of sufficient genetic mutations to progress and that particular epigenetic events must occur to accelerate the mutational process and provide growth advantages for the more aggressive clones of cells. Both genetic (mutational) and epigenetic (nonmutational) activities of carcinogenic agents can stimulate the process of cancer development.

In classic experiments based on the induction of cancer in mouse skin that were conducted over 40 years ago, carcinogens were categorized as initiators, those capable of causing an initial genetic insult to the target tissue, and promot-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

ers, those capable of promoting the growth of initiated tumor cells, generally through nonmutational events. Some carcinogens, such as those found in tobacco smoke, were considered “whole carcinogens"; that is, they were capable of both initiation and promotion. Today, cancer researchers recognize that the acquisition of important mutations is a continuing process in tumors and that promoters, or epigenetic processes that favor cancer growth, enhance the accumulation of genotoxic damage, which traditionally would be regarded as initiating activity.

As discussed above and in Chapter 4, 2,4-D, 2,4,5-T, and picloram have shown little evidence of genotoxicity in laboratory studies, except at very high doses, and little ability to facilitate cancer growth in laboratory animals. However, cacodylic acid and TCDD have shown the capacity to increase cancer development in animal experiments, particularly as promoters rather than as pure genotoxic agents. Extrapolating organ-specific results from animal experiments to humans is problematic because of important differences between species in overall susceptibility of various organs to cancer development and in organ-specific responses to particular putative carcinogens. Therefore, judgments about the “general” carcinogenicity of a chemical in humans are based heavily on the results of epidemiologic studies, especially on the question of whether there is evidence of excess cancer risk at multiple organ sites. As the evaluations of specific types of cancer in the remainder of this chapter indicate, the committee finds that TCDD appears to be a multisite carcinogen. That finding is in agreement with the International Agency for Research on Cancer (IARC), which has determined that TCDD is a category 1 “known human carcinogen” (Baan et al., 2009); with the US Environmental Protection Agency (EPA), which has concluded that TCDD is “likely to be carcinogenic to humans” (http://www.epa.gov/ttn/atw/hlthef/dioxin.html; updated Januarary 2000; accessed September 21, 2013); and with the National Toxicology Program (NTP), which regards TCDD as “known to be a human carcinogen” (NTP, 2011). It is important to emphasize that the goals and methods of IARC and EPA in making their determinations were different from those of the present committee: the missions of those organizations focus on evaluating risk to minimize future exposure, whereas this committee focuses on risk after exposure. Furthermore, recognition that TCDD and cacodylic acid are multisite carcinogens does not imply that they cause human cancer at every organ site.

The distinction between general carcinogen and site-specific carcinogen is more difficult to grasp in light of the common practice of beginning analyses of epidemiologic cohorts with a category of “all malignant neoplasms,” which is a routine first screen for any unusual cancer activity in the study population rather than a test of a biologically based hypothesis. When the distribution of cancers among anatomic sites is lacking in the report of a cohort study, a statistical test for an increase in all cancers is not meaningless, but it is usually less scientifically supportable than are analyses based on specific sites, for which more substantial biologically based hypotheses can be developed. The size of a cohort and the

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

length of the observation period often constrain the number of cancer cases observed and which specific types of cancer have enough observed cases to permit analysis. For instance, an analysis of cumulative results on diabetes and cancer in the prospective Air Force Health Study (Michalek and Pavuk, 2008) produced important information summarizing previous findings on the fairly common condition of diabetes, but the cancer analysis does not go beyond “all cancers.” The committee does not accept the cancer findings as an indication that exposure to Agent Orange increases the risk of every variety of cancer. It acknowledges that the results of the highly stratified analyses conducted suggest that the incidence of some cancers did increase in the Operation Ranch Hand veterans, but it views the “all cancers” results as a conglomeration of information on specific cancers—most important, melanoma and prostate cancer, on which provocative results have been published (Akhtar et al., 2004; Pavuk et al., 2006)—and as meriting individual longitudinal analysis to resolve outstanding questions.

For this report, updated mortality information was available on four occupational cohorts that have been followed in VAO updates, which included risk statistics for overall cancer mortality. In three of the four (Manuwald et al., 2012; Ruder and Yiin, 2011; Waggoner et al., 2011), there was a modest increase in cancer mortality; in the fourth, the observed cancer mortality matched expectation (Boers et al., 2012).

The committee notes that current information on overall mortality in US Vietnam veterans themselves has been elusive. Considerable confusion and alarm has arisen from Internet attribution of all of the approximately 800,000 deaths among all 9.2 million US Vietnam-era veterans to the 2.7 million who served in Vietnam (Brady, 2011; Gelman, 2013). The most recent reliable information was obtained in the 30-year update of mortality through 2000 of the deployed and nondeployed veterans in the Vietnam Experience Study (Boehmer et al., 2004), which found that mortality among the deployed veterans slightly exceeded that of their non-deployed counterparts, but was only about 9%. A followup study (O’Toole et al., 2010) of a random sample of 1,000 Australian Vietnam veterans selected from Australia’s comprehensive roster of 57,643 service members deployed to Vietnam may provide a somewhat newer estimate of mortality through 2004 of 11.7%, which may be fairly comparable with that of their American fellows.

The remainder of this chapter deals with the committee’s review of the evidence on each individual cancer site in accordance with its charge to evaluate the statistical association between exposure and cancer occurrence, the biologic plausibility and potential causal nature of the association, and the relevance to US veterans of the Vietnam War.

A number of studies of populations that received potentially relevant exposures were identified in the literature search for this review but did not characterize exposure with sufficient specificity for their results to meet the committee’s criteria for inclusion in the evidentiary database. For instance, the British Pesticide Users Health Study has followed almost 60,000 men and 4,000 women who

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

were certified for agricultural pesticide use in Great Britain since 1987. Frost et al. (2011) reported cancer incidence and mortality in this cohort up to 2004 for the full array of anatomic sites, but exposure was defined only as being a member of this cohort. Therefore, the cancer-specific findings of Frost et al. (2011) will not be repeatedly noted in the individual sections below. That is also the case for the mortality followup of Japanese Americans in the Honolulu Heart Program reported by Charles et al. (2010). Technically, this rubric would apply to the mortality and morbidity results reported by Waggoner et al. (2011) and Koutrous et al. (2010a); because of the context provided by the extensive pesticide-specific results that have been published on individual cancers in the Agricultural Health Study (AHS) and the knowledge that 2,4-D was one of the most frequently used pesticides in this large prospective cohort, however, those results are presented below, but not given full evidentiary weight. Numerous cancer studies of the case-control design addressing particular cancers had exposure characterizations that were not more specific than job titles, farm residence, or pesticide exposure; therefore, their results are not regarded as fully relevant for the purpose of this review, and such studies are mentioned only in passing in a discussion of the cancer investigated.

ORAL, NASAL, AND PHARYNGEAL CANCER

Oral, nasal, and pharyngeal cancers are found in many anatomic sites: the structures of the mouth (inside lining of the lips, cheeks, gums, tongue, and hard and soft palate—ICD-9 codes 140–145); oropharynx (ICD-9 146); nasopharynx (ICD-9 147); hypopharynx (ICD-9 148); other buccal cavity and pharynx (ICD-9 149); and nasal cavity and paranasal sinuses (ICD-9 160). Until recently, cancers that occur in the oral cavity and pharynx have been thought to be similar in descriptive epidemiology and risk factors, and cancer of the nasopharynx is thought to have a different epidemiologic profile. However, we now recognize that human papilloma virus (HPV) is an important risk factor for squamous-cell carcinoma of the head and neck, and risk estimates are highest for the base of the tongue and tonsils (oropharynx) (Marur et al., 2010).

The American Cancer Society (ACS) estimated that about 40,250 men and women would receive diagnoses of oral, nasal, or pharyngeal cancer in the United States in 2012 and that 7,850 men and women would die from these diseases (Siegel et al., 2012). Almost 91% of those cancers originate in the oral cavity or oropharynx. Most oral, nasal, and pharyngeal cancers are squamous-cell carcinomas. Nasopharyngeal carcinoma (NPC) is the most common malignant epithelial tumor of the nasopharynx but is relatively rare in the United States. There are three types of NPC: keratinizing squamous-cell carcinoma, nonkeratinizing carcinoma, and undifferentiated carcinoma.

The average annual incidences reported in Table 8-2 show that men are at greater risk than are women for those cancers and that the incidences increase

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-2 Average Annual Incidence (per 100,000) of Nasal, Nasopharyngeal, Oral-Cavity and Pharyngeal, and Oropharyngeal Cancers in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Nose, Nasal Cavity, and Middle Ear:
    Men1.51.52.52.21.93.72.92.63.3
    Women1.21.01.01.11.01.81.61.90.9
Nasopharynx:
    Men2.31.22.02.21.50.82.81.72.8
    Women1.10.60.40.80.70.31.00.90.9
Oral Cavity and Pharynx:
    Men0.80.71.80.80.62.31.41.23.9
    Women0.30.30.20.10.10.30.60.52.1
Oropharynx:
    Men2.01.93.51.91.65.22.22.05.0
    Women0.30.30.40.70.70.90.40.50.0

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

with age—but there are few cases, and care should be exercised in interpreting the numbers. Tobacco and alcohol use are established risk factors for oral and pharyngeal cancers. Reported risk factors for nasal cancer include occupational exposure to nickel and chromium compounds (d’Errico et al., 2009; Feron et al., 2001; Grimsrud and Peto, 2006), wood dust (d’Errico et al., 2009), leather dust (Bonneterre et al., 2007), and high doses of formaldehyde (Nielsen and Wolkoff, 2010).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COI and oral, nasal, and pharyngeal cancers. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

In Update 2006, at the request of the Department of Veterans Affairs (VA), the committee attempted to evaluate tonsil-cancer cases separately, but it was able to identify only three cohort studies that provided the number of tonsil-cancer cases in their study populations and concluded that the studies did not provide sufficient evidence to determine whether an association existed between exposure to the COIs and tonsil cancer. No new studies have offered any important

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

additional insight into the question. The committee responsible for Update 2006 recommended that VA evaluate the possibility of studying health outcomes, including tonsil cancer, in Vietnam-era veterans by using existing administrative and health-services databases. Anecdotal evidence provided to that committee suggested a potential association between the exposures in Vietnam and tonsil cancer. Increasing evidence indicating that some cancers of the oropharynx and oral cavity can have a viral (HPV) etiology is consistent with the mechanistic hypothesis explaining an excess of these cancers in Vietnam veterans: immune alterations associated with Agent Orange exposure may have increased susceptibility to HPV infection in the oral cavity and tonsils of Vietnam veterans, thereby making them more prone to the development of squamous-cell carinomas in these tissues. The present committee strongly reiterates the 2006, 2008, and 2010 recommendation that VA develop a strategy that uses existing databases to evaluate tonsil cancer in Vietnam-era veterans.

The small numbers of oral, nasal, or pharyngeal cancer cases in prior studies limit interpretation of the data. Cypel and Kang (2010) updated the study of Vietnam-era Army Chemical Corps (ACC) veterans, comparing mortality through 2005 in ACC veterans by Vietnam service. They reported a nonsignificant increase in oral-cavity and pharyngeal cancers in the deployed cohort compared with cases in the nondeployed cohort—a result that is consistent with a prior report on mortality through 1991 (Dalager and Kang, 1997).

McBride et al. (2009a) reported on mortality through 2004 in the New Zealand cohort of 1,599 workers who had been employed in manufacturing phenoxy herbicides from trichlorophenol (TCP); picloram was also produced in the plant. They reported a nonsignificant excess in mortality from buccal cavity and pharyngeal cancer and no deaths from nasopharyngeal cancer in either group.

Studies evaluated previously and in the present report are summarized in Table 8-3.

Update of the Epidemiologic Literature

Vietnam-Veteran Studies

There have been no Vietnam-veteran studies of exposure to the COIs and oral, nasal, or pharyngeal cancers since Update 2010.

Occupational Studies

Burns et al. (2011) published an update examining the cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased cancer rates overall. The incidence of lip, oral, and pharyngeal cancer

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-3 Selected Epidemiologic Studies—Oral, Nasal, and Pharyngeal Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIsAkhtar et al., 2004

Incidence

Ranch Hand veterans (n = 1,189)

    60.9 (0.4–1.9)

With tours between 1966–1970

    61.1 (0.5–2.3)

SEA comparison veterans (n = 1,776)

    50.6 (0.2–1.2)

With tours between 1966–1970

    40.6 (0.2–1.4)

Mortality

Through 1999—White subjects vs national rates

Ranch Hand veterans (n = 1,189)

    00.0 (nr)

SEA comparison veterans (n = 1,776)

    10.5 (nr)

US VA Cohort of Army Chemical Corps

All COIs

Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (July 1, 1965–March 28, 1973)

Mortality—Oral cavity and pharyngeal cancer

Through 2005

Cypel and Kang, 2010

Deployed veterans (2,872) vs nondeployed (2,737)

6 vs 21.7 (0.3–8.7)

Army Chemical Corps vs US men

Vietnam cohort

    61.5 (0.6–3.3)

Non-Vietnam cohort

    20.8 (0.1–2.8)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000 (ICD-140–149)

    6nrBoehmer et al., 2004

US CDC Selected Cancers Study—Case-control study of incidence (Dec 1, 1984–Nov 30, 1989) among US males born 1929–1953

All COIsCDC, 1990a

89 nasopharyngeal carcinomas

Vietnam service

    30.5 (0.2–1.8)

62 nasal carcinomas

Vietnam service

    20.7 (0.2–2.9)

State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed (lip, oral cavity, pharynx)

  121.0 (0.5–1.8)Visintainer et al., 1995
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference
International Vietnam-Veterans Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000 (head and neck)

2471.5 (1.3–1.6)ADVA,

Navy

  561.6 (1.1–2.0)2005a

Army

1741.6 (1.3–1.8)

Air Force

  170.9 (0.5–1.5)

Mortality

All branches, return–2001

ADVA,

Head and neck

1011.4 (1.2–1.7)2005b

Navy

  221.5 (0.9–2.1)

Army

  691.5 (1.1–1.8)

Air Force

    91.1 (0.5–2.0)

Nasal

    30.8 (0.2–2.2)

1980–1994

CDVA,

Lip (ICD-9 140)

    0nr1997a

Nasopharyngeal cancer (ICD-9 147)

    20.5 (0.1–1.7)

Nasal cavities (ICD-9 160)

    21.2 (0.1–4.1)

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence

1982–2000

ADVA,

Head and Neck

  442.0 (1.2–3.4)2005c

Mortality

1966–2001

ADVA,

Head and neck

  161.8 (0.8–4.3)2005c

Nasal

    00.0 (0.0–48.2)

1982–1994

CDVA,

Nasopharyngeal cancer (ICD-9 147)

    11.3 (0.0– > 10)1997b

Nasal cavities (ICD-9 160)

    00.0 (0.0– > 10)
OCCUPATIONAL—INDUSTRIAL IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

Kogevinas et al., 1997

Oral cavity, pharynx cancer (ICD-9 140–149)

  261.1 (0.7–1.6)

13,831 exposed to highly chlorinated

  221.3 (0.8–2.0)

PCDDs

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

7,553 not exposed to highly chlorinated PCDDs

    30.5 (0.1–1.3)

Nasal, nasal sinus cancer (ICD-9) 160)

    31.6 (0.3–4.7)

13,831 exposed to highly chlorinated PCDDs

    00.0 (0.0–3.5)

7,553 not exposed to highly chlorinated PCDDs

    33.8 (0.8–11.1)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Bucal cavity, pharynx (ICD-8 140–149)

  111.2 (0.6–2.1)

Nose, nasal cavities (ICD-8 160)

    32.9 (0.6–8.5)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

Coggon

Lip (ICD-9 140)

    0nret al., 1986

Tongue (ICD-9 141)

    11.1 (0.0–6.2)

Pharynx (ICD-9 146–149)

    10.5 (0.0–3.0)

Nose (ICD-9 160)

    34.9 (1.0–14.4)

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–1991 (lip, oral cavity, pharynx)

Hooiveld

All working anytime in 1955–1985

    12.3 (0.1–12.4)et al., 1998

Cleaned up 1963 explosion

    17.1 (0.2–39.6)

German Production Workers—2,479 workers at 4 plants (in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

All for plants—Buccal cavity, pharynx (ICD-9 140–149)

    93.0 (1.4–5.6)Becher et al., 1996

Tongue

    3nr

Floor of mouth

    2nr

Tonsil

    2nr

Pharynx

    2nr

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4, 5-TCP

Mortality 1951–1992

    0Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    68.2 (3.0–17.9)Becher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Mortality

Through 1987

90% CIZober et al.,

Buccal cavity, pharynx

    14.8 (0.3–22.9)1990

Squamous-cell carcinoma of tonsil

    1nr

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007 (ICD-9 140–149)

  112.2 (1.1–3.9)Manuwald

Men

    92.0 (0.9–3.8)et al., 2012

Women

    23.4 (0.4–12.5)

Mortality 1952–1989

    31.8 (0.4–5.2)Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004 (buccal cavity and pharynx)

McBride et al., 2009a

Ever-exposed workers

    32.6 (0.5–7.6)

Never-exposed workers

    00.0 (0.0–11.5)

Production Workers—Mortality 1969–2000

713 men and 100 women worked > 1 month in 1969–1984

    22.8 (0.3–9.9)’t Mannetje et al., 2005

Lip (ICD-9 140)

    0nr

Mouth (ICD-9 141–145)

    25.4 (0.7–20.0)

Oropharynx (ICD-9 146)

    0nr

Nasopharynx (ICD-9 147)

    00.0 (0.0–41.8)

Hypopharynx, other (ICD-9 148–149)

    0nr

Phenoxy herbicide sprayers (> 99% men)

    11.0 (0.0–5.7)’t Mannetje et al., 2005

Lip (ICD-9 140)

    0nr

Mouth (ICD-9 141–145)

    00.0 (0.0–7.5)

Oropharynx (ICD-9 146)

    0nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Nasopharynx (ICD-9 147)

    18.3 (0.2–46.3)

Hypopharynx, other (ICD-9 148–149)

    0nr

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

All Dow PCP-Exposed Workers (All workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (buccal, pharynx; ICD-9 140–149)

    50.8 (0.3–1.8)

PCP and TCP (n = 720)

    10.5 (0.0–2.7)

PCP (no TCP) (n = 1,402)

    40.9 (0.2–2.3)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    71.1 (0.4–2.2)Burns et al., 2011
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM (oral cavity, pharynx)

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  330.9 (0.6–1.3)

Ever

  150.5 (0.3–0.9)

Danish male, female paper workers

Rix et al.,

Buccal cavity (ICD-7 140–144)

1998

Men

  241.0 (0.7–1.5)

Women

    41.5 (0.4–3.8)

Pharynx (ICD-7 145–149)

Men

  152.0 (1.1–3.3)

Women

    22.1 (0.2–7.6)

Tonsil cancers among pharyngeal cancers

  11nr

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

90% CIRobinson et al., 1986

Buccal cavity, pharynx (ICD-7 140–148)

    10.1 (0.0–0.7)

Nasal (ICD-7 160)

    0nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Danish self-employed farmers

Lip

1821.8 (p < 0.05)

Tongue

    90.6 (nr)

Salivary glands

  130.9 (nr)

Mouth

  140.5 (p < 0.05)

Pharynx

  130.3 (p < 0.05)

Nasal cavities, sinuses

  110.6 (nr)

Danish farming employees

Lip

  432.1 (p < 0.05)

Tongue

    20.6 (nr)

Salivary glands

    00.0 (nr)

Mouth

    00.0 (p < 0.05)

Pharynx

    91.1 (nr)

Nasal cavities, sinuses

    51.3 (nr)

Danish gardeners—incidence from 3,156 male and 859 female gardeners (buccal cavity, pharynx, ICD-7 140–148)

HerbicidesHansen et al., 2007

10-yr followup (1975–1984) reported in Hansen et al. (1992)

    61.1 (0.4–2.5)

25-yr followup (1975–2001)

Born before 1915 (high exposure)

    30.7 (0.2–2.3)

Born 1915–1934 (medium exposure)

    60.7 (0.3–1.4)

Born after 1934 (low exposure)

    00.0 (0.0–1.0)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicidesAsp et al., 1994

Buccal, pharynx (ICD-8 140–149)

Incidence

    51.0 (0.3–2.3)

Mortality 1972–1989

    00.0 (0.0–3.0)

“Other Respiratory” (ICD-8 160, 161, 163)—nose, larynx, pleura

Incidence

    41.1 (0.3–2.7)

Mortality 1972–1989

    10.5 (0.0–2.9)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401) (buccal cavity, pharynx)

  180.3 (0.2–0.5)Torchio et al., 1994
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Italian Farmers—mortality odds ratios from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Self-employed

  130.9 (nr)

Employee

    40.5 (nr)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 649 incident buccal cavity cancer cases and 49 incident nasopharynx cancer cases vs 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides

Buccal cavity

    30.7 (0.2–2.2)

Nasopharynx

    25.6 (1.6–19.5)

Aged 20–59

    13.5 (0.6–22.6)

Aged ≥ 60

    113.4 (2.7–65.1)

Sawmill workers (n = 139)

Herbicides, chlorophenols

Nasopharynx

    0

NORWEGIAN farmers born 1925–1971—incidence, lip cancer

PesticidesNordby et al., 2004

Reported pesticide use

nr0.7 (0.4–1.0)

SWEDEN

Swedish pesticide applicators—incidence

Wiklund et al., 1989a

Lip cancer

  141.8 (1.0–2.9)

Incident cancer cases 1961–1973 with agriculture as economic activity in 1960 census (male, female)

Wiklund, 1983
99% CI

Lip

5081.8 (1.6–2.2)

Tongue

  320.4 (0.2–0.6)

Salivary Gland

  681.0 (0.7–1.4)

Mouth

  700.6 (0.5–0.8)

Throat

  840.5 (0.4–0.7)

Nose, nasal sinuses

  640.8 (0.6–1.2)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

Swaen

Nose

    0et al., 2004

Pharynx

    0

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  212.3 (1.4–3.5)

Nonwhites (n = 11,446)

    0
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Women

Whites (n = 2,400)

    112.2 (0.2–68.0)

Nonwhites (n = 2,066)

    00.0 (0.0–103.6)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  930.6 (0.5–0.7)

Commercial applicators

    50.5 (0.2–1.3)

Spouses

  220.6 (0.4–1.0)

Enrollment through 2002—buccal cavity
    Private applicators (men and women)

Alavanja et al., 2005
  660.7 (0.5–0.8)

Lip

  251.4 (0.9–2.1)

Spouses of private applicators (> 99% women)

  140.7 (0.4–1.2)

Lip

    21.4 (0.2–5.1)

Commercial applicators

    50.9 (0.3–2.2)

Lip

    32.7 (0.6–8.0)

Mortality

Enrollment through 2007, vs state rates (buccal cavity, pharynx)

  160.3 (0.2–0.6)Waggoner et al., 2011

Enrollment through 2000, vs state rates (buccal cavity, pharynx)

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

    50.3 (0.1–0.7)
    00.0 (0.0–25.4)

White Male Residents of Iowa—Lip cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

  202.1 (p < 0.01)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Incidence

10-yr followup to 1991—men

Bertazzi et al., 1993

Buccal cavity (ICD-9 140–149)

Zone B

    61.7 (0.8–3.9)

Zone R

  281.2 (0.8–1.7)

Nose, nasal cavities (ICD-9 160)

Zone R

    0nr

10-yr followup to 1991—women

Bertazzi et al., 1993

Buccal cavity (ICD-9 140–149)

Zone B

    0nr

Zone R

    0nr

Nose, nasal cavities (ICD-9 160)

Zone R

    22.6 (0.5–13.3)
CASE-CONTROL STUDIES

US Case-Control Studies

US males born 1929–1953, all 70 nasal cancers (52 carcinomas, 11 lymphomas, 5 sarcomas) in CDC (1990a) study population

Herbicides, pesticidesCaplan et al., 2000

Selected landscaping, forestry occupation

  261.8 (1.1–3.1)

Living, working on farm

  230.5 (0.3–0.8)

Herbicides, pesticides

  190.7 (0.4–1.3)

Phenoxy herbicides

    51.2 (0.4–3.3)

International Case-Control Studies

Residents of northern Sweden (44 nasal, 27 nasopharyngeal cancers)

Phenoxy acids, chlorophenolsHardell et al., 1982

Phenoxy herbicide exposed

    82.1 (0.9–4.7)

Chlorophenol exposure

    96.7 (2.8–16.2)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, 2,4-dichlorophenoxypropanoic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; AFHS, Air Force Health Study; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2 methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy) butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupational specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxins (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; PMR, proportionate mortality ratio; SEA, Southeast Asia; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

in the most restrictively defined cohort was not increased (standardized incidence ratio [SIR] = 1.09, 95% confidence interval [CI] 0.44–2.24), as was the case for the two more inclusive but potentially more biased cohorts.

Manuwald et al. (2012) reported on mortality in 1,191 men and 398 women who had been employed for at least 3 months in 1952–1984 at a chemical plant in Hamburg (a subcohort of the IARC phenoxy herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort at the date of their first employment at the plant, and vital status was sought through 2007. Standardized mortality ratios (SMRs) calculated relative to the population of Hamburg showed that death from lip, oral-cavity, or pharyngeal cancers was not significantly increased in men (SMR = 2.00, 95% CI 0.91–3.79) or women (SMR = 3.42, 95% CI 0.39–12.45) but was significantly increased in the entire cohort (SMR = 2.17, 95% CI 1.08–3.87).

Ruder and Yiin (2011) reported mortality from 1940 to 2005 in the NIOSH pentachlorophenol (PCP) cohort of 2,122 workers in the US four plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. In the total cohort, five deaths were attributed to buccal or pharyngeal cancer; this was consistent with the mortality experience of the US population (SMR = 0.76, 95% CI 0.25–1.77). There was only one death from this type of cancer in the PCP-plus-TCDD group, which also was not more than expected (SMR = 0.48, 95% CI 0.01–2.68). The results were effectively the same in the 1,402 workers who had not had any opportunity for occupational exposure to TCDD (SMR = 0.89, 95% CI 0.24–2.28).

The participants in the AHS are known to have had extensive exposure to the phenoxy herbicides, but the analyses of updated mortality through 2007 (Waggoner et al., 2011) and cancer incidence through 2006 (Koutros et al., 2010a) addressed only exposure to pesticides in general. The SMR was lower than expected for oral (buccal) and pharyngeal cancers in the applicators (16 deaths, SMR = 0.34, 95% CI 0.19–0.55), and only three deaths from these types of cancer were observed in their spouses. Koutros et al. (2010a) found 93 cases of oral-cavity and pharyngeal cancers in the private applicators (SIR = 0.56, 95% CI 0.45–0.69) and 22 cases in their spouses (SIR = 0.64, 95% CI 0.40–0.97). A nonsignificant increase in lip cancer was reported for the private applicators (SIR = 1.30, 95% CI 0.90–1.83), but these 33 cases may have more in common with skin cancers than with head and neck squamous-cell carcinomas. The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Environmental Studies

No new studies of environmental exposures to the COIs and these types of cancer have been published since Update 2010.

Case-Control Studies

A single case-control study of nasopharyngeal carcinoma (NPC) was identified in this publication period; it explored dietary, social, and environmental risk factors in 1,289 subjects (Aussem et al., 2012). Using a novel analytic procedure involving Baysian networks, the authors investigated whether exposure to pesticides and intake of domestic fumes from incomplete combustion of coal and wood were significantly associated with NPC risk. The characterization of exposure was insufficiently specific for the present committee to factor in the findings of the study. In any event, NPC is rare outside southern China and is known to be associated with Epstein-Barr virus infection, so it is unlikely to be a concern in American Vietnam veterans.

Biologic Plausibility

As noted above, there is increasing evidence that HPV contributes causally to cancers of the head and neck (Marur et al., 2010; Szentirmay et al., 2005) and to pharyngeal cancers in particular (Gillison and Shah, 2001; Gillison et al., 2012). It is unknown whether Agent Orange exposure contributes to a susceptibility to viral infection or action, but it warrants further exploration. The sparseness of data on the specific tumor site and a general lack of information on smoking, drinking, and viral exposure status in the few available epidemiologic studies preclude exploration of this hypothesis in the current literature.

Long-term animal studies have examined the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). A National Toxicology Program study (Yoshizawa et al., 2005a) reported an increase in the incidence of gingival squamous-cell carcinoma in female rats treated orally (by gavage) with TCDD at 100 ng/kg 5 days/week for 104 weeks. The incidence of gingival squamous-cell hyperplasia was significantly increased in all groups treated at 3–46 ng/kg. In addition, squamous-cell carcinoma of the oral mucosa of the palate was increased. This NTP study did not, however, find any pathologic effect of TCDD on nasal tissues (Nyska et al., 2005). Increased neoplasms of the oral mucosa were previously observed and described as carcinomas of the hard palate and nasal turbinates (Kociba et al., 1978). Kociba et al. (1978) also reported a small increase in the incidence of tongue squamous-cell carcinoma.

Recently, DiNatale et al. (2011) utilized head and neck squamous-cell carcinoma cell lines to investigate mechanisms for tumor progression associated

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

with this AHR activation. This tumor type typically produces large amounts of cytokines, and its IL6 expression levels correlate with disease aggressiveness. In this model, AHR activation by TCDD enhances IL6 production induced by another cytokine (IL 1β), so TCDD may promote head and neck squamous-cell carcinoma.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Most of the new studies that reported results on oral, nasal, and pharyngeal cancers noted estimated reductions or nonsignificant excesses in mortality from oral and pharyngeal cancers. With a total of 11 oral, pharyngeal, or lip cancers, however, a significantly increased risk was reported for the Hamburg cohort overall; but with nine and two cases, respectively, the increased estimates of risk for men and women did not achieve the traditional level (p = 0.05) of statistical significance. In the AHS, the incidence of oral and pharyngeal cancers was significantly decreased for both private applicators and their spouses. Those data are not sufficient, taken in combination with the previously reviewed literature, to suggest an association with the herbicides sprayed in Vietnam.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and oral, nasal, or pharyngeal cancers.

CANCERS OF THE DIGESTIVE ORGANS

Until Update 2006, VAO committees had reviewed “gastrointestinal tract tumors” as a group consisting of stomach, colorectal, and pancreatic cancers; esophageal cancer has been formally included only since Update 2004. With more evidence from occupational studies available, VAO updates now address cancers of the digestive organs individually. Findings on cancers of the digestive organs as a group (ICD-9 150–159) are too broad for useful etiologic analysis and will no longer be considered.

Esophageal cancer (ICD-9 150), stomach cancer (ICD-9 151), colon cancer (ICD-9 153), rectal cancer (ICD-9 154), and pancreatic cancer (ICD-9 157) are among the most common cancers. ACS estimated that about 226,160 people would receive diagnoses of those cancers in the United States in 2012 and that 114,690 people would die from them (Siegel et al., 2012). Other digestive cancers (for example, small intestine, anal, and hepatobiliary cancers) added about 58,520

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

new diagnoses and 27,820 deaths to the 2012 estimates for the United States (Siegel et al., 2012). Collectively, tumors of the digestive organs were expected to account for 17% of new cancer diagnoses and 25% of cancer deaths in 2012. The average annual incidences of gastrointestinal cancers are presented in Table 8-4.

The incidences of stomach, colon, rectal, and pancreatic cancers increase with age. In general, the incidences are higher in men than in women and higher

TABLE 8-4 Average Annual Incidence (per 100,000) of Selected Gastrointestinal Cancers in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Stomach:
    Men15. 013.723.223.321.038.635.931.266.2
    Women7.05.312.48.87.113.914.611.323.0
Esophagus:
    Men15.815.921.024.725.330.333.035.232.3
    Women3.02.66.14.23.89.57.87.213.2
Colon (excluding rectum):
    Men52.448.283.680.476.1127.3123.8120.1170.1
    Women41.037.061.958.754.593.499.695.9134.7
Rectum and rectosigmoid junction:
    Men32.530.537.942.040.241.259.857.458.4
    Women19.918.124.623.222.430.730.729.336.7
Liver and intrahepatic bile duct:
    Men35.928.584.635.528.274.538.030.251.7
    Women8.96.817.38.56.414.513.110.914.1
Pancreas:
    Men22.121.133.736.235.055.054.753.380.6
    Women15.915.223.125.524.735.837.435.061.4
Small Intestine:
    Men5.05.16.56.76.88.69.38.913.3
    Women3.63.56.54.54.08.66.76.611.9
Anus, anal canal, and anorectum:
    Men3.43.64.23.43.83.04.24.72.8
    Women4.65.04.54.95.14.15.56.15.1
Other digestive organs:
    Men0.80.72.01.71.21.92.32.51.1
    Women0.70.60.81.21.21.21.61.52.6
Gallbladder:
    Men1.00.81.51.51.13.42.92.53.3
    Women1.91.44.32.82.54.14.94.56.8
Other Biliary:
    Men2.62.25.25.24.95.27.16.85.6
    Women1.92.01.22.72.63.35.24.76.4

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

in blacks than in whites. Risk factors for the cancers vary but always include family history of the same form of cancer, some diseases of the affected organ, and diet. Tobacco use is a risk factor for pancreatic cancer and possibly stomach cancer (Miller et al., 1996). Infection with the bacterium Helicobacter pylori increases the risk of stomach and pancreatic cancer. Type 2 diabetes is associated with an increased risk of colorectal and pancreatic cancers (ACS, 2013a).

It is noteworthy that there has been one report of Vietnam veterans that included all gastrointestinal cancers collectively. Cypel and Kang (2010) published an update on disease-related mortality in ACC veterans who handled or sprayed herbicides in Vietnam in comparison with their non-Vietnam veteran peers or US men. Vital status was determined through December 31, 2005. In the analyses, the site-specific rates of digestive cancers were not examined. No statistically significant excess mortality from all cancers of the digestive tract was found in ACC Vietnam veterans compared with non-Vietnam veterans (adjusted relative risk [RR] = 1.01, 95% CI 0.56–1.83).

Several studies identified for the present update did analyses that combined several digestive cancers, so the results are not particularly informative for any cancer in the group. Boers et al. (2012) reported on stomach and pancreatic cancers, leaving an additional 28 cases of other digestive cancers, which closely matched expectation. Burns et al. (2011) reported on cancers of the stomach, colon, rectum, and pancreas individually, leaving eight deaths from “other GI and digestive cancers” (SIR = 0.73, 95% CI 0.32–1.44). After reporting on cancers of the esophagus, stomach, colon, rectum, and pancreas separately, 5 of 58 digestive cancers remained unidentified in the update on mortality in the Hamburg cohort (Manuwald et al., 2012).

Esophageal Cancer

Epithelial tumors of the esophagus (squamous-cell carcinomas and adenocarcinomas) are responsible for more than 95% of all esophageal cancers (ICD-9 150); 17,460 newly diagnosed cases and 15,070 deaths were estimated for 2012 (Siegel et al., 2012). The considerable geographic variation in the incidence of esophageal tumors suggests a multifactorial etiology. Rates of esophageal cancer have been increasing in the last 2 decades. Adenocarcinoma of the esophagus has slowly replaced squamous-cell carcinoma as the most common type of esophageal malignancy in the United States and western Europe (Blot and McLaughlin, 1999). Squamous-cell esophageal carcinoma rates are higher in blacks than in whites and higher in men than in women. Smoking and alcohol ingestion are associated with the development of squamous-cell carcinoma; these risk factors have been less thoroughly studied for esophageal adenocarcinoma, but they appear to be associated. The rapid increase in obesity in the United States has been linked to increasing rates of gastroesophageal reflux disease (GERD), and the resulting rise in chronic inflammation has been hypothesized as explaining

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

the link between GERD and esophageal adenocarcinoma. The average annual incidence of esophageal cancers is shown in Table 8-4.

Conclusions from VAO and Previous Updates

The committee responsible for VAO explicitly excluded esophageal cancer from the group of gastrointestinal tract tumors, for which it was concluded that there was limited or suggestive evidence of no association with exposure to the herbicides used by the US military in Vietnam. Esophageal cancer was not separately evaluated and was not categorized with this group until Update 2004, so by default it fell into the category of inadequate or insufficient evidence of an association. The committee responsible for Update 2006 concluded that there was not enough evidence on each of the COIs to sustain that negative conclusion for any of the cancers in the gastrointestinal group, and that because these various types of cancer are generally regarded as separate disease entities the evidence on each should be evaluated separately. Esophageal cancer was thus formally placed into the inadequate or insufficient category. No additional studies of esophageal cancer were reviewed in Update 2008.

Update 2010 considered a series of papers on mortality in TCP and PCP workers employed by Dow Chemical Company in Midland, Michigan, from 1937 to 1980. Collins et al. (2009a) followed 1,615 workers who worked at least 1 day in a department that had potential TCDD exposure, among whom five esophageal-cancer deaths were observed, for an SMR of 1.0 (95% CI = 0.3–2.2); none of the five had had concurrent PCP exposure. Collins et al. (2009b) described mortality in 773 PCP workers who were exposed to chlorinated dioxins that did not include TCDD; there were two observed deaths from esophageal cancer (SMR = 0.8, 95% CI 0.1–2.9). McBride et al. (2009a) reported on a mortality followup of the workers in the Dow AgroSciences plant in New Plymouth, New Zealand, who were potentially exposed to TCDD. The SMR for esophageal-cancer deaths in exposed workers was 2.5 (95% CI 0.7–6.4) compared with an SMR of 2.1 (95% CI 0.1–12.2) in the never-exposed group. In following up cancer incidence in the men and women exposed to dioxin in the Seveso accident, Pesatori et al. (2009) observed no esophageal cancers in the high-exposure zone and no exposure-related pattern in the occurrence of esophageal cancer in the moderate- and low-exposure areas.

Table 8-5 summarizes the results of the relevant studies concerning esophageal cancer.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veterans studies or environmental studies of exposure to the COIs and esophageal cancer have been published since Update 2010.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-5 Selected Epidemiologic Studies—Esophageal Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    61.2 (0.4–4.0)Boehmer et al., 2004
State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

    90.9 (0.4–1.6)Visintainer et al., 1995
International Studies of Vietnam Veterans

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  701.2 (0.9–1.5)ADVA,

Navy

  191.6 (0.9–2.4)2005a

Army

  401.1 (0.7–1.4)

Air Force

  111.5 (0.8–2.8)

Mortality

All branches, return–2001

  671.1 (0.8–1.3)ADVA,

Navy

  131.0 (0.5–1.7)2005b

Army

  421.0 (0.7–1.3)

Air Force

  121.5 (0.8–2.6)

1980–1994

  231.2 (0.7–1.7)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence

1982–2000

    91.9 (0.6–6.6)ADVA, 2005c

Mortality

1966–2001

  101.3 (0.5–3.6)ADVA, 2005c

1982–1994

    11.3 (0.0– > 10)CDVA, 1997b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1939–1992

  281.0 (0.7–1.4)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  201.3 (0.8–1.9)

7,553 not exposed to highly chlorinated PCDDs

    60.5 (0.2–1.1)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991
    80.6 (0.3–1.2)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    80.9 (0.4–1.9)Coggon et al., 1986

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007 (ICD-9 150)

Manuwald et al., 2012

Men

  112.6 (1.3–4.6)

Women

    0nr

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    42.5 (0.7–6.4)

Never-exposed workers

    12.1 (0.1–12.2)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    22.0 (0.2–7.0)’t Mannetje et al., 2005

Phenoxy herbicide sprayers (> 99% men)

    10.7 (0.0–4.0)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

Collins et al., 2009a

Trichlorophenol workers

    51.0 (0.3–2.2)

Pentachlorophenol workers

    20.8 (0.1–2.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    81.0 (0.4–2.0)

PCP and TCP (n = 720)

    20.8 (0.1–3.0)

PCP (no TCP) (n = 1,402)

    61.1 (0.4–2.3)
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  270.7 (0.4–1.0)

Ever

  260.8 (0.5–1.2)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

  320.4 (p < 0.05)

Employee

  130.9 (nr)

Women

Self-employed

    11.4 (nr)

Employee

    20.4 (nr)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

    31.6 (0.3–4.6)Asp et al.,

Mortality 1972–1989

    21.3 (0.2–4.7)1994

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 385 incident esophageal cancer cases vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides
    41.8 (0.7–4.8)

Aged 20–59

    11.6 (0.2–11.3)

Aged ≥ 60

    31.9 (0.6–5.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Sawmill workers (n = 139)

Herbicides, chlorophenols
    20.7 (0.2–2.9)

SWEDEN

Incidence cancer cases 1961–1973 with agriculture as economic activity in 1960 census (male, female)

16999% CI 0.6 (0.5–0.7)Wiklund et al., 1983

UNITED STATES

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

    520.6 (0.5–0.9)

Commercial applicators

    2nr

Spouses

    2nr

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  480.5 (0.4–0.7)

Spouses (n = 676)

    3nr

Enrollment through 2000, vs state rates Private applicators (men and women) Spouses of private applicators (> 99% women)

Blair et al., 2005a
  160.5 (0.3–0.9)
    10.3 (0.1–1.9)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    0Pesatori

Zone B

    10.3 (0.0–1.9)et al., 2009

Zone R

  351.3 (0.9–1.9)
CASE-CONTROL STUDIES

US Case-Control Studies

Nebraska—agricultural pesticide use and adenocarcinoma of the esophagus

Phenoxy herbicides, 2,4-DLee et al., 2004a
137
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed
Casesb
Exposure of Interest/Estimated Relative Risk (95% CI)bReference

Insecticides

0.7 (0.4–1.1)

Herbicides

0.7 (0.4–1.2)

International Case-Control Studies

UK men, 18–35 yrs of age from counties with particular chemical manufacturing—mortality

Herbicides, chlorophenolsMagnani et al., 1987

Herbicides

  nr1.6 (0.7–3.6)

Chlorophenols

  nr1.2 (0.7–2.2)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DCP, 2,4-dichlorophenol; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2 methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PM, proportionate mortality; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCP, pentachlorophenol; TCDD, 2,3,7,8-tetra-chlorodibenzo-p-dioxin; TCP, trichlorophenol.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Occupational Studies Starting with a set of 1,316 in 2,4-D-exposed workers, Burns et al. (2011) identified cancer cases through 2007 in the Michigan’s cancer registry from its start in 1985. The analysis of the third (and most stringently defined in terms of continued residence in Michigan) of the nested cohorts of workers included 1,108 men who were employed in a Dow facility in Midland during 1945–1994 and were alive on January 1, 1985. Esophageal cancers were not reported separately and so would have fallen in the category of “other GI and digestive cancers,” in which there were eight cases (SIR = 1.02, 95% CI 0.44–2.02).

Manuwald et al. (2012) reported mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment at the plant, and vital status was sought through 2007. No deaths from esophageal cancer in female workers were reported, but esophageal-cancer mortality relative to that in the population of Hamburg was increased in men (SMR = 2.56, 95% CI 1.27–4.57).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. In the total cohort, eight deaths were attributed to esophageal cancer; that is consistent with the mortality experience of the US population (SMR = 0.99, 95% CI 0.43–1.96). There were two deaths in the PCP-plus-TCDD group, not more than expected (SMR = 0.82, 95% CI 0.10–2.95). The results were effectively the same in the 1,402 workers who had not had any opportunity for occupational exposure to TCDD (SMR = 1.07, 95% CI 0.39–2.33).

The participants in the AHS are known to have had extensive exposure to the phenoxy herbicides, but the analyses of updated mortality (Waggoner et al., 2011) and cancer incidence (Koutros et al., 2010a) address only exposure to pesticides in general. Waggoner et al. (2011) reported lower numbers of deaths from cancer of the esophagus than expected on the basis of state rates in the applicators (SMR = 0.51, 95% CI 0.38–0.68). Only three cases of espophageal cancer were observed in the spouses. In the update of cancer incidence through 2006, Koutros et al. (2010a) found a significant decrease in the incidence of esophageal cancer in the private applicators (52 cases, SIR = 0.64, 95% CI 0.48–0.85). Only two cases of esophageal cancer were observed in the spouses. The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies Meyer et al. (2011) conducted a case-control study of esophageal cancer in Brazilians in which occupation was obtained from death certificates. Being an agricultural worker was used as a surrogate for pesticide exposure, so exposure specificity was inadequate for the purpose of this review.

Biologic Plausibility

Long-term animal studies have examined the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004), and no increase in the incidence of esophageal cancer has been reported in laboratory animals after exposure to them. A previous biomarker study analyzed esophageal-cell samples from patients who had been exposed to indoor air pollution of different magnitudes and did or did not have high-grade squamous-cell dysplasia or a family history of upper gastrointestinal-tract (UGI) cancer (Roth et al., 2009). AHR expression was higher in patients who had a family history of UGI cancer but was not associated with indoor air pollution, esophageal squamous-cell dysplasia category, age, sex, or smoking. The results suggest that enhanced expression of the AHR in patients who had a family his-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

tory of UGI cancer may contribute to UGI-cancer risk associated with AHR ligands—such as polycyclic aromatic hydrocarbons, which are found in cigarette smoke—and with TCDD.

In a small series, AHR expression was found to be higher in esophageal tumors than in corresponding normal mucosa (Zhang et al., 2012).

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Manuwald et al. (2012) reported a significant increase in mortality from esophageal cancer in the men in the Hamburg cohort of phenoxy-herbicide workers. In combination with the studies reviewed previously, however, that single new finding did not provide adequate evidence to establish an association between exposure to the COIs and esophageal cancer. No toxicologic studies provide evidence of the biologic plausibility of an association between the COIs and tumors of the esophagus.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and esophageal cancer.

Stomach Cancer

The incidence of stomach cancer (ICD-9 151) increases with age. ACS estimated that 13,020 men and 8,300 women would receive diagnoses of stomach cancer in the United States in 2012 and that 6,190 men and 4,350 women would die from it (Siegel et al., 2012). In general, the incidence is higher in men than in women and higher in blacks than in whites. Other risk factors include family history of this cancer, some diseases of the stomach, and diet. Infection with Helicobacter pylori increases the risk of stomach cancer. Tobacco use and consumption of nitrite- and salt-preserved food may also increase the risk (Brenner et al., 2009; Key et al., 2004; Miller et al., 1996). The average annual incidence of stomach cancer is shown in Table 8-4.

Conclusions from VAO and Previous Updates

Update 2006 considered stomach cancer independently for the first time. Prior updates developed a table of results for stomach cancer but drew conclusions about the adequacy of the evidence of its association with herbicide expo-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

sure in the context of gastrointestinal tract cancers. The committee responsible for VAO concluded that there was limited or suggestive evidence of no association between exposure to the herbicides used by the US military in Vietnam and gastrointestinal tract tumors, including stomach cancer. The committee responsible for Update 2006 concluded that there was not enough evidence on each of the COIs to sustain that negative conclusion for any of the cancers in the gastrointestinal group and that, because these various types of cancer are generally regarded as separate disease entities, the evidence on each should be evaluated separately. Stomach cancer was thus reclassified into the default category of inadequate or insufficient evidence to determine whether there is an association.

Positive findings of an association with phenoxy-herbicide exposure from a well-conducted nested case-control study of stomach cancer in the United Farm Workers of America cohort (Mills and Yang, 2007) led the committee responsible for Update 2008 to reconsider the results of several earlier studies. Reif et al. (1989) reported a significant relationship between stomach cancer and the nonspecific exposure of being a forestry worker. Cocco et al. (1999) had found an association with herbicide exposure but had not analyzed specific chemicals, and Ekström et al. (1999) found significant associations between the occurrence of stomach cancer and exposure to phenoxy herbicides in general and to several specific phenoxy-herbicide products. In updated mortality findings from Seveso concerning TCDD exposure, Consonni et al. (2008) found no increases in deaths from stomach cancer. In the absence of supportive findings from studies of Vietnam-veteran cohorts or IARC cohorts or from the US AHS, that committee retained stomach cancer in the inadequate or insufficient category.

Between Update 2008 and Update 2010, studies of three occupational cohorts and two environmental-study populations were published. In examining mortality in workers employed by Dow Chemical Company in Midland, Michigan, during 1937–1980, Collins et al. (2009a) observed eight cases of stomach cancer in 1,615 TCP workers (SMR = 1.4, 95% CI 0.6–2.7) and four deaths from stomach cancer in 773 PCP workers (SMR = 1.2, 95% CI 0.3–3.1). McBride et al. (2009a) reported on mortality in workers in the Dow AgroSciences plant in New Plymouth, New Zealand, who were potentially exposed to TCDD; mortality from stomach cancer was somewhat higher in the never-exposed group (SMR = 2.3, 95% CI 0.3–8.4) than in exposed workers (SMR = 1.4, 95% CI 0.4–3.6). In the third followup of a retrospective cohort study of two Dutch chlorophenoxyherbicide manufacturing factories, Boers et al. (2010) found that neither had increased mortality from stomach cancer. An update of cancer incidence in the Seveso cohort (Pesatori et al., 2009) found no evidence of an increase in stomach cancer. In a second environmental study, Turunen et al. (2008) assessed mortality in Finnish fishermen and their wives, presuming that their mortality would reflect their high consumption of contaminated fish; death from stomach cancer was not increased.

Table 8-6 summarizes the results of the relevant studies concerning stomach cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-6 Selected Epidemiologic Studies—Stomach Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

1982–2003—White SEA comparison veterans only (n = 1,482). Serum TCDD (pg/g) based on model with exposure variable loge(TCDD)

Pavuk et al., 2005

Per unit increase of –loge(TCDD) (pg/g) Quartiles (pg/g):

  241.8 (0.8–3.9)

0.4–2.6

    4nr

2.6–3.8

    31.0 (0.2–4.8)

3.8–5.2

    72.0 (0.5–8.2)

> 5.2

  103.3 (0.9–12.5)

Number of years served in SEA (per year of service)

Quartiles (years in SEA):

  241.2 (1.0–1.4)

0.8–1.3

    4nr

1.3–2.1

    41.0 (0.2–3.8)

2.1–3.7

    51.1 (0.3–4.2)

3.7–16.4

  112.1 (0.6–7.3)

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  160.6 (0.4–1.0)

With tours between 1966–1970

  140.6 (0.4–1.1)

SEA comparison veterans (n = 1,776)

  310.9 (0.6–1.2)

With tours between 1966–1970

  240.9 (0.6–1.3)

Mortality

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

    60.4 (0.2–0.9)

SEA comparison veterans (n = 1,776)

  140.7 (0.4–1.1)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    5nrBoehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1965–1982

Breslin

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  881.1 (0.9–1.5)et al., 1988

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  170.8 (0.4–1.6)
State Studies of US Vietnam Veterans

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    1nrAnderson et al., 1986
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

1040.9 (0.7–1.1)ADVA,

Navy

  281.1 (0.7–1.6)2005a

Army

  660.9 (0.7–1.1)

Air Force

  100.7 (0.3–1.3)

Mortality

All branches, return–2001

  760.9 (0.7–1.2)ADVA,

Navy

  221.3 (0.8–1.8)2005b

Army

  500.9 (0.7–1.2)

Air Force

    40.4 (0.1–1.0)

1980–1994

  321.1 (0.7–1.4)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence

1982–2000

  110.6 (0.2–1.2)ADVA, 2005c

Mortality

1966–2001

    70.7 (0.2–2.0)ADVA, 2005c

1982–1994

    41.7 (0.3– > 10)CDVA, 1997b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality ratesPhenoxy herbicides, chlorophenols

Mortality 1939–1992

  720.9 (0.7–1.1)Kogevinas

13,831 exposed to highly chlorinated PCDDs

  420.9 (0.7–1.2)et al., 1997

7,553 not exposed to highly chlorinated PCDDs

  300.9 (0.6–1.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Nested case-control study

  400.9 (0.6–1.2)

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates

TCDDKogevinas et al, 1993
    11.4 (nr)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

  260.9 (0.6–1.3)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982

Lynge, 1985

Men

  121.3 (nr)

Women

    10.7 (nr)

Mortality 1955–2006

  141.1 (0.8–1.5)Boers et al., 2012

TCDD plasma level (hazard ratios, by tertile)

Background (≤ 0.4)

    8

Low (0.4–1.9)

    10.1 (0.0–1.0)

Medium (1.9–9.9)

    20.5 (0.1–2.6)

High (≥ 9.9)

    32.5 (0.7–9.2)

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (HRs for lagged TCDD plasma levels)

    61.5 (1.1–2.2)Boers et al., 2012

Mortality 1955–2006

    52.2 (0.4–13.2)Boers et al. 2010

Mortality 1955–1991

    31.0 (0.2–2.9)Hooiveld et al., 1998

Mortality 1955–1985

    20.9 (0.1–3.4)Bueno de Mesquita et al., 1993

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

    41.2 (0.3–4.7)Boers et al., 2010
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1965–1986

    00.0 (0.0–6.5)Bueno de Mesquita et al., 1993

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0nrBecher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0nrBecher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    20.6 (0.1–2.3)Becher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992

    31.0 (0.2–2.9)Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    00.0 (0.0–3.4)

TCDD 0.1–0.99 μg/kg of body weight

    11.3 (0.0–7.0)

TCDD > 1 μg/kg of body weight

    21.7 (0.2–6.2)

Mortality

Through 1987

90% CIZober et al., 1990
    33.0 (0.8–7.7)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007 (ICD-9 140–149)

  171.0 (0.6–1.6)Manuwald et al., 2012

Men

  171.3 (0.7–2.0)

Women

    0nr

Mortality 1952–1989

  121.3 (0.7–2.2)Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1996

  121.2 (0.6–2.1)Manz et al., 1991

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    41.4 (0.4–3.6)

Never-exposed workers

    22.3 (0.3–8.4)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    21.1 (0.1–4.0)’t Mannetje et al., 2005

Phenoxy herbicide sprayers (> 99% men)

    31.4 (0.3–4.0)

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  131.0 (0.6–1.8)Steenland et al., 1999

Through 1987

    101.0 (0.5–1.9)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    41.4 (0.4–3.5)

Mortality—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991)

    00.0 (0.0–1.1)Collins et al., 1993

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    81.4 (0.6–2.7)Collins et al., 2009a

1940–1994 (n = 2,187 men)

  nr1.5 (0.7–2.7)Bodner et al., 2003

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    90.9 (0.4–1.7)

PCP and TCP (n = 720)

    31.0 (0.2–2.9)

PCP (no TCP) (n = 1,402)

    60.8 (0.3–1.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    30.8 (0.2–2.3)Burns et al., 2011

Through 1994 (n = 1,517) (digestive organs, peritoneum)

  160.7 (0.4–1.2)Burns et al., 2001

Through 1982 (n = 878)

    0nr (0.0–3.7)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP) Mortality 1940–1989 (n = 770)

    41.2 (0.3–3.1)Collins et al., 2009b Ramlow et al., 1996

0-yr latency

    41.7 (0.5–4.3)

15-yr latency

    31.8 (0.4–5.2)
Other Studies of Industrial Workers (not related to IARC or NIOSH phenoxy cohorts)Dioxins, phenoxy herbicides

1,412 white male US flavor and fragrance chemical plant workers (1945–1965)

Dioxin, 2,4,5-TExpected exposedThomas, 1987
    6cases
4.2
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries,

McLean et al., 2006

TCDD among 27 agents assessed by JEM

Exposure to nonvolatile organochlorine compounds

Never

1460.9 (0.8–1.1)

Ever

  980.9 (0.7–1.1)

14,362 Danish paper workers employed 1943–1990, followed through 1993

Rix et al., 1998

Men

  481.1 (0.8–1.4)

Women

    71.0 (0.4–2.1)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    51.2 (0.4–2.8)Henneberger et al., 1989

Pulp and Paper cohorts independent of IARC cohort

United Paperworkers International, 201 white men employed ≥ 10 yrs and dying 1970–1984

    10.5 (0.1–3.0)Solet et al., 1989
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

  1790% CI 1.2 (0.8–1.9)Robinson et al., 1986
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from stomach cancer June 1971–December 1987

Linkage of records for ~70,000 male Saskatchewan farmers (1971–1985)

2460.9 (0.8–1.0)Wigle et al., 1990

DENMARK

Danish farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

2860.9 (nr)

Employee

  711.2 (nr)

Women

Self-employed

    51.0 (nr)

Employee

    51.7 (nr)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

1260.7 (0.6–0.9)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
  391.0 (0.7–1.3)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident stomach cancer cases vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides
  132.2 (1.3–3.9)

Aged 20–59

    30.7 (0.2–2.2)

Aged ≥ 60

  102.4 (1.2–4.5)

Sawmill workers (n = 139)

Herbicides, chlorophenols
    71.0 (0.4–2.1)

SWEDEN

348 Swedish railroad workers (1957–October, 1978)—total exposure to herbicides

Phenoxy acidsAxelson et al., 1980
    32.2 (nr)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Incident stomach cancer cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
2,5991.1 (1.0–1.2)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000 (stomach, small intestine)

    30.4 (0.1–1.3)Swaen et al., 2004

Through 1987 (stomach, small intestine)

    10.5 (0.0–2.7)Swaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

6571.0 (1.0–1.1)

Nonwhites (n = 11,446)

1151.1 (0.9–1.3)

Women

Whites (n = 2,400)

  121.2 (0.6–2.0)

Nonwhites (n = 2,066)

  231.9 (1.2–2.8)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  610.9 (0.7–1.1)

Commercial applicators

    2nr

Spouses

  150.9 (0.5–1.5)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

4620.8 (0.8–0.9)

Spouses of private applicators (> 99% women)

1610.9 (0.7–1.0)

Commercial applicators

  241.0 (0.6–1.4)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  260.5 (0.3–0.8)

Spouses (n = 676)

    50.4 (0.1–1.0)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

  100.5 (0.2–1.0)
    41.1 (0.3–2.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

California United Farm Workers of America

2,4-D

Nested case-control study of agricultural exposure and gastric cancer in UFW cohort

Mills and Yang, 2007

Ever worked in area where 2,4-D used Quartile of lifetime exposure to 2,4-D (lb)

  421.9 (1.1–3.3)

0

  581.0

1–14

  172.2 (1.0–4.6)

15–85

  141.6 (0.7–3.5)

85–1,950

  112.1 (0.9–5.1)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of stomach cancer

Herbicides

Agricultural extension agents

  100.7 (0.4–1.4)Alavanja et al., 1988

Forest conservationists

p-trend < over years workedAlavanja et al., 1989
    90.7 (0.3–1.3)

Soil conservationists

Florida pesticide applicators licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Expected exposed cases
    43.3

White Male Residents of Iowa—stomach cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 30 yrs old when died 1964–1978—case-control

1,8121.3 (p < 0.05)Burmeister et al., 1983

H0: only for “modern methods” → born after 1900

Born before 1880

4581.3 (p < 0.05)

Born 1980–1900

6391.3 (p < 0.05)

Born after 1900

7151.3 (p < 0.05)

> 20 yrs old when died 1971–1978—PMR

3381.1 (p < 0.01)Burmeister, 1981

ENVIRONMENTAL

Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)

TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    30.9 (0.3–2.7)Pesatori

Zone B

  190.9 (0.6–1.4)et al., 2009
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Zone R

1310.8 (0.7–1.0)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone B

    71.0 (0.5–2.1)

Zone R

  450.9 (0.7–1.2)

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone B

    20.6 (0.2–2.5)

Zone R

  251.0 (0.6–1.5)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    30.7 (0.2–2.0)

Zone B

  240.8 (0.5–1.2)

Zone R

2121.0 (0.8–1.1)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A and B—men

  160.9 (0.5–1.5)

Zones A and B—women

  111.0 (0.6–1.9)

15-yr followup to 1991—men

Bertazzi et al., 1997, 1998

Zone B

  100.8 (0.4–1.5)

Zone R

  760.9 (0.7–1.1)

15-yr followup to 1991—women

Bertazzi et al., 1997, 1998

Zone A

    10.9 (0.0–5.3)

Zone B

    71.0 (0.4–2.1)

Zone R

  581.0 (0.8–1.3)

10-yr followup to 1986—men

Bertazzi et al., 1989a

Zone A, B, R

  400.8 (0.6–1.2)

10-yr followup to 1986—women

Bertazzi et al., 1989a

Zone A, B, R

  221.0 (0.6–1.5)

10-yr followup to 1986—men

Bertazzi et al., 1989b

Zone B

  71.2 (0.6–2.6)

Ecological Study of Residents of Chapaevsk, Russia

DioxinRevich et al., 2001

Incidence—Crude incidence rate in 1998 vs

Men

Regional (Samara)

nr44.0 (nr)

National (Russia)

nr48.1 (nr)

Women

Regional (Samara)

nr17.6 (nr)

National (Russia)

nr20.7 (nr)

Mortality—1995–1998 (SMR vs regional rates)

Men

  591.7 (1.3–2.2)

Women

  450.7 (0.5–0.9)

FINLAND

Finnish fishermen (n = 6,410) and spouses (n = 4,260) registered between 1980 and 2002 compared to national statistics

Serum dioxinTurunen et al., 2008

Fisherman

  160.8 (0.5–1.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Spouses

    20.3 (0.0–1.1)

JAPAN

Residents of municipalities with and without waste incineration plants (cross-sectional)

Dioxin emissions age-adjusted mortality (per 100,000)Fukuda et al., 2003

Men

With

38.2 ± 7.8 vs 39.0 ± 8.8 (p = 0.29)

Without

Women

With

20.7 ± 5.0 vs 20.7 ± 5.8 (p = 0.92)

Without

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

  241.6 (1.0–2.4)

West coast

  710.9 (0.7–1.2)

Mortality

East coast

  171.4 (0.8–2.2)

West coast

  630.9 (0.7–1.2)
CASE-CONTROL STUDIES

US Case-Control Studies

Eastern Nebraska—population-based case-control, agricultural pesticide use and adenocarcinoma of stomach

Herbicides, pesticidesLee et al., 2004a
170

Insecticides

0.9 (0.6–1.4)

Herbicides

0.9 (0.5–1.4)

International Case-Control Studies

Swedish—population-based case-control study of residents (40–79 yrs of age) with gastric adenocarcinoma (February 1989–January 1995)

Phenoxy herbicidesEkström et al., 1999

All occupational herbicide exposures

  751.6 (1.1–2.2)

Phenoxyacetic acid exposure

  621.8 (1.3–2.6)

   Hormoslyr (2,4-D, 2,4,5-T)

  481.7 (1.2–2.6)

   2,4-D only

    3nr (vs 0 controls)

   MCPA

  111.8 (0.8–4.1)

   Duration of Exposure

      Nonexposed to all herbicides

4901.0

      < 1 month

  111.6 (0.7–3.5)

      1–6 months

  301.9 (1.1–3.2)

      7–12 months

    71.7 (0.6–4.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

      > 1 yr

  131.4 (0.6–3.0)

   Other herbicide exposure

  131.0 (0.5–1.9)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportionate mortality ratio; SEA, Southeast Asia; SIR, standardized incidence ratio; SMR, standardized mortality ratio; TCDD, 2,3,7,8-tetrachlorod-ibenzo-p-dioxin; TCP, trichlorophenol; UFW, United Farm Workers of America; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veteran studies or environmental studies of exposure to the COIs and stomach cancer have been published since Update 2010.

Occupational Studies Burns et al. (2011) published an update examining cancer incidence in 1985–2007 in workers employed in 2,4-D production by Dow Chemical Company in Midland, Michigan, during 1945–1994. There was no evidence of significantly increased rates of cancer overall or of stomach cancer in particular. In the cohort defined most restrictively, the SIR of stomach cancer was 0.8 (95% CI 0.16–2.34), equivalent to the findings in the two more inclusive cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis, updated through 2006, of mortality in male workers in two Dutch phenoxy-herbicide factories, which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination; the 1,036 in factory B had produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. Using the estimated TCDD concentra-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

tions of the workers in both factories did not indicate an increased risk of stomach cancer posed by TCDD (hazard ratio [HR] = 1.06, 95% CI 0.77–1.47). The dose–response modeling applied only to the workers in factory A, however, found a significantly increased risk of stomach cancer (HR = 1.52, 95% CI 1.05–2.20), whereas the qualitative exposure analysis in Boers et al. (2010) had not (HR = 2.23, 95% CI 0.38–13.20).

Manuwald et al. (2012) reported on mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment in the plant, and vital status was sought through 2007. All 17 observed deaths from stomach cancer occurred in the male workers, but relative to the population of Hamburg this did not constitute an increase in stomach-cancer mortality in men (SMR = 1.27, 95% CI 0.74–2.03).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. In the total cohort, nine deaths were attributed to stomach cancer; this was consistent with the mortality experience of the US population (SMR = 0.89, 95% CI 0.40–1.68). There were three stomach-cancer deaths in the PCP-plus-TCDD group—also not more than expected (SMR = 0.98, 95% CI 0.20–2.88). The results were effectively the same in the 1,402 workers in the PCP-only group (SMR = 0.84, 95% CI 0.31–1.84).

The participants in the AHS are known to have had extensive exposure to the phenoxy herbicides, but the analyses of updated mortality (Waggoner et al., 2011) and cancer incidence (Koutros et al., 2010a) address only exposure to pesticides in general. Waggoner et al. (2011) updated mortality in the AHS cohort through 2007. The observed number of deaths from stomach cancer was significantly lower than expected in the applicators (26 deaths, SMR = 0.52, 95% CI 0.34–0.76), as was the case for the five deaths from this type of cancer in their spouses (SMR = 0.42, 95% CI 0.14–0.99). Reporting on cancer incidence through 2006, Koutros et al. (2010a) found 61 cases of oral-cavity and pharyngeal cancers in the private applicators (SIR = 0.86, 95% CI 0.66–1.10) and 15 cases in their spouses (SIR = 0.91, 95% CI 0.51–1.50). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies In a Spanish study, Santibanez et al. (2012) explored the relationship between 399 stomach cancers of varied histology and occupational

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

exposures estimated by application of a job—exposure matrix to work histories. Of chemicals that might have been of interest, only the category of “pesticides” was used, which is not specific enough for the results to be regarded as informative for the present review.

Biologic Plausibility

Long-term animal studies have examined the effect of exposure to the COIs (2,4-D and TCDD) on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). No increase in the incidence of gastrointestinal cancer has been reported in laboratory animals. However, studies of laboratory animals have observed dose-dependent increases in the incidence of squamous-cell hyperplasia of the forestomach or fundus of the stomach after administration of TCDD (Hebert et al., 1990; Walker et al., 2006). Similarly, in a long-term TCDD-treatment study in monkeys, hypertrophy, hyperplasia, and metaplasia were observed in the gastric epithelium (Allen et al., 1977). A transgenic mouse bearing a constitutively active form of the AHR has been shown to develop stomach tumors (Andersson et al., 2002a); the tumors are neither dysplastic nor metaplastic but are indicative of both squamous-cell and intestinal-cell metaplasia (Andersson et al., 2005). The validity of the transgenic-animal model is indicated by the similarities in the phenotype of the transgenic animal (increased relative weight of the liver and heart, decreased weight of the thymus, and increased expression of AHR target gene CYP1A1) and animals treated with TCDD (Brunnberg et al., 2006).

In a biomarker study of cancer patients, AHR expression and nuclear trans-location were significantly higher in stomach-cancer tissue than in precancerous tissue (Peng et al., 2009a). The results suggest that the AHR plays an important role in stomach carcinogenesis. AHR activation in a stomach-cancer cell line (AGS) has also been shown to enhance stomach-cancer cell invasiveness potentially through a c-Jun-dependent induction of matrix metalloproteinase-9 (Peng et al., 2009b).

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Boers et al. (2012) derived a predictive model based on job histories and current TCDD concentrations in a subset of the workers in two Dutch phenoxy-herbicide factories. Using estimates of each man’s serum TCDD at the end of his employment, they found a significant increase in the risk of death from stomach cancer in the workers in the factory that had TCDD contamination, whereas an earlier categorical analysis of the same data found an increase risk with a very wide confidence interval (Boers et al., 2010); when the workers in the factory that did not have TCDD contamination were added to the continuous analysis,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

the risk did not remain significant (Boers et al., 2012). Several case-control studies addressing agricultural exposures reported evidence of an association of stomach cancer: both Ekström et al. (1999) and Mills and Yang (2007) found an association with herbicides, and with phenoxy herbicides in particular; Cocco et al. (1999) found a relationship with herbicide exposure, but the results were not specific as to type of herbicide. There has been no suggestion of an association between TCDD and stomach cancer in the Seveso population (Consonni et al., 2008; Pesatori et al., 2009) nor has there been any suggestion of an association between the COIs and stomach cancer in the studies of Vietnam-veteran cohorts or in the AHS.

There is some evidence of biologic plausibility in animal models, but overall the epidemiologic studies do not support an association between exposure to the COIs and stomach cancer.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and stomach cancer.

Colorectal Cancer

Colorectal cancers include malignancies of the colon (ICD-9 153) and of the rectum and anus (ICD-9 154); less prevalent tumors of the small intestine (ICD-9 152) are often included. Findings on cancers of the retroperitoneum and other unspecified digestive organs (ICD-9 159) are considered in this category. Colorectal cancers account for about 55% of digestive tract tumors; ACS estimated that 157,760 people would receive diagnoses of colorectal cancer in the United States in 2012 and that 53,620 would die from it (Siegel et al., 2012). Excluding basal-cell and squamous-cell skin cancers, colorectal cancer is the third-most common form of cancer both in men and in women. The average annual incidence of colorectal cancers is shown in Table 8-4.

The incidence of colorectal cancer increases with age; it is higher in men than in women and higher in blacks than in whites. (Screening can affect the incidence, and it is recommended for all persons over 50 years old.) Other risk factors include family history of this form of cancer, some diseases of the intestines, and diet. Type 2 diabetes is associated with an increased risk of colorectal cancer (ACS, 2013a).

Conclusions from VAO and Previous Updates

Update 2006 considered colorectal cancer independently for the first time. Prior updates developed tables of results on colon and rectal cancer, but conclus-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

ions about the adequacy of the evidence of their association with herbicide exposure had been reached only in the context of gastrointestinal tract cancers. The committee responsible for VAO concluded that there was limited or suggestive evidence of no association between exposure to the herbicides used by the US military in Vietnam and gastrointestinal tract tumors, including colorectal cancer. The committee responsible for Update 2006 concluded that there was not enough evidence on each of the COIs to sustain that negative conclusion for any of the cancers in the gastrointestinal group and that, because these various types of cancer are generally regarded as separate disease entities, the evidence on each should be evaluated separately. Colorectal cancer was thus reclassified into the default category of inadequate or insufficient evidence to determine whether there is an association. The information considered in Update 2008 did not provide evidence to support moving colorectal cancers out of the category of inadequate or insufficient evidence.

The new information considered in Update 2010 also did not provide evidence to suggest that colorectal cancers be moved out of the category of inadequate or insufficient evidence. Collins et al. (2009a) found no increase of deaths from colorectal cancer in PCP workers in a Dow Chemical Company plant in Midland, Michigan, compared with the general US population and the state of Michigan. In a followup study of workers in the Dow AgroSciences plant in New Plymouth, New Zealand, McBride et al. (2009a) did not find an increased SMR for colorectal-cancer deaths in the workers who were exposed to TCDD compared with the never-exposed group. In updating cancer incidence in the Seveso population (males and females combined), Pesatori et al. (2009) found no cases of rectal cancer and a lower risk of colon cancer in the high-exposure zone than in the moderate- and low-exposure zones. Turunen et al. (2008) assessed mortality in Finnish fishermen and their wives and presumed that their high consumption of fish would result in harmful exposure to dioxin-like chemicals, but found no increase in mortality from colon, rectal, or anal cancer in this cohort relative to control populations.

Table 8-7 summarizes the results of the relevant studies concerning colon and rectal cancers.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and colorectal cancer have been published since Update 2010.

Occupational Studies Burns et al. (2011) updated, through 2007, cancer incidence in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-7 Selected Epidemiologic Studies—Colon and Rectal Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS US Vietnam Veterans

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    91.0 (0.4–2.6)Boehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982 (Colon, other gastrointestinal, ICD-8 152–154, 158, 159)

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

2091.0 (0.7–1.3)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  331.3 (0.7–2.2)

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality

Through 2004

Cypel and Kang, 2008

US Vietnam veterans

  110.5 (0.2–1.0)

Vietnam-veteran nurses—colon

    90.6 (0.2–1.4)

Through 1991

Dalager et al., 1995

US Vietnam veterans

    40.4 (0.1–1.2)

Vietnam-veteran nurses—colon

    40.5 (0.2–1.7)

State Studies of US Vietnam Veterans

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

Anderson et al., 1986

Colon

    61.0 (0.4–2.2)

Rectum

    1nr

International Studies of Vietnam-Veterans

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

Colon—All branches, 1982–2000

3761.1 (1.0–1.2)ADVA,

Navy

  911.3 (1.0–1.5)2005a

Army

2391.1 (0.9–1.2)

Air Force

  471.1 (0.8–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1939–1992

Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

Colon

  861.1 (0.9–1.3)

Rectum

  441.1 (0.8–1.4)

7,553 not exposed to highly chlorinated

PCDDs

Colon

  521.0 (0.8–1.3)

Rectum

  291.3 (0.9–1.9)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Nested case-control study

Colon (except rectum)

  411.1 (0.8–1.5)

Rectum

  241.1 (0.7–1.6)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPACoggon et al., 1986

Mortality through 1983

Colon

  191.0 (0.6–1.6)

Rectum

    80.6 (0.3–1.2)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982

Lynge, 1985

Men

Colon

  101.0 (nr)

Rectum

  141.4 (nr)

Women

Colon

    10.3 (nr)

Rectum

    21.0 (nr)

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–1991

Hooiveld et al., 1998

Colon

    31.4 (0.3–4.0)

Rectum

    11.0 (0.0–5.6)

Mortality 1955–1985

Bueno de

Large intestine, except colon

    32.4 (0.5–7.0)Mesquita et al., 1993

Rectum

    00.0 (0.0–5.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–1986

    31.8 (0.4–5.4)Bueno de Mesquita et al., 1993

Large intestine, except rectum

    00.0 (0.0–9.5)

Rectum

    00.0 (0.0–19.4)

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

Becher et al., 1996

Colon

    0nr

Rectum

    0nr

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

Becher et al., 1996

Colon

    12.2 (0.1–2.2)

Rectum

    0nr

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

Becher et al., 1996

Colon

    0nr

Rectum

    10.9 (0.0–4.9)

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992—colorectal

    51.0 (0.3–2.3)Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    21.1 (0.1–3.9)

TCDD 0.1–0.99 μg/kg of body weight

    21.4 (0.2–5.1)

TCDD > 1 μg/kg of body weight

    10.5 (0.0–3.0)

Mortality

Through 1987—colon, rectum

90% CIZober et al., 1990
    22.5 (0.4–7.8)

Through 1970—(n = 74; 70 initially exposed, 4 involved with cleaning and testing procedures)

    10.4 (nr)Theiss et al., 1982
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007 (ICD-9 140–149)

Manuwald et al., 2012

Colon (ICD-9 153)

  120.7 (0.4–1.3)

Men

    70.6 (0.3–1.3)

Women

    50.9 (0.3–2.1)

Rectum, rectosigmoid junction, anus (ICD-9 154)

  131.7 (0.9–2.9)

Men

  112.0 (0.98–3.5)

Women

    21.0 (0.1–3.7)

Mortality 1952–1989

Becher et al., 1996

Colon

    20.4 (0.1–1.4)

Rectum

    61.9 (0.7–4.0)

Mortality 1952–1989—stats on men only, 1,184 (tables for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966)

Manz et al., 1991

Colon

    80.9 (0.4–1.8)

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Large intestine

Ever-exposed workers

    30.6 (0.1–1.7)

Never-exposed workers

    00.0 (0.0–2.0)

Rectum

Ever-exposed workers

    62.0 (0.7–4.4)

Never-exposed workers

    22.1 (0.3–7.7)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

’t Mannetje

Phenoxy herbicide producers (men and women)

et al., 2005

Colon

    20.6 (0.0–2.3)

Rectum, rectosigmoid junction, anus

    52.5 (0.8–5.7)

Phenoxy herbicide sprayers (> 99% men)

Colon

    81.9 (0.8–3.8)

Rectum, rectosigmoid junction, anus

    41.5 (0.4–3.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

Steenland et al., 1999

Small intestine, colon

  341.2 (0.8–1.6)

Rectum

    60.9 (0.3–1.9)

Through 1987

Fingerhut et al., 1991

Entire NIOSH cohort

Small intestine, colon

  251.2 (0.8–1.8)

Rectum

    50.9 (0.3–2.1)

≥ 1-year exposure, ≥ 20-year latency

Small intestine, colon

  131.8 (1.0–3.0)

Rectum

    21.2 (0.1–4.2)

Mortality, colon cancer—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991)

    30.5 (0.1–1.3)Collins et al., 1993

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

Collins et al., 2009a

Large intestine

  181.2 (0.7–1.8)

Rectum

    20.6 (0.1–2.1)

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

Intestine (ICD-9 152–153)

1940–2005 (n = 2,122)

  261.1 (0.7–1.6)

PCP and TCP (n = 720)

  111.4 (0.7–2.6)

PCP (no TCP) (n = 1,402)

  150.9 (0.5–1.5)

Rectum (ICD-9 154)

1940–2005 (n = 2,122)

    20.4 (0.0–1.3)

PCP and TCP (n = 720)

    10.5 (0.0–3.0)

PCP (no TCP) (n = 1,402)

    10.3 (0.0–1.5)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

Burns et al., 2011

Colon

  161.0 (0.6–1.6)

Rectum

    60.8 (0.3–1.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Pulp and Paper cohorts independent of IARC cohort

United Paperworkers International, 201 white men employed ≥ 10 yrs and dying 1970–1984

Solet et al., 1989

Colon

    71.5 (0.6–3.0)

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

Robinson et al., 1986

Intestines (ICD-7 152, 153)

    70.4 (0.2–0.7)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

   

Colon

2770.7 (p < 0.05)
   

Rectum

3090.8 (p < 0.05)

Employee

   

Colon

  450.6 (p < 0.05)
   

Rectum

  550.8 (nr)

Women

Self-employed

   

Colon

  140.9 (nr)
   

Rectum

    50.6 (nr)

Employee

   

Colon

1120.9 (nr)
  

Rectum

  550.8 (nr)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

Torchio et al., 1994

Colon

  840.6 (0.5–0.7)

Rectum

nrnr

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997

Intestines

  271.1 (0.7–1.6)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident cancer cases (colon, rectum, or small intestine) vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides

Colon

    70.5 (0.2–1.1)

Rectum

  101.2 (0.6–2.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Colon

Private applicators

3390.9 (0.8–1.0)

Commercial applicators

  171.0 (0.6–1.6)

Spouses

1440.8 (0.7–1.0)

Rectum

Private applicators

1170.9 (0.7–1.1)

Commercial applicators

    81.2 (0.5–2.3)

Spouses

  300.7 (0.5–1.0)

Enrollment through 2005—Interactions between dicamba and body mass index

Andreotti et al., 2010

Trend (with dicamba use reported)

  961.1 (1.0–1.1)

Trend (with no dicamba use reported)

1021.0 (1.0–1.1)

Enrollment through 2005—colorectal cancer

Lee WJ et al., 2007

2,4-D

2040.7 (0.5–0.9)

2,4,5-T

  650.9 (0.7–1.2)

2,4,5-TP

  240.8 (0.5–1.2)

Dicamba

1100.9 (0.7–1.2)

Enrollment through 2002—colon cancer

Samanic et al., 2006

Dicamba—lifetime days exposure

None

  761.0

1– < 20

    90.4 (0.2–0.9)

20– < 56

  200.9 (0.5–1.5)

56– < 116

  130.8 (0.4–1.5)

≥ 116

  171.4 (0.8–2.9)
p-trend = 0.10

Dicamba—intensity-weighted quartiles

None

  761.0

Lowest

  160.6 (0.4–1.1)

Second

  170.7 (0.4–1.2)

Third

    60.5 (0.2–1.2)

Highest

  201.8 (1.0–3.1)
p-trend = 0.02

Enrollment through 2002

Alavanja et al., 2005

Colon

Private applicators (men, women)

2080.9 (0.8–1.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Spouses of private applicators (> 99% women)

  870.9 (0.7–1.1)

Commercial applicators (men, women)

  120.2 (0.6–2.1)

Rectum

Private applicators (men, women)

  940.8 (0.7–1.0)

Spouses of private applicators (> 99% women)

  230.6 (0.4–0.9)

Commercial applicators (men, women)

    71.3 (0.5–2.6)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Intestine

Applicators (n = 1,641)

1580.8 (0.6–0.9)

Spouses (n = 676)

  680.9 (0.7–1.1)

Rectum

Applicators (n = 1,641)

  320.7 (0.5–1.0)

Spouses (n = 676)

    4nr

Enrollment through 2000, vs state rates

Blair et al., 2005a

Colon

Private applicators (men, women) Spouses of private applicators (> 99% women)

  560.7 (0.6–1.0)
  31
1.2 (0.8–1.6)

Rectum

Private applicators (men, women) Spouses of private applicators (> 99% women)

nrnr
nrnr

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of cancer

Herbicides

Agricultural extension agents

Alavanja et al., 1988

Colon

  411.0 (0.7–1.5)

Rectum

    5nr

Forest conservationists

p-trend < over years worked
Alavanja et al., 1989

Colon

  441.5 (1.1–2.0)

Rectum

    91.0 (0.5–1.9)

Soil conservationists

Florida Licensed Pesticide Applicators [common phenoxy use assumed but not documented; had been listed by Blair et al., 1983]

Herbicides

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Colon

    50.8 (nr)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
CASE-CONTROL STUDIES

International Case-Control Studies

421 Egyptian colorectal cancer cases and 439 hospital controls

nrHerbicides 5.5 (2.4–12.3)Lo et al., 2010

Swedish patients (1970–1977)

Phenoxy acids, chlorophenolsHardell, 1981

Colon

Exposed to phenoxy herbicides

  111.3 (0.6–2.8)

Exposed to chlorophenols

    61.8 (0.6–5.3)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,4,5-TP, 2-(2,4,5-trichlorophenoxy) propionic acid; 2,5-DCP, 2,5-dichlorophenol; AFHS, Air Force Health Study; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportionate mortality ratio; SIR, standardized incidence ratio; SMR, standardized mortality ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cancer overall. In the most restrictively defined cohort, the SIR for colon cancer was 0.95 (95% CI 0.55–1.55), and the SIR for rectal cancer was 0.78 (95% CI 0.29–1.70). For both cancer types, the results were similar in the two more inclusive, but potentially more biased, cohorts.

Manuwald et al. (2012) reported a 23-year update of mortality in a cohort of chemical workers in Hamburg, Germany, who were exposed to dioxin. Compared to national rates, male workers had an increase in mortality from rectal cancer (SMR = 1.95, 95% CI 0.98–3.51) but not from colon cancer (SMR = 0.64, 95% CI 0.26–1.32). An increase in colorectal-cancer deaths was not seen in exposed women (SMR = 0.90, 95% C.I 0.29–2.12 for colon cancer and SMR = 1.01, 95% CI 0.11–3.65 for rectal cancer).

Ruder and Yiin (2011) reported mortality for 1940–2005 separately for intestinal cancer (ICD-9 152–153) and colon cancer in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, deaths from intestinal cancer were not substantially changed in the entire cohort (26 deaths, SMR = 1.07, 95% CI 0.70–1.57), the PCP-only group (15 deaths, SMR = 0.90, 95% CI 0.50–1.49), or the PCP-plus-TCDD group (11 deaths, SMR = 1.44, 95% CI 0.72–2.57). Only two deaths from rectal cancer were reported in the entire cohort—one in each subcohort—which was in accord with expectations.

The participants in the AHS are known to have had extensive exposure to the phenoxy herbicides, but the analyses of updated mortality (Waggoner et al., 2011) and cancer incidence (Koutros et al., 2010a) address only exposure to pesticides in general. The updated cancer incidence in the AHS (Koutros et al., 2010a) revealed no increase in SIR of colon cancer in private applicators (339 cases, SIR = 0.87, 95% CI 0.78–0.97) or their spouses (144 cases, SIR = 0.83, 95% CI 0.70–0.98). Cancer of the rectum also was not increased in these populations of private applicators (117 cases, SIR = 0.90, 95% CI 0.74–1.08) or their spouses (30 cases, SIR = 0.69, 95% CI 0.47–0.99). In the study by Waggoner et al. (2011), mortality from both intestinal and rectal cancer in the applicators (private and commercial combined) was significantly lower than expected.

The association between obesity and cancer risk was examined (Andreotti et al., 2010) in pesticide applicators and their spouses on the basis of data from the AHS. A small increase in the risk of colon cancer in men was the only statistically significant association with increased body -mass index (BMI; trend in HR with BMI = 1.05, 95% CI 1.02–1.09, p = 0.005); no such relationship was apparent in the women. Of the many pesticides tested for an interactive role in the BMI–colon cancer relationship in men, the only one that had any bearing on the COIs and on which results were reported is dicamba (2-methoxy-3,6-dichlorobenzoic acid), which showed no evidence of interaction. The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Biologic Plausibility

Long-term animal studies examining the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004) have reported no increase in the incidence of colorectal cancer. Recently, Xie et al. (2012) reported that AHR activation by TCDD induces robust proliferation in two human colon-cancer cell lines through Src-mediated epidermal growth factor receptor activation. That novel finding suggests that TCDD and other AHR ligands may contribute to colon carcinogenesis, but more studies are needed to understand the potential role of AHR activation in intestinal carcinogenesis.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The generic findings on the applicators and their spouses in the AHS showed indications of increased mortality from both colon and intestinal cancer in agricultural workers, but earlier assessment of colorectal cancer in this study population had found no increase in risks in association with exposure to individual phenoxy herbicides (Lee WJ et al., 2007). None of the epidemiologic studies reviewed that specifically addressed the COIs, however, yielded evidence of an association between the COIs and colorectal cancer. There is no evidence of biologic plausibility of an association between exposure to any of the COIs and tumors of the colon or rectum. Overall, the available evidence does not support an association between the COIs and colorectal cancer.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and colorectal cancer.

Hepatobiliary Cancers

Hepatobiliary cancers include cancers of the liver (ICD-9 155.0, 155.2) and the intrahepatic bile duct (ICD-9 155.1). ACS estimated that 21,370 men and 7,350 women would receive diagnoses of liver cancer or intrahepatic bile duct cancer in the United States in 2012 and that 13,980 men and 6,570 women would die from these cancers (Siegel et al., 2012). Gallbladder cancer and extrahepatic bile duct cancer (ICD-9 156) are fairly uncommon and are often grouped with liver cancers when they are addressed.

In the United States, liver cancers account for about 1.5% of new cancer cases and 3.3% of cancer deaths. Misclassification of metastatic cancers as primary liver cancer can lead to overestimation of the number of deaths attributable to liver cancer (Percy et al., 1990). In developing countries, especially those in sub-Saharan Africa and Southeast Asia, liver cancers are common and are among the leading causes of death. Known risk factors for liver cancer include chronic infection with hepatitis B or hepatitis C virus and exposure to the carcinogens aflatoxin and vinyl chloride. Alcohol cirrhosis and obesity-associated metabolic syndrome may also contribute to the risk of liver cancer. In the general population, the incidence of liver and intrahepatic bile duct cancer increases slightly with age; at the ages of 50–64 years, it is greater in men than in women and

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

greater in blacks than in whites. The average annual incidence of hepatobiliary cancers is shown in Table 8-4.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and hepatobiliary cancers. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, and Update 2008 did not change that conclusion.

Update 2010 considered followup reports on three previously studied populations. Collins et al. (2009a,b) examined mortality in workers employed in a Dow Chemical Company plant in Midland, Michigan, during 1937–1980. They found two cases of cancer of the hepatobiliary tract in 1,615 TCP workers (SMR = 0.5, 95% CI 0.1–1.6) but no observed deaths from that cancer in 773 PCP workers. The second occupational-mortality study was of workers in the Dow AgroSciences plant in New Plymouth, New Zealand, who were potentially exposed to TCDD; SMRs for hepatobiliary cancer calculated on the basis of national mortality figures were 1.4 (95% CI 0.2–5.1) in exposed workers and 0.0 (95% CI 0.0–8.2) in the never-exposed group (McBride et al., 2009a). The update of cancer incidence in the Seveso cohort did not find systematic evidence of hepatic or biliary cancers in any of the exposure zones (Pesatori et al., 2009).

Table 8-8 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and hepatobiliary cancer have been published since Update 2010.

Occupational Studies Malignant neoplasms of the hepatobiliary tract were not specifically reported in Boers et al. (2012), Burns et al. (2011), or Manuwald et al. (2012).

An update of cancer incidence in US PCP workers through 2005 reported no increase in cancers of the hepatobiliary tract (Ruder and Yiin, 2011). There were nine deaths from liver or biliary cancer for an SMR of 1.21 (95% CI 0.56–2.31) in all the workers, but they all occurred in the workers that had only PCP exposure and resulted in a somewhat higher but still nonsignificant risk estimate (SMR = 1.76, 95% CI 0.81–3.35).

Koutros et al. (2010a) published an update of cancer incidence in the AHS. In private applicators, there were 32 cases of liver cancer (SIR = 0.73, 95% CI 0.50–1.03) and eight cases of gallbladder cancer (SIR = 1.33, 95% CI 0.57–2.61).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-8 Selected Epidemiologic Studies—Hepatobiliary Cancers (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000—liver, intrahepatic bile ducts (ICD-9 155)

    5nrBoehmer et al., 2004 CDC, 1990a

US CDC Selected Cancers Study—case-control study of incidence (12/1/1984–11/30/1989) among US males born 1929–1953

    8All COIs 1.2 (0.5–2.7)

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982—liver, bile duct

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  341.0 (0.8–1.4)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    61.2 (0.5–2.8)
State Studies of US Vietnam Veterans

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    0nrAnderson et al., 1986a,b

International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  270.7 (0.4–1.9)ADVA, 2005a

Navy

    81.0 (0.4–1.9)

Army

  180.7 (0.4–1.1)

Air Force

    10.2 (0.0–1.2)

Mortality

All branches, return–2001

  480.9 (0.6–1.1)ADVA, 2005b

Navy

  111.0 (0.5–1.7)

Army

  330.9 (0.6–1.2)

Air Force

    40.6 (0.2–1.5)

1980–1994

CDVA, 1997a

Liver (ICD-9 155)

    80.6 (0.2–1.1)

Gallbladder (ICD-9 156)

    51.3 (0.4–2.8)

Australian Conscripted Army National Service

All COIs

18,940 deployed vs 24,642 nondeployed

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Incidence

1982–2000

    22.5 (0.1–147.2)ADVA, 2005c

Mortality

1966–2001 (liver, gallbladder)

    42.5 (0.4–27.1)ADVA, 2005c

1982–1994

    1nrCDVA, 1997b

OCCUPATIONAL—INDUSTRIAL

IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  150.7 (0.4–1.2)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  120.9 (0.5–1.5)

7,553 not exposed to highly chlorinated PCDDs

    30.4 (0.1–1.2)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Liver, gallbladder, bileduct (ICD-8 155–156)

    40.4 (0.1–1.1)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982

Lynge, 1985

Men

    31.0 (nr)

Women

    0nr

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1956–1989

    11.2 (0.0–6.9)Becher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992—liver, gallbladder, bile duct

    22.1 (0.3–7.5)Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    12.8 (0.1–15.5)

TCDD 0.1–0.99 μg/kg of body weight

    00.0 (0.0–15.4)

TCDD > 1 μg/kg of body weight

    12.8 (0.1–15.5)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–1989

    0Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    21.4 (0.2–5.1)

Never-exposed workers

    00.0 (0.0–8.2)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000—ICD-9 155

’t Mannetje et al., 2005

Phenoxy herbicide producers (men and women)

    11.6 (0.0–8.8)

Phenoxy herbicide sprayers (> 99% men)

    00.0 (0.0–4.2)

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

Steenland et al., 1999

Liver, biliary tract (ICD-9 155–156)

    70.9 (0.4–1.6)

Through 1987 (liver, biliary tract)

    61.2 (0.4–2.5)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    10.6 (0.0–3.3)

Mortality—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991); liver, biliary tract

    21.4 (0.2–5.2)Collins et al., 1993
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    20.5 (0.1–1.6)Collins et al., 2009a

March 1949–1978 (n = 121); 121 TCP workers with chloracne

    0nrZack and Suskind, 1980

Through 1982 (n = 878); liver, biliary tract (ICDA-8 155–156)

    01.2 (nr)Bond et al., 1988

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (liver and biliary; ICD–9 155–156)

    91.2 (0.6–2.3)

PCP and TCP (n = 720)

    0– (0.0–1.6)

PCP (no TCP) (n = 1,402)

    91.8 (0.8–3.4)

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP) Mortality 1940–1989 (n = 770); liver, primary (ICDA-8 155–156)

    00.0 (0.0–1.7)Collins et al., 2009b Ramlow et al., 1996

0-yr latency

    0nr

15-yr latency

    0nr

OCCUPATIONAL—PAPER AND PULP

TCDD

WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  270.9 (0.6–1.3)

Ever

  160.7 (0.4–1.1)

Danish paper workers

Rix et al., 1998

Men

Liver

  101.1 (0.5–2.0)

Gallbladder

    91.6 (0.7–3.0)

Women

Liver

    10.6 (0.0–3.2)

Gallbladder

    41.4 (0.4–3.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Pulp and Paper cohorts independent of IARC cohort

United Paperworkers International, 201 white men employed ≥ 10 yrs and dying 1970–1984

    22.0 (0.2–7.3)Solet et al., 1989
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Liver

   

Self-employed

  230.4 (p < 0.05)
   

Employee

    90.8 (nr)

Gallbladder

   

Self-employed

  350.8 (nr)
   

Employee

    70.8 (nr)

Women

Liver

   

Family workers

    50.5 (nr)

Gallbladder

   

Self-employed

    72.7 (p < 0.05)
   

Employee

    10.7 (nr)
   

Family workers

  171.0 (nr)

FINNISH Phenoxy Herbicide Sprayers (1,909

Phenoxy

men working 1955–1971 ≥ 2 wks) not IARC

herbicides

(liver, biliary tract)

Incidence

    30.9 (0.2–2.6)Asp et al., 1994

Mortality 1972–1989

    20.6 (0.1–2.2)

ITALIAN Licensed Pesticide Users—male

farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  150.6 (0.3–0.9)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

    7Phenoxy herbicidesGambini et al., 1997
1.3 (0.5–2.6)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident hepatobiliary cancer cases vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides

Liver

    10.8 (0.1–5.8)

Gallbladder

    34.1 (1.4–12.0)

Aged 20–59

    16.3 (1.1–36.6)

Aged ≥ 60

    23.5 (0.9–13.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Sawmill workers (n = 139)

Herbicides, chlorophenols

Gallbladder

    22.3 (0.6–9.1)

SWEDEN

Incident stomach cancer cases 1961–1973 with agriculture as economic activity in 1960 census

Wiklund, 1983
99% CI

Liver (primary)

1030.3 (0.3–0.4)

Biliary tract

1690.6 (0.5–0.7)

Liver (unspecified)

  670.9 (0.7–1.3)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    0nrSwaen et al., 2004

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

3261.0 (0.9–1.1)

Nonwhites (n = 11,446)

  240.7 (0.5–1.1)

Women

Whites (n = 2,400)

    60.7 (0.3–1.6)

Nonwhites (n = 2,066)

    20.4 (0.0–1.3)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Liver

Private applicators

  320.7 (0.5–1.0)

Commercial applicators

    1nr

Spouses

    60.8 (0.3–1.7)

Gallbladder

Private applicators

    81.3 (0.6–2.6)

Commercial applicators

    0nr

Spouses

Enrollment through 2002

    71.1 (0.4–2.3)Alavanja et al., 2005

Liver

Private applicators (men, women)

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10-yr followup to 1986—women

Bertazzi et al., 1989b

Zone A—gallbladder (ICD-9 156)

    112.1 (1.6–88.7)

Zone B—gallbladder (ICD-9 156)

    23.9 (0.9–16.2)

Zone R

Liver

    30.4 (0.1–1.4)

Gallbladder (ICD-9 156)

    51.2 (0.5–3.1)
Quail Run Mobile Home CohortTCDDHoffman et al., 1986

154 exposed residents vs 155 unexposed area residents

    0nr

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

    10.5 (0.0–2.7)

West coast

    90.9 (0.4–1.7)

Mortality

East coast

    61.3 (0.5–2.9)

West coast

  241.0 (0.6–1.5)

VIETNAM

Risk factor for hepatocellular carcinoma in Hanoi

HerbicidesCordier et al., 1993

Military service in South Vietnam for ≥ 10 yrs after 1960

  118.8 (1.9–41.0)

CASE-CONTROL STUDIES

International Case-Control Studies

Swedish patients (25–80 yrs of age) diagnosed with liver cancer (ICD-7 155, 156) between 1974–June 1981 vs national rates

102Phenoxy acids, chlorophenols 1.8 (0.9–4.0)Hardell, 1984

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; ICDA, International Classification of Diseases, Adapted for Use in the United States; JEM, job-exposure matrix; MCPA, methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCP, pentachlorophenol; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

In their spouses, there were six liver-cancer cases (SIR = 0.76, 95% CI 0.28–1.66) and seven gallbladder-cancer cases (SIR = 1.09, 95% CI 0.44–2.25). Waggoner et al. (2011) compared deaths from hepataboliary from the time of enrollment (1993–1997) through 2007 to state mortality rates. Rates of hepatobiliary cancers (liver and gallbladder) in applicators was less than expected (50 deaths, SMR = 0.70, 95% CI 0.52–0.93), but not in their spouses (18 deaths, SMR = 0.81, 95% CI 0.48–1.28). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Biologic Plausibility

Long-term animal studies have examined the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). Studies performed in laboratory animals have consistently demonstrated that long-term exposure to TCDD results in the formation of liver adenomas and carcinomas (Knerr and Schrenk, 2006; Walker et al., 2006). Furthermore, TCDD increases the growth of hepatic tumors that are initiated by treatment with a complete carcinogen. Pathologic liver changes have been observed after exposure to TCDD, including nodular hyperplasia and massive inflammatory cell infiltration (Kociba et al., 1978; NTP, 2006; Walker et al., 2006; Yoshizawa et al., 2007); inflammation can be heavily involved in the development and progression of many cancers, including liver cancers (Mantovani et al., 2008). In monkeys treated with TCDD, hyperplasia and an increase in cells that stain positive for alpha-smooth muscle actin have been observed (Korenaga et al., 2007). Postive staining for alpha-smooth muscle actin is thought to be indicative of a process (epithelial–mesenchymal transition) that is associated with the progression of malignant tumors (Weinberg, 2008).

Bile duct hyperplasia (but not tumors) has been reported in rodents following chronic treatment with TCDD (Knerr and Schrenk, 2006; Walker et al., 2006; Yoshizawa et al., 2007). Similarly, monkeys treated with TCDD developed metaplasia, hyperplasia, and hypertrophy of the bile duct (Allen et al., 1977). Hollingshead et al. (2008) showed that TCDD-activated AHR in human breast and endocervical cell lines induces sustained high concentrations of the interleu-kin-6 cytokine, which has tumor-promoting effects in numerous tissues, including cholangiocytes; thus, TCDD might promote carcinogenesis in biliary tissue.

TCDD may contribute to tumor progression by inhibiting p53 regulation (phosphorylation and acetylation) triggered by genotoxicants through the increased expression of the metastasis marker AGR2 (Ambolet-Camoit et al., 2010) and a functional interaction between the AHR and FHL2 (Kollara and Brown, 2009). The AHR was also shown to be a regulator of c-raf and proposed cross-talk between the AHR and the mitogen-activated protein kinase signaling pathway in chemically induced hepatocarcinogenesis (Borlak and Jenke, 2008).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TCDD inhibits ultraviolet-C radiation-induced apoptosis in primary rat hepatocytes and Huh-7 human hepatoma cells, and this supports the hypothesis that TCDD acts as a tumor-promoter by preventing initiated cells from undergoing apoptosis (Chopra et al., 2009).

Elyakim et al. (2010) found that human microRNA miR-191 was upregulated in hepatocellular carcinoma and that miR-191 was upregulated after TCDD treatment and may contribute to the mechanism of the carcinogenic activity of TCDD. Ovando et al. (2010) used toxicogenomics to identify genomic responses that may be contributing to the development of hepatotoxicity in rats treated chronically with the AHR ligands, TCDD or PCB 126. They identified 24, 17, and 7 genes that were differentially expressed in the livers of rats exposed to those AHR ligands and in human cholangiocarcinoma, human hepatocellular adenoma, and rat hepatocellular adenoma, respectively. That finding may help to elucidate the mechanisms by which dioxin-like compounds induce their hepatotoxic and carcinogenic effects.

In rodents, TCDD may promote hepatocarcinogenesis through cytotoxicity, chronic inflammation, and liver regeneration and through hyperplastic and hypertrophic growth due to sustained activation of the AHR (Köhle and Bock, 2007; Köhle et al., 2008). Species differences associated with AHR activation are demonstrated by the divergence in the transcriptomic responses to TCDD in mouse, rat, and human liver (Boutros et al., 2008, 2009; Carlson et al., 2009; Kim et al., 2009), but it should be noted that the in vitro human hepatocyte studies may not reflect the in vivo response of human liver to TCDD. In vitro studies with transformed cell lines and primary hepatocytes cannot replicate the complexity of a tissue response that is important in eliciting the toxic responses observed in vivo (Dere et al., 2006).

In a recent study, gene-expression changes were compared in adult female primary human and rat hepatocytes exposed to TCDD in vitro (Black et al., 2012). Whole-genome microarrays found that TCDD produced differing gene-expression profiles in rat and human hepatocytes both on an ortholog basis (conserved genes in different species) and on a pathway basis. For commonly affected orthologs or signaling pathways, the human hepatocytes were about one-fifteenth as sensitive as rat hepatocytes. Such findings are consistent with epidemiologic studies that show humans to be less sensitive to TCDD-induced hepatotoxicity.

Chronic exposure of rats to TCDD was associated with fatty liver degeneration and necrosis (Chen X et al., 2012). Another group reported that the hepatotoxic effects of TCDD were exacerbated in mice that had glutathione deficiency (Chen YJ et al., 2012). The combined exposure to PCBs and TCDD induced significant hepatotoxicity in rats (Lu C et al., 2010). Studying the effects of environmental chemicals on nuclear hormone receptors, Shah et al. (2011) demonstrated that in vitro assays for stratifying environmental contaminants can serve as surrogates in combination with rodent toxicity evaluations.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The marginally significant rSMRs of hepatobiliary cancer in applicators and their spouses in the AHS (Waggoner et al., 2011) assessed exposure only to pesticides in general, so they cannot be considered fully informative for the purpose of the present review. Even in combination with the previously reported isolated finding of a barely significant increase in mortality from biliary cancer in the moderate-exposure zone at Seveso (Pesatori et al., 2009), a consistent pattern of increased risk of biliary cancer is not established. Despite the evidence of TCDD’s activity as a hepatocarcinogen in animals, the evidence from epidemiologic studies remains inadequate to link the COIs with hepatobiliary cancer, which has a relatively low incidence in Western populations.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and hepatobiliary cancer.

Pancreatic Cancer

The incidence of pancreatic cancer (ICD-9 code 157) increases with age. ACS estimated that 22,090 men and 21,830 women would receive a diagnosis of pancreatic cancer in the United States in 2012 and that 18,850 men and 18,540 women would die from it (Siegel et al., 2012). The incidence is higher in men than in women and higher in blacks than in whites. Other risk factors include family history, diet, and tobacco use. Chronic pancreatitis, obesity, and type 2 diabetes are also associated with an increased risk of pancreatic cancer (ACS, 2013a). The average annual incidence of pancreatic cancer is shown in Table 8-4.

Conclusions from VAO and Previous Updates

Update 2006 considered pancreatic cancer independently for the first time. Prior updates developed tables of results for pancreatic cancer but reached conclusions about the adequacy of the evidence of its association with herbicide exposure in the context of gastrointestinal tract cancers. The committee responsible for VAO concluded that there was limited or suggestive evidence of no association between exposure to the herbicides used by the US military in Vietnam and gastrointestinal tract tumors, including pancreatic cancer. The committee

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

responsible for Update 2006 concluded that there was not enough evidence on each of the COIs to sustain that negative conclusion for any of the cancers in the gastrointestinal group and that, because these various types of cancer are generally regarded as separate disease entities, the evidence on each should be evaluated separately. Pancreatic cancer was thus reclassified into the default category of inadequate or insufficient evidence of an association. The Update 2006 committee reviewed the increased rates of pancreatic cancer in Australian National Service Vietnam veterans but concluded that the increased rates could be attributed to the rates of smoking in the cohort (ADVA, 2005c). The committee also noted the report of increased rates of pancreatic cancer in US female Vietnam nurse veterans (Dalager et al., 1995). That increase persisted in the followup study of the American female veterans (Cypel and Kang, 2008) considered in Update 2008, but the update on mortality in the Seveso population (Consonni et al., 2008) did not support an association with pancreatic cancer.

Collins et al. (2009a,b) reported on Dow Chemical Company PCP workers in Midland, Michigan, and did not find evidence of increased mortality from pancreatic cancer, whether or not they had also been engaged in TCP production, which would have provided an opportunity for exposure to TCDD and other chlorinated dioxins. McBride et al. (2009a) found no evidence of increased pancreatic-cancer deaths in either exposed workers or the never-exposed group in the Dow AgroSciences plant in New Plymouth, New Zealand. A nested case-control study of pancreatic cancer in the AHS cohort found no statistically significant associations with exposure to 2,4-D or dicamba (Andreotti et al., 2009). A followup study of two Dutch cohorts of chlorophenoxy-herbicide production workers did not find the risk of death from pancreatic cancer to be increased in either factory (Boers et al., 2010). Pesatori et al. (2009) did not find the incidence of pancreatic cancer to be increased in the Seveso cohort 20 years after the accident.

Table 8-9 summarizes the results of the relevant studies concerning pancreatic cancer.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and pancreatic cancer have been published since Update 2010.

Occupational Studies Burns et al. (2011) published an update examining cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With two cases observed, the incidence of pancreatic cancer in the most restrictively defined cohort was not

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-9 Selected Epidemiologic Studies—Pancreatic Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    51.0 (0.3–3.5)Boehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  820.9 (0.6–1.2)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  181.6 (0.5–5.8)

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality

Through 2004

Cypel and Kang, 2008

US Vietnam veterans

  172.1 (1.0–4.5)

Vietnam-veteran nurses

  142.5 (1.0–6.0)

Through 1991

Dalager et al., 1995

US Vietnam veterans

    72.8 (0.8–10.2)
   

Vietnam-veteran nurses

    75.7 (1.2–27.0)

Through 1987

Thomas et al., 1991

US Vietnam veterans

    52.7 (0.9–6.2)

State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  141.0 (0.6–1.7)Visintainer et al., 1995

Non-black

    90.7 (0.3–1.3)

Black

    59.1 (2.9–21.2)

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    4nrAnderson et al., 1986

International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  861.2 (0.9–1.4)ADVA, 2005a

Navy

  140.9 (0.5–1.5)

Army

  601.2 (0.9–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Air Force

  121.3 (0.7–2.3)

Mortality

All branches, return–2001

1011.2 (1.0–1.5)ADVA, 2005b

Navy

  181.0 (0.6–1.6)

Army

  711.3 (1.0–1.6)

Air Force

  111.1 (0.5–1.8)

1980–1994

  381.4 (0.9–1.8)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence

1982–2000

  172.5 (1.0–6.3)ADVA, 2005c

Mortality

1966–2001

  193.1 (1.3–8.3)ADVA, 2005c

1982–1994

    61.5 (nr)CDVA, 1997b

OCCUPATIONAL—INDUSTRIAL

IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  470.9 (0.7–1.3)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  300.9 (0.5–1.4)

7,553 not exposed to highly chlorinated PCDDs

  161.0 (0.7–1.4)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

  261.1 (0.7–1.6)Saracci et al., 1991

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    90.7 (0.3–1.4)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence

Incidence 1943–1982

Lynge, 1985

Men

    30.6 (nr)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Women

    0nr

Mortality

Mortality 1955–2006

    71.2 (0.8–1.7)Boers et al., 2012

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

    60.9 (0.5–1.6)Boers et al., 2012

Mortality 1955–2006

    40.9 (0.2–4.2)Boers et al. 2010

Mortality 1955–1991

    42.5 (0.7–6.3)Hooiveld et al., 1998

Mortality 1955–1985

    32.9 (0.6–8.4)Bueno de Mesquita et al., 1993

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCP; highly chlorinated dioxins unlikely

Mortality 1965–2006

    1nrBoers et al., 2010

Mortality 1965–1986

    00.0 (0.0–10.9)Bueno de Mesquita et al., 1993

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    21.7 (0.2–6.1)Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007 (ICD-9 157)

  100.9 (0.4–1.7)Manuwald et al., 2012

Men

    70.9 (0.4–1.9)

Women

    31.0 (0.2–2.9)

Mortality 1952–1989

    20.6 (0.1–2.3)Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    31.3 (0.3–3.9)

Never-exposed workers

    00.0 (0.0–4.9)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

’t Mannetje et al., 2005

Phenoxy herbicide producers (men, women)

    32.1 (0.4–6.1)

Phenoxy herbicide sprayers (> 99% men)

    00.0 (0.0–2.1)

NIOSH Mortality Cohort (12 US plants, 5,172

Dioxins, phenoxy

male production and maintenance workers

herbicides

1942–1984) (included in IARC cohort as of 1997)

Through 1993

  161.0 (0.6–1.6)Steenland et al., 1999

Through 1987

  100.8 (0.4–1.6)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    41.0 (0.3–2.5)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    60.7 (0.2–1.4)Collins et al., 2009a
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

  181.3 (0.8–2.0)

PCP and TCP (n = 720)

    61.4 (0.5–3.0)

PCP (no TCP) (n = 1,402)

  121.3 (0.7–2.2)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    20.4 (0.1–1.5)Burns et al., 2011

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP) Mortality 1940–1989 (n = 770)

    51.1 (0.3–2.5)Collins et al., 2009b Ramlow et al., 1996

0-yr latency

    20.7 (0.1–2.7)

15-yr latency

    20.9 (0.1–3.3)

Other Studies of Industrial Workers (not related to IARC or NIOSH phenoxy cohorts)

1,412 white male US flavor and fragrance chemical plant workers (1945–1965)

Dioxin, 2,4,5-TThomas, 1987
    61.4 (nr)

OCCUPATIONAL—PAPER AND PULP WORKERS

TCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  670.8 (0.7–1.1)

Ever

  691.1 (0.9–1.4)

Danish paper workers

Rix et al., 1998

Men

  301.2 (0.8–1.7)

Women

    20.3 (0.0–1.1)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    91.9 (0.9–3.6)Henneberger et al., 1989
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

United Paperworkers International, 201 white men employed ≥ 10 yrs and dying 1970–1984

    10.4 (0.0–2.1)Solet et al., 1989

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

    490% CI 0.3 (0.1–0.8)Robinson et al., 1986
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

1370.6 (p < 0.05)

Employee

  230.6 (p < 0.05)

Women

Self-employed

    71.2 (nr)

Employee

    41.3 (nr)

Family workers

  270.7 (p < 0.05)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  320.7 (0.5–1.0)Torchio
et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
    70.9 (0.4–1.9)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident pantreatic cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

    61.8 (0.8–4.1)

Aged 20–59

    0

Aged ≥ 60

    62.4 (1.1–5.4)

Sawmill workers (n = 139)

Herbicides, chlorophenols
    20.5 (0.1–1.8)

SWEDEN

Incident pancreatic cancer cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
7770.8 (0.8–0.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    51.2 (0.4–2.7)Swaen et al., 2004

Through 1987

    32.2 (0.4–6.4)Swaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

1,1331.1 (1.1–1.2)

Nonwhites (n = 11,446)

1251.2 (1.0–1.4)

Women

Whites (n = 2,400)

  231.0 (0.6–1.5)

Nonwhites (n = 2,066)

  160.7 (0.4–1.2)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  800.7 (0.6–0.9)

Commercial applicators

    51.0 (0.3–2.3)

Spouses

  320.7 (0.5–1.0)

Nested case-control (applicators, spouses combined)

Andreotti et al., 2009

2,4-D

  480.9 (0.5–1.5)

Dicamba

  230.9 (0.6–1.6)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  460.7 (0.5–1.0)

Spouses of private applicators (> 99% women)

  200.9 (0.6–1.4)

Commercial applicators

    31.1 (0.2–3.2)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

1710.8 (0.7–1.0)

Spouses (n = 676)

    1nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

  290.6 (0.4–0.9)

Spouses of private applicators (> 99% women)

  100.7 (0.3–1.2)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of pancreatic cancer

Herbicides

Agricultural extension agents

  211.3 (0.8–1.9)Alavanja et al., 1988

Forest conservationists

  221.5 (0.9–2.3)Alavanja et al., 1989

Florida Licensed Pesticide Applicators (common phenoxy use assumed but not documented; had been listed by Blair et al., 1983)

Herbicides

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Expected exposed cases
    44.0

White Male Residents of Iowa—pancreatic cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

4161.1 (nr)Burmeister, 1981

ENVIRONMENTAL

Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)

TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    11.2 (0.2–8.2)Pesatori et al., 2009

Zone B

    30.6 (0.2–1.7)

Zone R

  381.0 (0.7–1.4)

10-yr followup to 1991—men

Pesatori et al., 1992

Zone A, B

    21.0 (0.3–4.2)

10-yr followup to 1991—women

Pesatori et al., 1992

Zone A, B

    11.6 (0.2–12.0)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    21.2 (0.3–4.7)

Zone B

    50.5 (0.2–1.1)

Zone R

  761 0 (0 7–1 7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

20-yr followup to 1996

Bertazzi et al., 2001

Zones A and B—men

    40.7 (0.3–1.9)

Zones A and B—women

    10.3 (0.0–2.0)

15-yr followup to 1991—men

Bertazzi et al., 1997

Zone A

    11.9 (0.0–10.5)

Zone B

    20.6 (0.1–2.0)

Zone R

  200.8 (0.5–1.2)

15-yr followup to 1991—women

Bertazzi et al., 1997

Zone B

    10.5 (0.0–3.1)

Zone R

  110.7 (0.4–1.3)

10-yr followup to 1986—men

Bertazzi et al., 1989a,b

Zone A, B, R

    90.6 (0.3–1.2)

Zone B

    21.1 (0.3–2.7)

10-yr followup to 1986—women

Bertazzi et al., 1989a

Zone A, B, R

    41.0 (0.3–2.7)

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

    40.6 (0.2–1.6)

West coast

  371.0 (0.7–1.4)

Mortality

East coast

    50.7 (0.2–1.6)

West coast

  330.8 (0.6–1.2)

CASE-CONTROL STUDIES

International Case-Control Studies

UK men, 18–35 yrs of age from counties with particular chemical manufacturing—mortality

Herbicides, chlorophenolsMagnani et al., 1987

Herbicides

nr0.7 (0.3–1.5)

Chlorophenols

nr0.8 (0.5–1.4)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCDF, polychlorinated dibenzofuran; PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; PMR, proportionate mortality ratio; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; UK United Kingdom; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

increased (SIR = 0.42, 95% CI 0.05–1.52), nor was it increased in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) published the results of analyses of serum TCDD concentrations in the recently updated Dutch chlorophenoxy-herbicide cohorts, which had been published earlier. Boers et al. (2010) had published less sophisticated exposed-vs-unexposed results, which showed no increase in pancreatic-cancer deaths (HR for factory A = 0.86, 95% CI 0.18–4.19; only one pancreatic-cancer death in the factory B cohort). When the predicted serum TCDD concentrations generated by the model developed from the blood sampling were used, the risks of pancreatic cancer were not increased in the entire cohort (HR = 1.17, 95% CI 0.82–1.65) or in the factory A cohort alone (HR = 0.89, 95% CI 0.50–1.57).

Manuwald et al. (2012) reported on mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment in the plant, and vital status was sought through 2007. The observed numbers of deaths from pancreatic cancer were near expectation in men (SMR = 0.90, 95% CI 0.36–1.85), women (SMR = 1.0, 95% CI 0.20–2.93), and the entire cohort (SMR = 0.93, 95% CI 0.44–1.70).

Ruder and Yiin (2011) reported mortality in 1940–2005 for the NIOSH PCP cohort of 2,122 workers in the US four plants that had been involved in PCP production. Relative to US referent rates, there were slightly more deaths from pancreatic cancer in each group, but results were not substantially different in the entire cohort (18 deaths, SMR = 1.29, 95% CI 0.76–2.03), the PCP-only group (12 deaths, SMR = 1.25, 95% CI 0.65–2.19), or the PCP-plus-TCDD group (six deaths, SMR = 1.36, 95% CI 0.50–2.96).

Waggoner et al. (2011) reported on mortality rates in the AHS cohort and found fewer pancreatic cancers than expected in both applicators (103 deaths, SMR = 0.75, 95% CI 0.61–0.91) and in their spouses (38 cases, SMR = 0.72, 95% CI 0.51–0.99). Koutros et al. (2010a) updated cancer incidence through 2006 in the AHS cohorts of private applicators, their spouses, and commercial applicators. There was a significant decrease in the number of pancreatic-cancer cases observed in the private applicators (80 cases, SIR = 0.72, 95% CI 0.57–0.89). A nonsignificant decrease in mortality from pancreatic cancer was observed in spouses (32 cases, SIR = 0.72, 95% CI 0.49–1.01), but the incidences did not differ from expectation in the smaller groups of commercial applicators (five cases, SIR = 0.99, 95% CI 0.32–2.31). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Biologic Plausibility

Long-term animal studies have examined the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). No increase in the incidence of pancreatic cancer in laboratory animals after the administration of cacodylic acid, 2,4-D, or picloram has been reported. A 2-year study of female rats reported increased incidences of pancreatic adenomas and carcinomas after treatment at the highest dose of TCDD (100 ng/kg per day) (Nyska et al., 2004). Other studies have observed chronic active inflammation, acinar-cell vacuolation, and an increase in proliferation of the acinar cells surrounding the vacuolated cells (Yoshizawa et al., 2005b). As previously discussed, chronic inflammation and hyperproliferation are closely linked to the formation and progression of cancers, including cancer of the pancreas (Hahn and Weinberg, 2002; Mantovani et al., 2008). Metaplastic changes in the pancreatic ducts were also observed in female monkeys treated with TCDD (Allen et al., 1977).

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The large excess of pancreatic cancers in female Vietnam veterans vs their nondeployed counterparts observed by Thomas et al. (1991) and Dalager et al. (1995) prevailed in a study by Cypel and Kang (2008), who found a significant increase in all female Vietnam veterans and in the nurse subset. The committee responsible for Update 2006 reported a higher incidence of and mortality from pancreatic cancer in deployed Australian National Service veterans than in nondeployed veterans (ADVA, 2005c). A limitation of all the veteran studies considered has been the lack of control for the effect of smoking. In the 31 female and 62 male cases in the AHS case-control study considered in Update 2010 (Andreotti et al., 2009), however, the risk of pancreatic cancer was not associated with 2,4-D exposure, so the relative increase in the AHS cohort overall (Waggoner et al., 2011) would most certainly not be attributable to 2,4-D exposure. No increase in risk has been reported in US male Vietnam veterans or in IARC followup studies. The new updates on production cohorts and analyses from the AHS do not imply that exposures to the COIs are associated with the occurrence of pancreatic cancer.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and pancreatic cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

LARYNGEAL CANCER

ACS estimated that 9,840 men and 2,520 women would receive diagnoses of cancer of the larynx (ICD-9 161) in the United States in 2012 and that 2,880 men and 770 women would die from it (Siegel et al., 2012). Those numbers constitute a little more than 0.9% of new cancer diagnoses and 0.7% of cancer deaths. The incidence of cancer of the larynx increases with age, and it is more common in men than in women, with a sex ratio in the United States of about 4:1 in people 50–64 years old. The average annual incidence of laryngeal cancer is shown in Table 8-10.

Established risk factors for laryngeal cancer are tobacco use and alcohol use, which are independent and act synergistically. Occupational exposures—long and intense exposures to wood dust, paint fumes, and some chemicals used in the metalworking, petroleum, plastics, and textile industries—also could increase risk (ACS, 2012a). An Institute of Medicine committee concluded that asbestos is a causal factor in laryngeal cancer (IOM, 2006); infection with human papilloma virus is also thought to raise the risk of laryngeal cancer (Baumann et al., 2009; Hobbs and Birchall, 2004).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was limited or suggestive evidence of an association between exposure to at least one of the COIs and laryngeal cancer on the basis of the evidence discussed below in the section “Synthesis.” Although the small number of laryngeal cancers included in most studies generally limits their statistical power to support strong conclusions, additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-11 summarizes the results of the relevant studies.

TABLE 8-10 Average Annual Cancer Incidence (per 100,000) of Laryngeal Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men12.011.324.519.217.841.226.525.950.6
Women2.92.85.33.83.76.55.65.610.7

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-11 Selected Epidemiologic Studies—Laryngeal Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    00.0 (nr)Boehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988

  501.3 (nr)Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

  501.4 (p < 0.05)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

    40.7 (nr)
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  971.5 (1.2–1.8)ADVA, 2005a

Navy

  211.5 (0.9–2.1)

Army

  691.6 (1.2–1.9)

Air Force

    70.8 0.3–1.7)

Mortality

All branches, return–2001

  281.1 (0.7–1.5)ADVA, 2005b

Navy

    61.1 (0.4–2.4)

Army

  191.1 (0.7–1.7)

Air Force

    30.9 (0.2–2.5)

1980–1994

  121.3 (0.7–2.2)CDVA, 1997a

Australian Conscripted Army National Service

All COIs

(18,940 deployed vs 24,642 nondeployed)

Incidence

1982–2000

    80.7 (0.2–1.6)ADVA, 2005c

Mortality

1966–2001

    20.4 (0.0–2.4)ADVA, 2005c

1982–1994

    00 (0– > 10)CDVA, 1997b
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  211.6 (1.0–2.5)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  151.7 (1.0–2.8)

7,553 not exposed to highly chlorinated PCDDs

    51.2 (0.4–2.9)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991
    81.5 (0.6–2.9)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    41.7 (0.5–4.5)Coggon et al., 1986

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

IARC cohort as of 1997)

Mortality 1952–2007

    73.5 (1.4–7.2)Manuwald et al., 2012

Men

    63.8 (1.4–8.2)

Women

    12.5 (0.0–13.9)

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals)

    22.0 (0.2–7.1)Manz et al., 1991

vs national rates (also vs gas workers); same observation period as Becher et al., 1966

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    12.5 (0.1–14.0)

Never-exposed workers

    19.7 (0.2–54.3)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    0nr’t Mannetje et al., 2005
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1987

    72.1 (0.8–4.3)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    32.7 (0.6–7.8)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    31.3 (0.3–3.9)Collins et al., 2009a

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    51.5 (0.5–3.4)

PCP and TCP (n = 720)

    10.9 (0.0–5.1)

PCP (no TCP) (n = 1,402)

    41.7 (0.5–4.3)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    41.1 (0.3–2.9)Burns et al., 2011

Through 1982 (n = 878)

    13.0 (0.0–16.8)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    21.7 (0.2–6.2)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

    22.9 (0.3–10.3)Ramlow et al., 1996

0-yr latency

    22.9 (0.4–10.3)

15-yr latency

    1nr
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  180.9 (0.5–1.5)

Ever

  201.2 (0.8–1.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish gardeners (n = 3,124) exposed to pesticides

    90.7 (0.3–1.4)Kenborg et al., 2012

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  250.5 (0.3–0.7)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
70.9 (0.4–1.9)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 303 incident laryngeal cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

    21.1 (0.3–4.7)

SWEDEN

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    0nr

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    11.0 (0.0–5.1)Swaen et al., 2004

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

1620.7 (0.6–0.8)

Nonwhites (n = 11,446)

  321.1 (0.8–1.5)

Women

Whites (n = 2,400)

    0nr (0.0–3.3)

Nonwhites (n = 2,066)

    0nr (0.0–4.8)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)TCDD

Mortality

25-yr followup to 2001—men and women, all respiratory cancers (ICD-9 160–165) excluding lung cancers (ICD-9 162)

Consonni et al., 2008
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Zone A

    0nr

Zone B

≤     8nr

Zone R

≤   49nr

20-yr followup to 1996—men and women, all respiratory cancers (ICD-9 160–165) excluding lung cancers (ICD-9 162)

Bertazzi et al., 2001

Zone A

    0nr

Zone B

    8nr

15-yr followup to 1991—men

Bertazzi et al., 1997, 1998

Zone B

    6nr

Zone R

    32nr

15-yr followup to 1991—women

Bertazzi et al., 1997, 1998

Zone B

    0nr

Zone R

    6nr
Ecological Study of Residents of Chapaevsk, RussiaDioxinRevich et al., 2001

Incidence—Crude incidence rate in 1998 vs

Men

Regional (Samara)

    0

National (Russia)

11.3

Women

Regional (Samara)

0

National (Russia)

0.4

Mortality—1995–1998 (SMR vs regional rates)

Men

  132.3 (1.2–3.8)

Women

    10.1 (0.0–0.6)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; SMR, standardized mortality ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and laryngeal cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased cancer rates overall. With four cases observed, the incidence of laryngeal cancer in the most restrictively defined cohort was not increased (SIR = 1.13, 95% CI 0.30–2.88), as was the case in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) did not report any deaths from laryngeal cancer in the updated Dutch chlorophenoxy-herbicide cohorts.

Manuwald et al. (2012) reported mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment in the plant, and vital status was sought through 2007. SMRs calculated relative to the population of Hamburg showed that death from laryngeal cancer was increased in men (SMR = 3.75, 95% CI 1.37–8.16), and in the entire cohort the increase in risk was significant (SMR = 3.50, 95% CI 1.40–7.21), but a single death from laryngeal cancer did not constitute an increase in the women (SMR = 2.53, 95% CI 0.03–13.91). The prevalence of smoking was not controlled for in the study, but it has been suggested that it did not differ from that in the general population (Flesch-Janys et al., 1995).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Only five deaths from laryngeal cancer were found in the entire cohort. Relative to US referent rates, that did not constitute a substantial increase (SMR = 1.45, 95% CI 0.47–3.38), nor did the four deaths in the PCP-only group (SMR = 1.69, 95% CI 0.46–4.32). There was only a single laryngeal-cancer death in the PCP-plus-TCDD group (SMR = 0.92, 95% CI 0.02–5.14).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The new publications on the AHS (Koutros et al., 2010a; Waggoner et al., 2011) did not report separate findings on laryngeal cancers.

Kenborg et al. (2012) conducted a study that focused on Parkinson disease in a Danish cohort of 3,124 male union members who worked as professional gardeners in 1975. When studying that cohort previously, Hansen et al. (1992, 2007) had reported that herbicides (including phenoxy herbicides) constituted most of their exposure. In addressing the observation that smoking has repeatedly been found to be negatively associated with the occurrence of Parkinson disease, Kenborg et al. also investigated the incidence of several cancers that are recognized as being smoking-related. The incidence of cancer of the larynx in the gardeners was similar to the age-adjusted and calendar-period-adjusted incidence in the general male Danish population (nine cases, SIR = 0.72, 95% CI 0.33–1.37).

Biologic Plausibility

Long-term animal studies have examined the effect of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). No increase in the incidence of laryngeal cancer in laboratory animals after the administration of any of the COIs has been reported.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The original VAO committee reviewed five studies that presented data on laryngeal cancer separately (Bond et al., 1988; Coggon et al., 1986; Fingerhut et al., 1991; Manz et al., 1991; Sarracci et al., 1991). It concluded that “although the numbers are too small to draw strong conclusions, the consistency of a mild increase in relative risk is suggestive of an association for laryngeal cancer.” That committee also noted that the studies reviewed for laryngeal cancer did not control for potential confounders, such as smoking and alcohol consumption (IOM, 1994).

Since then, a combined analysis of many of the separate cohorts (the IARC Cohort of Phenoxy Herbicide Workers analyzed by Kogevinas et al., 1997) has shown significant effects in workers who were exposed to any phenoxyacetic acid herbicide or chlorophenol (21 deaths, RR = 1.6, 95% CI 1.0–2.5), especially workers who were exposed to TCDD or higher-chlorinated dioxins (15 deaths, RR = 1.7, 95% CI 1.0–2.8). Those RRs are remarkably close to the pooled estimate computed by the committee responsible for VAO. The study by Kogevinas et al. was a high-quality study that used an excellent method for assessing exposure, and its results were unlikely to have been affected by confounding in that the distribution of smoking in working cohorts is not likely to differ with degree of exposure (Siemiatycki et al., 1988). Another IARC cohort that was used in

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

studying pulp and paper workers also showed an increase in risk (20 deaths, RR = 1.2, 95% CI 0.8–1.9; McLean et al., 2006).

With regard to veteran studies, a positive association was found in the study of veterans in Australia that compared mortality from laryngeal cancer with that in the general population (ADVA, 2005a) but not in the study that compared Australian veterans of the Vietnam conflict with nondeployed soldiers (ADVA, 2005c). In contrast, Watanabe and Kang (1996) found a significant 40% excess of mortality from laryngeal cancer in Army personnel deployed to the Vietnam theater. The Operation Ranch Hand study is not large enough to have sufficient power to detect an association if one exists.

An environmental study (Revich et al., 2001) of residents of Chapaevsk, Russia, which was heavily contaminated by many industrial pollutants, including dioxin, showed an association with laryngeal cancer in men (RR = 2.3, 95% CI 1.2–3.8).

The continuing updates on various occupational cohorts are largely consistent with the prior work, reporting a nonsignificant excess of laryngeal cancer. Some 10% of laryngeal cancers now being diagnosed are associated with HPV, but this small fraction is unlikely to have a substantial effect on studies over time. Most reports show an increased risk of laryngeal cancer that is not statistically significant, most likely because of the small number of cases in any individual study. In larger studies with exposure characterizations that focus on the COIs, the associations are generally strong for laryngeal cancer.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is limited or suggestive evidence of an association between exposure to at least one COI and laryngeal cancer.

LUNG CANCER

Lung cancer (carcinoma of the lung or bronchus, ICD-9 162.2–162.9) is the leading cause of cancer death in the United States. ACS estimated that 116,470 men and 109,690 women would receive diagnoses of lung cancer in the United States in 2012 and that about 87,750 men and 72,590 women would die from it (Siegel et al., 2012). Those numbers represent roughly 14% of new cancer diagnoses and 28% of cancer deaths in 2012. The principal types of lung neoplasms are identified collectively as bronchogenic carcinoma and carcinoma of the lung. Cancer of the trachea (ICD-9 162.0) is often grouped with cancer of the lung and bronchus under ICD-9 162. The lung is also a common site of metastatic tumors.

In men and women, the incidence of lung cancer increases greatly beginning at about the age of 40 years. The incidence in people 50–54 years old is double that in people 45–49 years old, and it doubles again in those 55–59 years old.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The incidence is consistently higher in black men than in women or white men. The average annual incidence of lung cancer in the United States is shown in Table 8-12.

ACS estimates that 87% of lung-cancer deaths are attributable to cigarette-smoking (ACS, 2011). Smoking increases the risk of all histologic types of lung cancer, but the associations with squamous-cell and small-cell carcinomas are strongest. Other risk factors include exposure to asbestos, uranium, vinyl chloride, nickel chromates, coal products, mustard gas, chloromethyl ethers, gasoline, diesel exhaust, and inorganic arsenic. The latter statement does not imply that cacodylic acid, which is a metabolite of inorganic arsenic, can be assumed to be a risk factor. Important environmental risk factors include exposure to tobacco smoke and radon (ACS, 2013a).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was limited or suggestive evidence of an association between exposure to at least one COI and lung cancer on the basis of the evidence discussed below in the section “Synthesis.” Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-13 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and cancers of the lung, bronchus, or trachea have been published since Update 2010.

TABLE 8-12 Average Annual Incidence (per 100,000) of Lung and Bronchial Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men99.793.6175.7177.3168.5302.9302.2294.6465.8
Women74.474.3101.7140.8145.4164.3230.4241.5257.8

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-13 Selected Epidemiologic Studies—Lung, Bronchus, or Trachea Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US VietnamVeterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

1982–2003—White SEA comparison veterans only (n = 1,482). Serum TCDD (pg/g) based on model with exposure variable loge(TCDD)

Pavuk et al., 2005

Per unit increase of –loge(TCDD) (pg/g) Quartiles (pg/g):

  361.7 (0.9–3.2)

0.4–2.6

    61.0 (nr)

2.6–3.8

    81.1 (0.3–3.4)

3.8–5.2

    91.2 (0.4–3.5)

> 5.2

  131.9 (0.7–5.5)

Number of years served in SEA (per year of service)

Quartiles (years in SEA):

  361.1 (0.9–1.2)

0.8–1.3

    81.0 (nr)

1.3–2.1

    40.5 (0.2–1.8)

2.1–3.7

  110.7 (0.3–2.0)

3.7–16.4

  130.7 (0.3–2.0)

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  331.1 (0.8–1.6)

With tours between 1966–1970

  331.1 (0.8–1.6)

SEA comparison veterans (n = 1,776)

  481.2 (0.9–1.6)

With tours between 1966–1970

  371.2 (0.9–1.6)

Mortality

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  210.9 (0.6–1.3)

SEA comparison veterans (n = 1,776)

  381.1 (0.8–1.5)
US VA Cohort of Army Chemical Corps—Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (7/01/1965–3/28/1973)All COIs

Mortality—Respiratory system cancers

Through 2005

Cypel and Kang, 2010

Deployed veterans (2,872) vs nondeployed (2,737)

60 vs 261.3 (0.8–2.1)

ACC deployed men in Kang et al. (2006) reported sprayed herbicide vs did not spray

  191.4 (0.5–3.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Through 1991

  111.4 (0.4–5.4)Dalager and Kang, 1997

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality—trachea, bronchus, lung

1965–2000

  411.0 (0.6–1.5)Boehmer et al., 2004

Low grade pay at time of discharge

nr1.6 (0.9–3.0)

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988 (lung)

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

1,1391.1 (nr) (p < 0.05)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

2151.2 (1.0–1.3)

US VA Study of Marine Post-service Mortality—sample of Marines serving 1967–1969, deployed (n = 10,716) vs nondeployed (n = 9,346)

All COIs

Mortality (lung), earlier of discharge or April 1973 through 1991

  421.3 (0.8–2.1)Watanabe and Kang, 1995

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality

Through 2004—lung

  501.0 (0.7–1.4)Cypel and Kang, 2008

Vietnam veteran nurses

  350.8 (0.5–1.2)

US VA using the Patient Treatment Files—329 Vietnam-era veterans and 269 noncancer controls and 111 colon cancer controls (1983–1990)

All COIsMahan et al., 1997
1341.4 (1.0–1.9)

State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  800.9 (0.7–1.1)Visintainer et al., 1995

International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

5761.2 (1.1–1.3)ADVA,

Navy

1411.4 (1.2–1.7)2005a

Army

3721.2 (1.1–1.3)

Air Force

  631.0 (0.7–1.2)

Histologic type—all service branches combined

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

7,553 not exposed to highly chlorinated

PCDDs

Lung (ICD-9 162)

1481.0 (0.9–1.2)

Other respiratory organs (ICD-9 163–165)

    31.2 (0.3–3.6)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Trachea, bronchus, lung (ICD-9 162)

1731.0 (0.9–1.2)

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates

TCDDKogevinas et al, 1993
    21.4 (0.2–4.9)

(lung)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983 (lung, pleura, mediastinum, ICD-8 162–164)

1171.2 (1.0–1.4)Coggon et al., 1986

Background exposure

  391.0 (0.7–1.4)

Low-grade exposure

  351.1 (0.8–1.6)

High-grade exposure

  431.3 (1.0–1.8)

British Production Workers at 4 plants (included in IARC cohort) (lung)

Dioxins, but TCDD unlikely; MCPACoggon et al., 1991
  191.3 (0.8–2.1)

Workers with exposure above background

  141.2 (0.7–2.1)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence

Incidence 1943–1987 (lung, men only)

  131.6 (0.9–2.8)Lynge, 1993

Incidence 1943–1982

Lynge, 1985

Men

  381.2 (nr)

Women

    62.2 (nr)

Dutch production workers in Plant A and Plant B, combined (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (Plant A, 1,020 workers; Plant B, 1,036 workers) (respiratory cancers)

  541.0 (0.9–1.2)Boers et al., 2012

TCDD plasma level (HRs, by tertile) (trachea, bronchus, lung)

  521.0 (0.8–1.2)

Background (≤ 0.4)

  24Referent

Low (0.4–4.1)

  110.5 (0.3–1.1)

Medium (4.1–20.1)

  121.2 (0.6–2.3)

High (≥ 20.1)

    51.2 (0.5–3.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

963 men exposed during production 1955–1985 vs 1,317 unexposed; mortality in 1986 (respiratory system cancers, ICD-8 160–163)

9 vs 31.7 (0.5–6.3)Bueno de Mesquita et al., 1993

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

Boers et al., 2012

Respiratory cancer

  301.1 (0.9–1.3)

Trachea, bronchus, lung cancers

  281.1 (0.9–1.3)

Mortality 1955–2006

Boers et al., 2010

Respiratory cancer

  211.1 (0.5–2.5)

Trachea, bronchus, lung cancers

  201.2 (0.5–2.8)

Mortality 1955–1985

Bueno de Mesquita et al., 1993

Trachea, bronchus, lung cancers

    91.0 (0.5–1.9)

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

Boers et al., 2010

Respiratory cancer

  121.2 (0.6–2.7)

Trachea, bronchus, lung cancers

  121.2 (0.6–2.7)

Mortality 1965–1986

Bueno de Mesquita et al., 1993

Trachea, bronchus, lung cancers

    00.0 (0.0–1.3)

German Production Workers—2,479 workers at 4 plants (in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

All for plants

  471.4 (1.1–1.9)Becher et al., 1996

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    20.7 (0.0–2.5)Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    31.6 (0.3–4.6)Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

  111.5 (0.7–2.6)Becher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Mortality

1953–1992

Ott and Zober, 1996

Respiratory system

  131.2 (0.6–2.0)

TCDD 0.1–0.99 μg/kg of body weight

    20.7 (0.1–2.5)

TCDD ≥ 1 μg/kg of body weight

    82.0 (0.9–3.9)

Lung, bronchus

  111.1 (0.6–2.0)

TCDD 0.1–0.99 μg/kg of body weight

    20.8 (0.1–2.8)

TCDD ≥ 1 μg/kg of body weight

    82.2 (1.0–4.3)

Through 1987

90% CIZober et al., 1990
    42.0 (0.7–4.6)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg—1,144 men working > 1 month in 1952–1984 (generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007

  731.4 (1.1–1.8)Manuwald et al., 2012

Men

  681.5 (1.2–1.9)

Women

    50.8 (0.3–1.9)

Mortality 1952–1989

  311.5 (1.0–2.1)Becher et al., 1996

Mortality (lung) 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966

  261.7 (1.1–2.4)Manz et al., 1991

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

Respiratory cancer

  130.9 (0.5–1.6)

Trachea, bronchus, lung

  110.8 (0.4–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Never-exposed workers

Respiratory cancer

    51.2 (0.4–2.7)

Trachea, bronchus, lung

    41.0 (0.3–2.5)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984); mortality (1969–2000)

Trachea, bronchus, lung (ICD-9 162)

  121.4 (0.7–2.4)’t Mannetje et al., 2005

Other respiratory system sites (ICD-9 163–165)

    13.9 (0.1–21.5)

Sprayers (697 men and 2 women on register of New Zealand applicators, 1973–1984); mortality 1973–2000

Trachea, bronchus, lung (ICD-9 162)

    50.5 (0.2–1.1)’t Mannetje et al., 2005

Other respiratory system sites (ICD-9 163–165)

    12.5 (0.1–13.7)

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

1251.1 (0.9–1.3)Steenland et al., 1999

Chloracne subcohort (n = 608)

  301.5 (0.98–2.1)

Through 1987 (Entire cohort)

Fingerhut et al., 1991

Trachea, bronchus, lung (ICD-9 162)

  891.1 (0.9–1.4)

Respiratory system (ICD-9 160–165

  961.1 (0.9–1.4)

≥ 1-year exposure, ≥ 20-year latency

Trachea, bronchus, lung (ICD-9 162)

  401.4 (1.0–1.9)

Respiratory system (ICD-9 160–165

  431.4 (1.0–1.9)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615) (bronchus, trachea, lung)

  460.7 (0.5–0.9)Collins et al., 2009a

1940–1994 (n = 2,187 men) (lung)

  540.8 (0.6–1.1)Bodner et al., 2003

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

Respiratory cancer (ICD-9 160–165)

1940–2005 (n = 2,122)

1331.4 (1.2–1.6)c

PCP and TCP (n = 720)

  280.9 (0.6–1.3)

PCP (no TCP) (n = 1,402)

1051.6 (1.3–1.9)c
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Trachea, bronchus, lung (ICD-9 162)

1940–2005 (n = 2,122)

1261.4 (1.1–1.6)c

PCP and TCP (n = 720)

  270.9 (0.6–1.3)

PCP (no TCP) (n = 1,402)

  991.6 (1.3–1.9)c

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3) (lung, bronchus)

  360.9 (0.6–1.3)Burns et al., 2011

Through 1994 (n = 1,517) (respiratory system, ICD-8 160–163)

  310.9 (0.6–1.3)Burns et al., 2001

Through 1986 (n = 878) vs national vs 36,804 “unexposed” workers at same location

Bloemen et al., 1993

Respiratory system (ICD-8 162–163)

    90.8 (0.4–1.5)

Through 1982 (n = 878)

Bond et al., 1988

Lung (ICD-8 162–163)

    81.0 (0.5–2.0)

Respiratory (ICD-8 160–163) (exposure lagged 15 yrs)

Low cumulative exposure

    10.7 (nr)

Medium cumulative exposure

    21.0 (nr)

High cumulative exposure

    51.7 (nr)

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP) (bronchus, trachea, lung)

  301.0 (0.6–1.4)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

Ramlow et al., 1996

0-yr latency

Respiratory system (ICD-8 160–163)

  181.0 (0.6–1.5)

Lung (ICD-8 162)

  160.9 (0.5–1.5)

15-yr latency

Respiratory system (ICD-8 160–163)

  171.1 (0.6–1.8)

Lung (ICD-8 162)

  161.1 (0.6–1.8)

OCCUPATIONAL—PAPER AND PULP WORKERS

TCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries,

McLean et al., 2006

TCDD among 27 agents assessed by JEM

Exposure to nonvolatile organochlorine compounds

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Lung (ICD-9 162)

Never

3561.0 (0.9–1.1)

Ever

3141.0 (0.9–1.2)

Pleura (ICD-9 163)

Never

  172.8 (1.6–4.5)

Ever

    40.8 (0.2–2.0)

Other respiratory (ICD-9 164–165)

Never

    82.1 (0.9–4.2)

Ever

    20.7 (0.1–2.4)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Ontario Forestry Workers—1,222 men working ≥ 6 months 1950–1982

Herbicides

80 deaths through 1982; 18 cancers (lung greatest with 5)

    5nrGreen, 1991

DENMARK

Danish gardeners (n = 3,124) exposed to pesticides

1391.0 (0.9–1.2)Kenborg et al., 2012

Danish gardeners—incidence from 3,156 male and 859 female gardeners

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

  340.9 (0.6–1.3)

Born 1915–1934 (medium exposure)

  721.0 (0.8–1.2)

Born after 1934 (low exposure)

    80.8 (0.4–1.7)

10-year followup (1975–1984) of male gardeners

  411.0 (0.7–1.3)Hansen et al., 1992

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

Asp et al., 1994

Trachea, bronchus, lung (ICD-8 162)

  390.9 (0.7–1.3)

Other respiratory (ICD-8 160, 161, 163)

    41.1 (0.7–1.3)

Mortality 1972–1989

Trachea, bronchus, lung (ICD-8 162)

  371.0 (0.7–1.4)

Other respiratory (ICD-8 160, 161, 163)

    10.5 (0.0–2.9)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401) (lung)

1550.5 (0.4–0.5)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487

Phenoxy herbicidesGambini et al., 1997

Lung

  450.8 (0.6–1.1)

Pleura

    22.2 (0.2–7.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 4,224 incident lung cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

  301.3 (0.8–1.9)

SWEDEN

Swedish pesticide applicators—incidence

Wiklund et al., 1989a

Trachea, bronchus, lung

  380.5 (0.4–0.7)

348 Swedish railroad workers (1957–October, 1978)—total exposure to herbicides (lung)

    3Phenoxy acids 1.4 (nr)Axelson et al., 1980

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    14.2 (0.0–23.2)

Lumberjacks (n = 139)

    0

Unexposed lumberjacks (n = 241)

    51.2 (0.4–2.7)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000 (trachea, lung)

  270.7 (0.5–1.0)Swaen et al., 2004

Through 1987(trachea, lung)

  121.1 (0.6–1.9)Swaen et al., 1992
UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

6,4730.9 (0.9–0.9)

Nonwhites (n = 11,446)

6641.0 (0.9–1.1)

Women

Whites (n = 2,400)

  570.8 (0.6–1.1)

Nonwhites (n = 2,066)

  240.6 (0.4–0.9)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants (lung, bronchus)

Koutros et al., 2010a

Private applicators

4360.5 (0.4–0.5)

Commercial applicators

  260.8 (0.5–1.1)

Spouses

1330.4 (0.4–0.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Enrollment through 2002

Samanic et al., 2006

Dicamba—lifetime days exposure

None

  951.0

1– < 20

  140.8 (0.5–1.5)

20– < 56

  110.6 (0.3–1.3)

56– < 116

  121.0 (0.5–1.9)

≥ 116

  151.5 (0.8–2.7
p-trend = 0.13

Enrollment through 2002

Alavanja et al., 2005

Private applicators

Lung

2660.5 (0.4–0.5)

Respiratory system

2940.5 (0.4–0.5)

Spouses of private applicators (> 99% women)

Lung

  680.4 (0.3–0.5)

Respiratory system

  710.4 (0.3–0.5)

Commercial applicators

Lung

  120.6 (0.3–1.0)

Respiratory system

  140.6 (0.3–1.0)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Respiratory

Applicators (n = 1,641)

4220.4 (0.4–0.5)

Spouses (n = 676)

1100.4 (0.3–0.5)

Trachea, bronchus, lung

Applicators (n = 1,641)

4170.4 (0.4–0.5)

Spouses (n = 676)

1080.4 (0.3–0.5)

Other respiratory system

Applicators (n = 1,641)

    50.2 (0.1–0.3)

Spouses (n = 676)

    2nr

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

1290.4 (0.3–0.4)

Years handled pesticides

≤ 10 yrs

  250.4 (nr) (p < 0.05)

≥ 10 yrs

  800.3 (nr) (p < 0.05)

Spouses of private applicators (> 99% women)

  290.3 (0.2–0.5)

Florida Licensed Pesticide Applicators (common phenoxy use assumed but not documented)

Herbicides

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Only for lawn and ornamentals (lung, ICD-8 162–163)

    70.9 (nr)

Minnesota Highway Maintenance Workers (n = 4,849) who worked ≥ l day for the Department of Transportation and ≥ 1 day after January 1, 1945 (1984–1986)

HerbicidesBender et al., 1989

Trachea, bronchus, lung (ICD-9 162.0–162.8)

  540.7 (0.5–0.9)

All respiratory (ICD-9 160.0–165.9)

  570.7 (0.5–0.9)

ENVIRONMENTAL

Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)

TCDD

Incidence

20-yr followup to 1996—men and women (lung ICD-9 162)

Pesatori et al., 2009

Zone A

    71.1 (0.5–2.4)

Zone B

  371.0 (0.7–1.3)

Zone R

2801.0 (0.9–1.2)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone A

    20.8 (0.2–3.4)

Zone B

  181.1 (0.7–1.8)

Zone R

  960.8 (0.7–1.0)

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone R

  161.5 (0.8–2.5)

Mortality

25-yr followup to 2001—men and women (lung ICD-9 162)

Consonni et al., 2008

Zone A

  111.1 (0.6–2.0)

Zone B

  621.1 (0.9–1.4)

Zone R

3831.0 (0.8–1.1)

20-yr followup to 1996 (lung)

Bertazzi et al., 2001

Zones A, B—men

  571.3 (1.0–1.7)

Zones A, B—women

    40.6 (0.2–1.7)

15-yr followup to 1991—men (lung)

Bertazzi et al., 1998

Zone A

    41.0 (0.4–2.6)

Zone B

  341.2 (0.9–1.7)

Zone R

1760.9 (0.8–1.1)

15-yr followup to 1991—women (lung)

Bertazzi et al., 1998

Zone A

    0nr

Zone B

    20.6 (0.1–2.3)

Zone R

  291.0 (0.7–1.6)

Ecological Study of Residents of Chapaevsk, Russia

DioxinRevich et al., 2001
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Saskatchewan, Canada farmers (604 men, 223 women) diagnosed with lung cancer between November, 1983, and July, 1986

HerbicidesMcDuffie et al., 1990

Interviews with lung cancer patients (273 men and 103 women) who sprayed herbicides

1030.6 (nr)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; ACC, Army Chemical Corps; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupational specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; SEA, Southeast Asia; SIR, standardized incidence ratio; SMR, standardized mortality ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

c99% CI.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With 36 cases observed, the incidence of lung or bronchial cancer in the most restrictively defined cohort was not increased (SIR = 0.92, 95% CI 0.65–1.28). The category of other respiratory cancers was significantly increased (SIR = 4.76, 95% CI 1.53–11.11), but this category consisted of only one carcinoma of the sinuses and four cases of mesothelioma, which could be attributed with some certainty to occupational asbestos exposure, although no documentation was provided.

Boers et al. (2012) updated mortality in workers in two chlorophenoxy herbicide plants in the Netherlands by using semiquantitative measures of TCDD exposure. Plasma concentrations of TCDD in a subset of 187 workers were used to develop a predictive model of TCDD exposure, and a Cox proportional-hazards model was used to investigate associations between time-varying TCDD exposure

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

and cause-specific mortality. No relationship was found between TCDD exposure and respiratory cancers. HRs for predicted TCDD concentrations and cancers of the trachea, bronchus, and lung were not increased in the entire cohort (HR = 0.98, 95% CI 0.84–1.15 for each unit increase in TCDD exposure on a log scale) or in only the workers in factory A (HR = 1.07, 95% CI 0.86–1.33). That study was a reanalysis of the mortality data on the cohort updated through 2006; using crude exposure estimates based on job classification, Boers et al. (2010) had found that respiratory-cancer risks were not significantly increased. That finding is in contrast with the excess mortality from respiratory cancers reported in the second followup of the cohort (Hooiveld et al., 1998).

Manuwald et al. (2012) updated mortality though 2007 in a cohort of 1,589 male and female workers employed for at least 3 months during 1952–1984 in a factory in Hamburg, Germany, that produced various herbicides and insecticides, including 2,4,5-T, which was contaminated with TCDD and other higher-chlorinated dioxins and furans. SMRs were calculated by using the population of Hamburg as a reference group. Deaths due to cancer of the trachea, bronchus, and lung were significantly increased in men (68 deaths, SMR = 1.52, 95% CI 1.18–1.93) and in the total cohort (SMR = 1.43, 95% CI 1.12–1.80) but were not increased in the smaller group of women (five deaths, SMR = 0.80, 95% CI 0.26–1.88). The prevalence of smoking was not controlled for but was suggested not to differ from that in the general population (Flesch-Janys et al., 1995). Although those findings are consistent with earlier mortality reports on this cohort (Becher et al., 1996; Manz et al., 1991), an exposure–response relationship was not found (p = 0.30) for respiratory-cancer mortality when estimated cumulative occupational exposure to TCDD was stratified into quartiles.

Ruder and Yiin (2011) reported mortality through 2005 in a cohort of 2,122 US PCP production workers in four plants in the NIOSH Dioxin Registry relative to US referent rates. The workers in all four plants were exposed to PCP and to PCDDs and PCDFs as contaminants during the production of PCP. Two plants were also involved in TCP production, so a subcohort of 720 men was also exposed to 2,3,7,8-TCDD, a contaminant of TCP, but not of PCP. A total of 1,165 deaths occurred in 1940–2005, and overall cancer mortality was significantly increased (326 deaths, SMR = 1.17, 95% CI 1.05–1.31). There were excess deaths from tracheal, bronchial, and lung cancer (126 deaths, SMR = 1.36, 95% CI 1.13–1.62) in the entire cohort and in the PCP-only group (99 deaths, SMR = 1.56, 95% CI 1.27–1.90) but no increase in the PCP-plus-TCDD group (27 deaths, SMR = 0.91, 95% CI 0.60–1.33). The increase in the SMR for lung-cancer mortality did not increase with duration (days of work in PCP operations); it reached the concentration of statistical significance in the lowest group (up to 57 days) and in the third of the four categories (182 to < 650 days). The study has merit in that it followed all US workers employed in PCP manufacturing through 1992 for an average of 39 years from first exposure. The lack of information on smoking greatly limits conclusions regarding the contribution of the agents to the

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

increase in mortality from tracheal, bronchial, and lung cancers. Although there was potential for occupational exposure to TEQs in the entire cohort, the smaller subcohort with potential for TCDD exposure did not have increased mortality due to tracheal, bronchial, and lung cancers. In addition, the authors noted that there was no difference in mortality between the 236 workers who had diagnoses of chloracne and other workers, as found earlier by Bodner et al. (2003).

Koutros et al. (2010a) updated cancer incidence as of 2006 in members of the large prospective AHS cohort. SIRs of lung and bronchial cancers were significantly lower in private applicators (436 cases, SIR = 0.48, 95% CI 0.43–0.53) and their spouses (133 cases, SIR = 0.42, 95% CI 0.35–0.50) and unchanged in commercial applicators (26 cases, SIR = 0.75, 95% CI 0.49–1.09) relative to the general population in Iowa and North Carolina, the states selected for the study. Lower rates of smoking and increased physical activity are factors that may contribute to the lower risk of cancer at these sites.

Waggoner et al. (2011) reported mortality in the same AHS cohort from the time of enrollment (1993–1997) through 2007 vs state-specific rates. Death from tracheal, bronchial, and lung cancer was significantly decreased in private and commercial applicators (417 deaths, SMR = 0.43, 95% CI 0.39–0.47) and their spouses (108 deaths, SMR = 0.38, 95% CI 0.31–0.45). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Kenborg et al. (2012) conducted a study that focused on Parkinson disease in a Danish cohort of 3,124 male union members who worked as professional gardeners in 1975. When studying this cohort previously, Hansen et al. (1992, 2007) had reported that herbicides (including phenoxy herbicides) constituted most of their exposure. Kenborg et al. (2012) reported the incidence of several cancers recognized as being smoking-related. The incidence of lung cancer in the gardeners was similar to the age-adjusted and calendar-period–adjusted incidence in the general male Danish population (SIR = 1.02, 95% CI 0.86–1.20).

Biologic Plausibility

Long-term animal studies have examined the effects of exposure to the COIs on tumor incidence (Charles et al., 1996; Stott et al., 1990; Walker et al., 2006; Wanibuchi et al., 2004). As noted in previous VAO reports, there is evidence of an increased incidence of squamous-cell carcinoma of the lung in male and female rats exposed to TCDD at high concentrations (Kociba et al., 1978; Van Miller et al., 1977). A significant increase in neoplastic and nonneoplastic lung lesions was found in female rats exposed to TCDD for 2 years (Kociba et al., 1978; NTP, 1982a,b, 2006; Walker et al., 2006, 2007). The most common non-neoplastic lesions were bronchiolar metaplasia and squamous metaplasia of the alveolar epithelium. Cystic keratinizing epithelioma was the most commonly

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

observed neoplasm. The lung was also identified as a target organ in an NTP tumor-promotion study after 60 weeks of exposure to TCDD in ovariectomized female Sprague Dawley rats initiated with a single dose of diethyl-N-nitrosamine (Beebe et al., 1995; Tritscher et al., 2000). Those studies ended with increased incidences of alveolar epithelial hyperplasia and alveolar–bronchiolar metaplasia, results that were similar to what was observed in the earlier National Toxicology Program (NTP) studies (Tritscher et al., 2000).

A 2-year study of F344 rats exposed to cacodylic acid at 0–100 ppm and B6C3F1 mice exposed at 0–500 ppm failed to detect lung neoplasms at any dose (Arnold et al., 2006); this finding is consistent with those of previous studies. However, exposure to cacodylic acid had previously been shown to increase tumor multiplicity in mouse strains that were susceptible to developing lung tumors (for example, A/J strain; Hayashi et al., 1998) or in mice pretreated with an intitiating agent (4-nitroquinoline 1-oxide; Yamanaka et al., 1996). The data indicate that cacodylic acid may act as a tumor-promoter in the lung.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The evidence remains limited but suggestive of an association between exposure to at least one COI and the risk of developing or dying from lung cancer. In the present update, there are new supporting data from the followup studies of mortality in the Hamburg cohort of herbicide producers (Manuwald et al., 2012) and in US PCP workers (Ruder and Yiin, 2011). In the past, the most compelling evidence has come from studies of heavily exposed occupational cohorts, including British 2-methyl-4-chlorophenoxyacetic acid (MCPA) production workers (Coggon et al., 1986), German production workers (Becher et al., 1996), a BASF cohort (Ott and Zober, 1996), a NIOSH cohort (Fingerhut et al., 1991; Steenland et al., 1999), and Danish production workers (Lynge, 1993).

In the last update, Cypel and Kang (2010) found a significantly increased lung-cancer risk in Army Chemical Corps (ACC) veterans who used herbicides in Vietnam. The most recent findings from the Operation Ranch Hand study (Pavuk et al., 2005) suggested an increase in risk with serum TCDD concentration even in subjects who made up the comparison group, whose TCDD exposure was considerably lower than that of the Ranch Hand cohort (but not zero). The American and Australian cohort studies of Vietnam veterans (ADVA, 2005a,b,c; Dalager and Kang, 1997), which presumably cover a large proportion of exposed soldiers, showed higher than expected incidence of and mortality from lung cancer. The main limitations of those studies are that there was no assessment of exposure—as there was in, for example, the Ranch Hand study—and that some potential confounding variables, notably smoking, could not be accounted for. The committee believes that it is unlikely that the distribution of smoking dif-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

fered greatly between the two cohorts of veterans, so confounding by smoking is probably minimal. The studies therefore lend support to the findings of the Ranch Hand study. The methodologically sound AHS did not show any increased risk of lung cancer; however, although there was substantial 2,4-D exposure in this cohort (Blair et al., 2005b), dioxin exposure of the contemporary farmers was probably negligible.

In large part, the environmental studies have not been supportive of an association, although in the cancer-incidence update from Seveso, the highest risks occurred in the most exposed.

Also supportive of an association, however, are the numerous lines of mechanistic evidence, discussed in the section on biologic plausibility, which provide further support for the conclusion that the evidence of an association is limited or suggestive.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is limited or suggestive evidence of an association between exposure to at least one COI and carcinomas of the lung, bronchus, and trachea.

BONE AND JOINT CANCER

ACS estimated that about 1,600 men and 1,290 women would receive diagnoses of bone or joint cancer (ICD-9 170) in the United States in 2012 and that 790 men and 620 women would die from these cancers (Siegel et al., 2012). Primary bone cancers are among the least common malignancies, but the bones are frequent sites of tumors secondary to cancers that have metastasized. Only primary bone cancer is considered here. The average annual incidence of bone and joint cancer is shown in Table 8-14.

Bone cancer is more common in teenagers than in adults. It is rare among people in the age groups of most Vietnam veterans (50–64 years). Among the

TABLE 8-14 Average Annual Incidence (per 100,000) of Bone and Joint Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men1.01.30.31.31.31.11.51.52.8
Women0.80.90.41.51.51.51.21.40.4

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

risk factors for bone and joint cancer in adults are exposure to ionizing radiation in treatment for other cancers and a history of some noncancer bone diseases, including Paget disease.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and bone and joint cancer. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-15 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Case-Control Studies

No Vietnam-veteran studies or case-control studies of exposure to the COIs and bone or joint cancer have been published since Update 2010.

Occupational Studies

In an update of cancer incidence from 1985 through 2007 in 2,4-D production workers in the Dow Chemical Company in Midland, Michigan, Burns et al. (2011) found a single case of cancer of bone or soft tissue, with attendant nonsignificant estimates of exposure-related risk (SIR = 0.81, 95% CI 0.01–4.49 in the most restrictively defined cohort). Similarly, Waggoner et al. (2011) reported three deaths from cancer in the applicators in the AHS and two in their spouses. The numbers are too small to add significantly to the assessment of bone-cancer risk associated with exposure to the COIs.

Environmental Studies

One recent study (McNally et al., 2012) reported on the occurrence of bone cancer (Ewings sarcoma and osteosarcoma) in all of Great Britian in 1980–2005. The data on incidence from the cancer registries included 2,566 osteosarcoma cases and 1,650 Ewing sarcoma cases. There were essentially no exposure data, but the cases occurred in lower-socioeconomic areas, possibly indicating some association with agricultural exposures. This very large study has no exposure data and thus provides little information that is germane to the task of the present committee.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-15 Selected Epidemiologic Studies—Bone and Joint Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  270.8 (0.4–1.7)et al., 1986, 1988

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  111.4 (0.1–21.5)
State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans

Veterans aged 35–64 years in 1993—cases diagnosed 1988–1993 vs nonexposed veterans with gastrointestinal cancers

    40.9 (0.1–11.3)Clapp, 1997

New York

Deployed vs nondeployed veterans

    81.0 (0.3–3.0)Lawrence et al., 1985

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    1nrAnderson et al., 1986
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

    51.2 (0.4–2.8)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    31.1 (0.2–3.1)

7,553 not exposed to highly chlorinated

    21.4 (0.2–5.2)

PCDDs

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    10.9 (0.0–5.0)Coggon et al., 1986

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Mortality

Through 1987

90% CIZober et al., 1990
    00.0 (0.0–65.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

    00.0 (0.0–21.8)McBride et al., 2009a

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    0nr’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1987

    22.3 (0.3–8.2)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    15.5 (0.1–29.0)

Mortality—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991)

    25.0 (0.6–18.1)Collins et al., 1993

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3) (bone, soft tissue)

    10.8 (0.0–4.5)Burns et al., 2011

Through 1982 (n = 878)

    0nr (0.0–31.1)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–1989 (n = 770)

    0nrRamlow et al., 1996

0-yr latency

    0nr

15-yr latency

    0nr
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

Danish paper workers

Rix et al., 1998

Men

    10.5 (0.0–2.7)

Women

    0nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

    41.1 (0.4–2.4)Hertzman et al., 1997

Mortality 1950–1989

    51.3 (0.5–2.7)

No exposed to highly chlorinated PCDDs

    21.4 (0.2–5.2)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

    90.9 (nr)

Employee

    0nr

Women

Self-employed

    00.0

Employee

    16.3 (p < 0.05)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  100.8 (0.4–1.4)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
    10.5 (0.0–2.6)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident bone cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

    11.7 (0.2–13.3)

SWEDEN

Incident bone cancer cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
441.0 (0.6–1.4)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    0nrSwaen et al., 2004

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  491.3 (1.0–1.8)

Nonwhites (n = 11,446)

    41.0 (0.3–2.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Women

Whites (n = 2,400)

    11.2 (0.0–6.6)

Nonwhites (n = 2,066)

    00.0 (0.0–6.3)

White Male Residents of Iowa—bone cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

  561.1 (nr)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Mortality

15-yr followup to 1991—men

Bertazzi et al., 1998

Zone R

    20.5 (0.1–2.0)

15-yr followup to 1991—women

Bertazzi et al., 1998

Zone B

    12.6 (0.3–19.4)

Zone R

    72.4 (1.0–5.7)
Ecological Study of Residents of Chapaevsk, RussiaDioxinRevich et al., 2001

Mortality—1995–1998 (SMR vs regional rates)

Men

    72.1 (0.9–4.4)

Women

    71.4 (0.6–3.0)
CASE-CONTROL STUDIES

International Case-Control Studies

European Multicentric study of association between occupational exposure and risk of bone sarcoma (96 cases, 35–69 yrs of age vs 2,632 hospital- and population-based controls

  18Herbicides, pesticides 2.6 (1.5–4.6)Merletti et al., 2005

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CI, confidence interval; COI, chemical of interest; GI, gastrointestinal; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportionate mortality ratio; SMR, standardized mortality ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

No environmental studies with sufficiently specific characterization of exposure to the COIs and this health outcome have been published since Update 2010.

Biologic Plausibility

No animal studies have reported an increased incidence of bone and joint cancers after exposure to the COIs. The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The small amount of new data, in concert with the previous literature, summarized in Table 8-15 do not indicate an association between exposure to the COIs and bone cancer.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and bone and joint cancers.

SOFT-TISSUE SARCOMA

Soft-tissue sarcoma (STS) (ICD-9 164.1, 171) arises in soft somatic tissues in and between organs. Three of the most common types of STS—liposarcoma, fibrosarcoma, and rhabdomyosarcoma—occur in similar numbers in men and women. Because of the diverse characteristics of STS, accurate diagnosis and classification can be difficult. ACS estimated that about 6,110 men and 5,170 women would receive diagnoses of STS in the United States in 2012 and that about 2,050 men and 1,850 women would die from it (Siegel et al., 2012). The average annual incidence of STS is shown in Table 8-16.

TABLE 8-16 Average Annual Incidence (per 100,000) of Soft-Tissue Sarcoma (Including Malignant Neoplasms of the Heart) in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men5.45.45.26.87.24.58.68.76.7
Women4.54.46.35.45.27.77.07.63.4

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Among the risk factors for STS are exposure to ionizing radiation during treatment for other cancers and some inherited conditions, including Gardner syndrome, Li-Fraumeni syndrome, and neurofibromatosis. Several chemical exposures have been identified as possible risk factors (Zahm and Fraumeni, 1997).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was sufficient epidemiologic data to support an association between exposure to the COIs and STS. Additional information available to the committees responsible for subsequent updates has not changed that finding.

As seen with Hodgkin lymphoma and non-Hodgkin lymphoma, the available epidemiologic evidence suggests that phenoxy herbicides rather than TCDD may be associated with developing STS. Some of the strongest evidence of an association between STS and exposure to phenoxy herbicides comes from a series of case-control studies conducted in Sweden (Eriksson et al., 1981, 1990; Hardell and Eriksson, 1988; Hardell and Sandstrom, 1979). The studies, involving a total of 506 cases, show an association between STS and exposure to phenoxy herbicides, chlorophenols, or both. The VAO committee concluded that although those studies had been criticized, there is insufficient justification to discount the consistent pattern of increased risks and the clearly described and sound methods used. In addition, a reanalysis of the data by Hardell (1981) to evaluate the potential influence of recall bias and interviewer bias confirmed the original results. Hansen et al. (2007) conducted a historical-cohort study of male gardeners who were members of the Danish Union; cancer incidence was ascertained from 1975 to 2001. Birth date served as a surrogate for potential exposure to pesticides and herbicides; older cohorts represented higher exposure potential. Men born before 1915 were much more likely to die from STS, although this finding was based on only three cases. Reif et al. (1989) performed a series of case-control analyses in a sample of specified occupations and found a significant association between STS and having recently been employed as a forestry worker.

Those findings are supported by a significantly increased risk in a NIOSH study of production workers most highly exposed to TCDD (Fingerhut et al., 1991); Steenland et al. (1999) published an update of the NIOSH cohort, but STS was not among the outcomes evaluated. A similar increased risk was seen in the IARC cohort in deaths that occurred 10–19 years after first exposure (Kogevinas et al., 1992; Saracci et al., 1991) according to a fairly crude exposure classification. An updated and expanded study of the IARC cohort by Kogevinas et al. (1997) found a nonsignificantly increased risk of STS when followup was extended to 1992. Then NIOSH and IARC cohorts are among the largest and the most highly exposed occupational cohorts. Smaller studies of workers that are included in the multinational IARC cohort—Danish herbicide manufacturers (Lynge et al., 1985, 1993) and Dow production workers in Midland, Michigan, and New Zealand

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

(Collins et al., 2009a; ‘t Mannetje et al., 2005)—showed an increased risk of STS, but the results were commonly nonsignificant, possibly because of small samples (related to the relative rarity of STS in the population).

Several studies have reported on STS in relation to living near waste incinerators that release dioxin as a contaminant. Viel et al. (2000) reported on an investigation of apparent clusters of STS and non-Hodgkin lymphoma cases in the vicinity of a municipal solid waste incinerator in Doubs, France; Comba et al. (2003) and Costani et al. (2000) examined STS in the general population living near a chemical plant in the northern Italian city of Mantua; and Zambon et al. (2007) conducted a population-based case-control study in Venice, Italy, in an area that included 26 waste incinerators and other industrial plants. Each of those studies found a statistically significant excess of STS, but none showed any direct evidence of human exposure.

No cases of STS have been reported in Zones A and B in the Seveso cohort (Consonni et al., 2008); the incidence of STS was slightly increased in Zone R but not significantly (Pesatori et al., 2009). Veteran studies have not found a significant increase in STS. No increase was seen in Operation Ranch Hand veterans (AFHS, 1996, 2000; Michalek et al., 1990) or in VA studies of US Vietnam veterans (Breslin et al., 1986, 1988; Bullman et al., 1990; Watanabe and Kang, 1995; Watanabe et al., 1991). A slight increase in the incidence of STS was seen in Australian Air Force veterans compared with the Australian population but not in Army or Navy personnel (ADVA, 2005a), and no increase in mortality was seen in Australian veterans who served in any of the military branches (ADVA, 2005b). A nonsignificant increase in mortality from STS was also seen in state studies of veterans in Massachusetts, Michigan, and New York.

Table 8-17 summarizes the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies

No Vietnam-veteran studies or environmental studies of exposure to the COIs and STS have been published since Update 2010.

Occupational Studies

In an update of cancer incidence in 1985–2007 in 2,4-D production workers of Dow Chemical Company in Midland, Michigan, Burns et al. (2011) found a single case of cancer of the bone or soft tissue in the most restrictively defined cohort of exposed workers, with attendant nonsignificant estimates of exposure-related risk (SIR = 0.8, 95% CI 0.0–4.5). The numbers were too small to add substantially to the assessment of STS risk associated with exposure to Agent Orange–associated chemicals.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-17 Selected Epidemiologic Studies—Soft-Tissue Sarcoma (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Mortality

Through 1987—Ranch Hand personnel (n = 1,261) vs SEA veterans (19,102)

    1nrMichalek et al., 1990

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1984

Army, deployed (n = 24,145) vs nondeployed (n = 27,917)

  431.1Watanabe et al., 1991

Served in I Corps (n = 6,668)

  100.9 (0.4–1.6)Bullman et al., 1990

Marine Corps, deployed (n = 5,501) vs nondeployed (n = 4,505)

  110.7Watanabe et al., 1991

1965–1982

Breslin

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  301.0 (0.8–1.2)et al.,1986, 1988

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    80.7 (0.4–1.3)

US VA Study of Marine Post-service

All COIs

Mortality—sample of Marines serving 1967–1969, deployed (n = 10,716) vs nondeployed (n = 9,346)

Mortality, earlier of discharge or April 1973 through 1991

    0nrWatanabe and Kang, 1995

US VA Case-control study

234 Vietnam veterans vs 13,496 Vietnam-era veterans

  860.8 (0.6–1.1)Kang et al., 1986
State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans

Veterans aged 35–65 years in 1993—cases diagnosed 1988–1993 vs gastrointestinal cancers

  181.6 (0.5–5.4)Clapp, 1997

Diagnosed 1972–1983

    95.2 (2.4–11.1)Kogan and Clapp, 1988

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

    81.1 (0.5–2.2)Visintainer et al., 1995
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    62.0 (0.8–4.4)

7,553 not exposed to highly chlorinated PCDDs

    21.4 (0.2–4.9)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

    42.0 (0.6–5.2)Saracci et al., 1991

Nested case-control study

IARC cohort (men and women)—incidence

Kogevinas et al., 1995

   Exposed to 2,4,5-T

    54.3 (0.7–26.3)

   Exposed to TCDD

    55.2 (0.9–31.9)

Mortality—IARC cohort (16,863 men and 1,527 women) 10–19 years since first exposure

    46.1 (1.7–15.5)Kogevinas et al., 1992

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    11.1 (0.0–5.9)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1987 (men only)

    52.0 (0.7–4.8)Lynge, 1993

Incidence 1943–1982

Lynge, 1985

Men

    52.7 (0.9–6.3)

Women

    0nr

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–1991

    0nrHooiveld et al., 1998

Mortality 1955–1985

    00.0 (0.0–18.4)Bueno de Mesquita et al., 1993
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–1986

    00.0 (0.0–73.8)Bueno de Mesquita et al., 1993

German Production Workers—2,479 workers at 4 plants (in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992

Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    0nr

TCDD 0.1–0.99 μg/kg of body weight

    0nr

TCDD > 1 μg/kg of body weight

    0nr

Mortality

Through 1987

90% CIZober et al., 1990
    0nr

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966

    0nrManz et al., 1991

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    13.4 (0.1–19.5)

Never-exposed workers

    00.0 (0.0–34.9)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    00.0 (0.0–19.3)’t Mannetje et al., 2005
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    14.3 (0.1–23.8)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

    42.3 (0.6–5.9)Steenland et al., 1999

Chloracne subcohort (n = 608)

    311.3 (2.3–33.1)

Through 1987

    43.4 (0.9–8.7)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    39.2 (1.9–27.0)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    44.1 (1.1–10.5)Collins et al., 2009a

1940–1994 (n = 2,187 men)

    22.4 (0.3–8.6)Bodner et al., 2003

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois) (connective tissue and soft tissue)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (connective tissue and soft tissue)

    21.5 (0.2–5.5)

PCP and TCP (n = 720)

    12.3 (0.1–12.6)

PCP (no TCP) (n = 1,402)

    11.1 (0.0–6.4)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3) (bone, soft tissue)

    10.8 (0.0–4.5)Burns et al., 2011

Through 1982 (n = 878)

    0nrBond et al., 1988
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    12.2 (0.0–12.1)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

    0Expected number of exposed casesRamlow et al., 1996
0.2
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

    81.2 (0.5–2.4)

Ever

    40.8 (0.2–2.0)

Danish paper-mill workers

Rix et al., 1998

Men employed in sorting and packing

  121.2 (0.6–2.0)

Women employed in sorting and packing

    84.0 (1.7–7.8)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

  111.0 (0.6–1.7)Hertzman et al., 1997

Mortality 1950–1989

    61.2 (0.5–2.3)

DENMARK

Danish gardeners—incidence from 3,156 male and 859 female gardeners

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

    35.9 (1.9–18.2)

Born 1915–1934 (medium exposure)

    00.0 (0.0–3.8)

Born after 1934 (low exposure)

    11.8 (0.3–12.9)

10-year followup (1975–1984) of male gardeners

    35.3 (1.1–15.4)Hansen et al., 1992

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

    21.0 (0.1–3.5)Torchio et al., 1994
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 142 incident STS cases vs remainder of 19,904 men with any incident cancer

Forestry workers (n = 134)

HerbicidesReif et al., 1989

Aged 20–59

    43.2 (1.2–9.0)

Aged ≥ 60

    0

SWEDEN

Swedish pesticide applicators—incidence (n = 20,245)

    799% CI 0.9 (0.8–1.1)Wiklund et al., 1988, 1989a

354,620 Swedish agricultural and forestry workers identified from 1960 census, followed 1961–1979; compared to reference population

3310.9 (0.8–1.0)Wiklund and Holm, 1986

Incident STS cases 1961–1973 with agriculture as economic activity in 1960 census (connective tissue and muscle)

1621.1 (0.9–1.3)Wiklund, 1983

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  980.9 (0.8–1.1)

Nonwhites (n = 11,446)

  101.5 (0.7–2.8)

Women

Whites (n = 2,400)

    31.2 (0.2–3.5)

Nonwhites (n = 2,066)

    00.0 (0.0–1.9)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  100.7 (0.3–1.2)

Spouses of private applicators (> 99% women)

    30.5 (0.1–1.4)

Commercial applicators

nr0.0 (0.0–3.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

Enrollment through 2007, vs state rates (connective tissue)

Waggoner et al., 2011

Applicators (n = 1,641)

    90.7 (0.3–1.5)

Spouses (n = 676)

    61.0 (0.4–2.2)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

    40.7 (0.2–1.8)

Spouses of private applicators (> 99% women)

    31.4 (0.3–4.1)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of STS

Herbicides

USDA forest and soil

    21.0 (0.1–3.6)Alavanja et al., 1989

Florida Pesticide Applicators licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

    0nr
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    0nrPesatori et al., 2009

Zone B

    0nr

Zone R

    91.3 (0.6–2.7)

10-yr followup to 1991—men

Bertazzi et al., 1993;

Zone A

    0nr

Zone B

    0nrPesatori et al., 1992

Zone R

    62.8 (1.0–7.3)

10-yr followup to 1991—women

Bertazzi et al., 1993;

Zone A

    0nr

Zone B

    0nrPesatori et al., 1992

Zone R

    21.6 (0.3–7.4)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    0nr

Zone B

    0nr

Zone R

    40.8 (0.3–2.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

20-yr followup to 1996

Bertazzi et al., 2001

Zone A—men and women

    0nr

Zone B—men and women

    0nr

Zones A and B—men

    0nr

Zones A and B—women

    0nr

15-yr followup to 1991—men

Bertazzi et al., 1997, 1998

Zone A

nr

Zone B

    0nr

Zone R

    42.1 (0.7–6.5)

15-yr followup to 1991—women

Bertazzi et al., 1997, 1998

Zone A

nr

Zone B

    0nr

Zone R

    0nr

10-yr followup to 1986—men

Bertazzi et al., 1989a

Zone A, B, R

    25.4 (0.8–38.6)

Zone R

    26.3 (0.9–45.0)Bertazzi et al., 1989b

10-yr followup to 1986—women

Bertazzi et al., 1989a

Zone A, B, R

    12.0 (0.2–1.9)

Zone B

    117.0 (1.8–163.6)Bertazzi et al., 1989b

FINLAND

Finnish community exposed to chlorophenol contamination (men and women)

    6Chlorophenol 1.6 (0.7–3.5)Lampi et al., 1992

FRANCE

Residents near French solid-waste incinerator—incidence

DioxinViel et al., 2000

Spatial cluster

  451.4 (p = 0.004)

1994–1995

  123.4 (p = 0.008)

ITALY

Italian rice growers

Chlorophenoxy acids, chlorophenolsGambini et al., 1997
    14.0 (0.1–22.3)

NEW ZEALAND

Residents of New Plymouth Territorial Authority, New Zealand near plant manufacturing 2,4,5-T in 1962–1987

2,4,5-TRead et al., 2007

Incidence

  561.0 (0.8–1.4)c

1970–1974

    71.0 (0.4–2.1)

1975–1979

    30.4 (0.1–2.1)

1980–1984

  101.3 (0.6–2.4)

1985–1989

  111.2 (0.6–2.2)

1990–1994

    90.9 (0.4–1.7)

1995–1999

  141.3 (0.7–2.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Cross-Canada Study of Pesticides and Health—Men (≥ 19 yrs of age) diagnosed September 1991–December 1994 (n = 357) vs matched population-based controls (n = 1,506); exposure to:

Pahwa et al., 2011

Phenoxy herbicides

80 vs 3211.1 (0.8–1.5)

2,4-D

69 vs 2931.0 (0.7–1.4)

Mecoprop

26 vs 811.3 (0.8–2.2)

MCPA

13 vs 461.1 (0.6–2.2)

Diclofop-methyl

8 vs 251.2 (0.4–2.9)

Cross-Canada Study of Pesticides and Health—Men (≥ 19 yrs of age) diagnosed September 1991–December 1994 (n = 357) vs matched population-based controls (n = 1,506); exposure to:

Phenoxy herbicidesPahwa et al., 2006

Any phenoxyherbicide

80 vs 3211.1 (0.7–1.5)

2,4-D

69 vs 2931.0 (0.6–1.5)

Mecoprop

26 vs 811.0 (0.5–1.9)

MCPA

13 vs 461.1 (0.5–2.2)

Finnish STS patients vs controls within quintiles based on TEQ in subcutaneous fat—incidence

110DioxinTuomisto et al., 2004

Quintile 1 (median, ~12 ng/kg TEQ)

nr1.0

Quintile 2 (median, ~20 ng/kg TEQ)

nr0.4 (0.2–1.1)

Quintile 3 (median, ~28 ng/kg TEQ)

nr0.6 (0.2–1.7)

Quintile 4 (median, ~40 ng/kg TEQ)

nr0.5 (0.2–1.3)

Quintile 5 (median, ~62 ng/kg TEQ)

nr0.7 (0.2–2.0)

Italy

Population-based Veneto Tumour Registry, Italy, average exposure based on duration and distance of residence from 33 industrial sources—incidence

DioxinZambon et al., 2007

Sarcoma (ICD-9 158, 171, 173, visceral sites)

Men

   < 4 TCDD (fg/m3)

  311.0

   4–6

  391.1 (0.6–2.0)

   ≥ 6

  171.9 (0.9–4.0) p-trend = 0.15

Women

   < 4 TCDD (fg/m3)

  241.0

   4–6

  441.5 (0.8–2.7)

   ≥ 6

  172.4 (1.0–5.6) p-trend = 0.04
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Men, women combined

Connective, other soft tissue (ICD-9 171)

   < 4 TCDD (fg/m3)

  251.0

   4–6

  391.4 (0.7–2.5)

   ≥ 6

  173.3 (1.4–7.9) p-trend = 0.01

Skin (ICD-9 173)

   < 4 TCDD (fg/m3)

    51.0

   4–6

  100.0 (0.3–4.7)d

   ≥ 6

    20.3 (0.0–3.4) p-trend = 0.48

Retroperitoneum, peritoneum (ICD-9 158)

   < 4 TCDD (fg/m3)

    61.0

   4–6

  121.1 (0.3–3.4)

   ≥ 6

    30.8 (0.1–4.5) p-trend = 0.86

Visceral sites

   < 4 TCDD (fg/m3)

  191.0

   4–6

  221.2 (0.6–2.6)

   ≥ 6

  122.5 (1.0–6.3) p-trend = 0.08

Residents near industrial-waste incinerator in Mantua, Italy—incidence

Dioxin

Residence within 2 km of incinerator

    531.4 (5.6–176.1)Comba et al., 2003

Residents near chemical plant in Mantua, Italy—incidence

  20TCDD emissions 2.3 (1.3–3.5)Costani et al., 2000

Italian rice weeders (1981–1983)

Phenoxy herbicidesVineis et al., 1986

Among all living females (n = 31)

    52.4 (0.4–16.1)

New Zealand Pesticide Workers

Phenoxy herbicides
90% CI

Update of New Zealand workers (1976–1982)

1331.1 (0.7–1.8)Smith and Pearce, 1986

Reanalysis of New Zealand workers (1976–1980)

  171.6 (0.7–3.8)Smith et al., 1984

New Zealand workers exposed to herbicides (1976–1980)

  171.6 (0.8–3.2)Smith et al., 1983

Swedish agricultural and forestry workers (1974–1979)

Phenoxy acids, chlorophenolsEriksson et al., 1979,
  25(2.5–10.4) 5:1 matched1981
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Swedish patients (1970–1977)

Phenoxy acids, chlorophenolsHardell, 1981;

Exposed to phenoxy herbicides

  135.5 (2.2–13.8)Hardell and

Exposed to chlorophenols

    65.4 (1.3–22.5)Sandström, 1979

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; SEA, Southeast Asia; STS, soft-tissue sarcoma; TCDD, 2,3,7,8-tetrachloro-dibenzo-p-dioxin; TCP, trichlorophenol; TEQ, toxicity equivalent; USDA, United States Department of Agriculture; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cCommittee computed total SMR and SIR by dividing sum of observed values by sum of expected values over all years; 95% CIs on these total ratios were computed with exact methods.

dThere appears to be an error in this entry because lower 95% CI (0.3) is not smaller than odds ratio (0.0).

Ruder and Yiin (2011) reported mortality in PCP production that entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, two deaths from STS, one in each subcohort, did not represent an important increase in the entire cohort (SMR = 1.52, 95% CI 0.18–5.48), the PCP-only group (SMR = 1.14, 95% CI 0.03–6.36), or the PCP-plus-TCDD group (SMR = 2.26, 95% CI 0.06–12.6).

In the update of mortality in the AHS cohort, Waggoner et al. (2011) reported nine deaths from cancers of connective tissue in the applicators and six in their spouses. It is unclear whether this category contained any deaths from STS, but in any case, the resulting SMRs did not differ from expectations generated from the rates of the populations of Iowa and North Carolina.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Case-Control Studies

Using information assembled in the Cross-Canada Study of Herbicides and Health, Pahwa et al. (2011) used a case-control design to examine associations between STS and specific pesticide exposures. Men who had STS (357) were compared with the study wide control group (1,506) by using conditional logistic regression stratified by age and province of residence and further adjusted for medical history (measles, rheumatoid arthritis, mononucleosis, whooping cough, or cancer in a first-degree relative). No associations were found between STS and exposure to phenoxy herbicides overall (80 exposed cases, OR = 1.09, 95% CI 0.81–1.48); to 2,4-D (69 exposed cases, OR = 0.98, 95% CI 0.71–1.35); to 2-(4-chloro-2-methylphenoxy) propionic acid (Mecoprop, MCPP; 26 exposed cases, OR = 1.34, 95% CI 0.81–2.19); to MCPA (13 exposed cases, OR = 1.11, 95% CI 0.57–2.16); to methyl 2-[4-(2,4-dichlorophenoxy) phenoxy] propanoate (diclofop-methyl; eight exposed cases, OR = 1.21, 95% CI 0.41–2.85); or to dicamba (15 exposed cases, OR = 1.31, 95% CI 0.61–2.82).

Biologic Plausibility

In a 2-year study, dermal application of TCDD to Swiss-Webster mice led to an increase in fibrosarcomas in females but not in males (NTP, 1982b). There is some concern that the increase in fibrosarcomas may be associated with the treatment protocol rather than with TCDD. The NTP gavage study (NTP, 1982a) also found an increased incidence of fibrosarcomas in male and female rats and in female mice.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Previous committees have concluded that the occupational, environmental, and Vietnam-veteran studies showed sufficient evidence to link herbicide exposure to STS. Although confidence intervals in the new cohort studies were broad because of the rarity of observed cases in small samples, that conclusion is consistent with the findings of Ruder and Yiin (2011). The rather extensive Canadian case-control study of pesticide exposure and STS (Pahwa et al., 2011), however, did not provide additional supportive evidence.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is sufficient evidence of an association between exposure to at least one of the COIs and STS.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

SKIN CANCERS

Skin cancers are generally divided into two broad categories: neoplasms that develop from melanocytes (malignant melanoma, or simply melanoma) and neoplasms that do not. Nonmelanoma skin cancers (primarily basal-cell and squamous-cell carcinomas) have a far higher incidence than melanoma but are considerably less aggressive and therefore more treatable. The average annual incidence of melanoma is shown in Table 8-18.

The committee responsible for Update 1998 first chose to address melanoma studies separately from those of nonmelanoma skin cancer. Some researchers report results by combining all types of skin cancer without specifying type. The present committee believes that combined information is not interpretable (although there is a supposition that mortality figures refer predominantly to melanoma and that high incidence figures refer to nonmelanoma skin cancer); therefore, it is interpreting data only when results specify melanoma or nonmelanoma skin cancer.

ACS estimated that about 44,250 men and 32,000 women would receive diagnoses of cutaneous melanoma (ICD-9 172) in the United States in 2012 and that about 6,060 men and 3,120 women would die from it (Siegel et al., 2012). According to one report, more than 3 million cases of nonmelanoma skin cancer (ICD-9 173), primarily basal-cell and squamous-cell carcinomas, are diagnosed in the United States each year (ACS, 2013b); it is not required to report them to registries, so the numbers of cases are not as precise as those of other cancers. ACS reports that although melanoma accounts for less than 5% of skin-cancer cases, it is responsible for about 75% of skin-cancer deaths (ACS, 2012b). It estimates that 3,010 people die each year from nonmelanoma skin cancer (ACS, 2012b).

Melanoma occurs more frequently in fair-skinned people than in dark-skinned people; the risk in whites is roughly 20 times that in dark-skinned blacks. The incidence increases with age, more strikingly in males than in females. Other risk factors include the presence of particular kinds of moles on the skin, suppression of the immune system, and excessive exposure to ultraviolet

TABLE 8-18 Average Annual Cancer Incidence (per 100,000) of Skin Cancers (Excluding Basal-Cell and Squamous-Cell Cancers) in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Melanomas of the Skin:
      Men50.761.12.571.183.92.6  91108.25.0
      Women30.838.01.435.543.31.842.451.53.4

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009. SEER incidence data not available for nonmelanocytic skin cancer (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

(UV) radiation, typically from the sun. A family history of the disease has been identified as a risk factor, but it is unclear whether that is attributable to genetic factors or to similarities in skin type and sun-exposure patterns. In addition to the dermal forms of melanoma, these tumors occur much more infrequently in various tissues of the eye.

Excessive exposure to UV radiation is the most important risk factor for nonmelanoma skin cancer; some skin diseases and chemical exposures have also been identified as potential risk factors. Although exposure to inorganic arsenic is recognized as a risk factor for nonmelanoma skin cancer, this does not imply that exposure to cacodylic acid, which is a metabolite of inorganic arsenic, can be assumed to be a risk factor.

Melanoma

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and skin cancer. Additional information available to the committee responsible for Update 1996 did not change that conclusion. The committee responsible for Update 1998 considered the literature on melanoma separately from that of nonmelanoma skin cancer and found that there was inadequate or insufficient information to determine whether there is an association between the COIs and melanoma. The committees responsible for Update 2000, Update 2002, and Update 2004 concurred with the findings of Update 1998. The committee responsible for Update 2006 was unable to reach a consensus as to whether there was limited or suggestive evidence of an association between exposure to the COIs and melanoma or inadequate or insufficient evidence to determine whether there is an association, so melanoma was left in the latter category. The committee for Update 2008 determined that evidence of an association between exposure to the COIs and melanoma remained inadequate or insufficient to determine whether an association exists.

Cypel and Kang (2010) compared cause-specific mortality between deployed and nondeployed veterans in the Vietnam-era ACC cohort. In comparing the deployed with the nondeployed veterans, a moderate but not statistically significant increase in risk of malignant skin cancer was observed in the deployed cohort. Updates of mortality in TCP workers in New Zealand (McBride et al., 2009a) and in the Dow Chemical Company cohort in Midland, Michigan (Collins et al., 2009a) did not find evidence of an association between the COIs and melanoma. In evaluating the use of specific pesticides and melanoma in the AHS, Dennis et al. (2010) found that exposure only to arsenic-based pesticides, among the COIs, showed any increase in risk, which was weak and far from statistically significant. Updating cancer incidence in the Seveso cohort for the period 1977–1996

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

(Pesatori et al., 2009) continued to provide evidence that melanoma is associated with exposure to TCDD.

Table 8-19 summarizes the relevant melanoma studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veteran studies or environmental studies of exposure to the COIs and melanoma have been published since Update 2010.

Occupational Studies Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With eight cases observed, the incidence of melanoma in the most restrictively defined cohort was not increased (SIR = 1.18, 95% CI 0.51–2.33), as was the case for the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) studied an occupational cohort of 187 Dutch workers who were employed in two phenoxy-herbicide factories. Individual estimates of exposure were derived from a newly developed predictive model that used serum TCDD concentrations recently measured in a subset of the cohort. Estimates of mortality from melanoma were slightly but nonsignificantly increased (entire cohort, seven deaths, HR = 1.29, 95% CI 0.90–1.84; factory A, five deaths, HR = 1.27, 95% CI 0.76–2.23). An earlier analysis of the data (Boers et al., 2010), which categorized the subjects as exposed or not exposed on the basis of job histories, found no suggestion of a relationship between exposure to COIs and melanoma in the workers in factory A, where 2,4,5-T had been produced.

In reporting mortality in the NIOSH PCP cohort updated through 2005, Ruder and Yiin (2011) grouped an unspecified number of melanoma deaths in a classification (ICD-9 170–173, 190–199) that had 38 deaths, of which 2 were identified as STS deaths and 6 as deaths from “brain and other nervous system” cancer. The study provided no useful information on the risk of melanoma mortality in these workers.

Koutros et al. (2010a) and Waggoner et al. (2011) updated cancer incidence and overall mortality, respectively, in the AHS. Koutros et al. limited exposure characterization to job (applicators and spouses). They reported 173 incident melanomas in private applicators, for an SIR of 0.89 (95% CI 0.76–1.03), and 13 incident melanomas in commercial applicators, for an SIR of 1.09 (95% CI 0.58–1.86). They reported 92 incident cases in spouses, for an SIR of 1.17 (95% CI 0.94–1.43).

Waggoner et al. (2011) updated the vital status of the AHS cohort through 2007 and presented mortality data that differed little from the incidence data

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-19 Selected Epidemiologic Studies—Melanoma (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

1982–2003—White SEA comparison veterans only (n = 1,482). Serum TCDD (pg/g) based on model with exposure variable loge(TCDD)

Pavuk et al., 2005

Per unit increase of –loge(TCDD) (pg/g) Quartiles (pg/g):

  252.7 (1.1–6.3)

0.4–2.6

    31.0

2.6–3.8

    52.1 (0.4–11.0)

3.8–5.2

    83.2 (0.7–15.5)

> 5.2

    93.6 (0.7–17.2)

Number of years served in SEA (per year of service)

Quartiles (years in SEA):

  251.1 (0.9–1.3)

0.8–1.3

    31.0

1.3–2.1

    41.9 (0.3–10.3)

2.1–3.7

    83.2 (0.7–15.3)

3.7–16.4

  104.1 (0.9–19.7)

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  172.3 (1.4–3.7)

With tours between 1966–1970

  162.6 (1.5–4.1)

SEA comparison veterans (n = 1,776)

  151.5 (0.9–2.4)

With tours between 1966–1970

  121.5 (0.8–2.6)

White AFHS subjects

Veterans who spent at most 2 yrs in SEA

Per unit increase of –loge(TCDD) (pg/g)

  142.2 (1.3–3.9)

Comparison group

    31.0

Ranch Hand— < 10 TCDD pg/g in 1987

    43.0 (0.5–16.8)

Ranch Hand < 118.5 TCDD pg/g at end of service

    47.4 (1.3–41.0)

Ranch Hand > 118.5 TCDD pg/g at end of service

    37.5 (1.1–50.2)

Only Ranch Hands with 100% service in Vietnam, comparisons with no Vietnam service

Per unit increase of –loge(TCDD) (pg/g)

  141.7 (1.0–2.8)

Comparison group

    21.0
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Ranch Hand < 10 TCDD pg/g in 1987

    53.9 (0.4–35.3)

Ranch Hand < 118.5 TCDD pg/g at end of service

    47.2 (0.9–58.8)

Ranch Hand > 118.5 TCDD pg/g at end of service

    35.5 (0.6–46.1)

Ranch Hand veterans, comparisons through June 1997

Ketchum et al., 1999

Ranch Hand background exposure

    41.1 (0.3–4.5)

Ranch Hand low exposure

    62.6 (0.7–9.1)

Ranch Hand high exposure

    20.9 (0.2–5.6)

Comparisons

    91.0

Attended 1987 exam—Ranch Hand personnel (n = 995) vs SEA veterans (n = 1,299)

    41.3 (0.3–5.2)Wolfe et al., 1990

US VA Cohort of Army Chemical Corps—Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (July 1, 1965–March 28, 1973)

All COIs

Through 2005 (mortality)

Cypel and Kang, 2010

Deployed veterans (2,872) vs nondeployed (2,737)

5 vs 41.5 (0.4–6.2)

ACC deployed men in Kang et al. (2006) reported sprayed herbicide vs did not spray

Vietnam cohort

    51.3 (0.4–3.1)

Non-Vietnam cohort

    41.3 (0.4–3.4)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

1965–2000 (mortality)

    61.4 (0.4–4.9)Boehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin et al., 1986, 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

1451.0 (0.9–1.1)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  360.9 (0.6–1.5)

State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans

Veterans aged 35–65 years in 1993—melanoma cases diagnosed 1988–1993 vs gastrointestinal cancers

  211.4 (0.7–2.9)Clapp, 1997
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

    90.6 (0.3–1.2)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs 7,553 not exposed to highly chlorinated PCDDs

    50.5 (0.2–3.2)
40.0 (0.3–2.4)
Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence

Incidence 1943–1987 (men only)

    44.3 (1.2–10.9)Lynge, 1993

Mortality

Mortality 1955–2006

    71.3 (0.9–1.8)Boers et al., 2012

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

    51.3 (0.8–2.2)Boers et al., 2012

Mortality 1955–1991

    12.9 (0.1–15.9)Hooiveld et al., 1998

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    21.0 (0.1–3.7)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    00.0 (0.0–3.0)’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    10.6 (0.0–3.4)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    20.6 (0.1–2.3)Collins et al., 2009a

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    81.2 (0.5–2.3)Burns et al., 2011

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    10.7 (0.0–4.0)Collins et al., 2009b
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  200.8 (0.5–1.3)

Ever

  211.2 (0.7–1.8)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from melanoma June 1971–December 1987

Deaths among Saskatchewan farmers ≥ 35 yrs of age, 1971–1985

  241.1 (0.7–1.6)Wigle et al., 1990

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

  381.0 (0.7–1.3)Hertzman et al., 1997

Mortality 1950–1989

  171.4 (0.9–2.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Self-employed

  720.7 (p < 0.05)

Employee

  170.6 (nr)

Danish gardeners—incidence from 3,156 male and 859 female gardeners

HerbicidesHansen et al., 2007

25-year followup (1975–2001)

  311.3 (0.9–1.8)

Born before 1915 (high exposure)

  280.9 (0.6–1.4)

Born 1915–1934 (medium exposure)

  360.6 (0.4–0.9)

Born after 1934 (low exposure)

    50.3 (0.1–0.7)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

    91.2 (0.6–2.3)Torchio et al., 1994

SWEDEN

Incident melanoma cases 1961–1973 with agriculture as economic activity in 1960 census

2680.8 (0.7–1.0)Wiklund, 1983

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

    0nr

Foremen (n = 15)

    0nr

Lumberjacks (n = 139)

    0nr

Unexposed lumberjacks (n = 241)

    0nr

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    53.6 (1.2–8.3)Swaen et al., 2004

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

2441.0 (0.8–1.1)

Nonwhites (n = 11,446)

    51.2 (0.4–2.9)

Women

Whites (n = 2,400)

    51.1 (0.4–2.7)

Nonwhites (n = 2,066)

    11.2 (0.0–6.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

1730.9 (0.8–1.0)

Commercial applicators

  131.1 (0.6–1.9)

Spouses

  921.2 (0.9–1.4)

Licensed, male pesticide applicators—150 cutaneous melanomas among 24,704 pesticide applicators

Dennis et al., 2010

Ever-exposed to arsenic-based pesticides vs never-exposed

  111.3 (0.7–2.4)

Ever used lead arsenate insecticide

  101.2 (0.6–2.3)

Enrollment through 2002

Samanic et al., 2006

Dicamba—lifetime days exposure

None

  321.0

1– < 20

  101.0 (0.5–2.1)

20– < 56

  181.6 (0.8–3.0)

56– < 116

    60.7 (0.3–1.8)

≥ 116

    60.8 (0.3–2.1)
p-trend = 0.51

Enrollment through 2002

Alavanja et al., 2005

Private applicators

1001.0 (0.8–1.2)

Spouses of private applicators (> 99% women)

  671.6 (1.3–2.1)

Commercial applicators

    71.1 (0.4–2.2)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  380.8 (0.5–1.1)

Spouses (n = 676)

  100.8 (0.4–1.4)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

13 20.7 (0.4–1.3) 0.4 (0.1–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
CASE-CONTROL STUDIES

International Case-Control Studies

British Columbia—melanoma cases recruited for a study evaluating effects of ultraviolet exposure and gene variants using plasma specimens and sun-exposure data (80 cases vs 310 controls)

PCBsGallagher et al., 2011

Highest PCB-exposure quintile

  296.0 (2.0–18.2)

Dioxin-like PCBs

  252.8 (1.0–8.0)

Non-dioxin-like PCBs

  307.0 (2.3–21.4)

European—uveal melanoma patients (n = 323), diagnosed 1994–1997, identified from hospital records (diagnosed 1994–1995) in nine countries and matched controls (n = 3,198)

HerbicidesBehrens et al., 2012

Personal application of herbicides

    80.5 (0.2–1.3)

Personal mixing of herbicides

    60.5 (0.2–1.5)

UK men, 18–35 yrs of age from counties with particular chemical manufacturing—mortality

Herbicides, chlorophenolsMagnani et al., 1987

Herbicides

nr1.2 (0.4–4.0)

Chlorophenols

nr0.9 (0.4–2.3)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; ACC, Army Chemical Corps; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupational specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCB, polychlorinated biphenyl; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; SEA, Southeast Asia; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aCohorts are male and outcome mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

in Koutros et al. (2010a). Using a similar job classification as a surrogate for exposure, they reported 38 deaths compared with 50 expected for an SMR of 0.76 (95% CI 0.54–1.05). In spouses, they reported 10 deaths compared with 13 expected for an SMR of 0.75 (95% CI 0.36–1.38). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Case-Control Studies Gallagher et al. (2011) studied melanoma and its association with plasma concentrations of PCBs by using an unusual case-control design. They ascertained cases by using the resources (plasma specimens and sun-exposure data) from melanoma cases originally recruited for evaluating the effects of UV exposure and gene variants on risk of melanoma in the Genes, Environment & Melanoma (GEM) study (Begg et al., 2005; Berwick et al., 2006). Controls for that study were drawn from a different study, conducted at about the same time in the same geographic region (British Columbia), that was designed to investigate the effect of solar UV exposure and plasma organochlorine compounds on risk of non-Hodgkin lymphoma (Spinelli et al., 2007). The studies were similar in design: they both recruited participants by using the population-based BC Cancer Registry, and they used the same computer-assisted telephone interview protocol to collect information on sun exposure, phenotype, and sun sensitivity. Cases from the GEM study included 153 patients, of whom 86 (56%) were able to be recontacted for drawing of additional blood for this investigation. Blood was drawn in 2002–2005 for controls and in 2008 for cases. The laboratory analyses were well controlled to ensure comparability. Plasma samples from 460 controls were assayed for 14 PCB congeners and 11 chlorine-based pesticides or their metabolites; after matching on age and area of residence, 309 were available for use in the study. A total of three cases were not included in the study because of the inability to match with controls. The exposure assessment included 14 PCB congeners (dioxin-like mono-ortho PCBs 105, 118, and 156 and non-dioxin-like PCBs 28, 52, 99, 101, 128, 138, 153, 170, 180, 183, and 187) and 11 persistent pesticides.

Many of the accepted risk factors for melanoma were found to be associated with the disease in this study. Analysis showed significant associations between PCB congeners and melanoma although they were rather imprecise. Total PCB concentrations were associated with disease, with a significant dose–response relationship. The highest risk was in the highest PCB-exposure quartile (OR = 6.02, 95% CI 2.00–18.17). The dioxin-like mono-ortho PCBs, however, showed a significant association (OR = 2.84, 95% CI 1.01–7.97), which was less pronounced than that of the non-dioxin-like PCBs (OR = 7.02, 95% CI 2.30–21.43). There was some indication of an association of pesticide exposure with melanoma but it was limited to nonachlor, Mirex, and hexachlorobenzene.

Thus, the study provided evidence of an association between chemicals that have dioxin-like activity and melanoma but with important limitations. First, the number of cases was small, and participation was low, so there is a question of unmeasured bias. In addition, although the authors attempted to control for sun exposure, this is notoriously difficult. The cases and controls arose from different studies and, although every attempt was made to match them, they may not have been comparable in some respects (such as ethnicity). The presence of disease could alter the measured exposures. The confidence limits of the point estimates are imprecise, and this lessens confidence in their generalizability. In addition,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

there is little exposure specificity in the association, so it is difficult to interpret in light of the biologic data. Finally, only dioxin-like mono-ortho PCBs were reported, which typically contribute only a small percentage to total TEQs, making it difficult to accurately determine whether an association exists with total TEQs, and the largest associations were found for the non-dioxin-like compounds.

Behrens et al. (2012) conducted a case-control study of uveal (ocular) melanoma and pesticide exposure, but exposure to unspecified herbicides does not reach the level of specificity that the committee has regarded as necessary for full relevance. The significant finding in the category of 1–9 years of “application of any herbicide on farm where subject worked” is intriguing but contrary to expectations of a dose–response association. The results with respect to personal application and mixing of herbicides are more pertinent for the committee’s purposes, and they are firmly not positive.

Biologic Plausibility

TCDD and related herbicides have not been found to cause melanoma in animal models. In general, rodents, which are used in most toxicology studies, are not a good model for studying melanoma. TCDD does produce nonmelanoma skin cancers in animal models (Wyde et al., 2004). As discussed elsewhere in this chapter, TCDD is a known tumor-promoter and could act as a promoter for skin-cancer initiators, such as UV radiation. Ikuta et al. (2009) examined the physiologic role of the AHR in human skin and theorized that overactivation can lead to skin cancers, but they provided no evidence that melanoma incidence is increased after TCDD exposure. Recent work in this field has shown that the AHR mediates UVB-induced skin-tanning in a murine model through action on melanocytes; this is evidence that skin pigmentation and potentially the regulatory action of the target cell for melanoma may be affected by TCDD. Studies of human cells have also confirmed a role of the AHR in regulation of keratinocytes and melanocytes. Kalmes et al. (2011) have shown that AHR signaling in immortalized HaCaT cells is associated with cell-cycle progression. In human melanocytes, Luecke et al. (2010) demonstrated that TCDD exposure induced tyrosinase and tyrosinase-related protein 2 gene expression—an indication that AHR signaling after TCDD exposure modulates melanogenesis. O’Donnell et al. (2012) further showed that the activity of the AHR was associated with proliferation of melanoma cells. Finally, it was recently shown in a Han Chinese population that normal genetic variants of the AHR are associated with the occurrence of vitiligo; this strongly suggests that the AHR is associated with melanocyte distribution in humans.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Synthesis

No compelling association between the COIs and melanoma was observed in any of the three new occupational studies.

The committee responsible for Update 2006 was unable to reach a consensus as to whether there was limited or suggestive evidence of an association between exposure to the COIs and melanoma or inadequate or insufficient evidence to determine whether there is an association. That committee considered the findings from the Air Force Health Study (AFHS) on melanoma, evaluated in terms of TCDD measurements (Akhtar et al., 2004; Pavuk et al., 2005), to be of prime interest. However, the data from the final AFHS examination cycle indicate that many more melanoma cases were diagnosed in the comparison veterans than in the Operation Ranch Hand veterans. Consequently, the committee responsible for Update 2006 recommended that the final data on the Ranch Hand and comparison veterans be analyzed in a uniform manner to document the full melanoma experience of the AFHS subjects and to permit definitive evaluation of the possible association between the COIs and melanoma. That request remains unaddressed.

This is the first update in which any information on ocular melanoma has been identified. The case-control study of Behrens et al. (2012) found some increases in the incidence of uveal melanoma in association with unspecified herbicides; this is not the degree of herbicide specificity required for results to be considered fully relevant. A Vietnam veteran submitted information (Data from Rutz [2012] available in the National Academies Public Access Records Office [http://www8.nationalacademies.org/cp/ManageRequest.aspx?key=49448]) received in response to a Freedom of Information Act request to VA about the frequency with which choroidal melanoma (a specific type of uveal melanoma) was diagnosed in VA facilities; the document indicated that a large number of such cases had been seen, but the lack of documentation explaining how the VA had gathered the data and exactly what they represented prevented the committee from being able to assess their import. Because literature searches did not identify any epidemiology studies of ocular melanoma in association with the COIs, the committee submitted an inquiry to Carol and Mark Shields, who responded (Data from Shields [2012] available in the National Academies Public Access Records Office [http://www8.nationalacademies.org/cp/ManageRequest.aspx?key=49448]) that their analyses of more than 2,000 cases of uveal melanoma had not revealed any association with the COIs.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and melanoma (dermal or ocular).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Basal-Cell Cancer and Squamous-Cell Cancer (Nonmelanoma Skin Cancer)

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and skin cancer, and additional information available to the committee responsible for Update 1996 did not change that conclusion. The committee responsible for Update 1998 considered the literature on nonmelanoma skin cancer separately from that on melanoma and concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and basal-cell or squamous-cell cancer. The committees responsible for Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-20 summarizes the relevant studies.

Update of the Epidemiologic Literature

No epidemiology studies of exposure to the COIs and basal-cell or squamous-cell cancer have been published since Update 2010.

Biologic Plausibility

There are no new studies on animal models of skin cancer that are relevant to this update. TCDD has been shown to produce nonmelanoma skin cancer in animal models (Wyde et al., 2004). As discussed elsewhere in this chapter, TCDD is a known tumor-promoter and could act as a promoter for skin-cancer initiators, such as UV radiation, but no experiments have been conducted specifically to support this potential mechanism.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

In accord with the results of reports previously assessed, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and basal-cell or squamous-cell cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-20 Selected Epidemiologic Studies—Other Nonmelanoma (Basal-Cell and Squamous-Cell) Skin Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence—basal cell, squamous cell

1982–2003—White SEA comparison veterans only (n = 1,482). Serum TCDD (pg/g) based on model with exposure variable loge(TCDD)

2531.2 (0.9–1.4)Pavuk et al., 2005

Per unit increase of –loge(TCDD) (pg/g) Quartiles (pg/g):

0.4–2.6

  50nr

2.6–3.8

  591.2 (0.8–1.8)

3.8–5.2

  711.5 (1.1–2.3)

> 5.2

  731.4 (0.9–2.0)

Number of years served in SEA (per year of service)

2531.0 (0.9–1.1)

Quartiles (years in SEA):

0.8–1.3

  55nr

1.3–2.1

  500.9 (0.6–1.4)

2.1–3.7

  731.1 (0.8–1.6)

3.7–16.4

  751.2 (0.8–1.7)

Attended 1987 exam—Ranch Hand personnel (n = 995) vs SEA veterans (n = 1,299)

Wolfe et al., 1990

Basal-cell carcinoma

  781.5 (1.0–2.1)

Squamous-cell carcinoma

    61.6 (0.5–5.1)

International Vietnam-Veteran Study

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

Validation Study (expected number of exposed cases)

Men

6,936nrCDVA, 1998a

Women

  37nrCDVA, 1998b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates    40.9 (0.3–2.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1939–1992

Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    41.3 (0.3–3.2)

7,553 not exposed to highly chlorinated PCDDs

    00.0 (0.0–3.4)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    33.1 (0.6–9.0)Coggon et al., 1986

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Through 1994 (n = 1,517)

    0nrBurns et al., 2001
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

4930.7 (p < 0.05)

Employee

  980.7 (p < 0.05)

Women

Self-employed

    50.3 (p < 0.05)

Employee

  100.9 (nr)

Family worker

  900.6 (p < 0.05)

Danish gardeners—incidence from 3,156 male and 859 female gardeners (skin, ICD-7 190–191)

  31Herbicides 1.3 (0.9–1.8)Hansen et al., 2007

25-year followup (1975–2001)

Born before 1915 (high exposure)

  280.9 (0.6–1.4)

Born 1915–1934 (medium exposure)

  360.6 (0.4–0.9)

Born after 1934 (low exposure)

    50.3 (0.1–0.7)

ICELANDIC pesticide users (n = 2,449, 1,860 men and 589 women), 2,4-D used most often, little 2,4,5-T

Zhong and Rafnsson, 1996

Men

    52.8 (0.9–6.6)

Men, women combined

    52.6 (0.8–6.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

    30.6 (0.1–1.8)Torchio et al., 1994

SWEDEN

Incident melanoma cases 1961–1973 with agriculture as economic activity in 1960 census Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

99% CIWiklund, 1983
7081.1 (1.0–1.2)
Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    116.7 (0.2–92.7)

Lumberjacks (n = 139)

    0

Unexposed lumberjacks (n = 241)

    32.0 (0.4–5.8)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000—melanoma, squamous-cell carcinoma, unknown skin cancer (mortality presumably attributable to melanoma)

    53.6 (1.2–8.3)Swaen et al., 2004

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states (skin, including melanoma)

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

4251.1 (1.0–1.2)

Nonwhites (n = 11,446)

  131.0 (0.5–1.7)

Women

Whites (n = 2,400)

    61.0 (0.4–2.1)

Nonwhites (n = 2,066)

    31.8 (0.4–5.4)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)TCDD

Incidence

20-yr followup to 1996—men and women

Pesatori et al., 2009

Zone A

    31.4 (0.5–4.3)

Zone B

    50.4 (0.2–0.9)

Zone R

  880.9 (0.8–1.2)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone A

    12.4 (0.3–17.2)

Zone B

    20.7 (0.2–2.9)

Zone R

  201.0 (0.6–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone A

    13.9 (0.5–28.1)

Zone B

    21.3 (0.3–5.1)

Zone R

  131.0 (0.6–1.9)

Other International Environmental Study

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

  222.3 (1.5–3.5)

West coast

  691.1 (0.9–1.4)

Mortality

East coast

    00.0 (0.0–15.4)

West coast

    53.1 (1.0–7.1)
CASE-CONTROL STUDIES

International Case-Control Studies

Alberta, Canada residents—squamous-cell carcinoma—incidence

HerbicidesGallagher et al., 1996

All herbicide exposure

  791.5 (1.0–2.3)

Low herbicide exposure

  331.9 (1.0–3.6)

High herbicide exposure

  463.9 (2.2–6.9)

Alberta, Canada residents—basal-cell carcinoma

HerbicidesGallagher et al., 1996

All herbicide exposure

  701.1 (0.8–1.7)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; MCPA, 2-methyl-4-chlorophenoxyacetic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; SEA, Southeast Asia; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and basal-cell or squamous-cell cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

BREAST CANCER

Breast cancer (ICD-9 174 for females, ICD-9 175 for males) is the second-most common type of cancer (after nonmelanoma skin cancer) in women in the United States. ACS estimated that 226,870 women would receive diagnoses of breast cancer in the United States in 2012 and that 39,510 would die from it (Siegel et al., 2012). Overall, those numbers represent about 29% of the new cancers and 14% of cancer deaths in women. Incidence data on breast cancer are presented in Table 8-21.

Breast-cancer incidence generally increases with age. In the age groups of most Vietnam veterans, the incidence is higher in whites than in blacks. Established risk factors other than age include personal or family history of breast cancer and some characteristics of reproductive history—specifically, early menarche, late onset of menopause, and either no pregnancies or first full-term pregnancy after the age of 30 years. A pooled analysis of six large-scale prospective studies of invasive breast cancer showed that alcohol consumption up to a daily average of 60 g (2.1 oz), which spanned the consumption reported by more than 99% of the women, was associated with a small linear increase in incidence in comparison with nondrinkers (Smith-Warner et al., 1998). It is generally accepted that breast-cancer risk is increased by prolonged use of hormone-replacement therapy, particularly preparations that combine estrogen and progestins (Chlebowski et al., 2003). The potential of other personal behavioral and environmental factors (including use of exogenous hormones) to affect breast-cancer incidence is being studied extensively.

Most of the roughly 10,000 female Vietnam veterans who were potentially exposed to herbicides in Vietnam are approaching or have reached menopause. Given the high incidence of breast cancer in older and postmenopausal women in general, it is expected on the basis of demographics alone that the breast-cancer burden in female Vietnam veterans will increase in the near future.

The vast majority of breast-cancer epidemiologic studies involve women, but the disease also occurs rarely in men, with 2,190 new cases expected in 2012 (Siegel et al., 2012). Reported instances of male breast cancer are noted below, but the committee’s conclusions are based on the studies in women.

TABLE 8-21 Average Annual Incidence (per 100,000) of Breast Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men2.02.02.83.43.34.95.05.33.3
Women279.6284.3273.8359.9373.0348.0420.8438.5389.5

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and breast cancer. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, and Update 2004 did not change that conclusion. After consideration of a new study with positive findings on an association between 2,4-D exposure and breast cancer in female farmworkers in California (Mills and Yang, 2005)—in conjunction with the earlier findings of Kang et al. (2000), Kogevinas et al. (1997), Revich et al. (2001), and Warner et al. (2002)—the committee responsible for Update 2006 was unable to reach consensus as to whether there might be limited or suggestive evidence of an association between the COIs and breast cancer. An increase in the incidence of breast cancer in the residents of Zone A in Seveso may be emerging with greater latency (Pesatori et al., 2009), but in light of null findings on mortality from breast cancer in the important cohorts of female Vietnam-era veterans (Cypel and Kang, 2008) and Seveso residents (Consonni et al., 2008), all members of the committees for Update 2008 and Update 2010 concurred that breast cancer should remain in the category of inadequate or insufficient evidence to determine whether there is an association.

Table 8-22 summarizes the relevant research.

Update of the Epidemiologic Literature

Vietnam-Veteran Studies

No Vietnam-veteran studies of exposure to the COIs and breast cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated the incidence of cancer through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. One case of male breast cancer was observed in Cohorts 1 and 2, but the residience requirements excluded it from Cohort 3.

There were 398 women in the Hamburg cohort (a subcohort of the IARC phenoxy-herbicide cohort). They had been employed for at least 3 months during 1952–1984 in a chemical plant that produced insecticides and herbicides,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-22 Selected Epidemiologic Studies—Breast Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    0nrBoehmer et al., 2004

US VA Cohort of Female Vietnam Veterans

All COIs

Incidence

Breast cancer

1701.2 (0.9–1.5)Kang et al., 2000

Mortality

Through 2004

  571.0 (0.7–1.4)Cypel and Kang, 2008

Vietnam-veteran nurses

  440.9 (0.6–1.4)

Through 1991

  261.0 (0.6–1.8)Dalager et al., 1995

Through 1987

  171.2 (0.6–2.5)Thomas et al., 1991
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

    70.9 (0.4–1.9)ADVA, 2005a

Navy

    10.6 (0.0–3.3)

Army

    51.0 (0.3–2.2)

Air Force

    11.1 (0.0–6.3)

Validation Study

Expected number of exposed cases

Women

  175 (2–11)CDVA, 1998b

Mortality

All branches, return–2001

    42.2 (0.6–5.4)ADVA, 2005b

Navy

    12.5 (0.0–13.5)

Army

    32.5 (0.5–7.2)

Air Force

    00.0 (0.0–14.6)

1980–1994 (men)

    35.5 (1.0– > 10.0)CDVA, 1997a

Australian Conscripted Army National Service (18 940 deployed vs 24 642 nondeployed)

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Incidence

1982–2000

    00.0 (0.0–2.4)ADVA, 2005c

Mortality

1966–2001

nrADVA, 2005c
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992 (13,831 exposed to highly chlorinated PCDDs vs 7,553 unexposed)

Phenoxy herbicidesKogevinas et al., 1997

Men

    21.6 (0.2–2.1)

Exposed to highly chlorinated PCDDs

    22.6 (0.3–9.3)

Not exposed to highly chlorinated PCDDs

    0nr

Women

  121.2 (0.6–2.1)

Exposed to highly chlorinated PCDDs

    92.2 (1.0–4.1)

Not exposed to highly chlorinated PCDDs

    30.5 (0.1–1.6)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Men

    23.5 (0.4–12.5)

Women

    10.3 (0.0–1.7)

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates

TCDDKogevinas et al, 1993
70.9 (0.4–1.9)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982 (women)

  130.9 (nr)Lynge, 1985

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007

Manuwald et al., 2012

Women

  191.9 (1.1–2.9)

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966

    92.2 (1.0–4.1)Manz et al., 1991
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    21.4 (0.2–5.0)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

’t Mannetje et al., 2005

Phenoxy herbicide producers

Men

    132 (0.8–175)

Women

    11.3 (0.0–7.2)

Phenoxy herbicide sprayers (> 99% men)

Men

    00.0 (0.0–214)

Women

    00.0 (0.0–86.0)

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    10.5 (0.0–2.9)

PCP and TCP (n = 720)

    0nr

PCP (no TCP) (n = 1,402)

    10.6 (0.0–3.1)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    0nrBurns et al., 2011
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine

compounds

Never

  210.9 (0.6–1.4)

Ever

  320.9 (0.6–1.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

    50.5 (nr)

Employee

    31.4 (nr)

Women

Self-employed

  410.9 (nr)

Employee

  250.6 (p < 0.05)

Family worker

4290.8 (p < 0.05)

SWEDEN

Incident breast cancer cases 1961–1973 with agriculture as economic activity in 1960 census

Wiklund, 1983

Men, women

99% CI
4440.8 (0.7–0.9)

Men

nr1.0 (nr)

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  180.7 (0.4–1.2)

Nonwhites (n = 11,446)

    41.7 (0.5–4.4)

Women

Whites (n = 2,400)

  711.0 (0.8–1.3)

Nonwhites (n = 2,066)

  300.7 (0.5–1.0)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  331.0 (0.7–1.3)

Commercial applicators

    0nr

Spouses

7701.0 (0.9–1.1)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  271.1 (0.7–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Spouses of private applicators (> 99% women)

4741.0 (0.9–1.1)

Commercial applicators

    10.6 (0.1–3.5)

Enrollment through 2001

Engel et al., 2005

Wives’ own use of phenoxy herbicides

  410.8 (0.6–1.1)

2,4-D

  410.8 (0.6–1.1)

Husbands’ own use of phenoxy herbicides

1101.1 (0.7–1.8)

2,4-D

1070.9 (0.6–1.4)

2,4,5-T

  441.3 (0.9–1.9)

2,4,5-TP

  192.0 (1.2–3.2)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  110.9 (0.5–1.7)

Spouses (n = 676)

1360.8 (0.7–0.9)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

3 540.9 (0.2–2.7) 0.9 (0.7–1.1)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    81.4 (0.7–2.9)Pesatori et al., 2009

Zone B

  300.9 (0.6–1.2)

Zone R

2491.0 (0.9–1.2)

Zone A only (15+ yrs after accident)

    52.6 (1.1–6.2)

Zone A only (10–14 yrs after accident)

    21.4 (0.4–5.7)

Zone A only (5–9 yrs after accident)

    10.8 (0.1–5.7)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone R

    11.2 (0.1–10.2)

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone A

    10.5 (0.1–3.3)

Zone B

  100.7 (0.4–1.4)

Zone R

1061.1 (0.9–1.3)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    20.6 (0.2–2.4)

Zone B

  130.6 (0.3–1.2)

Zone R

1330.9 (0.7–1.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

20-yr followup to 1996

Bertazzi et al., 2001

Zones A and B—women

  140.7 (0.4–1.3)

15-yr followup to 1991—women

Bertazzi et al., 1997

Zone A

    10.6 (0.0–3.1)

Zone B

    90.8 (0.4–1.5)

Zone R

  670.8 (0.6–1.0)

10-yr followup to 1986—women

Bertazzi et al., 1989a,b

Zone A

    11.1 (0.1–7.5)

Zone B

    50.9 (0.4–2.1)

Zone R

  280.6 (0.4–0.9)
Seveso (Italy) Women’s Health Study—981 women who were infants to 10–40 yrs of age when exposed—incidenceTCDD

Cancer incidence (1976–2009)

Warner et al., 2011

Hazard ratios from lipid-adjusted serum TCDD levels and breast cancer; TCDD (ppt):

Log10 TCDD (ppt)

  331.4 (0.9–2.3)

11–20 yrs followup (1987–1996)

  102.2 (1.1–4.6)

21–32 yrs followup (1997–2009)

  201.1 (0.6–1.9)

With 10-fold increase in TCDD

  152.1 (1.0–4.6)Warner et al., 2002
Ecological Study of Residents of Chapaevsk, RussiaDioxinRevich et al., 2001

Women

Regional (Samara)

nr50.7 (nr)

National (Russia)

nr46.2 (nr)

Mortality—1995–1998 (SMR vs regional rates)

Women

  582.1 (1.6–2.7)

FINLAND

Finnish fishermen (n = 6,410) and spouses (n = 4,260) registered between 1980 and 2002 compared to national statistics

Serum dioxinTurunen et al., 2008

Fisherman’s wives

  180.8 (0.5–1.3)
CASE-CONTROL STUDIES

US Case-Control Studies

California—Women undergoing breast biopsies in San Francisco area hospitals—79 breast-cancer cases vs 52 controls with benign breasts conditions—incidence

PCDDs, PCDFsReynolds et al., 2005

Total TEQs (pg/g) in adipose breast tissue

≤ 14.0

  241.0

14.1–20.9

  220.7 (0.3–1.9)

≤ 21.0

  330.3 (0.3–2.0) p-trend = 0.99
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

California—Registry-based study of 128 Hispanic agricultural farmworkers (women) diagnosed 1988–2001 and 640 cancer-free controls.

HerbicidesMills and Yang, 2005

Cancer diagnosis 1987–1994

Low 2,4-D use

  120.6 (0.2–1.9)

High 2,4-D use

    80.6 (0.2–1.7)

Cancer diagnosis 1995–2001

Low 2,4-D use

  192.2 (1.0–4.9)

High 2,4-D use

  212.1 (1.1–4.3)

California Teachers Study Cohort—residential proximity to use of “endocrine disruptors” (including 2,4-D, cacodylic acid)

2,4-D, cacodylic acidReynolds et al., 2004

Quartiles of use (lb/mi2)

< 1

1,0271.0

1–21

2741.0 (0.8–1.1)

22–323

1140.9 (0.7–1.1)

≥ 324

1371.0 (0.9–1.3)

California women (n = 146) receiving medical care in Woodland Hills (1995–1996), 73 breast-cancer cases vs 73 controls undergoing mammoplasty

  73Organochlorines nrBagga et al., 2000

New York—Population-based study of lifetime residential pesticide use in Long Island; 1,508 newly diagnosed cases and 1,556 matched controls (1996–1997)

PesticidesTeitelbaum et al., 2007

Used lawn and garden pesticides

Never

2401.0

Ever

1,2541.3 (1.1–1.6)

Product for weeds

1,1091.4 (1.2–1.8)

North Carolina—862 female farmworkers, residents diagnosed 1993–1996 and 790 controls.

HerbicidesDuell et al., 2000

Used pesticides in garden

2282.3 (0.7–3.1)

Laundered clothes for pesticide user

1194.1 (2.8–5.9)

Connecticut patient at Yale–New Haven hospital with breast related surgery; dlcongener 156

nrdl-PCBs 0.9 (0.8–1.0)Holford et al., 2000

International Case-Control Studies

Canadian women in Quebec City—315 newly diagnosed breast-cancer cases (and plasma concentrations) vs hospital- and population-based controls

Organochlorines,Demers et al., 2000
314nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Denmark females with breast cancer in Copenhagen City Heart Study (n = 195), 2 blood samples taken (1987–1978, 1981–1983)

OrganochlorinesOverall survival RRHøyer et al., 2000
1952.8 (1.4–5.6)

France—Besançon residents in zones of dioxin exposure around solid-waste incinerator (434 incident breast-cancer cases; 2,170 randomly selected controls) (1996–2002)

DioxinViel et al., 2008

Women, 20–59 yrs of age

Very low

  411.0

Low

  811.1 (0.7–1.6)

Intermediate

  641.3 (0.8–1.9)

High

  110.9 (0.4–1.8)

Women, 20–59 yrs of age

Very low

  501.0

Low

1110.9 (0.6–1.3)

Intermediate

  721.0 (0.7–1.4)

High

    40.3 (0.1–0.9)

Greenland Inuit women with breast cancer (n = 31) vs 115 matched controls, 2000–2003

POPs, dl PCBsBonefeld-Jorgensen et al., 2011

Dl-PCbs in serum (median: cases vs controls)

56.8 vs 65.4 pg/g lipid
p = 0.0009

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,4,5-TP, 2 (2,4,5-trichlorophenoxy) propionic acid; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; dl, dioxin-like; IARC, International Agency for Research on Cancer; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methyl-chlorophenoxypropionic acid; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCDF, polychlorinated dibenzofurans; PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; ppt, parts per trillion; RR, relative risk; SIR, standardized incidence ratio; SMR, standardized mortality rate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; TEQ, toxicity equivalent; VA, US Department of Veterans Affairs.

aSubjects are female and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

including 2,4,5-T, so they had the possibility of exposure to TCDD. Manuwald et al. (2012) reported on their mortality through 2007. Relative to the population of Hamburg, 19 breast-cancer deaths represented a significantly increased risk in the women (SMR = 1.86, 95% CI 1.12–2.91). A Cochran-Armitage trend test on deaths from breast cancer according to quartiles of cumulative exposure did not find evidence of a dose–response relationship; the second and fourth quartiles had significantly increased risks, but the third quartile matched the lowest quartile, with only two breast-cancer deaths. That constitutes a somewhat stronger finding than had previously been reported by Manz et al. (1991).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. An SMR for breast cancer in the 1,402 PCP production workers (including 67 women) who had not been exposed to TCDD was derived on a sex-and race-specific basis using 5-year intervals of age and calendar time. With only a single death, the resulting finding (SMR = 0.55, 95% CI 0.01–3.07) was not informative.

In that the members of the applicator cohort in the AHS are largely men and those in the spouse cohort predominantly women, for this cancer it is the spouses who are more informative. Koutros et al. (2010a) did not find an increase in the incidence of female breast cancer through 2006 (770 cases, SIR = 1.00, 95% CI 0.93–1.08); Waggoner et al. (2011) found that mortality from breast cancer through 2007 was significantly below expectation (136 deaths, SMR = 0.80, 95% CI 0.67–0.94). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Environmental Studies

Warner et al. (2011) added more than 10 years of observation of cancer incidence in the women in the Seveso Women’s Health Study, updating the borderline significant results on breast cancer published earlier (Warner et al., 2002) to cover the period from the 1976 explosion through 2009. Of the 981 women participating in the earlier study, 833 were reinterviewed. A total of 66 cases were reported, which represented a distinct increase in the risk of any cancer (HR = 1.86, 95% CI 1.29–2.52) in association with lipid-adjusted, log-transformed serum TCDD concentrations at the time of the accident; 33 of the cases were breast cancers. After adjustment for age at the time of the explosion, marital status, parity, and family history of breast cancer, the occurrence of breast cancer was not as clearly associated with serum TCDD concentrations (HR = 1.46, 95% CI 0.89–2.33) as Warner et al. (2002) had found it to be up to 1998 (HR = 2.1, 95% CI 1.0–4.6). With stratification by decade since the industrial accident in 1976, the breast-cancer risk appeared to have peaked in the interval 11–20 years after (HR = 2.23, 95% CI 1.09–4.56) and to have subsided in the period 21–32 years after (HR = 1.06,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

95% CI 0.58–1.93). The small size of the cohort curtails the analyses that can be conducted, but the availability of serum TCDD concentrations measured from blood samples gathered fairly soon after the single-substance accident (which minimizes uncertainty about what exposure had been experienced and reduces the need for back-extrapolation) contributes substantially to the value of the results.

Case-Control Studies

The incidence of breast cancer in Inuits has traditionally been much lower that that in other Western populations, but there has been a notable increase in the frequency in this population over the last several decades. Bonefeld-Jorgensen et al. (2011) conducted a case-control study of breast cancer in Greenland Inuits. The registry of breast-cancer cases in Greenland during 2000–2003 was screened for Inuits (defined as women who had at least two grandparents born in Greenland), and 31 (80%) were entered into the study. They were matched by age and district to 115 controls assembled in a previous study of serum concentrations of persistant organic pollutants. The focus of this study was on perfluorinated compounds, but there also was reporting of serum concentrations of 12 PCB congeners—including dioxin-like, mono-ortho PCBs 105, 118, and 156—and overall AHR-mediated transcriptional activity. The median concentrations of dioxin-like, mono-ortho PCBs did not differ between cases and controls (149 and 198 pg/g lipid, respectively; p = 0.36). Further, AHR TEQs were significantly lower in cases than in controls (median, 56.8 and 65.4 pg/g lipid, respectively; p = 0.009). Therefore, the study results did not provide evidence of an association between dioxin-like activity and the occurrence of breast cancer in this population. However, since these values are based solely on mono-ortho PCBs, which typically contribute only a small percentage to total TEQs, no conclusions can be drawn.

Biologic Plausibility

The experimental evidence indicates that 2,4-D, 2,4,5-T, and TCDD are weakly genotoxic at most. However, TCDD is a demonstrated carcinogen in animals and is recognized as having carcinogenic potential in humans because of the mechanisms discussed in Chapter 4.

With respect to breast cancer, experimental data have shown a role of TCDD in carcinogenesis and promotion and evidence of a protective effect, particularly with regard to metastasis. Studies performed in laboratory animals (Sprague-Dawley rats) indicate that the effect of TCDD may depend on the age of the animal. For example, TCDD exposure was found to inhibit mammary-tumor growth in the adult rat (Holcombe and Safe, 1994) but to increase tumor growth in the neonatal rat (21 days old) (Desaulniers et al., 2001). Other studies have failed to demonstrate an effect of TCDD on mammary-tumor incidence or growth (Desaulniers et al., 2004).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Fenton (2009) recently reviewed the literature on TCDD and breast cancer and suggested that a mechanism may be related to endocrine disruption, which might indicate a close association between the development of mammary cancers and mammary gland differentiation. Agents capable of disrupting the ability of the normal mammary epithelial cell to enter or maintain its appropriate status (a proliferative, differentiated, apoptotic state), to maintain its appropriate architecture, or to conduct normal hormone (estrogen) signaling are likely to act as carcinogens (Fenton, 2006; McGee et al., 2006). In that light, it is interesting that postnatal exposure of pregnant rats to TCDD has been found to alter proliferation and differentiation of cells in the mammary gland (Birnbaum and Fenton, 2003; Vorderstrasse et al., 2004). A recent study has shown that TCDD directly targets mammary epithelial cells and the surrounding stromal fat cells during pregnancy-induced mammary gland differentiation; this indicates interference with stromal-epithelial cross-talk as one of several underlying pathways (Lew et al., 2011). Jenkins et al. (2007) used a rat carcinogen-induced mammary-cancer model to show that prenatal exposure to TCDD alters mammary gland differentiation and increases susceptibility to mammary cancer by altering the expression of estrogen-receptor (ER) genes and of genes involved in oxidative-stress defense. Thus, the effect of TCDD may depend on the timing of the exposure and on the magnitude of gene expression at the time of exposure; TCDD may influence mammary-tumor development only if exposure to it occurs during a specific window during breast development (Rudel et al., 2011). The breast is the only human organ that does not fully differentiate until it becomes ready for use; nulliparous women have less-differentiated breast lobules, which are presumably more susceptible to carcinogenesis.

Paradoxically, activation of the AHR by dioxin or by the nondioxin ligand indole-3-carbinol has also been shown to protect against breast cancer by mechanisms that disrupt migration and metastasis (Bradlow, 2008; Hsu et al., 2007). Administration of TCDD to mice that harbor highly metastatic breast-cancer cells in the mammary fat pad reduced the metastasis by 50% without suppressing primary tumor size—indication that TCDD’s protective effects are selective to the metastatic process (Wang et al., 2011). It is possible that some protective effects may be mediated through the known cross-talk between the AHR and ERα, which has been studied extensively at the molecular level for potential therapeutic benefit. Recent data show that AHR controls ERa-mediated gene stimulation through recruitment of receptor interacting protein 140 (RIP140), which can both activate and repress ER actions (Madak-Erdogan and Katzenellenbogen, 2012). In the presence of dioxin, the AHR can repress specific estrogen-dependent genes in MCF-7 breast-cancer cells (Labrecque et al., 2012). TCDD can also activate AHR-mediated G1cell-cycle arrest (Barhoover et al., 2010); however, in the presence of a progesterone receptor, TCDD enriches the G2/M phase and stimulates proliferation of MCF-7 cells (Chen YJ et al., 2012). Together, those results demonstrate a complicated interplay between the AHR and other nuclear

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

transcription factors that can either stimulate or inhibit breast-cancer growth in a manner that depends on cell-context.

TCDD has been shown to modulate the induction of DNA-chain breaks in human breast-cancer cells by regulating the activity of the enzymes responsible for estradiol catabolism and generating more reactive intermediates, which might contribute to TCDD-induced carcinogenesis by altering the ratio of 4-OH-estra-diol to 2-OH-estradiol, a marker of breast-cancer risk (Lin et al., 2007, 2008). A similar imbalance in metabolite ratios has been observed in pregnant Taiwanese women, in whom the ratio of 4-OH-estradiol to 2-OH-estradiol decreased with increasing exposure to TCDD (Wang et al., 2006). Expression of CYP1B1—the cytochrome P450 enzyme responsible for 2-OH-estradiol formation—but not CYP1A1—the one responsible for 4-OH-estradiol formation—was found to be highly increased in premalignant and malignant rat mammary tissues in which the AHR was constitutively active in the absence of ligand (Yang et al., 2008). On the basis of recent mechanistic data, it has been proposed that the AHR contributes to mammary-tumor cell growth by inhibiting apoptosis while promoting transition to an invasive, metastatic phenotype (Marlowe et al., 2008; Schlezinger et al, 2006; Vogel et al., 2011).

Recent evidence has shown that AHR activation by TCDD in human breast and endocervical cell lines induces sustained high concentrations of the interleu-kin-6 (IL-6) cytokine, which has tumor-promoting effects in numerous tissues, including breast tissue, so TCDD might promote carcinogenesis in these tissues (DiNatale et al., 2010; Hollingshead et al., 2008). Similarly, TCDD induced IL-8 expression in an AHR-dependent manner and may contribute to the inflammatory type of breast cancer (Vogel et al., 2011). Degner et al. (2009) have shown that AHR ligands can upregulate the expression of COX-2, and this may lead to a proinflammatory environment that can support tumor development.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

In the early 1990s, it was suggested that exposure to some environmental chemicals, such as organochlorine compounds, might play a role in the etiology of breast cancer through estrogen-related pathways. The relationship between organochlorines and breast-cancer risk has been studied extensively, especially in the last decade; TCDD and dioxin-like compounds have been among the organochlorines so investigated. Today, there is no clear evidence of a causal role of most organochlorines in human breast cancer (Salehi et al., 2008).

Because of concerns raised by a combination of a new study that had good exposure assessment and positive findings (Mills and Yang, 2005) and several earlier studies (Kang et al., 2000; Kogevinas et al., 1997; Revich et al., 2001; Warner et al., 2002), some members of the committee responsible for Update

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

2006 believed that there was suggestive evidence of an association, but that committee was unable to reach a consensus. After reviewing new studies that had null findings on mortality from breast cancer in the important cohorts of female Vietnam-era veterans (Cypel and Kang, 2008) and Seveso residents (Consonni et al., 2008), the committee for Update 2008 readily reached a consensus that breast cancer should remain in the category of inadequate or insufficient evidence of an association. The committee for Update 2010 concurred, although the 20-year followup of cancer incidence in Seveso (Pesatori et al., 2009) had reported a significantly increasing relationship between breast-cancer incidence and time from the accident until diagnosis in the women in Zone A: 15 or more years (RR = 2.57, 95% CI 1.07–6.20), 10–14 years (RR = 1.42, 95% CI 0.35–5.68), and 5–9 years (RR = 0.81, 95% CI 0.11–5.74); that is, accounting for latency led to stronger associations.

In the present update, the followup of the Seveso Women’s Health Study through 2009 by Warner et al. (2011) showed an abating of the risk of breast cancer (HR = 1.46, 95% CI 0.89–2.33) from what Warner et al. (2002) had reported through 1998 (HR = 2.1, 95% CI 1.0–4.6) and in contrast with the findings in the entire cohort through 1996 reported by Pesatori et al. (2009). The marginal increase in the Hamburg cohort (Manuwald et al., 2012) was counterbalanced by null results in the Dow Chemical Company 2,4-D production workers (Burns et al., 2011). The case-control study of Greenland Inuits provided no evidence of an association with dioxin-like activity.

Conclusion

Having considered the new evidence and the results of studies reviewed in previous updates, the present committee concludes that there is inadequate or insufficient evidence to determine whether there is an association (either positive or negative) between exposure to the COIs and breast cancer.

CANCERS OF THE FEMALE REPRODUCTIVE SYSTEM

This section addresses cancers of the cervix (ICD-9 180), endometrium (also referred to as the corpus uteri; ICD-9 182.0–182.1, 182.8), and ovary (ICD-9 183.0). Additional cancers of the female reproductive system that are infrequently reported separately are cancers of the uterus (ICD-9 179), placenta (ICD-9 181), fallopian tube and other uterine adnexa (ICD-9 183.2–183.9), and other female genital organs (ICD-9 184); findings on these cancers are included in this section. ACS estimates of the numbers of new female reproductive-system cancers in the United States in 2012 are presented in Table 8-23; they represent roughly 11% of new cancer cases and 11% of cancer deaths in women (Siegel et al., 2012).

Cervical cancer occurs more often in blacks than in whites, but endometrial and ovarian cancers occur more often in whites. The incidence of endometrial and ovarian cancers is higher in older women and in those who have family histories of these cancers. Use of unopposed (without progestogen) estrogen-hormone therapy and obesity, which increases endogenous concentrations of estrogen, both increase the risk of endometrial cancer. HPV infection, particularly infection with HPV types 16 and 18, is the most important risk factor for cervical cancer. Use of oral contraceptives is associated with a substantial reduction in the risk of ovarian cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-23 Estimates of New Cases of Deaths from Selected Cancers of the Female Reproductive System in the United States in 2012

SiteNew CasesDeaths
Cervix12,170  4,220
Endometrium47,130  8,010
Ovary22,28015,500
Other female genital [organs]  2,680     840

SOURCE: Siegel et al., 2012

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and female reproductive cancers. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 has been sparse and has not changed that conclusion.

Tables 8-24, 8-25, and 8-26 summarize the results of the relevant studies on cancers of the cervix, uterus, and ovary, respectively.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and female reproductive cancers have been published since Update 2010.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-24 Selected Epidemiologic Studies—Cervical Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Cohort of Female Vietnam Veterans

Incidence

All COIs

Female Vietnam veterans

  571.1 (0.7–1.7)Kang et al., 2000
International Vietnam-Veterans Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

Expected number of exposed casesCDVA, 1998b

Validation Study

Self-reported cervical cancer

    81 (0–5)
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality ratesDioxin, phenoxy herbicides

Mortality 1939–1992

    31.1 (0.2–3.3)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs 7,553 not exposed to highly chlorinated PCDDs

0 30.0 (0.0–3.8) 1.8 (0.4–5.2)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1987

    73.2 (1.3–6.6)Lynge, 1993

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Cervix uteri (ICD-10 C53)

    00.0 (0.0–14.6)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 19922

Self-employed

    70.5 (p < 0.05)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Employees

  120.8 (nr)

Family workers

1000.5 (p < 0.05)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Incident cervical cancer cases 1961–1973 with agriculture as economic activity in 1960 census

  8299% CI 0.6 (0.4–0.8)Wiklund, 1983

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Women

Whites (n = 2,400)

    60.9 (0.3–2.0)

Nonwhites (n = 2,066)

  212.0 (1.3–3.1)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    22.7 (0.7–10.8)Pesatori et al., 2009

Zone B

    71.5 (0.7–3.1)

Zone R

  280.8 (0.6–1.3)
Ecological Study of Residents of Chapaevsk, RussiaDioxinRevich et al., 2001

Incidence—Crude incidence rate in 1998 vs

Regional (Samara)

nr11.7 (nr)

National (Russia)

nr13.2 (nr)

Mortality—1995–1998 (SMR vs regional rates)

  131.8 (1.0–3.1)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophen-oxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; SMR, standardized mortality rate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; VA, US Department of Veterans Affairs.

aSubjects are female and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-25 Selected Epidemiologic Studies—Uterine Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Cohort of Female Vietnam Veterans

Incidence

All COIs

Female Vietnam veterans

  411.0 (0.6–1.6)Kang et al., 2000

Mortality

Through 2004—US non-Vietnam veterans

    50.8 (0.2–2.8)Cypel and Kang, 2008

vs non-Vietnam nurses

    51.3 (0.3–5.0)

Through 1991—US Vietnam veterans

    42.1 (0.6–5.4)Dalager et al., 1995
International Vietnam-Veterans Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

Expected number of exposed cases

Validation Study

Self-reported uterine cancer

    41 (0–5)CDVA, 1998b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality ratesDioxin, phenoxy herbicides

Mortality 1939–1992

    33.4 (0.7–10.0)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    11.2 (0.0–6.5)

7,553 not exposed to highly chlorinated PCDDs

    42.3 (0.6–5.9)

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Corpus uteri (ICD-10 C54–C55)

    00.0 (0.0–30.6)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Self-employed

    80.6 (nr)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Employees

    90.9 (nr)

Family workers

1030.8 (p < 0.05)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Incident NHL cases 1961–1973 with agriculture as economic activity in 1960 census

13599% CI 0.9 (0.7–1.1)Wiklund, 1983

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Women

Whites (n = 2,400)

  151.2 (0.7–2.1)

Nonwhites (n = 2,066)

  171.4 (0.8–2.2)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

    4nr

Commercial applicators

    1nr

Spouses

1480.9 (0.8–1.1)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group)TCDD

Incidence

20-yr followup to 1996 (Uterus, ICD-9 179–182)

Zone A

    42.3 (0.9–6.3)Pesatori et al., 2009

Zone B

  100.9 (0.5–1.7)

Zone R

  610.8 (0.6–1.0)

20-yr followup to 1996 (Endometrium, ICD-9 182)

Zone A

    11.2 (0.2–8.8)

Zone B

    30.6 (0.2–1.9)

Zone R

  270.7 (0.5–1.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

25-yr followup to 2001

Zone A

    0    0Consonni et al., 2008

Zone B

    20.5 (0.1–1.9)

Zone R

  411.3 (0.9–1.8)

20-yr followup to 1996

Zone A, B

    20.5 (0.1–1.9)Bertazzi et al., 2001

15-yr followup to 1991

Zone B

    10.3 (0.0–2.4)Bertazzi et al., 1997, 1998

Zone R

  271.1 (0.8–1.7)
CASE-CONTROL STUDIES

International Case-Control studies

Swedish women—endometrial cancer and serum concentrations of chlorinated pesticides and PCB congeners

Pesticides, PCB congenersWeiderpass et al., 2000
1541.0 (0.6–2.0)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CATI, computer-assisted telephone interviewing; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; NHL, non-Hodgkin lymphoma; nr, not reported; PCB, polychlorinated biphenyl; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tet-rachlorodibenzo-p-dioxin; VA, US Department of Veterans Affairs.

aSubjects are female and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Occupational Studies

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. They reported a single death, specified only as female genital cancer (ICD-9 179–184) in the 1,402 PCP production workers (including 67 women) who had not been exposed to TCDD (SMR = 0.90, 95% CI 0.02–5.03). That finding is not informative

Updated information from the AHS on incidence of and mortality from both uterine and ovarian cancers were presented by Koutros et al. (2010a) and Waggoner et al. (2011). Five incident cases of uterine cancer were reported in the applicators, most of whom were male, whereas the incidence in the predomi-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-26 Selected Epidemiologic Studies—Ovarian Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Cohort of Female Vietnam Veterans

Incidence

All COIs

Female Vietnam veterans

  161.8 (0.7–4.6)Kang et al., 2000
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

Expected number of exposed cases

Validation Study

Self-reported uterine cancer

    10 (0–4)CDVA, 1998b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality ratesDioxin, phenoxy herbicides

Mortality 1939–1992

    10.3 (0.0–1.5)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs 7,553 not exposed to highly chlorinated PCDDs

    00.0 (0.0–2.6)
10.5 (0.0–2.5)

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates

TCDDKogevinas et al, 1993
10.7 (nr)

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; PicloramMcBride et al., 2009a

Mortality 1969–2004

Ovarian cancer (ICD-10 C56)

    00.0 (0.0–9.5)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Self-employed

  120.9 (nr)

Employees

    50.5 (nr)

Family workers

1040.8 (p < 0.05)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

UNITED STATES

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

    92.5 (1.1–4.7)

Commercial applicators

    0nr

Spouses

  580.7 (0.6–0.9)

Enrollment through 2002

Alavanja et al., 2005

Private applicators (men, women) Spouses of private applicators (> 99% women)

    83.0 (1.3–5.9)
320.6 (0.4–0.8)

Commercial applicators (men, women)

    00.0 (0.0–16.0)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

    51.6 (0.5–3.8)

Spouses (n = 676)

  450.7 (0.5–0.9)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men, women) Spouses of private applicators (> 99% women)

    43.9 (1.1–10.1)
130.7 (0.4–1.2)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996 (Uterus, ICD-9

179–182)

Zone A

    11.1 (0.2–7.9)Pesatori et al., 2009

Zone B

    10.2 (0.0–1.3)

Zone R

  451.1 (0.8–1.5)

Mortality

25-yr followup to 2001

Zone A

    11.2 (0.2–8.5)Consonni et al., 2008

Zone B

    20.4 (0.1–1.6)

Zone R

  371.0 (0.7–1.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

20-yr followup to 1996

Zone A, B

    30.7 (0.2–2.0)Bertazzi et al., 2001

15-yr followup to 1991

Zone B

    12.3 (0.3–16.5)Bertazzi et al., 1997, 1998

Zone R

  211.0 (0.6–1.6)
CASE-CONTROL STUDIES

International Case-Control studies

Italian women—hospital-based study of women with primary mesothelial ovarian tumors (n = 60) and 127 subjects with non-ovarian malignancies

HerbicidesDonna et al., 1984
184.4 (1.9–16.1)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; CATI, computer-assisted telephone interviewing; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; VA, US Department of Veterans Affairs.

aSubjects are female and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

nantly female spouses did not differ from expectation (148 cases, SIR = 0.94, 95% CI 0.79–1.10) (Koutros et al., 2010a). Waggoner et al. (2011) did not find any change in mortality in the spouses from uterine cancer through 2007 (19 deaths, SMR = 0.70, 95% CI 0.42–1.09). Nine incident cases of ovarian cancer in the private applicators in the study by Koutros et al. (2010a) constituted a significant increase (SIR = 2.45, 95% CI 1.12–4.65), whereas 58 cases in spouses resulted in a decreased estimate of risk (SIR = 0.72, 95% CI 0.55–0.93). In the study by Waggoner et al. (2011), five deaths from ovarian cancer in the applicators did not suggest any difference from the general state populations (SMR = 1.61, 95% CI 0.54–3.76), and a deficit in observed ovarian cancer deaths in the spouses was reported (45 deaths, SMR = 0.70, 95% CI 0.51–0.94). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Biologic Plausibility

Yoshizawa et al. (2009) have shown that chronic administration of TCDD and other AHR ligands to adult female Harlan Sprague-Dawley rats results in chronic inflammation and increases in reproductive-tissue tumors, including cystic endometrial hyperplasia and uterine squamous-cell carcinoma. The mechanism of action might be related to endocrine disruption and chronic inflammation. Hollingshead et al. (2008) showed that TCDD activation of the AHR in human breast and endocervical cell lines induces sustained high concentrations of the IL-6 cytokine. It is noteworthy that effects of TCDD treatment differed between MCF-7 breast-cancer cells and ECC-1 endometrial carcinoma cells with respect to activation and repression of genes; this shows the role of cell context and organ specificity in responses to TCDD with regard to cancer promotion (Labrecque et al., 2012).

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

New information on specific female reproductive cancers since Update 2010 was limited to findings from the AHS, which were inconsistent and not specific for any of the COIs.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and uterine, ovarian, or cervical cancer.

PROSTATE CANCER

ACS estimated that 241,740 new cases of prostate cancer (ICD-9 185) would be diagnosed in the United States in 2012 and that 28,170 men would die from it (Siegel et al., 2012). That makes prostate cancer the second-most common cancer in men (after nonmelanoma skin cancers); it is expected to account for about 29% of new cancer diagnoses and 9% of cancer deaths in men in 2012. The average annual incidence of prostate cancer is shown in Table 8-27.

The incidence of prostate cancer varies widely with age and race. The risk more than doubles from the ages of 50–54 years to the ages of 55–59 years, and it nearly doubles again from the ages of 55–59 years to the ages of 60–64 years. As a group, American black men have the highest recorded incidence of prostate cancer in the world (Miller et al., 1996); their risk is roughly twice that in whites

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-27 Average Annual Incidence (per 100,000) of Prostate Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
347.6329.6611.7609.1585.61,026.5892.0865.221,416.7

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

in the United States, 5 times that in Alaska natives, and nearly 8.5 times that in Korean Americans. Little is known about the causes of prostate cancer. Other than race and age, risk factors include a family history of the disease and possibly some elements of the Western diet, such as high consumption of animal fats. The drug finasteride, which has been widely used to treat benign enlargement of the prostate, was found to decrease the prevalence of prostate cancer substantially in a major randomized trial (Thompson et al., 2003). Finasteride acts by decreasing the formation of potent androgen hormones in the prostate.

The study of the incidence of and mortality from prostate cancer is complicated by trends in screening for the disease. The widespread adoption of serum prostate-specific antigen (PSA) screening in the 1990s led to very large increases in prostate-cancer incidence in the United States, which have recently subsided as exposure to screening has become saturated. The long-term influence of better screening on incidence and mortality in any country or population is difficult to predict and will depend on the rapidity with which the screening tool is adopted, its differential use in men of various ages, and the aggressiveness of tumors detected early with this test (Gann, 1997). Because exposure to PSA testing is such a strong determinant of prostate-cancer incidence, epidemiologic studies must be careful to exclude differential PSA testing as an explanation of a difference in risk observed between two populations.

Prostate cancer tends not to be fatal, so mortality studies might miss an increase in incidence of the disease. Findings that show an association between an exposure and prostate-cancer mortality should be examined closely to determine whether the exposed group might have had poorer access to treatment that would have increased the likelihood of survival.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was limited or suggestive evidence of an association between exposure to the COIs and prostate cancer. Additional information available to the committees responsible for

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, and Update 2008 did not change that conclusion.

Eight studies that addressed whether exposure to the COIs is associated with prostate cancer were considered in Update 2010, and they were all effectively neutral, small sample size being the primary limitation. The only strong result that was in any way related to prostate cancer was the finding by Shah et al. (2009) that of 1,495 veterans who had undergone radical prostatectomy and were followed for 5 years, those who were exposed to Agent Orange had an increased risk of biochemical progression of 1.47 (95% CI 1.08–2.00). Accordingly, the committee for Update 2010 agreed with the conclusion of its predecessors.

Table 8-28 summarizes results of the relevant studies, including both morbidity and mortality studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies

No Vietnam-veteran studies or environmental studies of exposure to the COIs and prostate cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With 51 cases observed, the incidence of prostate cancer in the most restrictively defined cohort was not increased (SIR = 0.76, 95% CI 0.57–1.00), as was the case in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis of the mortality, updated through 2006, in male workers in two Dutch phenoxy-herbicide factories, which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination, whereas the 1,036 working in factory B had produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. Using the estimated TCDD concentrations of the workers in both factories did not provide evidence of an increased risk of prostate-cancer death associated with TCDD (HR

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-28 Selected Epidemiologic Studies—Prostate Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

2,516 veterans (1,019 Ranch Hand, 1,497 SEA veterans) who participated in ≥ 1 physical examination and had recorded serum TCDD measurements

Pavuk et al., 2006

20-yr cumulative TCDD (ppt-yr)

Comparison group

  811.0

Ranch Hand low (≤ 434 ppt-yr)

  311.0 (0.7–1.6)

Ranch Hand high (> 434 ppt-yr)

  281.2 (0.8–1.9)
p-trend = 0.42

Last tour in SEA before 1969 (heavy spraying)

Yes

Comparison group

  171.0

Ranch Hand low (≤ 434 ppt-yr)

    91.0 (0.4–2.3)

Ranch Hand high (> 434 ppt-yr)

  152.3 (1.1–4.7)
p-trend = 0.04

No

Comparison group

  641.0

Ranch Hand low (≤ 434 ppt-yr)

  221.1 (0.7–1.8)

Ranch Hand high (> 434 ppt-yr)

  130.9 (0.5–1.6)
p-trend = 0.75

Less than 2 yrs served in SEA

Yes

Comparison group

  161.0

Ranch Hand low (≤ 434 ppt-yr)

  201.9 (1.0–3.7)

Ranch Hand high (> 434 ppt-yr)

  142.2 (1.0–4.5)
p-trend = 0.03

No

Comparison group

  651.0

Ranch Hand low (≤ 434 ppt-yr)

  110.8 (0.4–1.5)

Ranch Hand high (> 434 ppt-yr)

  141.1 (0.6–1.9)
p-trend = 0.89

1982–2003—White SEA comparison veterans only (n = 1,482). Serum TCDD (pg/g) based on model with exposure variable loge(TCDD)

Pavuk et al., 2005

Per unit increase of –loge(TCDD) (pg/g)

  831.1 (0.7–1.5)

Quartiles (pg/g):

0.4–2.6

  131.0

2.6–3.8

  241.7 (0.8–3.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

3.8–5.2

  241.5 (0.7–2.9)

> 5.2

  221.2 (0.6–2.4)

Number of years served in SEA (per year of service)

  831.1 (1.0–1.2)

Quartiles (years in SEA):

0.8–1.3

    81.0

1.3–2.1

  111.3 (0.5–3.2)

2.1–3.7

  282.2 (1.0–4.9)

3.7–16.4

  362.4 (1.1–5.2)

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  361.5 (1.0–2.0)

With tours between 1966–1970

  341.7 (1.2–2.3)

SEA comparison veterans (n = 1,776)

  541.6 (1.2–2.1)

With tours between 1966–1970

  421.6 (1.2–2.2)

White AFHS subjects who spent at most 2 yrs in SEA

Per unit increase of –loge(TCDD)

  281.5 (0.9–2.4)

Comparison group

    71.0

Ranch Hand— < 10 TCDD pg/g in 1987

  101.5 (0.5–4.4)

Ranch Hand— < 118.5 TCDD pg/g at end of service

    62.2 (0.7–6.9)

Ranch Hand— > 118.5 TCDD pg/g at end of service

    56.0 (0.4–24.6)

Only Ranch Hands with 100% service in Vietnam and comparisons with no service in Vietnam

Per unit increase of –loge(TCDD)

  201.1 (0.6–1.8)

Comparison group

    31.0

Ranch Hand— < 10 TCDD pg/g in 1987

    92.5 (0.4–16.1)

Ranch Hand— < 118.5 TCDD pg/g at end of service

    42.4 (0.4–16.0)

Ranch Hand— > 118.5 TCDD pg/g at end of service

    44.7 (0.8–29.1)

Mortality

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

    20.7 (0.1–2.3)

SEA comparison veterans (n = 1,776)

    30.8 (0.2–2.1)

US VA Cohort of Army Chemical Corps

All COIs

Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (July 1, 1965–March 28, 1973)

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality—Prostate cancers

Through 2005

Cypel and Kang, 2010

Deployed veterans (2,872) vs nondeployed (2,737)

5 vs 21.0 (0.2–5.6)

ACC veterans vs US men

Vietnam cohort

    51.1 (0.3–2.5)

Non-Vietnam cohort

    21.0 (0.1–3.4)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    10.4 (nr)Boehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

  580.9 (nr)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

    90.8 (nr)

1965–1982

Breslin

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  300.9 (0.6–1.2)et al.,1986, 1988

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    51.3 (0.2–10.3)

State Studies of US Vietnam Veterans

Veterans with radical prostatectomies examined in VA Healthcare facilities (California, Georgia, North Carolina)

Shah et al., 2009

AO-exposed veterans with biochemical progression

nr1.5 (1.1–2.0)

Northern California—prostate cancer (self-reported [before diagnosis] of AO expo vs not) Massachusetts veterans aged 35–65 years in 1993—prostate cases diagnosed 1988–1993 vs gastrointestinal cancers

Chamie et al., 2008 Clapp, 1997
2392.9 (2.3–3.6)
150.8 (0.4–1.6)

Michigan Vietnam veterans using the VA Medical Center in Ann Arbor, Michigan (n = 47); 142 frequency-matched controls

Giri et al., 2004

Cases reporting AO exposure

  11OR 2.1 (0.8–5.2)

Cases in white veterans reporting AO exposure

nrOR 2.7 (0.9–8.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

Visintainer et al., 1995

Male genital system

  191.1 (0.6–1.7)Clapp, 1997

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    0nrAnderson et al., 1986a,b
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

6921.3 (1.2–1.3)ADVA, 2005a

Navy

1371.2 (1.0–1.4)

Army

4511.8 (1.2–1.4)

Air Force

1041.3 (1.0–1.5)

Validation Study

Expected number of exposed casesAIHW, 1999
212147 (123–171)

Men

428147 (123–171)CDVA, 1998a

Mortality

All branches, return–2001

1071.2 (1.0–1.5)ADVA, 2005b

Navy

  221.3 (0.8–1.8)

Army

  651.2 (0.9–1.5)

Air Force

  191.4 (0.8–2.1)

Sample of 1,000 Male Australian Vietnam

All COIs

Veterans—prevalence

450 interviewed 2005–2006 vs respondents to 2004–2005 national survey

nr1.3 (0.3–6.7)O’Toole et al., 2009

Australian Conscripted Army National Service

All COIs

(18,940 deployed vs 24,642 nondeployed)

Incidence

1982–2000

  651.2 (0.9–1.5)ADVA, 2005c

Mortality

1966–2001

    00.0 (0.0–0.7)ADVA, 2005c

1982–1994

  361.5 (1.0–2.0)CDVA, 1997b

Other Australian Vietnam veterans

All COIs

606 prostate cancer cases in Western Australia

Leavy et al., 2006

Vietnam service

  252.1 (0.9–5.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  681.1 (0.9–1.4)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  431.1 (0.8–1.5)

7,553 not exposed to highly chlorinated

  251.1 (0.7–1.6)

PCDDs

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991
301.1 (0.8–1.6)

British MCPA Plant—production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

  181.3 (0.8–2.1)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Mortality 1955–2006

  141.1 (0.8–1.5)Boers et al., 2012

Incidence 1943–1982

    90.8 (nr)Lynge, 1985

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

    81.3 (0.9–1.9)Boers et al., 2012

Mortality 1955–2006

6 vs 22.9 (0.6–14.2)Boers et al., 2010

Mortality 1955–1985

    22.2 (0.3–7.8)Bueno de Mesquita et al., 1993

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

4 vs 22.7 (0.5–14.9)Boers et al., 2010

Mortality 1965–1986

    14.8 (0.1–26.5)Bueno de Mesquita et al., 1993
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    11.5 (0.0–8.5)Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    10.7 (0.0–3.7)Becher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992

Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    32.5 (0.5–7.4)

TCDD 0.1–0.99 μg/kg of body weight

    11.1 (0.0–5.9)

TCDD > 1 μg/kg of body weight

    00.0 (0.0–2.5)

Mortality

1953–1992

Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    00.0 (0.0–5.7)

TCDD 0.1–0.99 μg/kg of body weight

    00.0 (0.0–7.5)

TCDD > 1 μg/kg of body weight

    00.0 (0.0–4.6))

Through 1987

90% CIZober et al., 1990
    00.0 (0.0–6.1)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007

  191.4 (0.8–2.1)Manuwald et al., 2012
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1952–1989

    71.5 (0.6–3.0)Becher et al., 1996

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966

    71.4 (0.6–2.9)Manz et al., 1991

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    10.2 (0.0–1.2)

Never-exposed workers

    21.9 (0.2–6.7)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    10.4 (0.0–2.1)’t Mannetje et al., 2005

Sprayers (697 men and 2 women on register of New Zealand applicators, 1973–1984)

Mortality 1973–2000

    20.6 (0.1–2.2)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  281.2 (0.8–1.7)Steenland et al., 1999

Through 1987

  171.2 (0.7–2.0)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    91.5 (0.7–2.9)

Mortality—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991)

    91.6 (0.7–3.0)Collins et al., 1993

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

Collins et al., 2009a
  211.4 (0.9–2.2)

1940–1994 (n = 2,187 men)

Bodner et al., 2003
nr1.7 (1.0–2.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

  261.0 (0.7–1.5)

PCP and TCP (n = 720)

    81.1 (0.5–2.1)

PCP (no TCP) (n = 1,402)

  181.0 (0.6–1.6)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

  510.8 (0.6–1.0)Burns et al., 2011

Through 1994 (n = 1,517)

    71.3 (0.5–2.8)Burns et al., 2001

Through 1982 (n = 878)

    11.0 (0.0–5.8)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    81.0 (0.4–1.9)Collins et al., 2009b
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

1170.9 (0.7–1.0)

Ever

  840.9 (0.7–1.2)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    91.0 (0.5–1.9)Henneberger et al., 1989

United Paperworkers International, 201 white men employed ≥ 10 yrs and dying 1970–1984

    41.1 (0.3–2.9)Solet et al., 1989

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortalit throu h March 1977

90% CIRobinson et al., 1986
171.2 (0.7–1.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from prostate cancer June 1971–December 1987

HerbicidesMorrison et al., 1993

Herbicides sprayed on ≥ 250 acres vs 0 acres

  202.2 (1.3–3.8)

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

2821.0 (0.9–1.1)Hertzman et al., 1997

Mortality 1950–1989

1161.2 (1.0–1.4)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

3990.9 (p < 0.05)

Employee

  630.8 (p < 0.05)

Danish gardeners—incidence from 3,156 male and 859 female gardeners

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

  391.3 (1.0–1.8)

Born 1915–1934 (medium exposure)

  350.9 (0.6–1.2)

Born after 1934 (low exposure)

    30.4 (0.1–1.3)

10-year followup (1975–1984) of male gardeners

  201.2 (0.7–1.8)Hansen et al., 1992

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

    60.4 (0.1–0.8)Asp et al., 1994

Mortality 1972–1989

    50.8 (0.3–1.8)

ICELAND

Icelandic men (1,860), women (859) exposed to agricultural pesticides, primarily 2,4-D (other endocrine organs, ICD-9 194)—incidence

2,4-DZhong and Rafnsson, 1996
100.7 (0.3–1.3)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  661.0 (0.7–1.2)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
  191.0 (0.6–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident prostate cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

  120.7 (0.4–1.3)

SWEDEN

Swedish Cancer-Environment Registry—National cancer registry linked to census

HerbicidesSharma-Wagner et al., 2000

36,269 incident prostate cancer cases 1961–1979 with 1960 census occupation of:

Agriculture, stock raising

6,0801.1 (1.0–1.1) (p < 0.01)

Farmers, foresters, gardeners

5,2191.1 (1.0–1.1) (p < 0.01)

Paper-mill workers

3040.9 (0.8–1.0)

Pulp grinding

  391.4 (1.0–1.9) (p < 0.05)

Incident prostate cancer cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
3,8901.0 (0.9–1.0)

Licensed Swedish Pesticide Sprayers—Incidence of prostate cancer

Phenoxy herbicidesDich and Wiklund, 1998
4011.1 (1.0–1.2)

Born 1935 or later

    72.0 (0.8–4.2)

Born before 1935

3941.1 (1.0–1.2)

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    24.7 (nr)

Lumberjacks (n = 139)

    30.9 (nr)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    61.0 (0.4–2.2)Swaen et al., 2004

Through 1987

    11.3 (0.0–7.3)Swaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

3,7651.2 (1.1–1.2)

Nonwhites (n = 11,446)

5641.1 (1.1–1.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

1,7191.2 (1.1–1.3)

Commercial applicators

  731.3 (1.0–1.6)

Spouses

    71.1 (0.4–2.2)

Enrollment through 2002

Samanic et al., 2006

Dicamba—lifetime days exposure

None

3431.0

1– < 20

1061.0 (0.8–1.3)

20– < 56

1020.9 (0.7–1.2)

56– < 116

  761.0 (0.7–1.3)

≥ 116

  671.1 (0.8–1.5)
p-trend 0.45

Enrollment through 2002

Alavanja et al., 2005

Private applicators

1,0461.3 (1.2–1.3)

Spouses of private applicators (> 99% women)

    51.2 (0.4–2.8)

Commercial applicators

  411.4 (1.0–1.9)

Enrollment through 1999 (n = 55,332)

5661.1 (1.1–1.2)Alavanja et al., 2003

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

1710.8 (0.7–1.0)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

  480.7 (0.5–0.8)
00.0 (0.0–1.6)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of prostate cancer

Herbicides

Agricultural extension agents

nr1.0 (0.7–1.5)Alavanja et al., 1988

Forest conservationists

p-trend < over years workedAlavanja et al., 1989
nrp < 0.05

Soil conservationists

nrP < 0.26
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Florida Licensed Pesticide Applicators (common phenoxy use assumed but not documented; had been listed by Blair et al., 1983)

Herbicides

30,155 white men licensed 1975–1993

Incidence 1975–1993

3531.9 (1.7–2.1)Fleming et al., 1999a

Mortality 1975–1993

  642.4 (1.8–3.0)Fleming et al., 1999b

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Expected number of exposed cases
    23.8 (nr)

> 30 yrs old when died 1964–1978—case-control

4,8271.2 (p < 0.05)Burmeister et al., 1983

H0: only for “modern methods” → born after 1900

Born before 1880

1,5391.5 (nr)

Born 1980–1900

2,0811.3 (nr)

Born after 1900

1,2070.8 (nr)

> 20 yrs old when died 1971–1978—PMR

1,1381.1 (p < 0.01)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    0Pesatori et al., 2009

Zone B

    70.9 (0.5–2.0)

Zone R

  390.8 (0.5–1.1)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone R

  160.9 (0.5–1.5)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    10.9 (0.1–6.2)

Zone B

    80.9 (0.4–1.8)

Zone R

  651.1 (0.8–1.4)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A, B—men

    81.1 (0.5–2.2)

15-yr followup to 1991—men

Bertazzi et al., 1997

Zone B

    61.2 (0.5–2.7)

Zone R

  391.2 (0.8–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10-yr followup to 1986—men

Bertazzi et al., 1989b

Zone B

    32.2 (0.7–6.9)

Zone R

  161.6 (0.9–2.7)
Other International Environmental Studies

FINLAND

Finnish fishermen (n = 6,410) and spouses (n = 4,260) registered between 1980 and 2002 compared to national statistics

Serum dioxinTurunen et al., 2008

Fishermen

  361.0 (0.7–1.4)

Spouses

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

  381.1 (0.8–1.5)

West coast

2241.0 (0.9–1.1)

Mortality

East coast

  121.0 (0.5–1.8)

West coast

1231.1 (0.9–1.3)
CASE-CONTROL STUDIES

CANADA—1,516 prostate cancer patients identified in the British Columbia Cancer Registry vs 4,994 matched controls; estimated lifetime exposure to:

PesticidesBand et al., 2011

2,4-D

  112.7 (1.1–6.6)

2,4-DB

  241.8 (1.0–3.0)

MCPA

  141.8 (1.0–3.2)

Dicamba

  222.0 (1.0–4.2)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DB, 4-(2,4-dichlorophenoxy)butyric acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; ACC, Army Chemical Corps; AFHS, Air Force Health Study; AO, Agent Orange; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methyl-chlorophenoxypropionic acid; MOS, military occupation specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; PMR, proportionate mortality ratio; SEA, Southeast Asia; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cStatistically significant with the 95% CI not including 1.0.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

= 1.08, 95% CI 0.79–1.49). The dose–response modeling applied only to the workers in factory A also did not find a significantly increased risk of prostate-cancer death (HR = 1.29, 95% CI 0.85–1.94), and the estimate of risk from the qualitative exposure analysis in Boers et al. (2010) was imprecise (HR = 1.93, 95% CI 0.61–14.15).

Manuwald et al. (2012) reported on mortality through 2007 in 1,191 men in the Hamburg cohort (a subcohort of the IARC phenoxy-herbicide cohort). They had been employed for at least 3 months during 1952–1984 in a chemical plant producing insecticides and herbicides, including 2,4,5-T, so they had the possibility of exposure to TCDD. SMRs showed that mortality from prostate cancer was not higher than that in the population of Hamburg (SMR = 1.37, 95% CI 0.82–2.13).

Ruder and Yinn (2011) reported mortality from 1940–2005 for the NIOSH PCP cohort of 2,053 male workers from the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. In the total cohort, 26 deaths were attributed to prostate cancer; this was consistent with mortality in the US population (SMR = 1.03, 95% CI 0.67–1.51). There were eight deaths from this type of cancer in the PCP-plus-TCDD group, which also was as expected (SMR = 1.08, 95% CI 0.47–2.12). The results were comparable in the 1,333 men in the PCP-only group (SMR = 1.01, 95% CI 0.60–1.60).

In the update of cancer incidence in the AHS through 2006, Koutros et al. (2010a) found significant increases in the incidence of prostate cancer in both the private (1,719 cases, SIR = 1.19, 95% CI 1.14–1.25) and the commercial applicators (73 cases, SIR = 1.28, 95% CI 1.00–1.61); the seven cases of prostate cancer reported in the spouses (most of whom were female) did not represent any deviation from expectation (7 cases, SIR = 1.05, 95% CI 0.42–2.15). Waggoner et al. (2011) found that mortality from prostate cancer in the applicators was lower than predicted on the basis of the state rates (171 deaths, SMR = 0.81, 95% CI 0.70–0.95). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies

Band et al. (2011) identified all cases of cancer entered into the British Columbia Cancer Registry in 1983–1990. In a case-control study, the 1,516 cases of prostate cancer identified and enrolled in the study (% participation rate) were matched by age to 4,944 men who had other cancers (excluding those of the lung and unknown primary site). All cases were histologically confirmed. Participants completed a questionnaire that requested a complete job history, alcohol and smoking behaviors, and other demographic information. A job-exposure matrix derived for the province’s agricultural industry in eight regions for the period 1950–1998 was used to estimate cumulative exposures to 290

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

chemicals—including 180 pesticides, of which 53 were herbicides—from the work histories of every farmer in the sample. The herbicides reported on included 2,4-D, 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB), MCPA, and dicamba. Because the job-exposure matrix was specific for British Columbia, subjects who had worked as farmers but only outside British Columbia were excluded, leaving a working sample of 1,153 cases and 3,999 controls, who included 113 and 316 farmers, respectively. Conditional logistic regressions were adjusted for the nonagricultural potentially confounding variables marital status, education, smoking, alcohol consumption, ethnicity, and whether the questionnaire had been completed by a proxy using an exposure of ever or never for each agent; analysis for trend was conducted over the categories none, low, or high when there were at least 15 exposed cases.

Correlations between the occurrence of prostate cancer and exposure to the various pesticides were calculated and were fairly substantial among the COIs, but not with particular fungicides or insecticides. Associations with prostate cancer were significant for 19 (13.7%) of the 139 pesticide active ingredients to which any of the subjects had been exposed, including 2,4-D (11 exposed cases, OR = 2.72, 95% CI 1.12–6.57), 2,4-DB (24 exposed cases, OR = 1.77, 95% CI 1.04–3.03), and MCPA (22 exposed cases, OR = 1.83, 95% CI 1.04–3.23); associations were marginally significant for dicamba (14 exposed cases, OR = 2.02, 95% CI 0.98–4.15). 2,4-D did not have enough exposed cases for the trend analysis, but for both 2,4-DB and MCPA there were significant trends with degree of exposure (p = 0.02 for both). The assumption that none of the non-farmers had any occupational exposure to those agricultural chemicals is probably valid, but some misclassification may have arisen from personal use.

Several recent publications (Andreotti and Silverman, 2012; Barry et al., 2011, 2012; Koutros et al., 2010b, 2011) reported on a nested case-control sub-study within the AHS on relationships among prostate cancer, pesticide exposure (including exposure to the COIs, such as 2,4-D and 2,4,5-T), and genetic markers. All men eligible for inclusion in the study were white applicators who had not had any cancer other than nonmelanoma skin cancer before enrollment in the AHS and had provided a buccal cell sample. Two controls, matched on age and alive at the time of the case’s diagnosis, were sought for each case. The final study sample consisted of 776 prostate-cancer cases diagnosed in 1993–2004 and 1,444 controls. The focus of the substudy was on the interaction between pesticide exposure and genetic markers; how pesticide exposure modified the association between genetic markers and prostate cancer. Some useful information about the effect of exposure to the COIs and prostate cancer can be gleaned as a byproduct of the interaction analyses, but it came primarily from the perspective of biologic plausibility. Koutros et al. (2011) did report main effects adjusted for age, state, and family history of prostate cancer and trend for low and for high exposure vs no exposure to the various pesticides and prostate cancer. The results did not support significantly increased risks associated with 2,4-D, 2,4,5-T, and 2,4,5-TP; for

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

the high-exposure group for 2,4,5-T there was a significant decrease in risk (OR = 0.60, 95% CI 0.42–0.84). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Biologic Plausibility

Prostate cells and prostate-cancer cell lines are responsive to TCDD in induction of various genes, including those involved in drug metabolism. Simanainen et al. (2004) used different rat lines (TCDD-resistant Hans/Wistar and TCDD-sensitive Long Evans) and showed that TCDD treatment resulted in a significant decrease in the weight of prostate lobes; the effect did not appear to be line-specific. Different responses to TCDD in human prostate-cancer cell lines LNCaP and PC3 have been reported, including increased proliferation or no growth and stimulation or repression of AHR activity, which may be a function of coactivator-corepressor concentrations in the cells (Kollara and Brown, 2009, 2010). TCDD suppressed expression of genes associated with cell-cycle progression in LNCaP cells but also suppressed DNA-repair genes and increased Wnt5a concentrations; these effects could lead to divergent responses with regard to prostate-cancer progression (Hruba et al., 2011). In utero and lactational exposure to TCDD increases aging-associated cribiform hyperplasia in the murine prostate, which may be a precancerous lesion (Fritz et al., 2005). In a followup, progeny of a genetic cross between AHR-null mice and the transgenic adenocarcinoma of the mouse-prostate (TRAMP) strain that models prostate cancer showed that the presence of the AHR inhibited the formation of prostate tumors that have a neuroendocrine phenotype (Fritz et al., 2008). In agreement with a possible protective role, negative associations were found in the AFHS between the risk of benign prostate hyperplasia and both TCDD exposure and serum testosterone concentration (Gupta et al., 2006). As in breast cancer, this suggests that timing of exposure may be critical in adult-onset prostate disease, with early-life exposures increasing prostate-cancer susceptibility and adult AHR activation reducing it. Inasmuch as male Vietnam veterans were exposed to Agent Orange during adulthood, the early-life exposure findings are not relevant to this population.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The occupational studies reviewed in this update did not contain much evidence of an association between the COIs and prostate cancer. However, the increased risks reported from the non-pesticide-specific analysis of the AHS cohort were consistent with earlier positive findings concerning prostate cancer, and the case-control study of specific agricultural exposures in British Columbia

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

(Band et al., 2011) was fully supportive of there being an association between phenoxy herbicides and prostate cancer. The existing body of epidemiologic evidence supporting an association between exposure to the COIs and prostate cancer is robust enough that this committee finds no justification for reversing the conclusion of prior VAO committees that there is limited or suggestive evidence of an association.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there remains limited or suggestive evidence of an association between exposure to at least one of the COIs and prostate cancer.

TESTICULAR CANCER

ACS estimated that 8,590 men would receive diagnoses of testicular cancer (ICD-9 186.0–186.9) in the United States in 2012 and that 360 men would die from it (Siegel et al., 2012). Other cancers of the male reproductive system that are infrequently reported separately are cancers of the penis and other male genital organs (ICD-9 187). The average annual incidence of testicular cancer is shown in Table 8-29.

Testicular cancer occurs more often in men under 40 years old than in older men. On a lifetime basis, the risk in white men is about four times that in black men. Cryptorchidism (undescended testes) is a major risk factor for testicular cancer. Family history of the disease also appears to be a risk factor. Several other hereditary, medical, and environmental risk factors have been suggested, but the results of research are inconsistent (Bosl and Motzer, 1997).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between

TABLE 8-29 Average Annual Incidence (per 100,000) of Testicular Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
2.93.40.51.71.80.81.21.30.0

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

exposure to the COIs and testicular cancer. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-30 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam veteran studies, environmental studies, or case-control studies of exposure to the COIs and testicular cancer have been published since Update 2010.

Occupational Studies

Ruder and Yiin (2011) did not report any deaths from testicular cancer in the 2,053 men in the updated NIOSH PCP cohort.

In an update of cancer incidence in the AHS by Koutros et al. (2010a), no increases in the incidence of testicular cancer were found in private applicators (32 cases, SIR = 0.97, 95% CI 0.67–1.37) or in commercial applicators (six cases, SIR = 1.21, 95% CI 0.45–2.64). Waggoner et al. (2011) did not report on mortality from this type of cancer. The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Biologic Plausibility

No animal studies of the incidence of testicular cancer after exposure to any of the COIs have been published since Update 2010. That is undoubtedly due to the lack of a valid animal model of testicular cancer. The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The evidence from epidemiologic studies is inadequate to link herbicide exposure and testicular cancer. The relative rarity of this cancer makes it difficult to develop risk estimates with any precision. Most cases occur in men 25–35 years old, and men who have received such a diagnosis could be excluded from military service; this could explain the slight reduction in risk observed in some veteran studies.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-30 Selected Epidemiologic Studies—Testicular Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Cohort of Army Chemical Corps—Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (July 1, 1965–March 28, 1973)

All COIs

Mortality

Through 2005

Cypel and Kang, 2010

Deployed veterans (2,872) vs nondeployed

    2

(2,737)

Through 1991

    24.0 (0.5–14.5)Dalager and Kang, 1997

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

1141.1 (nr)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

  281.0 (nr)

1965–1984

Watanabe et al., 1991

Army, deployed (n = 24,145) vs nondeployed (n = 27,917)

1091.2 (ns)

Served in I Corps (n = 6,668)

  122.6 (1.1–6.2)Bullman et al., 1990

Marine Corps, deployed (n = 5,501) vs nondeployed (n = 4,505)

  280.8 (ns)Watanabe et al., 1991

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  901.1 (0.8–1.5)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  261.3 (0.5–3.6)
State Studies of US Vietnam Veterans

District of Columbia patients (18–42 yrs of age) in 3 hospitals, diagnosed with testicular cancer (1976–June 30, 1981)

  312.3 (1.0–5.5)Tarone et al., 1991

Massachusetts Vietnam-era veterans

Veterans aged 35–65 years in 1993—cases diagnosed 1988–1993 vs gastrointestinal cancers

  301.2 (0.4–3.3)Clapp, 1997
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

    72.3 (0.9–4.6)Saracci et al., 1991

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    42.2 (0.6–5.7)Coggon et al., 1986

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    00.0 (0.0–15.6)

Never-exposed workers

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003; testes and other male genital (n = 1,615)

    11.6 (0.0–8.9)Collins et al., 2009a

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Through 1994 (n = 1,517)

    12.2 (0.0–12.5)Burns et al., 2001

Through 1982 (n = 878)

    14.6 (0.0–25.7)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP); testes and other male genital

Collins et al., 2009b
00.0 (0.0–12.5)

Mortality 1940–1989 (n = 770)

    0nrRamlow et al., 1996
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

    21.1 (0.1–4.1)

Ever

    53.6 (1.2–8.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

CANADA

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

  181.0 (0.6–1.4)Hertzman et al., 1997

Mortality 1950–1989 (male genital cancers)

1161.0 (0.8–1.1)

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

  740.9 (nr)

Employee

  230.6 (p < 0.05)

ICELANDIC men (1,860), women (859) exposed to agricultural pesticides, primarily 2,4-D—incidence

2,4-DZhong and Rafnsson, 1996
21.2 (0.1–4.3)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 339 incident testicular cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

    61.0 (0.4–2.6)

SWEDEN

Incident testicular cancer cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
1011.0 (0.7–1.2)

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  320.8 (0.6–1.2)

Nonwhites (n = 11,446)

    61.3 (0.5–2.9)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
CASE-CONTROL STUDIES

International Case-Control Studies

Swedish Cancer Registry (1989–1992)—testicular cancer patients (20–75 yrs old) (n = 148)

HerbicidesHardell et al., 1998

Exposed to herbicides

    40.3 (0.1–1.0)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CATI, computer-assisted telephone interviewing; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MOS, military occupation specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and testicular cancer.

BLADDER CANCER

Urinary bladder cancer (ICD-9 188) is the most common urinary tract cancer. Cancers of the urethra and paraurethral glands and other and unspecified urinary cancers (ICD-9 189.3–189.9) are infrequently reported separately; any findings on these cancers would be reported in this section. ACS estimated that 55,600 men and 17,910 women would receive a diagnosis of bladder cancer in the United States in 2012 and that 10,510 men and 4,370 women would die from it (Siegel et al., 2012). In males, in whom this cancer is about twice as common as it is in females, those numbers represent about 7% of new cancer diagnoses and 3% of cancer deaths. Overall, bladder cancer is fourth in incidence in men in the United States.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Bladder-cancer risk rises rapidly with age. In men in the age groups that characterize most Vietnam veterans, bladder-cancer incidence is about twice as high in whites as in blacks. The average annual incidence of urinary bladder cancer is shown in Table 8-31.

The most important known risk factor for bladder cancer is tobacco use, which accounts for about half the bladder cancers in men and one-third of them in women (Miller et al., 1996). Occupational exposure to aromatic amines (also called arylamines), polycyclic aromatic hydrocarbons, and some other organic chemicals used in the rubber, leather, textile, paint-products, and printing industries is associated with higher incidence. In some parts of Africa and Asia, infection with the parasite Schistosoma haematobium contributes to the high incidence.

Exposure to inorganic arsenic is also a risk factor for bladder cancer. Although cacodylic acid is a metabolite of inorganic arsenic, as discussed in Chapter 4, the data are insufficient to conclude that studies of inorganic-arsenic exposure are directly relevant to exposure to cacodylic acid, so the literature on inorganic arsenic is not considered in this section.

Conclusions from VAO and Previous Updates

The committees responsible for VAO and Update 1996 concluded that there was limited or suggestive evidence of no association between exposure to the COIs and urinary bladder cancer. Additional information available to the committee responsible for Update 1998 led it to change that conclusion to one of inadequate or insufficient information to determine whether there is an association. The committees responsible for Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-32 summarizes the results of the relevant studies.

TABLE 8-31 Average Annual Incidence (per 100,000) of Bladder Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men43.446.926.277.384.648.7130.6141.495.1
Women12.213.57.721.423.214.533.636.527.7

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-32 Selected Epidemiologic Studies—Urinary Bladder Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  141.1 (0.6–1.7)

With tours between 1966–1970

  141.3 (0.7–2.1)

SEA comparison veterans (n = 1,776)

    80.4 (0.2–0.8)

With tours between 1966–1970

    40.3 (0.1–0.7)

Mortality

Through 1999—White subjects vs national rates

Ranch Hand veterans

    10.9 (nr)

SEA comparison veterans

    10.6 (nr)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    1nrBoehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

    90.6 (0.3–1.2)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    42.4 (0.1–66.4)
State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans

Veterans served 1958–1973—cases diagnosed 1988–1993 (served in Vietnam) (updates Clapp et al., 1991)

  800.6 (0.2–1.3)Clapp et al. 1997

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans (includes lymphosarcoma, reticulosarcoma)

    1nrAnderson et al., 1986
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Incidence

All branches, 1982–2000

1641.0 (0.9–1.2)ADVA, 2005a

Navy

  341.0 (0.7–1.4)

Army

1041.0 (0.8–1.2)

Air Force

  261.3 (0.8–1.8)

Mortality

All branches, return–2001

  220.7 (0.4–1.0)ADVA, 2005b

Navy

    40.6 (0.2–1.6)

Army

  130.7 (0.3–1.1)

Air Force

    51.1 (0.4–2.5)

1980–1994

  111.1 (0.6–1.9)CDVA, 1997a

Australian Conscripted Army National Service

All COIs

(18,940 deployed vs 24,642 nondeployed)

Incidence—1982–2000

  190.7 (0.4–1.1)ADVA, 2005c

Mortality

1966–2001

    10.3 (0.0–1.7)

1982–1994

    10.6 (nr)CDVA, 1997b
OCCUPATIONAL—INDUSTRIAL IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  341.0 (0.7–1.5)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs 7,553 not exposed to highly chlorinated PCDDs

24
10
1.4 (0.9–2.1) 0.7 (0.3–1.2)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

  130.8 (0.4–1.4)Saracci et al., 1991

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    80.9 (0.4–1.7)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982 (men only)

  110.8 (nr)Lynge, 1985
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1955–2006

  151.1 (0.8–1.4)Boers et al., 2012

TCDD plasma level (hazard ratios, by tertile)

Background (≤ 0.4)

    4nr

Low (0.4–4.1)

  102.4 (0.8–8.3)

Medium (4.1–20.1)

    74.0 (1.1–14.3)

High (≥ 20.1)

    23.1 (0.6–17.0)

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

  111.0 (0.7–1.5)Boers et al., 2012

Mortality 1955–2006

9 vs 22.3 (0.5–10.3)Boers et al., 2010

Mortality 1955–1991

    43.7 (1.0–9.5)Hooiveld et al., 1998

Accidentally exposed subcohort

    12.8 (0.1–15.5)

Mortality 1955–1985

    11.5 (0.0–8.8)Bueno de Mesquita et al., 1993

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

2 vs 21.1 (0.2–7.2)Boers et al., 2010

Mortality 1965–1986

    00.0 (0.0–20.5)Bueno de Mesquita et al., 1993

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Incidence

1960–1992

Ott and Zober, 1996

TCDD < 0.1 μg/kg of body weight

    10.7 (0.0–4.0)

TCDD 0.1–0.99 μg/kg of body weight

    33.0 (0.6–8.9)

TCDD > 1 μg/kg of body weight

    10.8 (0.0–4.4)

Mortality

1960–1992

TCDD < 0.1 μg/kg of body weight

    00.0 (0.0–5.7)

TCDD 0.1–0.99 μg/kg of body weight

    24.1 (0.5–14.7)

TCDD > 1 /k of bod weight

    00 0 (0 0–5 4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Through 1987

90% CIZober et al., 1990
    0nr (0.0–15.0)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–2007

  131.8 (1.0–3.1)Manuwald et al., 2012

Men

  111.8 (0.9–3.3)

Women

    21.8 (0.2–6.6)

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    00.0 (0.0–2.9)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    0nr’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    0nr’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  162.0 (1.1–3.2)Steenland et al., 1999

Chloracne subcohort (n = 608)

    63.0 (1.4–8.5)

Through 1987 (bladder, other)

    91.6 (0.7–3.0)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency Mortality—754 Monsanto workers, among most highly exposed workers from Fingerhut et al. (1991)

    41.9 (0.5–4.8)
166.8 (3.9–11.1)Collins et al., 1993

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    61.2 (0.5–2.7)Collins et al., 2009a

1940–1994 (n = 2,187 men)

nr0.7 (0.1–2.0)Bodner et al., 2003
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (bladder and other urinary organs, ICD-9 188, 189.3, 189.9)

    81.1 (0.5–2.1)

PCP and TCP (n = 720)

    10.4 (0.0–2.3)

PCP (no TCP) (n = 1,402)

    71.4 (0.6–2.9)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

  191.2 (0.7–1.9)Burns et al., 2011

Through 1994 (n = 1,517)

    10.5 (0.1–2.8)Burns et al., 2001

Through 1982 (n = 878)

    0nr (0.0–7.2)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    20.7 (0.1–2.7)Collins et al., 2009b
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  501.0 (0.7–1.3)

Ever

  431.1 (0.8–1.5)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    41.2 (0.3–3.2)Henneberger et al., 1989

Pulp and Paper cohorts independent of IARC cohort

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortalit throu h March 1977

90% CIRobinson et al., 1986
81.2 (0.6–2.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence 1969–1989

  330.9 (0.7–1.2)Hertzman et al., 1997 Green, 1991

Mortality 1950–1989

  941.0 (0.8–1.2)

Herbicide sprayers routinely exposed to herbicides for 6 months or more (1950–1982)

Phenoxy herbicides

Diseases of genitourinary system

    11.0 (0.0–5.6)

DENMARK

Danish gardeners (n = 3,124) exposed to pesticides

  590.8 (0.6–1.1)Kenborg et al., 2012

Danish farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al. 1992

Men

Self-employed

3000.6 (p < 0.05)

Employee

  700.7 (p < 0.05)

Women

Self-employed

    10.2 (nr)

Employee

    20.6 (nr)

Family worker

  250.6 (p < 0.05)

Danish gardeners—incidence from 3,156 male and 859 female gardeners (urinary system, ICD-7 180–181)

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

  251.1 (0.7–1.6)

Born 1915–1934 (medium exposure)

  230.5 (0.4–0.8)

Born after 1934 (low exposure)

    10.2 (0.0–1.1)

10-year followup (1975–1984) of male gardeners

  180.9 (0.5–1.4)Hansen et al., 1992

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

Asp et al., 1994

No latency

  121.6 (0.8–2.8)

10-yr latency

  111.7 (0.8–3.0)

Mortality

No latency

    10.5 (0.0–2.6)

10-yr latency

    10.5 (0.0–3.0)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  310.5 (0.4–0.8)Torchio et al., 1994
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
  121.0 (0.5–1.8)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident stomach cancer cases vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides
    40.7 (0.3–1.8)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    20.7 (0.1–2.4)Swaen et al., 2004

UNITED STATES

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

1910.6 (0.5–0.7)

Commercial applicators

  160.2 (0.7–1.9)

Spouses

  290.6 (0.4–0.9)

Enrollment through 2002

Samanic et al., 2006

Dicamba—lifetime days exposure

None

  431.0

1– < 20

    60.5 (0.2–1.3)

20– < 56

    90.7 (0.3–1.4)

56– < 116

    60.6 (0.3–1.5)

≥ 116

    80.8 (0.4–1.9)
p-trend = 0.66

Enrollment through 2002

Alavanja et al., 2005

Private applicators

1840.7 (0.6–0.8)

Spouses of private applicators (> 99% women)

  170.7 (0.4–1.1)

Commercial applicators

  131.1 (0.6–1.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  350.6 (0.4–0.8)

Spouses (n = 676)

    90.8 (0.4–1.6)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

    70.4 (0.1–0.7)

Spouses of private applicators (> 99% women)

    20.8 (0.1–2.7)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of NHL

Herbicides

Agricultural extension agents

    80.7 (0.4–1.4)Alavanja et al., 1988

Forest conservationists

p- trend < over years workedAlavanja et al., 1989
    80.8 (0.3–1.6)

Florida Licensed Pesticide Applicators (common phenoxy use assumed but not documented; had been listed by Blair et al., 1983)

Herbicides

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

HerbicidesBlair et al., 1983

Any pesticide (dose-response by length of licensure)

Expected exposed cases
    31.6 (nr)

White Male Residents of Iowa—NHL cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

2740.9 (nr)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    31.4 (0.5–4.5)Pesatori et al., 2009

Zone B

  171.3 (0.8–2.2)

Zone R

  840.9 (0.8–1.2)

10-yr followup to 1991—men

Pesatori et al., 1992

Zone A, B

  101.6 (0.9–3.1)

Zone R

  391.0 (0.7–1.4)

10-yr followup to 1991—women

Zone A, B

    10.9 (0.1–6.8)

Zone R

    40.6 (0.2–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    11.0 (0.2–7.4)

Zone B

    60.9 (0.4–2.0)

Zone R

  420.9 (0.6–1.2)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A and B—men

    61.2 (0.5–2.7)

15-yr followup to 1991—men

Bertazzi et al., 1998

Zone B

    12.4 (0.3–16.8)

Zone R

  210.9 (0.6–1.5)

15-yr followup to 1991—women

Bertazzi et al., 1998

Zone B

    30.9 (0.3–3.0)

Zone R

    40.6 (0.2–1.8)
Ecological Study of Residents of Chapaevsk, RussiaDioxinRevich et al., 2001

Mortality—1995–1998 (SMR vs regional rates)

Men

  312.6 (1.7–3.6)

Women

  170.8 (0.5–1.3)
Other International Environmental Studies

FINLAND

Finnish community exposed to chlorophenol contamination (men and women)—incidence

ChlorophenolLampi et al., 1992
141.0 (0.6–1.9)

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

  100.7 (0.4–1.3)

West coast

  550.9 (0.7–1.1)

Mortality

East coast

    51.3 (0.4–3.1)

West coast

  201.0 (0..6–1.6)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportional mortality ratio; SEA, Southeast Asia; SIR, standardized incidence ratio; SMR, standardized mortality rate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and bladder cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With 19 cases observed, the incidence of bladder cancer in the most restrictively defined cohort was not increased (SIR = 1.22, 95% CI 0.73–1.90), as was the case in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis of mortality updated through 2006 in male workers in two Dutch phenoxy-herbicide factories, which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination, whereas the 1,036 working in factory B had produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. Using the estimated TCDD concentrations of the workers in both factories did not indicate an increased risk of bladder-cancer mortality associated with TCDD (HR = 1.07, 95% CI 0.83–1.38). The dose–response modeling applied only to the workers in factory A did not find an increased risk of death from bladder cancer (HR = 0.98, 95% CI 0.66–1.45), whereas the estimated risk from the qualitative exposure analysis in Boers et al. (2010) was imprecise (HR = 2.27, 95% CI 0.50–10.28).

Manuwald et al. (2012) reported mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment in the plant, and vital status was sought through 2007. SMRs calculated relative to the population of Hamburg showed that death from bladder cancer was not increased in men (SMR = 1.83, 95% CI 0.91–3.28) or in women (SMR = 1.82, 95% CI 0.20–6.56), but in the entire cohort the increase in risk was marginally significant (SMR = 1.83, 95% CI 0.97–3.13).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, deaths from cancers of the bladder or other urinary organs were not substantially increased in the entire cohort (eight deaths, SMR = 1.08, 95% CI 0.47–2.13) or in the PCP-only group (seven deaths, SMR = 1.41, 95% CI 0.57–2.90). Only a single death from cancer of the urinary organs was observed in the PCP-plus-TCDD group (SMR = 0.41, 95% CI 0.01–2.90).

In the update of cancer incidence through 2006, Koutros et al. (2010a) found decreased incidences of bladder cancer in private applicators (191 cases, SIR = 0.59, 95% CI 0.51–0.68) and in their spouses (29 cases, SIR = 0.60, 95% CI 0.40–0.86). Waggoner et al. (2011) found mortality due to bladder cancer to be lower than expected in the applicators (35 deaths, SMR = 0.55, 95% CI 0.38–0.76) but not significantly so in their spouses (nine deaths, SMR = 0.83, 95% CI 0.38–1.58). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Kenborg et al. (2012) conducted a study focused on Parkinson disease in a Danish cohort of 3,124 male union members who worked as professional gardeners in 1975. When previously studying this cohort, Hansen et al. (1992, 2007) had reported that herbicides (including phenoxy herbicides) constituted most of their exposure. In conjunction with addressing the observation that smoking has been repeatedly found to be negatively associated with the occurrence of Parkinson disease, Kenborg et al. (2012) also investigated the incidence of several cancers that are recognized as being smoking-related. The incidence of bladder cancer in the gardeners was similar to the age-specific and calendar-period-specific incidence in the general male Danish population (59 cases, SIR = 0.82, 95% CI 0.62–1.05).

Biologic Plausibility

In laboratory animals, cacodylic acid has been shown to induce primarily bladder tumors (Cohen et al., 2006; Wang et al., 2009). In a study of male F344 rats, cacodylic acid administered in drinking water resulted in formation of bladder tumors at the highest concentrations (50 and 200 ppm) (Wei et al., 2002). In another report (Arnold et al., 2006), administration of cacodylic acid in the diet resulted in formation of papillomas and carcinomas in the bladders of female and male F344 rats but not B6C3F1 mice. In a study that used a rat-cancer-initiation-promotion model, cacodylic acid was found to be a weak cancer-initiator but a tumor-promoter at high doses (Fukushima et al., 2005). Direct intravesical administration of cacodylic acid (DMAV) in female adult rats resulted

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

in increased bromodeoxyuridine labeling in urothelial cells indicating DNA damage, weak neutrophil infiltration, and modest increases in oxidative-stress indexes (Takahashi et al., 2011). Other recent studies have shown cacodylic acid concentrations to be lower in bladder-cancer patients than in matched controls (Pu et al., 2007) and to be negatively associated with the incidence of urinary cancer (Huang et al., 2008). In contrast, greater oxidative DNA damage has been found in association with higher cacodylic acid concentrations in urothelial-cancer patients (Chung et al., 2008), although this was not the case in primary human hepatocytes (Dopp et al., 2008).

No studies have reported an increased incidence of urinary bladder cancer in TCDD-treated animals. Working with tissues from urothelial-cancer patients, Ishida et al. (2010) found that activation of the AHR pathway by TCDD enhances cancer-cell invasion by upregulating matrix metalloproteinase-1 and -9 expression and is associated with poor prognosis in upper urinary tract urothelial cancer. In contrast, transgenic mice that have deletion of the AHR exhibit immune-cell infiltration in bladder submucosa and loss of e-cadherin in some epithelial cells with local invasion in aged mice (Butler et al., 2012); although direct studies with TCDD were not undertaken, these findings suggest a protective effect of AHR signaling in bladder cancer.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Available analyses of an association between exposure to the COIs and bladder-cancer risk are characterized by low precision because of the small numbers, low exposure specificity, and lack of ability to control for confounding. Over the last several updates, laboratory data have emerged suggesting that cacodylic acid may be a bladder-tumor-promoter, but there have also been observations that cacodylic acid concentrations are lower in patients who have urinary cancer than in controls without any cancer diagnosis. The evidence in either direction remains too preliminary to alter the conclusion that the cumulative evidence of such an association is inadequate or insufficient.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and bladder cancer.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

RENAL CANCER

Cancers of the kidney other than the renal pelvis (ICD-9 189.0) and cancer of the renal pelvis (ICD-9 189.1) are often grouped in epidemiologic studies; cancer of the ureter (ICD-9 189.2) is sometimes also included. Although diseases of those organs have different characteristics and could have different risk factors, there is some logic to grouping them: the structures are all exposed to filterable chemicals, such as polycyclic aromatic hydrocarbons, that appear in urine. ACS estimated that 40,250 men and 24,520 women would receive diagnoses of renal cancer (ICD-9 189.0, 189.1) in the United States in 2012 and that 8,650 men and 4,920 women would die from it (Siegel et al., 2012). Those figures represent 2–4% of all new cancer diagnoses and cancer deaths. The average annual incidence of renal cancer is shown in Table 8-33.

Renal cancer is twice as common in men as in women. In the age groups that include most Vietnam veterans, black men have a higher incidence than do white men. With the exception of Wilms tumor, which is more likely to occur in children, renal cancer is more common in people over 50 years old.

Tobacco use is a well-established risk factor for renal cancer. People who have some rare syndromes—notably, von Hippel-Lindau syndrome and tuberous sclerosis—are at higher risk. Other potential risk factors include obesity, heavy acetaminophen use, kidney stones, and occupational exposure to asbestos, cadmium, and organic solvents. Firefighters, who are routinely exposed to numerous pyrolysis products, are in a known higher-risk group.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and renal cancer. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-34 summarizes the results of the relevant studies.

TABLE 8-33 Average Annual Incidence (per 100,000) of Kidney and Renal Pelvis Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men42.140.562.961.160.285.480.780.6102.3
Women20.520.524.628.529.333.136.335.948.2

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-34 Selected Epidemiologic Studies—Renal Cancer (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veteran

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    1nrBoehmer et al., 2004

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  550.9 (0.5–1.5)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

130.9 (0.5–1.5)
State Studies of US Vietnam Veterans

Massachusetts Vietnam veterans diagnosed 1972–1983

    91.8 (1.0–3.5)Kogan and Clapp, 1988

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  211.4 (0.9–2.2)Visintainer et al., 1995

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans (includes lymphosarcoma, reticulosarcoma)

    2nrAnderson et al., 1986
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

1251.0 (0.8–1.2)ADVA, 2005a

Navy

  341.3 (0.9–1.7)

Army

  770.9 (0.7–1.1)

Air Force

  141.1 (0.6–1.8)

Mortality

All branches, return–2001

  501.0 (0.7–1.2)ADVA, 2005b

Navy

  121.1 (0.6–1.9)

Army

  330.9 (0.6–1.3)

Air Force

    50.8 (0.3–1.8)

1980–1994

  221.2 (0.7–1.8)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence—1982–2000

  190.7 (0.4–1.0)ADVA, 2005c

Mortality

1966–2001

    40.4 (0.1–1.1)

1982–1994

    33.9 (nr)CDVA, 1997b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality ratesDioxin, phenoxy herbicides

Mortality 1939–1992

  291.1 (0.7–1.6)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  261.6 (1.1–2.4)

7,553 not exposed to highly chlorinated PCDDs

    30.3 (0.1–0.9)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991
111.0 (0.5–1.7)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983

    51.0 (0.3–2.3)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982 (men only)

    30.6 (nr)Lynge, 1985

Mortality 1955–2006

    81.2 (0.8–1.6)Boers et al., 2012

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (HRs for lagged TCDD plasma levels)

    80.8 (0.5–1.5)Boers et al., 2012

Mortality 1955–2006

    8HR = “infinitively large”Boers et al., 2010

Mortality 1955–1991

    43.7 (1.0–9.5)Hooiveld et al 1998
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Total cohort—kidney cancer

    44.1 (1.1–10.4)

Total cohort—“urinary organs”

    83.9 (0.7–7.6)

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,4,5-TCP; 2,5-DCP

Mortality 1952–2007 (kidney and other and unspecified urinary organs)

    92.1 (0.9–3.9)Manuwald et al., 2012

Men

    72.0 (0.8–4.1)

Women

    22.3 (0.3–8.1)

Mortality 1952–1989—stats on men only, 1,184 (tables all for 1,148 men, not necessarily German nationals) vs national rates (also vs gas workers); same observation period as Becher et al., 1966

    31.6 (0.3–4.6)Manz et al., 1991

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    32.3 (0.5–6.7)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    11.2 (0.0–6.6)’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    32.7 (0.6–8.0)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  131.6 (0.8–2.7)Steenland et al., 1999

Through 1987 (bladder, other)

    81.4 (0.6–2.8)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    21.1 (0.1–3.8)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    20.4 (0.1–1.5)Collins et al., 2009a
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (kidney, ICD-9 189.0–189.2)

    81.2 (0.5–2.4)

PCP and TCP (n = 720)

    41.8 (0.5–4.6)

PCP (no TCP) (n = 1,402)

    40.9 (0.3–2.3)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3) (kidney, renal pelvis)

    50.8 (0.3–1.8)Burns et al., 2011

Through 1994 (n = 1,517)

    20.9 (0.1–3.3)Burns et al., 2001

Through 1982 (n = 878)

    0nr (0.0–6.2)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    41.7 (0.5–4.4)Collins et al., 2009b
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  410.9 (0.7–1.3)

Ever

  180.5 (0.3–0.8)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    31.5 (0.3–4.4)Henneberger et al., 1989

Pulp and Paper cohorts independent of IARC cohort

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

90% CIRobinson
61.2 (0.5–3.0)et al., 1986
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

DENMARK

Danish farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

1410.6 (p < 0.05)

Employee

  180.4 (p < 0.05)

Women

Self-employed

    40.9 (nr)

Employee

    31.0 (nr)

Family Worker

  300.8 (nr)

Danish gardeners—incidence from 3,156 male and 859 female gardeners (urinary system, ICD-7 180–181)

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

  251.1 (0.7–1.6)

Born 1915–1934 (medium exposure)

  230.5 (0.4–0.8)

Born after 1934 (low exposure)

    10.2 (0.0–1.1)

10-year followup (1975–1984) of male gardeners

  180.9 (0.7–1.8)Hansen et al., 1992

(lymphohematopoietic, ICD-7 200–2005)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

  160.6 (0.4–1.0)Torchio et al., 1994

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident stomach cancer cases vs remainder of 19,904 men with any incident cancer

Reif et al., 1989

Forestry workers (n = 134)

Herbicides
    20.6 (0.2–2.3)

SWEDEN

Incident cancer cases 1961–1973 with agriculture as economic activity in 1960 census (male, female)

99% CIWiklund, 1983
7750.8 (0.7–0.9)
THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    41.3 (0.4–3.4)Swaen et al., 2004
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

5221.1 (1.0–1.2)

Nonwhites (n = 11,446)

  300.8 (0.5–1.1)

Women

Whites (n = 2,400)

    60.8 (0.3–1.7)

Nonwhites (n = 2,066)

    61.4 (0.5–3.1)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

1480.8 (0.7–1.0)

Commercial applicators

    2nr

Spouses

  390.7 (0.5–1.0)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  710.9 (0.7–1.1)

Spouses (n = 676)

  120.6 (0.3–1.1)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of NHL

Herbicides

Agricultural extension agents

nr1.7 (0.9–3.3)Alavanja et al., 1988

Forest conservationists

p- trend < over years workedAlavanja et al., 1989
2.30.1

Soil conservationists

2.10.6

Florida Licensed Pesticide Applicators (common phenoxy use assumed but not documented; had been listed by Blair et al., 1983)

Herbicides

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

    10.5 (nr)Blair et al., 1983
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

UK men, 18–35 yrs of age from counties with particular chemical manufacturing—mortality

Herbicides, chlorophenolsMagnani et al., 1987

Herbicides

nr1.3 (0.6–3.1)

Chlorophenols

nr0.9 (0.4–1.9)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; HR, hazard ratio; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportional mortality ratio; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male, and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and renal cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With five cases observed, the incidence of cancer of the kidney or renal pelvis in the most restrictively defined cohort was not increased (SIR = 0.76, 95% CI 0.25–1.78), as was the case in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis of mortality updated through 2006 in male workers in two Dutch phenoxy-herbicide factories,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination, whereas the 1,036 working in factory B had produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. Using the estimated TCDD concentrations of the workers in both factories did not indicate increased mortality from renal cancer associated with TCDD (HR = 1.16, 95% CI 0.82–1.63). The dose–response modeling applied only to the workers in factory A did not find an increased renal-cancer mortality (HR = 0.83, 95% CI 0.46–1.49), whereas Boers et al. (2010) had been unable to calculate a risk of renal cancer because none of the eight deaths from renal cancer occurred in the workers in the nonexposed category.

Manuwald et al. (2012) reported mortality through 2007 in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. SMRs calculated relative to the population of Hamburg showed that mortality from cancer of the “kidney or other and unspecified urinary organs” was not increased in men (seven deaths, SMR = 2.00, 95% CI 0.80–4.12) or in women (two deaths, SMR = 2.25, 95% CI 0.25–8.11), but in the entire cohort the increase neared significance (SMR = 2.05, 95% CI 0.94–3.89).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, mortality from renal cancer was not substantially increased in the entire cohort (eight deaths, SMR = 1.20, 95% CI 0.52–2.37) or in the PCP-plus-TCDD group (four deaths, SMR = 1.80, 95% CI 0.49–4.61). In the larger PCP-only group, four deaths from renal cancer were reported (SMR = 0.90, 95% CI 0.25–2.31).

In the update of cancer incidence through 2006 in the AHS, Koutros et al. (2010a) reported decreased rates of renal cancer in both the private applicators (148 cases, SIR = 0.82, 95% CI 0.69–0.96) and their spouses (39 cases, SIR = 0.71, 95% CI 0.50–0.97). Similar findings were reported in Waggoner et al. (2011) in both applicators (71 cases, SIR = 0.87, 95% CI 0.68–1.09) and their spouses (12 cases, SIR = 0.61, 95% CI 0.32–1.07). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Biologic Plausibility

No animal studies have reported an increased incidence of renal cancer after exposure to the COIs. Working with tissues from urothelial-cancer patients, Ishida et al. (2010) found that activation of the AHR pathway by TCDD enhances cancer-cell invasion by upregulating matrix metalloproteinase-1 and -9 expression and is associated with poor prognosis in upper urinary tract urothelial cancer. The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Available analyses of an association between exposure to the COIs and renal-cancer risk are limited by the small number of cases and lack of exposure specificity. No data have emerged since Update 2010 to alter the committee’s conclusion that the evidence is inadequate or insufficient to determine whether there is an association.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and renal cancer.

BRAIN CANCER

Nervous-system cancers (ICD-9 191–192) involve the central nervous system (CNS) and include tumors of the brain and spinal cord, the cranial nerves, and the meninges (the outer coverings of the brain and spinal cord). Any of the cell types in the CNS can develop into cancer. Tumors of the peripheral nervous system and autonomic nervous system are considered soft-tissue tumors (ICD-9 171). Most cancers in the CNS are not primary tumors arising from nervous system tissues, but originated in other parts of the body, such as the lung or breast, and have metastasized to the brain or spinal cord. This section focuses on cancers that originate in the CNS.

Cancer of the eye (ICD-9 190) was considered in Update 2006, but the present committee decided that findings concerning cancer of the eye would be tracked with results on brain cancer because when it is reported it is often grouped with brain cancer.

The average annual incidence of primary CNS cancer is shown in Table 8-35. About 95% of cases originate in the brain, cranial nerves, and cranial meninges. In people over 45 years old, about 90% of tumors that originate in the brain are

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-35 Average Annual Incidence (per 100,000) of Brain and Other Nervous System Cancers in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men13.615.09.216.418.59.019.622.312.2
Women7.98.75.711.012.27.013.114.59.4

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

gliomas—astrocytoma, ependymoma, oligodendroglioma, or glioblastoma multiforme. Astrocytoma is the most common; glioblastoma multiforme has the worst prognosis. Meningiomas make up 20–40% of CNS cancers; they tend to occur in middle age and are more common in women than in men. Most meningiomas are benign and can be removed surgically.

ACS estimated that about 12,630 men and 10,280 women would receive diagnoses of brain and other nervous-system cancers in the United States in 2012 and that 7,720 men and 5,980 women would die from them (Siegel et al., 2012). Those numbers represent about 1.5% of new cancer diagnoses and 2.3% of cancer deaths. ACS estimated that 1,310 men and 1,300 women would receive diagnoses of cancers of the eye and orbit in the United States in 2012 and that 120 men and 150 women would die from them (Siegel et al., 2012).

In reviewing the descriptive epidemiology of these cancers, it is important to recognize the variation with which specific cancers are included in published reports, many of which distinguish between benign and malignant tumors. Another variation is whether cancers derived from related tissues (such as the pituitary or the eye) are included with CNS cancers. Various types of cancer are usually grouped; although this may bias results in unpredictable ways, the most likely consequence is dilution of risk estimates toward the null.

The only well-established environmental risk factor for brain tumors is exposure to high doses of ionizing radiation (ACS, 2012c; Wrensch et al., 2002). Other environmental exposures—such as to vinyl chloride, petroleum products, electromagnetic fields, and cell-phone use—are unproved as risk factors. The causes of most cancers of the brain and other portions of the nervous system are not known.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was limited or suggestive evidence of no association between exposure to the COIs and brain cancer. The committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, and Update 2004 did not change that conclusion.

The committee responsible for Update 2006 changed the classification for brain cancer (formally expanding it to include cancers of the eye and orbit) to

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and brain cancer. That committee considered one study that suggested a relationship between phenoxy acid herbicides and adult gliomas (Lee et al., 2005); studies that reported slightly but not statistically significantly higher risks of brain cancer in deployed than in nondeployed Australian Vietnam-era veterans (ADVA, 2005a,b) and in pesticide applicators in the AHS (Alavanja et al., 2005); and several studies that had essentially neutral findings (Carreon et al., 2005; Magnani et al., 1987; McLean et al., 2006; Ruder et al., 2004; Torchio et al., 1994). Overall, the studies discussed in Update 2006 suggested that a conclusion of no association between exposure to the COIs and brain cancer had been too definitive.

The committee for Update 2008 agreed that brain cancers should remain in the inadequate or insufficient category after review of two new studies. The relevance of the largely null findings on association with occupational exposure to herbicides from a case-control study of gliomas and meningiomas (Samanic et al., 2008) was limited in that no specific compounds were addressed. In evaluating mortality through 2001 in the Seveso cohort, Consonni et al. (2008) found no increase in mortality from brain cancer in any of the three exposure zones with increasing exposure and no indication of a dose–response relationship.

Update 2010 considered several new studies. A study of Vietnam-era Army Chemical Corps veterans found no difference in brain cancer rates between deployed and nondeployed veterans (Cypel and Kang, 2010), and studies of TCP and 2,4,5-T production workers in two settings also found no difference in brain-cancer incidence (Collins et al., 2009a) or brain-cancer mortality (Collins et al., 2009b; McBride et al, 2009a) compared with general population rates. A 20-year followup of brain cancer after the Seveso exposure incident found a nonstatistically significantly increased rate of brain cancer in those in the closest zone (RR = 2.43, 95% CI 0.60–9.79), but not in Zones B and R (Pesatori et al., 2009).

Table 8-36 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies

No Vietnam-veteran studies or environmental studies of exposure to the COIs and brain cancer have been published since Update 2010.

Occupational Studies

Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. Three brain-cancer cases were identified; this was not significantly different from popu-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-36 Selected Epidemiologic Studies—Brain Tumors (Shaded Entrie Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—White subjects vs national rates (brain and nervous system)

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

    51.8 (0.7–4.1)

With tours between 1966–1970

    52.2 (0.8–4.8)

SEA comparison veterans (n = 1,776)

    20.5 (0.1–1.8)

With tours between 1966–1970

    20.7 (0.1–2.3)

Mortality

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

    31.3 (0.3–3.6)

SEA comparison veterans (n = 1,776)

    10.3 (nr)

US VA Cohort of Army Chemical Corps—Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (7/1/1965–3/28/1973)

All COIs

Mortality—brain tumors

Through 2005

Cypel and

Deployed veterans (2,872) vs nondeployed (2,737)

4 vs 21.7 (0.3–10.2)Kang, 2010

ACC veterans vs US men

Vietnam cohort

    40.9 (0.2–2.2)

Non-Vietnam cohort

    20.5 (0.1–2.0)

Through 1991

    21.9 (nr)Dalager and Kang, 1997

894 ACC members assigned to Vietnam in 1966–1971—

    2nrThomas and Kang, 1990

Through 1987

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000 (meninges, brain, other CNS)

    91.2 (0.4–3.2)Boehmer et al., 2004

Post-service–1983

    3nrBoyle et al., 1987
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

1161.0 (0.3–3.2)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  251.1 (0.2–7.1)

US VA Cohort of Female Vietnam VeteransMortality—brain, CNS

All COIs

Through 2004 (all female Vietnam veterans)

    82.0 (0.7–5.9)Cypel and Kang, 2008

Vietnam veteran nurses only

    83.6 (0.9–14.5)

Through 1991

    41.4 (0.4–3.7)Dalager et al., 1995
State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  361.1 (0.8–1.5)Visintainer et al., 1995

New York

—deployed vs nondeployed (brain, CNS)

    40.5 (0.2–1.5)Lawrence et al., 1985

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    80.8 (0.3–1.5)Anderson et al., 1986a,b
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000 (brain)

  971.1 (0.9–1.2)ADVA, 2005a

Navy

  241.2 (0.7–1.7)

Army

  631.0 (0.8–1.3)

Air Force

  101.1 (0.6–2.1)

Mortality

All branches, return–2001 (brain, CNS)

  991.0 (0.8–1.1)ADVA, 2005b

Navy

  231.0 (0.6–1.4)

Army

  660.9 (0.7–1.2)

Air Force

    90.9 (0.4–1.6)

1980–1994

  391.1 (0.7–1.4)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed) Incidence (brain, CNS)

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1982–2000

  231.4 (0.7–2.6)ADVA, 2005c

Mortality (brain, CNS)

1966–2001

  271.6 (0.9–3.1)ADVA, 2005c

1982–1994

  131.4 (nr)CDVA, 1997b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  220.7 (0.4–1.0)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  120.6 (0.3–1.1)

7,553 not exposed to highly chlorinated PCDDs

  100.8 (0.4–1.5)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

    60.4 (0.1–0.8)Saracci et al., 1991

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983 (brain, CNS)

  111.2 (0.6–2.2)Coggon et al., 1986

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1982

    40.7 (nr)Lynge, 1985

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    0Becher et al., 1996

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–1989

    32.3 (0.5–6.8)Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    42.0 (0.6–5.2)

Never-exposed workers

    00.0 (0.0–5.5)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    10.8 (0.0–4.6)’t Mannetje et al., 2005

Sprayers (697 men and 2 women on register of New Zealand applicators, 1973–1984)

Mortality 1973–2000

    10.6 (0.0–3.4)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993 (brain, CNS)

    80.8 (0.4–1.6)Steenland et al., 1999

Through 1987 (brain, CNS)

Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    21.1 (0.1–3.8)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    30.6 (0.1–1.7)Collins et al., 2009a
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1940–1994 (n = 2,187 men)

nr0.6 (0.1–1.8)Bodner et al., 2003

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (brain, other nervous system)

    60.9 (0.3–1.9)

PCP and TCP (n = 720)

    10.4 (0.0–2.4)

PCP (no TCP) (n = 1,402)

    51.1 (0.4–2.6)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3) (brain, other CNS)

    31.1 (0.2–3.2)Burns et al., 2011

Through 1994 (n = 1,517)

    31.1 (0.1–3.2)Burns et al., 2001

Through 1982 (n = 878) (brain, other system tissues)

    0nr (0.0–4.1)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    10.4 (0.0–2.3)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

Ramlow et al., 1996

0-yr latency

    1nr

15-yr latency

    1nr
OCCUPATIONAL—PAPER AND PULP WORKERSTCDD

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  441.0 (0.7–1.4)

Ever

  280.8 (0.5–1.2)

New Hampshire pulp and paper workers, 883 white men working ≥ 1 yr, mortality through July 1985

    21.2 (0.1–4.2)Henneberger et al., 1989
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Northwestern US paper and pulp workers—5 mills in Washington, Oregon, and California, 3,523 worked ≥ 1 yr 1945–1955, mortality through March 1977

    40.6 (0.2–2.1)Robinson et al., 1986
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from brain cancer June 1971–December 1987

210 histologically confirmed deaths attributed to brain cancer in farmers ≥ 35 yrs of age

Morrison et al., 1992

Herbicides sprayed on ≥ 250 acres vs 0 acres

  240.8 (0.5–1.2)

70,000 male Saskatchewan farmers identified in 1971 census data linked to mortality records (brain)

  961.0 (0.8–1.3)Wigle et al., 1990

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

1941.1 (nr)

Employee

  390.9 (nr)

Women

Self-employed

    51.0 (nr)

Employee

    20.5 (nr)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC (eye, brain)

Phenoxy Herbicides

Incidence

    30.7 (0.1–2.0)Asp et al., 1994

Mortality 1972–1989

    31.2 (0.3–3.6)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

Torchio et al., 1994

Brain, nervous system

  150.5 (0.3–0.9)

Eye

    42.4 (0.7–6.1)

Italian rice growers with documented phenoxy use (n = 1,487) (brain, CNS)

Phenoxy herbicidesGambini et al., 1997
    40.9 (0.2–2.3)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident brain cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134) (brain, CNS)

    41.2 (0.4–3.3)

SWEDEN

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

    0

Foremen (n = 15)

    0

Lumberjacks (n = 139)

    0

Unexposed lumberjacks (n = 241)

    10.9 (0.0–5.1)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    41.6 (0.4–4.1)Swaen et al., 2004

Through 1987

    33.2 (0.6–9.3)Swaen et al., 1992
UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

Brain

4471.2 (1.1–1.3)

Eye

  171.6 (0.9–2.5)

Nonwhites (n = 11,446) (brain)

  161.0 (0.6–1.6)

Women

Whites (n = 2,400) (brain)

    91.1 (0.5–2.1)

Nonwhites (n = 2,066) (brain)

    10.4 (0.0–2.1)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  510.8 (0.6–1.0)

Commercial applicators

    51.2 (0.4–2.8)

Spouses

  260.9 (0.6–1.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Enrollment through 2002

Alavanja et al., 2005

Private applicators
Spouses of private applicators (> 99% women)

  330.8 (0.6–0.8)
150.9 (0.5–1.4)

Commercial applicators

    51.9 (0.6–4.3)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641) (brain, other nervous system)

  590.8 (0.6–1.0)

Spouses (n = 676)

  250.8 (0.5–1.2)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

  190.7 (0.4–1.1)

Years handled pesticides

≤ 10 yrs

    50.9 (ns)

> 10 yrs

  120.6 (ns)

Spouses of private applicators (> 99% women)

  111.1 (0.5–1.8)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of brain cancer

Herbicides

Agricultural extension agents

nr1.0 (0.4–2.4)Alavanja et al., 1988

Forest conservationists Soil conservationists

    61.7 (0.6–3.7)Alavanja et al., 1989

Pesticide applicators in Florida licensed 1965–1966 (n = 3,827)—mortality through 1976

    5Herbicides 2.0 (nr)Blair et al., 1983

White Male Residents of Iowa—brain cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

1111.1 (ns)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    22.4 (0.6–9.8)Pesatori et al., 2009

Zone B

    40.8 (0.3–2.1)

Zone R

  371.0 (0.7–1.5)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone R

    60.6 (0.3–1.4)

10-yr followup to 1991—women

Bertazzi et al. 1993

Zone R

    61.4 (0.6–3.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    0nr

Zone B

    30.7 (0.2–2.1)

Zone R

  341.1 (0.8–1.6)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A, B—men

    10.4 (0.1–3.0)

Zones A, B—women

    31.9 (0.6–6.0)

15-yr followup to 1991—men

Bertazzi et al., 1998

Zone B

    10.8 (0.1–5.5)

Zone R

  121.3 (0.7–2.5)

15-yr followup to 1991—women

Bertazzi et al., 1998

Zone B

    33.2 (1.0–10.3)

Zone R

    81.1 (0.5–2.4)

10-yr followup to 1986—men

Bertazzi et al., 1989a

Zone A, B, R

    51.2 (0.4–3.1)

10-yr followup to 1986—women

Bertazzi et al., 1989a

Zone A, B, R

    52.1 (0.8–5.9)
Other International Environmental Studies

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

East coast

    30.5 (0.1–1.5)

West coast

  240.9 (0.6–1.4)

Mortality

East coast

    20.6 (0.1–2.1)

West coast

  151.1 (0.6–1.7)
CASE-CONTROL STUDIES

US Case-Control Studies

NIOSH UMHS—farm pesticide exposure and glioma risk in adults (18–80 yrs of age) living in Iowa, Michigan, Minnesota, Wisconsin (glioma cases diagnosed 1995–January 1997)

Arsenicals, phenoxy herbicides, 2.4-D

798 glioma cases vs 1,175 population-based controls (excluding proxy, 438 vs 1,141)

Yiin et al., 2012

Herbicide use—including proxy (160 vs 265)

0.8 (0.6–1.0)

Herbicide use—excluding proxy (90 vs 260)

0.8 (0.6–1.1)

341 female glioma cases vs 528 population-based controls

Carreon et al., 2005

Arsenicals

  131.0 (0.5–1.9)

Phenoxy herbicides

  250.9 (0.5–1.5)

2,4-D

  240.9 (0.5–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

457 male glioma cases vs 648 population-based controls

Ruder et al., 2004

Arsenicals

  150.7 (0.4–1.4)

Phenoxy herbicides

  670.9 (0.6–1.2)

2,4-D

nrnr

US hospital-based study of 462 glioma and 195 meningioma patients vs 765 patient controls; cumulative lifetime occupational exposure to herbicides vs unexposed

HerbicidesSamanic et al., 2008

Gliomas

Men

  650.9 (0.6–1.3)

Low quartile

  201.0 (0.5–1.9)

Second quartile

  161.0 (0.5–2.1)

Third quartile

  120.6 (0.3–1.3)

Fourth quartile

  170.8 (0.4–1.6) p-trend = 0.50

Women

  351.3 (0.8–2.0)

Below median

  231.5 (0.8–2.7)

Above median

  121.0 (0.5–2.1)
p-trend = 0.91

Meningiomas (women only)

  332.4 (1.4–4.3)

Below median

  162.1 (1.0–4.4)

Above median

  172.9 (1.3–6.2) p-trend = 0.01

Nebraska men and women diagnosed with gliomas between 1988 and 1993; association between farming and pesticide use (251 cases vs 498 controls)

Lee et al., 2005

Phenoxy herbicides—combined reports (identical with results for 2,4-D specifically)

  321.8 (1.0–3.3)

By self

    70.6 (0.2–1.6)

By proxy

  253.3 (1.5–7.2)

2,4,5-T—combined reports

    71.3 (0.5–3.6)

By self

    20.4 (0.1–2.3)

By proxy

    52.7 (0.7–9.8)

International Case-Control Studies

Irish farmers and farmworkers

HerbicidesDean, 1994

Men

195nr

Women

  72nr

Italian hospital-based study of 240 brain glioma patients vs 742 controls

HerbicidesMusicco et al., 1988

Male, female farmers

  611.6 (1.1–2.4)

French hospital-based study of 125 brain glioma patients vs 238 controls

HerbicidesCordier et al., 1988

Woodworkers

OR = 1.6
(p > 0.05)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

UK men, 18–35 yrs of age from counties with particular chemical manufacturing—mortality

Herbicides, chlorophenolsMagnani et al., 1987

Herbicides

nr1.2 (0.7–2.1)

Chlorophenols

nr1.1 (0.7–1.8)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophen-oxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; ACC, Army Chemical Corps; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CNS, central nervous system; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupation specialty; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; ns, not statistically significant; OR, odds ratio; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PMR, proportional mortality ratio; SEA, Southeast Asia; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

lation rates in any of three approaches used by Burns et al. for handling possible movement of workers outside of Michigan. In the cohort defined with the most stringency the SIR was 1.09 (95% CI 0.22–3.19).

Mortality in a cohort of 2,122 PCP production workers in four plants in the NIOSH Dioxin Registry was compared with US population rates (Ruder and Yiin, 2011). Causes of death were determined by nosologist review of death certificates or linkage with the National Death Index. In the total cohort, six deaths were attributed to cancers of the brain and other parts of the CNS; this was consistent with mortality in the US population (SMR = 0.89, 95% CI 0.33–1.94). There was only one death from this type of cancer in the PCP-plus-TCDD group, and this also was not more than expected (SMR = 0.43, 95% CI 0.01–2.41). The results in the 1,402 workers in the PCP-only group were similar and again generally uninformative (SMR = 1.13, 95% CI 0.37–2.64).

In the AHS, no difference in the incidence of brain cancer through 2006 was observed in private applicators (SIR = 0.78, 95% CI 0.58–1.03), in commercial applicators (SIR = 1.19, 95% CI 0.39–2.78), or in spouses (SIR = 0.94, 95% CI 0.61–1.37) (Koutros et al., 2010a). Similar results were reported when Waggoner et al. (2011) compared the AHS cohort’s mortality through 2007 with the mortality in the general populations in Iowa and North Carolina. Mortality from brain and other nervous system cancers was not increased in pesticide applica-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

tors (SMR = 0.76, 95% CI 0.58–0.98) or in their spouses (SMR = 0.83, 95% CI 0.54–1.23). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies

In the NIOSH Upper Midwest Health Study, Yiin et al. (2012) analyzed risk factors for 798 glioma cases identified in Iowa, Michigan, Minnesota, and Wisconsin from medical facilities and screening of state cancer registries. Controls (1,175) were randomly selected from state driver’s license and nondriver ID records and Health Care Financing Administration Medicare data and were frequency-matched by state and age group. Over 90% of eligible cases and over 70% of eligible controls participated. Histories of use of specific pesticides and job histories were collected by questionnaire, which was administered to a proxy if a person was unable to complete the questionnaire. No increased risk of glioma was seen in association with use of herbicides in general, phenoxy herbicides, or most specifically 2,4-D, whether self-reported exposure or exposure based on industrial-hygienist assessment of job history was used. In some cases, significant reductions in risk were seen, although these did not remain significant in analyses that excluded data from proxy respondents.

In an older study that was not previously reviewed, Cordier et al. (1988) analyzed 125 glioma cases and 238 controls (65% and 71% participation, respectively) recruited from a hospital in France. Occupations and work descriptions were obtained by questionnaire. A nonsignificantly increased risk of glioma with adjustment for age and residence was seen in woodworkers (OR = 1.6, 95% CI not provided, but p > 0.05), a group potentially exposed to organochlorine-based preservatives that include chlorophenols and dioxins. In a post hoc exploratory analysis of the 20 woodworkers (nine cases, 11 controls), there was a trend (p < 0.10) toward greater odds of glioma with exposure to the chemicals as determined by blinded review of the work descriptions, but these findings need to be interpreted with caution given the small numbers of woodworkers and the post hoc nature of the analysis.

Several other case-control studies explored the association between pesticide exposure and brain cancer, but the unclear methods and the lack of exposure specificity beyond “pesticides” limited the informativeness of these studies with reference to the COIs (Bhat et al., 2010; Prochazka et al., 2010; Rashid et al., 2010).

Biologic Plausibility

No animal studies have reported an association between exposure to the COIs and brain cancer. The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Synthesis

Since Update 2010, several studies relevant to the possibility of an association between the COIs and brain cancer have been identified, including cohort and case-control studies. Most recent studies do not identify a relationship between exposure to the COIs and the development of brain cancers. A few studies are somewhat suggestive of an association, but these studies have limited exposure specificity or limited precision because of small sample size.

Conclusion

On the basis of the epidemiologic evidence from new and previously reported studies of populations that had potential exposure to the COIs, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and brain cancer or other nervous system cancers.

ENDOCRINE CANCERS

Cancers of the endocrine system as grouped by the Surveillance, Epidemiology, and End Results program (see Table B-2 in Appendix B) have a disparate group of ICD codes: thymus cancer (ICD-9 164.0), thyroid cancer (ICD-9 193), and other endocrine cancer (ICD-9 194).

ACS estimated that 13,250 men and 43,210 women would receive diagnoses of thyroid cancer in the United States in 2012 and that 780 men and 1,000 women would die from it, and it estimated that 1,350 men and 1,170 women would receive diagnoses of other endocrine cancers in 2012 and that 460 men and 460 women would die from them (Siegel et al., 2012). Incidence data on cancers of the endocrine system are presented in Table 8-37.

Thyroid cancer is the most prevalent endocrine cancer. Many types of tumors can develop in the thyroid, most of them benign. The thyroid contains two

TABLE 8-37 Average Annual Incidence (per 100,000) of Endocrine System Cancer in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men14.715.310.016.116.711.218.519.511.1
Women31.832.221.331.932.924.234.034.026.0

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

main types of cells: follicular cells make and store thyroid hormones and make thyroglobulin; C cells make the hormone calcitonin, which helps to regulate calcium metabolism. Different cancers of varied severity can develop from each kind of cell, and the classification of thyroid cancer is still evolving (Liu et al., 2006; Nikiforov, 2011). Papillary carcinoma is the most common and usually affects women of childbearing age; it metastasizes slowly and is the least malignant type of thyroid cancer. Follicular carcinoma accounts for about 15% of all cases and has greater rates of recurrence and metastasis. Medullary carcinoma is a cancer of parafollicular cells in the thyroid and tends to occur in families; it requires treatment different from other types of thyroid cancer. Anaplastic carcinoma (also called giant-cell cancer and spindle-cell cancer) is rare but is the most aggressive form of thyroid cancer; it does not respond to radioiodine therapy and metastasizes quickly, invading such nearby structures as the trachea and causing compression and breathing difficulties.

Thyroid cancer can occur in all age groups. Radiation exposure is recognized as a risk factor for thyroid cancer, so increased incidence is observed in people who received radiation therapy directed at the neck (a common treatment in the 1950s for enlarged thymus, adenoids, and tonsils and for skin disorders) or who were exposed to iodine-125 from the Chernobyl nuclear power plant accident. If radiation exposure occurred in childhood, the risk of thyroid cancer is further increased. Other risk factors are a family history of thyroid cancer and chronic goiter.

Conclusions from VAO and Previous Updates

The committees responsible for VAO, Update 1996, Update 1998, Update 2000, Update 2002, and Update 2004 did not consider endocrine cancers separately and therefore reached no conclusion as to whether there was an association between exposure to the COIs and endocrine cancers. The committees responsible for Update 2006, Update 2008, and Update 2010 did consider endocrine cancers separately and concluded that there was inadequate or insufficient evidence to determine whether there is an association between the COIs and endocrine cancers.

Table 8-38 summarizes the pertinent results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies

No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and thyroid or other endocrine cancers have been published since Update 2010.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-38 Selected Epidemiologic Studies—Endocrine Cancers (Thyroid, Thymus, and Other) (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1982 (thyroid and other endocrine, ICD-9 193–194)

Breslin et al.,1986,

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  150.6 (0.3–1.2)1988

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    40.6 (0.1–3.4)
State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans

Veterans aged 35–65 years in 1993—cases diagnosed 1988–1993 vs thyroid cancer

    41.2 (0.3–4.5)Clapp, 1997
International Vietnam-Veterans Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence—thyroid

All branches, 1982–2000

  170.6 (0.3–0.9)ADVA, 2005a

Navy

    30.5 (0.1–1.3)

Army

  110.5 (0.3–1.0)

Air Force

    31.2 (0.2–3.5)

Mortality—thyroid

All branches, return–2001

    20.5 (0.0–1.8)ADVA, 2005b

Navy

    11.2 (0.0–6.5)

Army

    10.4 (0.0–2.0)

Air Force

    00.0 (0.0–7.8)

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence—thyroid

1982–2000

    40.6 (0.1–2.2)ADVA, 2005c

Mortality—thyroid

1966–2001

    11.2 (0.0–91.7)ADVA, 2005c
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality 1939–1992

Kogevinas et al., 1997

Thyroid (ICD-9 193)

    41.7 (0.5–4.3)

13,831 exposed to highly chlorinated PCDDs

    21.4 (0.2–4.9)

7,553 not exposed to highly chlorinated PCDDs

    22.2 (0.3–7.9)

Other endocrine organs (ICD-9 194)

    53.6 (1.2–8.4)

13,831 exposed to highly chlorinated PCDDs

    22.3 (0.3–8.1)

7,553 not exposed to highly chlorinated PCDDs

    36.4 (1.3–18.7)

British MCPA Plant—Production 1947–1982 (n = 1,545) (included in IARC cohort) and spraying 1947–1972 (n = 2,561) (not included in IARC cohort)

MCPA

Mortality through 1983 (thyroid)

    11.8 (0.4–9.8)Coggon et al., 1986

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004 (thyroid, other endocrine)

McBride et al., 2009a

Ever-exposed workers

    00.0 (0.0–19.8)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    0nr’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    0nr’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Through 1982 (n = 878)

    0nrBond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–1989 (n = 770)

    0nrRamlow et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Herbicide sprayers routinely exposed to herbicides for 6 months or more (1950–1982)

Phenoxy herbicidesGreen, 1991
1
nr

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

  130.7 (nr)

Employee

    51.1 (nr)

Women

Self-employed

    11.3 (nr)

Employee

    11.4 (nr)

Family worker

  151.7 (p < 0.05)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks), not IARC

Phenoxy herbicides

Incidence (thyroid, other endocrine)

Asp et al., 1994

No latency

    21.9 (0.3–7.0)

10-yr latency

    22.4 (0.3–8.6)

15-yr latency

    23.4 (0.4–12.2)

Mortality (thyroid)

No latency

    13.8 (0.1–21.3)

10-yr latency

    14.7 (0.1–26.4)

15-yr latency

    16.5 (0.2–36.2)

ICELANDIC men (1,860), women (859) exposed to agricultural pesticides, primarily 2,4-D (other endocrine organs, ICD-9 194)—incidence

    22,4-D 1.3 (0.1–4.7)Zhong and Rafnsson, 1996

SWEDEN

Swedish pesticide applicators—incidence

    61.1 (0.4–2.4)Wiklund et al., 1989a

Incident NHL cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983

Thyroid

1260.9 (0.7–1.1)

Other endocrine gland

1170.7 (0.5–0.9)

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

  391.3 (1.0–1.8)

Nonwhites (n = 11,446)

    10.6 (0.0–3.0)

Women

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Whites (n = 2,400)

    10.8 (0.0–4.4)

Nonwhites (n = 2,066)

    11.1 (0.0–6.4)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  391.0 (0.7–1.3)

Commercial applicators

    51.4 (0.5–3.3)

Spouses

  490.9 (0.7–1.2)

Enrollment through 2002 (thyroid, other endocrine)

Alavanja et al., 2005

Private applicators

  291.3 (0.8–1.8)

Spouses of private applicators (> 99% women)

  240.9 (0.5–1.4)

Commercial applicators

    31.6 (0.3–5.0)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

    81.5 (0.7–3.0)

Spouses (n = 676)

    1nr

Enrollment through 2000, vs state rates (thyroid)

Blair et al., 2005a

Private applicators (men and women)

    31.8 (0.4–5.3)

Spouses of private applicators (> 99% women)

    00.0 (0.0–2.2)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821TCDD
Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)

Incidence

20-yr followup to 1996—men and women

Zone A

    12.6 (0.4–18.9)Pesatori et al., 2009

Zone B

    41.6 (0.6–4.4)

Zone R

  191.2 (0.7–1.9)

Seveso population (1976–1996); incidence cases identified by hospital discharge records

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Zone A (prolactinoma)

    16.2 (0.9–45.5)Pesatori et al., 2008

Zone B (nonfunctioning pituitary tumors)

    21.9 (0.5–7.7)

Zone R (2 nonfunctioning pituitary adenomas and 3 prolactinomas)

50.7 (0.3–1.8)

Mortality

15-yr followup to 1991—men

Bertazzi et al., 1997, 1998

Zone B

    14.9 (0.6–39.0)

Zone R

    0nr
15-yr followup to 1991—womenBertazzi et al., 1997, 1998

Zone B

    13.2 (0.4–24.5)

Zone R

    20.8 (0.2–3.6)
CASE-CONTROL STUDIES

International Case-Control Studies

Sweden—male, female thyroid cancers from Swedish Cancer Registry, 1980–1989

Phenoxy herbicides, chlorophenolsHallquist et al., 1993

Phenoxy herbicide exposure

    30.5 (0.0–2.0)

Chlorophenols

    42.8 (0.5–18.0)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Occupational Studies

In the update of cancer incidence in the AHS through 2006, Koutros et al. (2010a) found that the incidence of thyroid cancer was not significantly increased in private applicators (39 cases, SIR = 0.98, 95% CI 0.69–1.33), in commercial applicators (five cases, SIR = 1.40, 95% CI 0.45–3.26), or in their spouses (49 cases, SIR = 0.90, 95% CI 0.67–1.19). Updated mortality in the AHS cohort through 2007 (Waggoner et al., 2011) included only one death from thyroid can-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

cer in spouses, but eight deaths in applicators (SMR = 1.53, 95% CI 0.66–3.02). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Biologic Plausibility

The NTP conducted carcinogenesis bioassays in Osborne-Mendel rats and B6C3F1 mice that were exposed to TCDD by gavage (NTP, 1982a). The incidence of follicular-cell adenoma, but not of carcinoma, increased with increasing TCDD dose in male and female rats; the increase was significant in male but not in female rats. There was a significant increase in follicular-cell adenoma in female but not in male mice. The NTP carried out a similar study in female Sprague-Dawley rats more recently (NTP, 2006), and Walker et al. (2006) compared the data from that study and the results of the Dow Chemical Company assessment of TCDD carcinogenicity (Kociba et al, 1978). In the NTP and Dow studies, the incidence of thyroid cancer (C-cell adenoma and carcinoma) decreased with increasing dose of TCDD. However, an increased incidence of slight thyroid follicular-cell hypertrophy was noted in rats that were given TCDD at 22 ng/kg of body weight or more. A more recent 2-year NTP study (Yoshizawa et al., 2010) treated female Sprague-Dawley rats with either TCDD, 2,3,4,7,8-penta-chlorodibenzofuran, dioxin-like PCB congeners (PCB 126 or 118), a non-dioxin-like PCB (PCB 153), or mixtures of these chemicals; it failed to find any increases in either thyroid adenoma or carcinoma. Thus, although studies show that dioxin and dioxin-like compounds alter thyroid hormones and increase follicular-cell hyperplasia, there is little evidence of an increase in thyroid cancer.

As indicated in Chapter 4, 2,4-D and 2,4,5-T are at most weakly mutagenic or carcinogenic. No studies that addressed a possible association between exposure to those herbicides and thyroid cancer in animal models have been identified.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The studies reviewed previously did not provide sufficient evidence to determine whether there is an association between exposure to the COIs and thyroid or other endocrine cancers. The participants in the AHS are known to have had extensive exposure to the phenoxy herbicides, but the analyses of updated mortality (Waggoner et al., 2011) and cancer incidence (Koutros et al., 2010a) address only exposure to pesticides in general, so they cannot be considered fully informative for the purpose of this review. Consequently, the present committee retained the categorization for endocrine cancers assigned by previous VAO committees.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Conclusion

On the basis of the epidemiologic evidence reviewed here, the committee concludes that there is insufficient evidence to determine whether there is an association between exposure to the COIs and thyroid or other endocrine cancers.

LYMPHOHEMATOPOIETIC CANCERS

Lymphohematopoietic cancers (LHCs) constitute a heterogeneous group of clonal hematopoietic and lymphoid-cell disorders, including leukemias, lymphomas, and multiple myeloma. They are among the most common types of cancer induced by environmental and therapeutic agents. As in the case of other cancers that are subject to idiosyncratic grouping in reports of results of epidemiologic studies (notably, head and neck cancers and gastrointestinal cancers), the conclusions that the VAO committees have drawn about associations between herbicide exposure to the COIs and specific LHCs have been complicated and curtailed by the lack of specificity and by inconsistencies in groupings in the available evidence. For LHCs, that has been a function not only of epidemiologists’ seeking to combine related cancers to produce categories that have enough cases to permit statistical analysis but also of alterations in the prevailing system used by the medical community to classify these malignancies. Categorization of cancers of the lymphatic and hematopoietic systems has continued to evolve, guided by growing information about gene expression and lineage of the clonal cancer cells that characterize each of a broad spectrum of neoplasms arising in these tissues (Jaffe, 2009). The World Health Organization (WHO) categorization presented in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (WHO, 2008) bases its primary partition on whether the cancer cells are of myeloid or lymphoid origin (see Figure 8-1).

Stem cells arising in the bone marrow generate two major lineages of leukocytes: myeloid and lymphoid. Myeloid cells include monocytes and three types of granulocytes (neutrophils, eosinophils, and basophils). Lymphoid cells include T and B lymphocytes and a smaller set of cells called natural killer (NK) cells. All those cells circulate in the blood and are collectively referred to as white blood cells or leukocytes. Monocytes move out of the bloodstream into inflamed tissues, where they differentiate into macrophages or dendritic cells. Stem cells that are destined to become T lymphocytes migrate from the bone marrow to the thymus, where they acquire antigen-specific receptors. Antigen stimulation induces the T cells to differentiate into the several types involved in cell-mediated immunity. Progenitor or pre-B cells mature in the bone marrow into antigen-specific B cells. On encountering their cognate antigens, B cells differentiate into antibody-secreting plasma cells involved in humoral immunity; these result in multiple myeloma when they undergo malignant transformation.

LHCs originate in specific pluripotent or lineage-restricted cells at different

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

image

FIGURE 8-1 Hematopoiesis of stem cell differentiation.
SOURCE: © Terese Winslow, 2007; US government has certain rights.

stages in hematopoiesis and immune-cell development. The normal cells are transformed into a malignant tumor through multistep processes that involve genetic and epigenetic alterations. Traditionally, LHCs have been divided into leukemias, lymphomas, myelomas, and so on, according to their cell and site of origin (see Figure 8-1). That information and morphologic, cytochemical, and immunophenotypic data are used to characterize LHCs further by their distinct subtypes.

Leukemias occur when a cell residing in the bone marrow becomes cancerous and its daughter cells crowd normal cells in the bone marrow or are released from the bone marrow and circulate in the blood. Leukemias have generally been classified as myeloid or lymphoid, depending on the lineage of the original mutated cell. If the original mutated cell of a cancer of the blood arises in a lymphocytic cell line, the cancer is called lymphocytic leukemia; lymphocytic leukemias have been partitioned into acute lymphocytic leukemia (ALL) forms if they are derived from precursor B or T lymphoid cells, and indolent lymphoproliferative disorders (ILDs) derived from more mature lymphoid cells, which tend to replicate less rapidly. Although “chronic lymphocytic leukemia” is commonly used to refer to this group of ILDs, CLL is actually a specific form of ILD. Similarly, myeloid

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

leukemias arise from a myeloid cell line and are classified into acute (AML) and chronic (CML) forms.

Lymphoma is a general term for cancers that arise from lymphocytes (B, T, or NK cells). Lymphomas generally present as solid tumors at lymphoid proliferative sites, such as lymph nodes and spleen. As stem cells mature into B or T cells, they pass through several developmental stages, each with unique functions. The developmental stage at which a cell becomes malignant defines the kind of lymphoma. About 85% of lymphomas are of B-cell origin, and 15% of NK-cell or T-cell origin, referred to as NKTCL by WHO (Jaffe et al., 2001) and Liao et al. (2012). There are two major types of B-cell lymphoma: Hodgkin lymphoma (HL), previously referred to as Hodgkin disease, and non-Hodgkin lymphoma (NHL). B cells give rise to a number of types of neoplasms that are given names based on the stage at which B-cell development was arrested when the cells became cancerous. Follicular, large-cell, and immunoblastic lymphomas result when a malignancy develops after a B cell has been exposed to antigens (such as bacteria and viruses). CLL is now believed to be a tumor of antigen-experienced (memory) B cells, not naïve B cells (Chiorazzi et al., 2005); small lymphocytic lymphoma (SLL), which presents primarily in lymph nodes rather than in the bone marrow and blood, is now considered to be the same disease as CLL at a different stage (Jaffe et al., 2008).

Myeloma is another type of lymphohematopoietic malignancy derived from antibody-secreting plasma cells, which also have a B-cell lineage, that accumulate in the marrow of various bones. In most cases (90%), tumors are formed at multiple sites, and the disease is called multiple myeloma (MM). The related premalignant condition AL amyloidosis also arises from B-cell–derived plasma cells. It occurs in 5–15% of patients who have MM and causes abnormal deposition of antibody fragments. Monoclonal gammopathy of undetermined significance (MGUS) is also recognized as a clonal condition that may progress to MM.

ICD partitions these malignancies into leukemias and lymphomas primarily on the basis of whether cancer cells circulated in the blood (disseminated) or appeared in the lymphatic system (solid tissue), respectively, before subdividing according to cell type. The emerging WHO classification of lymphohematopoietic malignancies (Campo et al., 2008; Jaffe, 2009) stratifies cancers of the blood and lymph nodes into disease categories according to their cell lineages—lymphoid or myeloid—as shown in Figure 8-1. It represents a substantial advance in understanding the biologic paths by which these cancers develop. The present committee decided, however, that it would not be productive to reformulate this entire section to correspond to the WHO categories. In practice, LHCs have routinely been reported in a variety of groupings, so it is a continuing challenge to parse out results, noting when results for broader groupings are presented in the results tables for several more specific diagnoses while recognizing that the specific results will be muted by being “misclassified” with other entities. Most epidemiologic studies already in the evidentiary database that did specify diseases

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

precisely used ICD-9 or earlier versions, but some recent studies have applied ICD-10. Furthermore, the existing records that will serve as the basis of many current and even future studies will use earlier and evolving classifications, so this is likely to remain the case even in new literature for a considerable period. The nomenclature has become more uniform in recent studies, but the possibility of ambiguity remains if earlier researchers did not use a unique code in accordance with some established system.

Because it has been the objective of VAO committees to address disease entities in as great specificity as possible with the available data, overall results on the coarser grouping of LHCs are of little consequence for the conclusions of association that have been drawn for the more specific entities. The committee for Update 2010 noted, however, that the common biologic origin of LHCs that have been judged to have a substantial amount of evidence supporting association with the COIs (HL, NHL, CLL, hairy cell leukemia [HCL], MM, and AL amyloidosis) means that the WHO approach is supportive of and consistent with these decisions on the part of VAO committees.

VA has asked previous VAO committees to address CLL, AML, and HCL individually. Scrutiny of the entire body of epidemiologic results on leukemia for findings on particular types (as had been the most common manner of grouping) revealed several studies that showed increased risks specifically of CLL (or ILDs more generally), but did not provide support for an association of AML with exposure to the COIs. The committee for Update 2002 advised VA that CLL is recognized as a form of the already recognized-as-service-related condition NHL, whereas the committee for Update 2006 did not recognize an association between the COIs and AML. Later, the committee responsible for Update 2008 advised VA that HCL should be grouped with ILDs. In light of the history and in accord with the current WHO classification, the present committee has incorporated data specifically on CLL and HCL into the section on NHL. After a brief synopsis of biologic plausibility of the LHCs overall, the more common cancers of the lymphatic system are described in the sections below on HL, NHL, and MM (with a section on the related condition, AL amyloidosis), and then evidence on leukemias in general is discussed with a focus on information regarding those of myeloid origin.

Biologic Plausibility

Recent data indicate that the AHR pathway plays an integral role in B-cell maturation and that TCDD and dioxin-like chemical (DLC) exposure may alter the function of these cells and lead to critical changes in the immune response. Suppression of the immune response by TCDD and similar chemicals in rodents and primates has been known for over 30 years, but the effect on human cells is less clear. Some recent reports indicate that TCDD and DLCs elicit similar effects in humans. Activation of nontransformed human B cells results in an increase in

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

expression of the AHR, and additional data indicate that this pathway has a role in normal B-cell function (Allan and Sherr, 2010). Furthermore, treatment of these cells with benzo[a]pyrene suppresses B-cell differentiation. Lu H et al. (2010) demonstrated that although human B cells appeared less responsive to TCDD in terms of increasing expression of AHR battery genes the ability of TCDD to decrease immunoglobulin M production was similar in both mouse and human B cells. Data on human hematopoietic stem cells (HSCs) and from the use of knockout AHR mouse models show that the AHR is critical in HSC maturation and differentiation (Fracchiolla et al., 2011; Singh et al., 2011). TCDD not only alters HSC maturation but also alters proliferation and migration in vivo and in vitro (Casado et al., 2011); this indicates that exposure may have multiple effects on how these immune cells function.

On occasion, the observed number of cases is so small that researchers cannot perform useful analyses for each type of LHC and will provide summary statistics for the entire group of them. In updating mortality in the Hamburg cohort in 1952–2007, Manuwald et al. (2012) found nonsignificant increases in mortality from LHC in both men (SMR = 1.53, 95% CI 0.89–2.45) and women (SMR = 1.84, 95% CI 0.74–3.80), which combined to give a significant association between TCDD and all LHC deaths in the whole cohort (SMR = 1.61, 95% CI 1.03–2.40). In a Dutch cohort of workers in two phenoxy-herbicide plants, Boers et al. (2012) assessed plasma TCDD concentrations at the time of the assumed last exposure and reported a modest but nearly significant increase in the hazard ratio for LHC in the total cohort (HR = 1.12, 95% CI 0.94–1.35) but no increase in plant A, where workers were occupationally exposed to TCDD (HR = 0.96, 95% CI 0.71–1.30).

Hodgkin Lymphoma

HL (ICD-9 201), also known as Hodgkin disease, is distinguished from NHL primarily on the basis of its neoplastic cells, mononucleated Hodgkin cells, and multinucleated Reed–Sternberg cells originating in germinal-center B cells (Küppers et al., 2002). HL’s demographics and genetics are also characteristic. ACS estimated that 4,960 men and 4,100 women would receive diagnoses of HL in the United States in 2012 and that 670 men and 520 women would die from it (Siegel et al., 2012). The average annual incidence is shown in Table 8-39.

The possibility that HL has an infectious etiology has been a topic of discussion since its earliest description. A higher incidence in people who have a history of infectious mononucleosis has been observed in some studies, and a link with Epstein–Barr virus has been proposed. In addition to the occupational associations discussed below, higher rates of the disease have been observed in people who have suppressed or compromised immune systems.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-39 Average Annual Incidence (per 100,000) of Hodgkin Disease in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men3.74.12.83.84.04.55.05.35.0
Women1.91.73.92.12.22.43.74.14.3

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Conclusions from VAO and Previous Updates

The committee responsible for VAO determined that there were sufficient epidemiologic data to support an association between exposure to the COIs and HL. Additional studies available to the committees responsible for later updates have not changed that conclusion.

Of the 32 studies reviewed by the committee responsible for VAO, two well-conducted Swedish studies with good exposure characterization provide the most comprehensive information on the association between exposure to phenoxy herbicides (2,4-D and 2,4,5-T), picloram, or chlorophenols and HL. Hardell et al. (1981) considered NHL and HL together, and Hardell and Bengtsson (1983) considered HL separately; they found statistically significant associations with exposure to phenoxy acids (after excluding people who were exposed to chlorophenols) and with exposure to chlorophenols. In a study of 54 HL cases, Persson et al. (1989) found a large but not statistically significant risk associated with exposure to phenoxy acids. Several of the other case-control and occupational-cohort studies reviewed in VAO showed increased risk of HL, but only a few of the results were statistically significant. As with NHL, even the largest studies of production workers who were exposed to TCDD did not indicate an increased risk. The few studies of HL in Vietnam veterans tended to show increased risks, but only one (Holmes et al., 1986) was statistically significant.

Update 1996 reviewed studies that showed no excess of HL in the IARC phenoxy-herbicide cohort (Kogevinas et al., 1993) or in US farmers in 23 states (Blair et al., 1993). A smaller study of Finnish herbicide appliers (Asp et al., 1994) showed a nonsignificant increase, whereas Persson et al. (1993) reported a significant increase in Swedish farmers who were exposed to phenoxy acid herbicides. Studies of the Seveso cohort (Bertazzi et al., 1993) and of Vietnam-era veterans in Michigan (Visintainer et al., 1995) did not provide data that strengthened the association.

In Update 1998, a proportionate mortality ratio analysis that compared the experience of 33,833 US Army and Marine Corps Vietnam veterans who died

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

during 1965–1988 with that of 36,797 deceased non-Vietnam veterans found a significant increase in Marine Corps veterans, but not Army veterans, who had served in Vietnam (Watanabe and Kang, 1996). Two studies of manufacturing workers found no association between TCDD and HL (Becher et al., 1996) or between PCP and HL (Ramlow et al., 1996). An update of the large IARC phenoxy herbicide cohort (Kogevinas et al., 1997) showed no association between phenoxy herbicides or chlorophenols and HL but did show a nonsignificant increase in HL in workers who were exposed to TCDD or higher-chlorinated hydrocarbons. Waterhouse et al. (1996) demonstrated a significant increase in the combined incidence of lymphopoietic neoplasms in a prospective study of a Michigan farming community. A 15-year followup study of the Seveso cohort (Bertazzi et al., 1997) found no deaths from HL in Zone A and a nonsignificant increase in deaths from HL in men and women in Zone B.

The committee responsible for Update 2000 reviewed the 15-year update of the Operation Ranch Hand study (AFHS, 2000), but the findings on HL were nonsignificant. In a retrospective cohort study of Dutch production and contract workers who were exposed to phenoxy herbicides, chlorophenols, and contaminants during 1950–1976, Hooiveld et al. (1998) reported increased but nonsignificant findings. Rix et al. (1998) compared mortality in a cohort of Danish paper-mill workers with that in the general Danish population and found a statistically significant increase in men but not women. In an update and expansion of cohorts involved in the NIOSH study, Steenland et al. (1999) found that the three deaths attributed to HL were consistent with the number expected. The 20-year mortality update after the Seveso accident reported no additional HL deaths in Zone A or B (Bertazzi et al., 2001).

The only new study reviewed in Update 2002 followed mortality to 1994 in a cohort of Dow Chemical Company workers (Burns et al., 2001); the single death attributed to HL resulted in a slight but nonsignificant increase.

Update 2004 reviewed a study by Akhtar et al. (2004) that found no excess of lymphopoietic cancers when comparing incidence and mortality between Ranch Hand veterans and veterans who had not served in Southeast Asia. Swaen et al. (2004) extended followup of mortality by 13 years in a cohort of Dutch herbicide appliers; with no additional deaths observed, the earlier increase in HL remained nonsignificant (Swaen et al., 1992).

Update 2006 reviewed reports on the cancer experience of Australian Vietnam veterans. In comparison with the general population, the incidence of HL was significantly higher when veterans from the different armed forces were combined (ADVA, 2005a); there was a significant association between HL and service in the Army, but Navy and Air Force veterans showed nonsignificant increases. Mortality from HL was nonsignificantly higher in the Army veterans but not in all veterans combined or in the other branches (ADVA, 2005b). A comparison of deployed and nondeployed Vietnam-era Australian conscripted

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Army National Service veterans (ADVA, 2005c) found no association between deployment and the incidence of or mortality from HL. In a multinational IARC cohort of 60,468 pulp and paper industry workers, McLean et al. (2006) found that death from HL was significantly higher in those who had ever been exposed to nonvolatile organochlorine compounds (which would include TCDD) but not in those who had never been exposed. Two reports from the US AHS (Alavanja et al., 2005; Blair et al., 2005a) found no excess risk of HL in pesticide applicators, commercial applicators, and their spouses. In the Cross-Canada Study of Pesticides and Health, Pahwa et al. (2006) found no association of any exposure to phenoxy herbicides, 2,4-D, Mecoprop, or MCPA and HL.

The committee responsible for Update 2008 reviewed a study by Cypel and Kang (2008) that compared mortality from lymphopoietic cancers in female Vietnam veterans with that of female era veterans and the US population; deaths from lymphopoietic cancers were not higher in those who served in Vietnam. Consonni et al. (2008) reported no statistically significant increase in deaths from HL in the Seveso cohort 25 years after the accident.

The committee for Update 2010 reviewed several occupational cohorts, a case-control study, and an update of cancer incidence in the Seveso cohort. No deaths from HL were identified in Dow PCP workers in Midland, Michigan (Collins et al., 2009b), but the TCP workers (Collins et al., 2009a) had an increased SMR of HL with a wide confidence interval. McBride et al. (2009a) examined mortality in TCP manufacturing workers in the Dow AgroSciences plant in New Plymouth, New Zealand, but a single observed HL death yielded inconclusive results. A French hospital-based case-control study of lymphoid neoplasms (Orsi et al., 2009) found a modest increase in the risk of HL after occupational exposure to herbicides in general and a greater increase after occupational exposure to phenoxy herbicides in particular, but neither was statistically significant; no association was observed with domestic use of herbicides. In the 20-year followup of cancer incidence in the Seveso cohort (Pesatori et al., 2009), there were still no cases of HL in Zone A, whereas a modest nonsignificant increase in HL risk was found in Zone R and a less clear increase in Zone B.

Table 8-40 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veteran studies or environmental studies of exposure to the COIs and HL specifically have been published since Update 2010.

Occupational Studies Only a single case of HL was diagnosed in the period January 1987–December 2007 in 1,316 men who had worked at any time during 1945–1994 at Dow Chemical Company’s 2,4-D production plant in Midland,

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-40 Selected Epidemiologic Studies—Hodgkin Lymphoma (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—white subjects vs national rates (lymphopoietic cancerc)

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  100.9 (0.4–1.5)

With tours between 1966–1970

    70.7 (0.3–1.4)

SEA comparison veterans (n = 1,776)

    90.6 (0.3–1.0)

With tours between 1966–1970

    40.3 (0.1–0.8)

Attended 1987 exam—Ranch Hand personnel (n = 995) vs SEA veterans (n = 1,299)

    0nrWolfe et al., 1990

Mortality

Through 1987—Ranch Hand personnel (n = 1,261) vs SEA veterans (19,102)

    0nrMichalek et al., 1990

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    20.9 (nr)Boehmer et al., 2004

Post-service–1983

    0nrBoyle et al., 1987

US CDC Selected Cancers Study—case-control study of incidence (Dec 1, 1984–Nov 30, 1989) among US males born 1929–1953 (CDC, 1990a)

All COIsCDC, 1990a

Vietnam veterans

  281.2 (0.7–2.4)

Army

  121.0 (0.5–2.0)

Marine Corps

    41.7 (0.5–5.9)

Air Force

    51.7 (0.6–4.9)

Navy

    71.1 (0.4–2.6)

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served

All COIs

7/4/1965–3/1/1973

1965–1988

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

1251.0 (nr)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

  251.9 (1.2–2.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1965–1984

Watanabe et al., 1991

Army, deployed (n = 24,145) vs nondeployed (n = 27,917)

Vs Army non-Vietnam veterans

1161.0 (nr)

Vs all non-Vietnam veterans

1161.1 (nr)

Marine Corps, deployed (n = 5,501) vs nondeployed (n = 4,505)

Vs Marine non-Vietnam veterans

  251.9 (nr)

Vs all non-Vietnam veterans

  251.0 (nr)

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  921.2 (0.7–1.9)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

  221.3 (0.7–2.6)

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality

Through 2004

  180.7 (0.4–1.3)Cypel and Kang, 2008

Vietnam-veteran nurses

  140.7 (0.3–1.3)
State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  201.1 (0.7–1.8)Visintainer et al., 1995

New York—deployed vs nondeployed (lymphoma, HD)

  1099% CI 1.0 (0.4–2.2)Lawrence et al., 1985

West Virginia—deployed vs nondeployed

    58.3 (2.7–19.5)Holmes et al., 1986

923 White male Vietnam veterans with Wisconsin death certificate (1968–1978) vs proportions for Vietnam-era veterans

    4nrAnderson et al., 1986
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  512.1 (1.5–2.6)ADVA, 2005a

Navy

    71.3 (0.5–2.6)

Army

  402.3 (1.6–3.0)

Air Force

    42.1 (0.6–5.3)

Mortality

All branches, return–2001

  130.9 (0.5–1.5)ADVA, 2005b

Navy

    20.6 (0.1–2.1)

Army

  111.1 (0.5–1.9)

Air Force

    00.0 (0.0–2.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Australian Conscripted Army National

All COIs

Service (18,940 deployed vs 24,642 nondeployed)

Incidence

1982–2000

  120.9 (0.4–2.0)ADVA, 2005c

Mortality

1982–2000

  120.9 (0.4–2.0)ADVA, 2005c

1966–2001

    41.7 (0.3–11.8)ADVA, 2005c

1983–1985

    0nrFett et al., 1987
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  101.0 (0.5–1.8)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    81.3 (0.6–2.5)

7,553 not exposed to highly chlorinated PCDDs

    10.3 (0.0–1.5)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

    20.4 (0.1–1.4)Saracci et al., 1991

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates

TCDDKogevinas et al, 1993
1nr

Mortality—IARC cohort (16,863 men and 1,527 women) 10–19 years since first exposure

    30.6 (0.1–1.7)Kogevinas et al, 1992

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–1991

    13.2 (0.1–17.6)Hooiveld et al., 1998

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951-1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0nrBecher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1965–1989

    0nrBecher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1956–1989

    0nrBecher et al., 1996

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Mortality

Through 1987 [Table 2]

    0nrZober et al., 1990

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–1989

    0nrBecher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; 2,4,5-TCP; MCPA; MCPB; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    14.2 (0.1–23.3)

Never-exposed workers

    00.0 (0.0–47.1)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984) Mortality 1969–2000

15.6 (0.1–31.0)’t Mannetje et al., 2005

Sprayers (697 men and 2 women on register of New Zealand applicators, 1973–1984)

Mortality 1973–2000

    00.0 (0.0–16.1)’t Mannetje et al., 2005
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

    31.1 (0.2–3.2)Steenland et al., 1999

Chloracne subcohort (n = 608) (lymphatic, hematopoietic; ICD-9 200–208)

    61.1 (0.4–2.5)

Through 1987

    31.2 (0.3–3.5)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    12.8 (0.1–15.3)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    00.0 (0.0–6.4)Collins et al., 2009a

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    10.6 (0.0–3.6)

PCP and TCP (n = 720)

    0nr (0.0–6.9)

PCP (no TCP) (n = 1,402)

    11.0 (0.0–5.4)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    11.3 (0.0–7.2)Burns et al., 2011

Through 1994 (n = 1,517)

    11.5 (0.0–8.6)Burns et al., 2001

Through 1982 (n = 878)

    12.7 (0.0–14.7)Bond et al., 1988

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    21.8 (0.2–6.4)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

Ramlow et al., 1996

0-yr latency

    0nr

15-yr latency

    0nr
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

    70.6 (0.2–1.2)

Ever

  171.8 (1.0–2.8)

Danish paper workers

Rix et al., 1998

Men

  182.0 (1.2–3.2)

Women

    21.1 (0.1–3.8)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Ontario Forestry Workers—1,222 men working ≥ 6 months 1950–1982

80 deaths through 1982; 18 cancers (lung greatest with 5)

    0nrGreen, 1991

DENMARK

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

  270.6 (p < 0.05)

Employee

  131.0 (nr)

Women

Self-employed

    11.1 (nr)

Employee

    11.2 (nr)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

    21.7 (0.2–6.0)Asp et al., 1994

Mortality 1972–1989

    00.0 (0.0–5.0)

Except for lung cancer, numbers too small for reporting mortality 1972–1980

    0nrRiihimaki et al., 1982

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed

1970–1974

Mortality 1970–1986 (n = 23,401)

  111.0 (0.5–1.7)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
    10.7 (0.0–3.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

SWEDEN

Swedish Cancer-Environment Registry—National Cancer Registry linked to census

Herbicides

Incidence data from Swedish Cancer Environment Register (1971–1984) linked

Eriksson et al., 1992

to 1970 census

Male sawmill workers

  102.1 (1.0–4.0)

Male farmers

  971.2 (nr)

Male forestry workers

  351.2 (nr)

Male horticulture workers

  111.2 (nr)

20,245 Swedish pesticide applicators with license issued between 1965 and 1976 354,620 Swedish agriculture, forestry workers

  151.5 (0.8–2.4)Wiklund et al., 1989a
Wiklund et al., 1988a

Workers in land or in animal husbandry

2421.0 (0.9–1.2)

Workers in silviculture

  152.3 (1.3–3.7)

Incident HD cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
2261.0 (0.9–1.2)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    0nrSwaen et al., 2004

Through 1987

    13.3 (0.0–18.6)Swaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates

Herbicides PCMRsBlair et al., 1993

1984–1988 from 23 states

Men

Whites (n = 119,648)

  561.0 (0.8–1.3)

Nonwhites (n = 11,446)

    20.7 (0.1–2.6)

Women

Whites (n = 2,400)

    00.0 (0.0–3.4)

Nonwhites (n = 2,066)

    00.0 (0.0–7.2)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Private applicators

  181.0 (0.6–1.5)

Commercial applicators

    1nr

Spouses

    70.9 (0.3–1.7)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  110.9 (0.4–1.6)

Spouses of private applicators (> 99% women)

    40.7 (0.2–1.9)

Commercial applicators

    10.8 (0.1–4.2)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

    51.0 (0.3–2.4)

Spouses (n = 676)

Enrollment through 2000, vs state rates

    31.1 (0.2–3.3)Blair et al., 2005a

Private applicators (men and women)

    31.7 (0.3–4.8)

Spouses of private applicators (> 99% women)

    00.0 (0.0–2.5)

US Department of Agriculture Workers—nested case-control study of white men dying

Herbicides

1970–1979 of HD

Agricultural extension agents

Alavanja et al., 1988

PM analysis

    62.7 (1.2–6.3)

Case-control analysis

    61.1 (0.3–3.5)

USDA forest, soil conservationists

    42.2 (0.6–5.6)Alavanja et al., 1989

White Male Residents of Iowa—HD on death certificate, usual occupation: farmers vs not

Herbicides

> 20 yrs old when died 1971–1978—PMR

  471.2 (ns)Burmeister, 1981
ENVIRONMENTAL
Seveso, Italy, Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    0nrPesatori et al., 2009

Zone B

    31.2 (0.4–3.8)

Zone R

  231.5 (0.9–2.3)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone B

    11.7 (0.2–12.8)

Zone R

    41.1 (0.4–3.1)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone B

    12.1 (0.3–15.7)

Zone R

    31.0 (0.3–3.2)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    0nr

Zone B

    32.2 (0.7–6.9)

Zone R

    90.9 (0.5–1.9)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A, B—men

    22.6 (0.6–10.9)

Zones A, B—women

    23.7 (0.9–16.0)

15-yr followup to 1991—men

Bertazzi et al., 1997

Zone B

    23.3 (0.4–11.9)

15-yr followup to 1991—women

Bertazzi et al., 1997

Zone B

    26.5 (0.7–23.5)

Zone R

    41.9 (0.5–4.9)
Other International Environmental Studies

FRANCE

Residents near French solid-waste incinerator—incidence

DioxinViel et al., 2000

1980–1995

    91.5 (nr) (p = 0.89)

NEW ZEALAND

Residents of New Plymouth Territorial Authority, New Zealand, near plant manufacturing 2,4,5-T in 1962–1987

2,4,5-TRead et al., 2007

Incidence

  491.1 (0.8–1.5)d

1970–1974

    91.2 (0.6–2.3)

1975–1979

    91.1 (0.5–2.2)

1980–1984

    81.1 (0.5–2.1)

1985–1989

    91.3 (0.6–2.5)

1990–1994

    71.3 (0.5–2.7)

1995–1999

    40.7 (0.2–1.7)

2000–2001

    31.0 (0.2–3.1)

Mortality

  221.3 (0.8–2.0)d

1970–1974

    71.6 (0.7–3.3)

1975–1979

    41.2 (0.3–3.0)

1980–1984

    62.1 (0.8–4.5)

1985–1989

    31.2 (0.2–3.5)

1990–1994

    10.6 (0.0–3.5)

1995–1999

    10.6 (0.0–3.6)

2000–2001

    0nr
CASE-CONTROL STUDIES

US Case-Control Studies

Kansas residents–duration and frequency of herbicide use—incidence

Phenoxy herbicides, 2.4-DHoar et al., 1986

All farmers

  710.8 (0.5–1.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Farm-use of herbicides (phenoxy acids, others)

  280.9 (0.5–1.5)

Farmers using herbicides > 20 days/yr

    31.0 (0.2–4.1)

Farmers using herbicides > 15 days/yr

  101.2 (0.5–2.6)

Tecumseh, Michigan, residents participating in longitudinal study (1959–1987)

HerbicidesWaterhouse et al., 1996
132.0 (1.1–3.4)

Hancock County, Ohio, residents—farmers

    32.7 (nr)Dubrow et al., 1988

International Case-Control Studies

Canadian residents (≥ 19 yrs of age) in any of 6 provinces

Phenoxy herbicidesKarunanayake et al., 2012

Any phenoxy herbicide

  650.9 (0.7–1.3)

2,4-D

  570.9 (0.6–1.3)

Mecoprop

  201.4 (0.8–2.4)

MCPA

  111.0 (0.4–2.2)

Diclofopmethyl

  101.8 (0.7–4.5)

Canadian residents (≥ 19 yrs of age) in any of 6 provinces

Phenoxy herbicidesPahwa et al., 2006

Any phenoxy herbicide

  651.0 (0.7–1.4)

2,4-D

  571.0 (0.7–1.4)

Mecoprop

  201.3 (0.7–2.2)

MCPA

  111.2 (0.6–2.6)

France hospital-based case-control study

HerbicidesOrsi et al., 2009

Occupational use of herbicides

    71.5 (0.6–4.1)

Phenoxy herbicides

    62.5 (0.8–7.7)

Domestic use of herbicides

  190.8 (0.4–1.6)

Italian incident cases of malignancies of hematolymphopoietic system (HD = 258) in men and women (20–74 yrs of age) from agricultural and mixed use areas

HerbicidesMiligi et al., 2006

Men

    50.4 (0.1–1.3)

Women

    10.5 (0.1–4.0)

Italy—Residents of Milan area (men and women)—incidence

HerbicidesLaVecchia et al., 1989

Agricultural occupations

nr2.1 (1.0–3.8)

Chemical-industry occupations

nr4.3 (1.4–10.2)

New Zealand National Cancer Registry (1977–1981) (≥ 20 yrs of age) with agricultural occupations—incidence (ICD-9 200, 202)

HerbicidesPearce et al., 1985
1071.1 (0.6–2.0)

Swedish Regional Cancer Registry—HD patients

Phenoxy herbicidesPersson et al., 1993

Exposed to phenoxy herbicides

90% CI
    57.4 (1.4–40.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Örebro (Sweden) Hospital (men and women)—incidence

Phenoxy herbicides, chlorophenolsPersson et al., 1989
90% CI

Farming

    61.2 (0.4–3.5)

Exposed to phenoxy acids

    43.8 (0.7–21.0)

Sweden—Umea Hospital patients (men and women, 25–85 yrs of age) (1974–1978)

Phenoxys, chlorophenolsHardell and Bengtsson, 1983

Exposed to phenoxy acids

  145.0 (2.4–10.2)

Exposed to high-grade chlorophenols

    66.5 (2.2–19.0)

Exposed to low-grade chlorophenols

    52.4 (0.9–6.5)

Swedish patients (1970–1977)

Phenoxy acids, chlorophenolsHardell, 1981

Exposed to phenoxy herbicides

  414.8 (2.9–8.1)

Exposed to chlorophenols

  504.3 (2.7–6.9)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophen-oxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; HD, Hodgkin disease; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; PMR, proportional mortality ratio; SEA, Southeast Asia; SIR, standardized incidence ratio; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; USDA, United States Department of Agriculture; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cLymphopoietic cancers comprise all forms of lymphoma (including Hodgkin disease and non-Hodgkin lymphoma) and leukemia (ALL, AML, CLL, CML).

dCommittee computed total SMR and SIR by dividing sum of observed values by sum of expected values over all years; 95% CIs on these total ratios were computed with exact methods.

Michigan (Burns et al., 2011). That provides little information about whether HL is associated with 2,4-D exposure (SIR = 1.30, 95% CI 0.02–7.23) in the most restrictively defined cohort.

In the NIOSH cohort of 2,122 PCP workers, Ruder and Yiin (2011) reported a single death from HL (ICD-9 201), which occurred in the 1,402 people in the PCP-only group (SMR = 0.97, 95% CI 0.02–5.41); there were none in the 720 men in the PCP-plus-TCDD group.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

In the update of cancer incidence through December 31, 2006, in participants in the AHS, Koutros et al. (2010a) did not find increases in the incidence of HL in the private applicators (SIR = 0.96, 95% CI 0.57–1.52) or in their spouses (SIR = 0.85, 95% CI 0.34–1.74). The preponderance of the HL cases occurred in the subsample drawn from Iowa (15 of 18 cases in applicators [SIR = 1.27, 95% CI 0.71–2.09] and 6 of 7 cases in their spouses [SIR = 1.02, 95% CI 0.37–2.21]). In the update of mortality in the AHS cohort through 2007, Waggoner et al. (2011) observed only five deaths from HL in the applicators (SMR = 1.03, 95% CI 0.34–2.41) and a single death from HL in their spouses. The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies In an early report of the Cross-Canada Study of Pesticides and Health, Pahwa et al. (2003) had not found an increased risk of HL in those exposed to any type of herbicide for at least 10 hours/year. Karunanayake et al. (2012) presented results on exposure of any duration to individual pesticides. The 316 HL cases had been diagnosed during September 1, 1991–December 31, 1994, and age-matched to 1,506 controls randomly selected from provincial insurance, voter, or telephone lists. With adjustment for age, province, and several aspects of medical history, herbicides of interest in this review showed no statistically significant associations with the incidence of HL; for all phenoxy herbicides, 65 exposed cases, OR = 0.94, 95% CI 0.66–1.34; for 2,4-D, 57 exposed cases, OR = 0.88, 95% CI 0.61–1.34; for Mecoprop, 20 exposed cases, OR = 1.35, 95% CI 0.76–2.40; for MCPA, 11 exposed cases, OR = 0.97, 95% CI 0.42–2.22; for diclofop-methyl, 10 exposed cases, OR = 1.77, 95% CI 0.70–4.47; and for dicamba, 32 exposed cases, OR = 1.16, 95% CI 0.71–1.90.

Zakerinia et al. (2012) conducted an Iranian hospital-based case-control study of 200 cases of lymphoma (54 HL, 100 NHL, and 46 MM admitted from January 2007 through April 2008) and 200 controls admitted through the emergency room and matched on age, sex, and state of residence. A detailed job history gathered by interview was the source of information on exposure to pesticides (herbicides, insecticides, and fungicides). The analyses for the subtypes of pesticides were conducted only on the full set of lymphomas, so this study does not provide fully relevant information for the purpose of this review.

Biologic Plausibility

HL arises from the malignant transformation of a germinal-center B cell and is characterized by malignant cells that have a distinctive structure and phenotype; these binucleate cells are known as Reed–Sternberg cells (Jaffe et al., 2008). No animal studies have shown an increase in HL after exposure to the COIs. Reed–Sternberg cells have not been demonstrated in mice or rats, so there is no

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

good animal model of HL. Thus, there are no specific animal data to support the biologic plausibility of an association between the COIs and HL.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The relative rarity of HL complicates the evaluation of epidemiologic studies because their statistical power is generally low. Earlier studies (Eriksson et al., 1992; Hardell et al., 1981; Holmes et al., 1986; LaVecchia et al., 1989; Persson et al., 1993; Rix et al., 1998; Waterhouse et al., 1996; Wiklund et al., 1988) were generally well conducted and included excellent characterization of exposure, and they formed the basis of previous VAO committees’ conclusions. Later findings have not contradicted those conclusions, especially given that most studies have had low statistical power. Although it has not been demonstrated as clearly as for NHL, a positive association between the COIs and the development of HL is biologically plausible because of the common lymphoreticular origin of HL and NHL and their common risk factors.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is sufficient evidence of an association between exposure to at least one of the COIs and HL.

Non-Hodgkin Lymphoma

NHL (ICD-9 200.0–200.8, 202.0–202.2, 202.8–202.9) is a general name for cancers of the lymphatic system other than HL or MM. NHL consists of a large group of lymphomas that can be partitioned into acute and aggressive (fast-growing) or chronic and indolent (slow-growing) types of either B-cell or T-cell origin. B-cell NHL includes Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, large-cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle-cell lymphoma. T-cell NHL includes mycosis fungoides and anaplastic large-cell lymphoma. Precursor T-lymphoblastic lymphoma is not considered a type of NHL; it is considered part of T-lymphoblastic lymphoma/leukemia, a precursor lymphoid neoplasm included with the broad group of “acute lymphoid leukemias,” which can be of either T-cell or B-cell origin.

As noted in earlier VAO updates, in response to requests from VA, CLL and HCL have been recognized as sharing many traits with NHL (including B-cell origin and immunohistochemical properties). The proposed WHO classification of NHL notes that CLL (ICD-9 204.1) and its lymphomatous form, SLL, are both derived from mature B cells (Chiorazzi et al., 2005; IARC, 2001). The present

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

VAO committee has determined that it is more appropriate to consider those lymphatic malignancies with other forms of NHL. Therefore, discussion of CLL and HCL will no longer follow the general section on leukemia but has been moved into the NHL grouping.

ACS estimated that 38,160 men and 31,970 women would receive diagnoses of NHL in the United States in 2012 and that 10,320 men and 8,620 women would die from it (Siegel et al., 2012). The incidence of NHL is uniformly higher in men than in women and typically higher in whites than in blacks. In the groups that characterize most Vietnam veterans, incidence increases with age. In addition, ACS estimated that about 9,490 men and 6,570 women would receive diagnoses of CLL in the United States in 2012 and that 2,730 men and 1,850 women would die from it (Siegel et al., 2012). Nearly all cases occur after the age of 50 years. Average annual incidences of NHL are shown in Table 8-41 with the additional incidences of CLL.

The causes of NHL are poorly understood. People who have suppressed or compromised immune systems are known to be at higher risk, and some studies show an increased incidence in people who have HIV, human T-cell leukemia virus type I, Epstein–Barr virus, or gastric Helicobacter pylori infections. The human retrovirus HTLV-1 causes adult T-cell lymphoma, but early reports that HTLV-2 might play a role in the etiology of HCL have not been substantiated. A broad spectrum of behavioral, occupational, and environmental risk factors have been proposed as contributors to the occurrence of NHL, but given the diversity of malignancies included under this name, it is not too surprising that—aside from infectious agents, immune problems, and particular chemotherapies—specific risk factors have not been definitively established (Morton et al., 2008; Wang and Nieters, 2010).

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was sufficient evidence to support an association between exposure to at least one of the COIs and

TABLE 8-41 Average Annual Incidence (per 100,000) of Non-Hodgkin Lymphoma in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men38.139.136.755.457.842.778.482.751.7
Women27.028.321.939.341.133.452.355.835.8

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

NHL. Additional information available to the committees responsible for later updates has not changed that conclusion.

As with HL, epidemiologic data reviewed by previous VAO committees suggest that the phenoxy herbicides (including 2,4-D) rather than TCDD may be associated with NHL. The original VAO committee concluded that a positive association existed between exposure to herbicides and the development of NHL, and studies reviewed by later committees have continued to support that finding. A large, well-conducted case-control study in Sweden by Hardell (1981) examined NHL and HL together and found a significantly increased risk associated with exposure to phenoxy acids or chlorophenols on the basis of 105 cases. Those results were replicated in further investigations of the validity of the exposure assessment and potential biases (Hardell, 1981). Another Swedish case-control study by Hardell et al. (1994) showed a statistically significant risk in a comparison of the occupational histories of 105 people who were exposed to phenoxy herbicides and chlorophenols and received diagnoses of NHL in 1974–1978 with 335 control subjects. Similar data by Persson et al. (1989) showed an increased risk of NHL in those exposed to phenoxy acids on the basis of a logistic regression analysis of 106 cases.

Studies of production workers have shown some association between TCDD exposure and NHL. A larger study of 21,863 workers in the IARC phenoxy-herbicide cohort by Kogevinas et al. (1997) found a nonsignificant increase in NHL risk. Subjects in that expanded multinational study were followed from 1939 to 1992. Other studies of Danish and Dutch phenoxy-herbicide workers who were part of the IARC cohort have shown a nonsignificant increased risk of NHL (Boers et al., 2010; Bueno de Mesquita et al., 1993; Hooiveld et al., 1998; Lynge, 1993). A cohort of 2,479 workers in four plants in Germany with exposure to phenoxy herbicide and contaminants (dioxins and furans) had significantly increased risk of NHL on the basis of five cases (Becher et al., 1996). A variety of herbicides were produced in the plants, including those known to have been contaminated with TCDD. Increases in risk—but nonsignificant ones—have also been found in the NIOSH mortality study (Steenland et al., 1999). Risks were not significantly increased in the Dow Chemical Company Midland, Michigan, or Plymouth, New Zealand, chemical production workers, phenoxy-herbicide sprayers, or 2,4-D production workers (Bloemen et al., 1993; Bodner et al., 2003; Burns et al., 2001; Collins et al., 2009a,b; McBride et al., 2009a,b; Ramlow et al., 1996; ‘t Mannetje et al., 2005). A multinational IARC cohort study of paper and pulp workers found a statistically significant increase in workers who were exposed to chlorophenols (McLean et al., 2006).

Studies of farmers and agricultural workers have been generally positive for an association between herbicides or TCDD and NHL; however, only a few were statistically significant. A meta-analysis of several studies of the association between employment as a farmer in the central United States and NHL showed a statistically significant risk (Keller-Bryne et al., 1997). All the studies of US agri-

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

cultural workers reviewed showed increased RRs, and two NCI studies of farmers in Kansas and Nebraska (Hoar et al., 1986; Zahm et al., 1990) showed patterns of increased risk linked to use of 2,4-D. A study of a subcohort of Hispanic workers in a larger cohort of 139,000 California members of the United Farm Workers of America (Mills et al., 2005) and a population-based case-control study in Italy of NHL and CLL cases (combined) identified during 1991–1993 (Miligi et al., 2006) both showed statistically significant associations with 2,4-D.

A large, well-conducted, population-based, Cross-Canada Study of Pesticides and Health reported on pesticide use and NHL incidence in men identified from cancer registries of six Canadian provinces in 1991–1994. Statistically significant associations were found between exposure to phenoxy herbicides, 2,4-D, or Mecocrop and NHL. A reanalysis of the data from that study confirmed the findings on phenoxy herbicides but found that the association with 2,4-D, although still increased, was no longer significantly so (McDuffie et al., 2001). A population-based case-control study in 2000–2001 in men and women 20–74 years old living in New South Wales, Australia, found an increased risk of NHL associated with “substantial” exposure to phenoxy herbicides (Fritschi et al., 2005). Spinelli et al. (2007) reported on a population-based case-control study in Vancouver and Victoria, British Columbia, and found strong monotonic increases in serum concentrations of two dioxin-like PCBs (PCB 118 and 156). Chiu et al. (2004) and Lee et al. (2004b) conducted a pooled (combined) analysis of two case-control studies that were carried out in three Midwestern US states—Iowa and Minnesota (Cantor et al., 1992) and Nebraska (Zahm et al., 1990)—and found that risks were increased in farmers by use of herbicides, including 2,4-D and 2,4,5-T. In a study of NHL incidence in people who lived in the vicinity of 13 French municipal waste incinerators, Viel et al. (2008) found a small but statistically significant increase in the risk of NHL and evidence of a dose–response relationship with increased exposure to dioxin. A case-control study of NHL rates in people who lived near a municipal solid-waste incinerator in Bensaçon, France, found that incidence of NHL was significantly increased in the area determined to have the highest dioxin contamination, but no increases were found in the low and intermediate categories (Floret et al., 2003). A French hospital-based case-control study of lymphoid neoplasms (Orsi et al., 2009) did not find the occurrence of NHL to be associated with occupational or domestic use of pesticides or phenoxy herbicides in particular.

Evidence of an association between the COIs and NHL in Vietnam veterans, the primary population of interest in the VAO updates, has been lacking. The Centers for Disease Control and Prevention (CDC) Selected Cancers Study (CDC, 1990a) showed a significantly increased risk of NHL in all Vietnam veterans; however, in analysis according to branch of service, Army and Air Force personnel were not at increased risk. Marine Corps veterans had higher mortality in the CDC Selected Cancers Study and significantly increased risks in several other studies (Breslin et al., 1988; Burt et al., 1987; Watanabe and Kang, 1996;

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Watanabe et al., 1991), but the implications of these findings are unclear. No increased risk has been seen in Operation Ranch Hand veterans (AFHS, 2000; Akhtar et al., 2004; Michalek et al., 1990; Wolfe et al., 1990) or in members of the Army Chemical Corps (Boehmer et al., 2004).

With 25 years of followup of the Seveso population and a relatively small number of observed cases, evidence of an increased incidence of NHL is emerging in the subgroup in the most highly exposed zones (Bertazzi et al., 1989b, 1993, 1997, 2001; Consonni et al., 2008; Pesatori et al., 1992, 2009).

The findings of several PCB-focused studies (Bertrand et al., 2010; Engel et al., 2007; Laden et al., 2010) are consistent with the associations with NHL repeatedly observed in connection with the COIs in the VAO series, but the extent of intercorrelation of these persistent organic pollutants greatly curtails the degree to which any effect can be specifically attributed to dioxin-like activity.

Table 8-42 summarizes the results of the relevant studies of all forms of NHL.

Update 2002 was the first to discuss CLL separately from other leukemias. The epidemiologic studies indicated that farming, especially with exposure to 2,4-D and 2,4,5-T, is associated with significant mortality from CLL. Many more studies support the hypothesis that herbicide exposure can contribute to NHL risk. Most cases of CLL and NHL reflect malignant transformation of germinal-center B cells, so these diseases could have a common etiology.

Studies concerning CLL reviewed in Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 are summarized in Table 8-43.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veteran studies or environmental studies of exposure to the COIs and NHL have been published since Update 2010.

Occupational Studies Burns et al. (2011) published an update of cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With 14 cases observed, the increase in risk of NHL in the most restrictively defined cohort did not reach statistical significance (SIR = 1.71, 95% CI 0.93–2.87), as was the case in the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis of the mortality data updated through 2006 in male workers in two Dutch phenoxy-herbicide factories, which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination, whereas the 1,036 working in factory B had

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-42 Selected Epidemiologic Studies—Non-Hodgkin Lymphoma (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—White subjects vs national rates (lymphopoietic cancerc)

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  100.9 (0.4–1.5)

With tours between 1966–1970

    70.7 (0.3–1.4)

SEA comparison veterans (n = 1,776)

    90.6 (0.3–1.0)

With tours between 1966–1970

    40.3 (0.1–0.8)

Attended 1987 exam—Ranch Hand personnel (n = 995) vs SEA veterans (n = 1,299)

    1nrWolfe et al., 1990

Mortality

Through 1987—Ranch Hand personnel (n = 1,261) vs SEA veterans (19,102)

    0nrMichalek et al., 1990

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Army enlisted Vietnam veterans (all lymphomas) (1965–1983)

    71.8 (nr)O’Brien et al., 1991

Mortality

1965–2000

    60.9 (0.3–2.9)Boehmer et al., 2004 CDC, 1990b

US CDC Selected Cancers Study—case-control study of incidence (12/1/1984–11/30/1989) among US males born 1929–1953 (CDC, 1990a)

All COIs
991.5 (1.1–2.0)

Army Vietnam veterans

  451.2 (0.8–1.8)

Marine Vietnam veterans

  101.8 (0.8–4.3)

Air Force Vietnam veterans

  121.0 (0.5–2.2)

Navy Vietnam veterans

  321.9 (1.1–3.2)

Blue Water Navy Vietnam veterans

  282.2 (1.2–3.9)

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

171

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

  461.7 (1.2–2.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1965–1984—Army, deployed (n = 24,145) vs nondeployed (n = 27,917) (ICD-8 200, 202)

1401.7 (1.2–2.2)Watanabe et al., 1991

Army Vietnam veterans vs combined

Army and Marine Vietnam-era veterans

1400.9 (nr)

Marine Vietnam veterans vs non-Vietnam veterans

  421.8 (1.3–2.4)

Marine Vietnam veterans vs combined Army and Marine Vietnam-era veterans

  421.2 (nr)

1965–1982 (ICDA-8 200, 202)

Breslin et al., 1986, 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

1080.8 (0.6–1.0)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

352.1 (1.2–3.8)

Nested case-control study of NHL

  391.1 (0.7–1.5)Burt et al., 1987

Army combat Vietnam veterans

  173.2 (1.4–7.4)

Marine combat Vietnam veterans

  640.9 (0.7–1.3)

Army Vietnam veterans (service 1967–1969)

  172.5 (1.1–5.8)

Marine Vietnam veterans (service 1967–1969)

    41.8 (0.4–8.0)

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality

Through 2004 (lymphopoietic cancersc)

  180.7 (0.4–1.3)Cypel and Kang, 2008

Vietnam–veteran nurses

  140.7 (0.3–1.3)

Through 1987 (ICD-8 200, 200–203, 208)

    31.3 (0.3–1.8)Thomas et al., 1991

US Navy Enlisted Personnel (1974–1983)

Active duty

  680.7 (0.5–0.9)Garland et al., 1988

VA Case-Control Studies

US Vietnam veterans—incidence

1001.0 (0.7–1.5)Dalager et al., 1991
State Studies of US Vietnam Veterans

Massachusetts Vietnam-era veterans who served 1958–1973—cases diagnosed 1982–1988 (served in Vietnam)

1.2 (0.6–2.4)Clapp et al., 1991

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  321.5 (1.0–2.1)Visintainer et al., 1995

New York—deployed vs nondeployed

  101.0 (0.4–2.2)Lawrence et al., 1985

West Virginia—deployed vs nondeployed

    21.1 (nr)Holmes et al., 1986
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  341.3 (0.9–1.8)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  241.4 (0.9–2.1)

7,553 not exposed to highly chlorinated PCDDs

    91.0 (0.5–1.9)

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

Saracci et al., 1991

Nested case-control study

IARC cohort (men and women)—incidence

Kogevinas et al, 1995

Exposed to 2,4,5-T

  101.9 (0.7–4.8)

Exposed to TCDD

  111.9 (0.7–5.1)

Mortality—IARC cohort (16,863 men and 1,527 women) 10–19 years since first exposure

Kogevinas et al, 1992
111.0 (0.5–1.7)

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Mortality 1955–2006

    71.4 (1.1–1.7)Boers et al., 2012

TCDD plasma level (HRs, by tertile)

Background (≤ 0.4)

    1nr

Low (0.4–4.1)

    33.8 (0.4–34.3)

Medium (4.1–20.1)

    27.8 (0.7–89.3)

High (≥ 20.1)

    18.1 (0.4–149.1)

Incidence 1943–1987 (men only)

  101.7 (0.5–4.5)Lynge, 1993

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–2006 (HRs for lagged TCDD plasma levels)

    61.3 (1.0–1.7)Boers et al., 2012

Mortality 1955–2006

4 vs 30.9 (0.2–4.5)Boers et al., 2010

Mortality 1955–1991

    33.8 (0.8–11.0)Hooiveld et al., 1998

Mortality 1955–1985

    12.0 (0.1–11.4)Bueno de Mesquita et al., 1993
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

1 vs 0nrBoers et al., 2010

Mortality 1965–1986

    15.6 (0.1–31.0)Bueno de Mesquita et al., 1993

German Production Workers—2,479 workers at 4 plants (in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

All for plants

    63.3 (1.2–7.1)Becher et al., 1996

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    212.0 (1.5–43.5)Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1965–1989

    0Becher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1956–1989

    0Becher et al., 1996

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,5-DCP; 2,4,5-T; 2,4,5-TCP

Mortality 1952–2007

    71.6 (0.6–3.3)Manuwald

Men

    51.6 (0.5–3.7)et al., 2012

Women

    21.7 (0.2–6.0)

Mortality 1952–1989

    43.8 (1.0–9.6)Becher et al.,
1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    31.6 (0.3–4.7)

Never-exposed workers

    11.6 (0.0–8.7)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    10.9 (0.0–4.9)’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    10.7 (0.0–3.8)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  121.1 (0.6–1.9)Steenland et al., 1999

Chloracne subcohort (n = 608)

    61.1 (0.4–2.5)

(Lymphatic and hematopoietic, ICD-9 200–208)

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615)

    91.3 (0.6–2.5)Collins et al., 2009a

1940–1994 (n = 2,187 men)

nr1.4 (0.6–2.7)Bodner et al., 2003

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122) (ICD-9 200, 202, 273.3)

  171.8 (1.0–2.8)

PCP and TCP (n = 720)

    82.5 (1.1–4.9)

PCP (no TCP) (n = 1,402)

    91.4 (0.6–2.7)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

  141.7 (0.9–2.9)Burns et al., 2011

Through 1994 (n = 1,517)

    31.0 (0.2–2.9)Burns et al., 2001

Through 1986 (n = 878) vs national vs 36,804 “unexposed” workers at same location

    22.0 (0.2–7.1)Bloemen et al., 1993

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

    82.4 (1.0–4.7)Collins et al., 2009b

Mortality 1940–1989 (n = 770)

Ramlow et al., 1996

All lymphopoietic cancer (ICDA-8 200–209)

0-yr latency

    71.4 (0.6–2.9)

15-yr latency

    51.3 (0.4–3.1)

Other, unspecified lymphopoietic cancer (ICDA-8 200, 202–203, 209)

0-yr latency

    52.0 (0.7–4.7)

15-yr latency

    42.0 (0.5–5.1)
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries,

McLean et al., 2006

TCDD among 27 agents assessed by JEM

Exposure to nonvolatile organochlorine compounds

Never

  350.9 (0.7–1.3)

Ever

  250.9 (0.6–1.3)

Exposure to chlorophenols

  504.3 (2.7–6.9)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from NHL June 1971–December 1987

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Farm operators ≥ 35 yrs of age (June 1971–December 1987)

Morrison et al., 1994

All farm operators

nr0.8 (0.7–0.9)

Highest quartile of herbicides sprayed

  192.1 (1.1–3.9)

Highest quartile of herbicide sprayed relative to no spraying

    63.0 (1.1–8.1)

Farm operators ≥ 35 yrs of age during study period (June 1971–December 1985)

Wigle et al., 1990

All farmers

1030.9 (0.8–1.1)

Spraying herbicides on 250+ acres

  102.2 (1.0–4.6)

DENMARK

Danish gardeners—incidence from 3,156 male and 859 female gardeners

Hansen et al., 2007

25-year followup (1975–2001)

Herbicides

Born before 1915 (high exposure)

  161.4 (0.9–2.3)

Born 1915–1934 (medium exposure)

  251.2 (0.8–1.8)

Born after 1934 (low exposure)

    10.2 (0.0–1.0)

10-year followup (1975–1984) of male gardeners

  151.4 (0.8–2.4)Hansen et al., 1992

(lymphohematopoietic, ICD-7 200–2005)

NHL (ICD-7 200, 202, 205)

    61.7 (0.6–3.8)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wk) not IARC

Phenoxy herbicides

Incidence

Asp et al., 1994

No latency

    10.4 (0.0–2.0)

10-yr latency

    10.4 (0.0–2.4)

Except for lung cancer, numbers too small for reporting mortality 1972–1980

    0nrRiihimaki et al., 1982

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401) (ICD-8 202.0–202.9)

  150.9 (0.5–1.5)Torchio et al., 1994

Incidence 1976–1983 (n = 25,945)

Corrao et al., 1989

Licensed pesticide users and nonusers

  451.4 (1.0–1.9)

Farmers in arable land areas

  311.8 (1.2–2.5)

Italian rice growers with documented phenoxy use (n = 1,487)

PhenoxyGambini et al., 1997
4herbicides
1.3 (0.3–3.3)

SWEDEN

20,245 Swedish pesticide applicators with license issued between 1965 and 1976

  271.1 (0.7–1.6)Wiklund et al., 1989b
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

354,620 Swedish agriculture, forestry workers

Wiklund et al., 1988

Workers in land, animal husbandry

6701.0 (0.9–1.1)

Timber cutters

1110.9 (0.7–1.1)

Incident NHL cases 1961–1973 with agriculture as economic activity in 1960 census

99% CIWiklund, 1983
4761.1 (0.9–1.2)

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    0

Lumberjacks (n = 139)

    11.9 (0.0–10.7)

Unexposed lumberjacks (n = 241)

    10.8 (0.0–4.5)

THE NETHERLANDS

Dutch Licensed Herbicide

Sprayers—1,341 certified before 1980

Through 1987

    0nrSwaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

8431.2 (1.1–1.3)

Nonwhites (n = 11,446)

  240.7 (0.5–1.1)

Women

Whites (n = 2,400)

  181.1 (0.6–1.7)

Nonwhites (n = 2,066)

    61.1 (0.4–2.3)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

NHL

Private applicators

1951.0 (0.9–1.1)

Commercial applicators

    90.8 (0.4–1.6)

Spouses

  861.0 (0.8–1 2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

B-cell

Private applicators

1671.0 (0.9–1.2)

Commercial applicators

    80.9 (0.4–1.7)

Spouses

  781.1 (0.8–1.3)

Enrollment through 2002

Samanic et al., 2006

Dicamba—lifetime days exposure

None

  391.0

1– < 20

  181.8 (1.0–3.2)

20– < 56

  141.3 (0.7–2.5)

56– < 116

    70.9 (0.4–2.2)

≥ 116

    71.2 (0.5–2.9)
p-trend = 0.92

Enrollment through 2002

Alavanja et al., 2005

Private applicators

1141.0 (0.8–1.2)

Spouses of private applicators (> 99% women)

  420.9 (0.6–1.2)

Commercial applicators

    61.0 (0.4–2.1)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  900.8 (0.7–1.0)

Spouses (n = 676)

  421.1 (0.8–1.5)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

  330.9 (0.6–1.2)
161.2 (0.7–2.0)

California United Farm Workers of

America

Nested case-control analysis of Hispanic workers in cohort of 139,000 CA United Farm Workers

Mills et al., 2005

Ever used 2,4-D

nr3.8 (1.9–7.8)

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of NHL

Herbicides

Agricultural extension agents (from Table 3)

nr1.2 (0.7–2.3)Alavanja et al., 1988

White Male Residents of Iowa—NHL cancer on death certificate, usual occupation: farmers vs not

Herbicides

> 30 yrs old when died 1964–1978—case-control H0: only for “modern methods” → born after 1900

1,1011.3 (nr)Burmeister et al., 1983
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Born before 1880

1542.9 (nr)

Born 1980–1900

3361.6 (nr)

Born after 1900

6110.9 (nr)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    10.8 (0.1–5.7)Pesatori et al., 2009

Zone B

  121.5 (0.9–2.7)

Zone R

  490.9 (0.7–1.2)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone A

    0nr

Zone B

    32.3 (0.7–7.4)

Zone R

  121.3 (0.7–2.5)

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone A

    0nr

Zone B

    10.9 (0.1–6.4)

Zone R

  101.2 (0.6–2.3)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    33.4 (1.1–10.5)

Zone B

    71.2 (0.6–2.6)

Zone R

  401.0 (0.7–1.4)

20-yr followup to 1996

Bertazzi et al., 2001

Zone A—men and women

    23.3 (0.8–13.1)

Zone B—men and women

    51.2 (0.5–3.0)

Zones A and B—men

    31.2 (0.4–3.9)

Zones A and B—women

    41.8 (0.7–4.9)

15-yr followup to 1991—men

Bertazzi et al., 1997, 1998

Zone A

    00.0 (0.0–18.1)

Zone B

    21.5 (0.2–5.3)

Zone R

  101.1 (0.5–2.0)

15-yr followup to 1991—women

Bertazzi et al., 1997, 1998

Zone A

    00.0 (0.0–19.6)

Zone B

    00.0 (0.0–3.0)

Zone R

    80.9 (0.4–1.7)

10-yr followup to 1986—men

Bertazzi et al., 1989a,b

Zone B

nrnr

Zone R

    31.0 (0.3–3.4)

10-yr followup to 1986—women

Zone B

    21.0 (0.3–4.2)

Zone R

    41.6 (0.5–4.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
Other International Environmental Studies

FINLAND

Finnish community exposed to chlorophenol contamination (men and women)—incidence

ChlorophenolLampi et al., 1992
162.8 (1.4–5.6)

FRANCE

Residents near French solid-waste incinerator in Besançon. NHL cases diagnosed 2003–2005—incidence

Dioxin, furans, PCBsViel et al., 2011

pg WHO1998-TEQ/g lipid:

Σ PCDD

13.41.1 (1.0–1.3) (p-trend < 0.01)

Σ PCDF

9.41.2 (1.0–1.4) (p-trend = 0.01)

Σ dl-PCBs

33.11.0 (1.0–1.1) (p-trend = 0.01)

Residents near French solid-waste incinerator—incidence

DioxinViel et al., 2008

Highly exposed census group vs slightly exposed

nr1.1 (1.0–1.3)

Residents near municipal solid-waste incinerator—incidence

DioxinFloret et al., 2003

High-exposure category

  312.3 (1.4–3.8)

Residents near municipal solid-waste incinerator—incidence

DioxinViel et al., 2000

Spatial cluster

2861.3 (p = 0.00003)

1994–1995

1091.8 (p = 0.00003)

NEW ZEALAND

Residents of New Plymouth Territorial Authority, New Zealand, near plant manufacturing 2,4,5-T in 1962–1987

2,4,5-TRead et al., 2007

Incidence

2231.0 (0.9–1.1)d

1970–1974

  331.8 (1.2–2.5)

1975–1979

  291.3 (0.9–1.9)

1980–1984

  220.8 (0.5–1.3)

1985–1989

  240.7 (0.5–1.1)

1990–1994

  350.8 (0.6–1.1)

1995–1999

  611.1 (0.8–1.4)

2000–2001

  190.8 (0.5–1.3)

Mortality

1381.1 (0.9–1.3)d

1970–1974

  191.6 (0.9–2.4)

1975–1979

  241.6 (1.0–2.4)

1980–1984

  141.0 (0.5–1.6)

1985–1989

  251.3 (0.9–2.0)

1990–1994

  230.9 (0.6–1.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1995–1999

  210.7 (0.4–1.1)

2000–2001

  121.0 (0.5–1.8)
CASE-CONTROL STUDIES

US Case-Control Studies

Cental US—meta-analysis of NHL and farmers

PesticidesKeller-Byrne et al., 1997
nr1.3 (1.2–1.6)

Pooled incidence data on herbicide use from 3 case-control studies in Iowa/Minnesota,

HerbicidesChiu et al., 2004

Kansas, and Nebraska (n = 973)

Farmers (no herbicide use)

2941.2 (1.0–1.5)

Farmers (herbicide use)

2731.0 (0.8–1.2)

Pooled data from case-control studies in Iowa, Minnesota, and Nebraska—effect of asthma on NHL and pesticide use (n = 872)

PesticidesLee et al., 2004b

Asthmatics—incidence

Herbicide exposure—phenoxy acid

  171.3 (0.7–2.4)

Exposure among farmers

2,4-D

  171.3 (0.7–2.5)

2,4,5-T

    72.2 (0.8–6.1)

Nonasthmatics—incidence

Herbicide exposure—phenoxy acid

1761.0 (0.8–1.3)

Exposure among farmers

2,4-D

1721.0 (0.8–1.3)

2,4,5-T

  361.1 (0.7–1.8)

Kansas residents–duration and frequency of herbicide use—incidence

Phenoxy herbicides, 2.4-DHoar et al., 1986

All farmers

1331.4 (0.9–2.1)

Farm-use of herbicides

    76.0 (1.9–19.5)

NCI SEER study (Iowa, Los Angeles County, Detroit, Seattle), 1998–2000; 1,321 NHL patients and 1,057 controls—residential exposures

2,4-DHartge et al., 2005

2,4-D exposure in carpet dust (ng/g)

Under detection limit

1471.0

< 500

2571.1 (0.8–1.6)

500–999

  860.9 (0.6–1.5)

1,000–9,999

1650.7 (0.5–1.0)

> 10,000

  240.8 (0.4–1.7)

Nebraska residents (men and women), NHL reclassified according to specific chromosomal translocation (t[14;18] [q32;q21])—incidence

HerbicidesChiu et al., 2006

Translocation present in cases

Herbicides

  252.9 (1.1–7.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Translocation present in cases

Herbicides

  220.7 (0.3–1.2)

Females on Eastern Nebraska farms

HerbicidesZahm et al., 1993
1191.0 (0.7–1.4)

Eastern Nebraska residents—incidence

2,4-DZahm et al., 1990

Ever done farm work

1470.9 (0.6–1.4)

Ever mixed or applied 2,4-D

  431.5 (0.9–2.5)

Upstate New York—population-based study, women (20–79 yrs old), 1995–1998 (376 cases vs 463 controls)

Herbicides, pesticidesKato et al., 2004

Home use only of herbicides, pesticides (times)

0

2311.0

1–4

  330.9 (0.5–1.5)

5–17

  300.7 (0.4–1.3)

18–39

  271.0 (0.6–1.7)

≥ 40

  400.9 (0.5–1.5)

Hancock County, Ohio, residents—farmers

  151.6 (0.8–3.4)Dubrow et al., 1988

Washington state residents—incidence (1983–1985)

Phenoxy herbicides, chlorinated phenolsWoods et al., 1987

Phenoxy herbicide use

nr1.1 (0.8–1.4)

Chlorophenol use

nr1.0 (0.8–1.2)

Farming occupations

nr1.3 (1.0–1.7)

Forestry herbicide appliers

nr4.8 (1.2–19.4)

Self-reported chloracne

nr2.1 (0.6–7.0)

Wisconsin residents—farmers (ICD-8 200.0, 200.1, 202.2)

HerbicidesCantor, 1982
1751.2 (1.0–1.5)

International Case-Control Studies

Asian patients (≥ 20 yrs old) from China, Korea, and Japan diagnosed with NKTCL between March 2000 and March 2005–occupational exposures

Herbicides, pesticidesXu et al., 2006

Pesticide use

  234.0 (2.0–8.1)

Herbicide

  133.2 (1.4–7.4)

Insecticide

  203.5 (1.7–7.1)

Fungicide

  106.1 (2.0–18.5)

Australian population-based study in New Wales (2000–2001)

Phenoxy compoundsFritschi et al., 2005

Phenoxy herbicides

Nonsubstantial exposures

  100.7 0.3–1.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Australian residents in Victorian Cancer Registry (1982–1987)

Phenoxy compoundsSmith and Christophers, 1992

Exposure > 1 day

  151.5 (0.6–3.7)

Exposure > 30 days

    72.7 (0.7–9.6)

Canadian population based study (March 2000–February 2004), men and women subjects and matched controls (20–79 yrs of age)—organochlorines and NHL

dl-PCBsSpinelli et al., 2007

Total dl–PCBs

Lowest quartile

  821.0

Second quartile

  961.4 (0.9–2.2)

Third quartile

  821.6 (1.0–2.5)

Highest quartile

1432.4 (1.5–3.7)
p-trend < 0.001

Canadian multicenter population-based study (September 1991–December 1994), male NHL patients (n = 517) and controls (n = 1,506) and impact of exposure to multiple pesticides

Phenoxy herbicides, 2,4-DHohenadel et al., 2011

Exposure to multiple herbicides

0

3691.0 (nr)

1

  451.2 (0.9–1.8)

2–4

  731.6 (1.2–2.2)

5+

  261.6 (1.0–2.6)

Exposure to phenoxy herbicides

0

3841.0 (nr)

1

  661.3 (1.0–1.8)

2+

  631.8 (1.3–2.5)

Exposure to Mecoprop

  232.1 (1.2–5.4)

Exposure to 2,4-D

  490.9 (0.7–1.3)

Canadian multicenter population-based study (September 1991–December 1994), male NHL patients (n = 517) and controls (n = 1,506) and pesticide exposure of ≥ 10 h/yr

Phenoxy herbicides, 2,4-DMcDuffie et al., 2001

Exposed to phenoxy herbicides

1311.4 (1.1–1.8)

2,4-D

1111.3 (1.0–1.7)

Mecoprop

  532.3 (1.6–3.4)

Danish residents (Copenhagen and Aarhus) in the Diet, Cancer and Health prospective study diagnosed with NHL from enrollment (1994–5/1977) through 2008

OrganochlorinesBräuner et al., 2012

Organochlorines in adipose tissue (ug/ kg lipids)

dl-PCB 118

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10–25

  531.0 (nr)

25–34

  630.9 (0.5–1.6)

34–48

  581.0 (0.6–1.7)

48–62

  340.7 (0.3–1.3)

62–150

  250.7 (0.4–1.4)

dl-PCB 156

13–28

  621.0 (nr)

28–34

  510.6 (0.3–1.0)

34–41

  540.7(0.4–1.2)

41–50

  450.9 (0.5–1.8)

50–88

  230.7 (0.3–1.4)

Denmark—Danish farmworkers—incidence

PhenoxyRonco et al., 1992
147herbicides
1.0 (nr)

Italian farmworkers—mortality

  141.3 (nr)

France hospital-based case-control study

HerbicidesOrsi et al., 2009

Occupational use of herbicides

  251.3 (0.7–2.2)

Phenoxy herbicides

  110.9 (0.4–1.9)

Domestic use of herbicides

  861.0 (0.7–1.5)

German population-based study (1986–1998), men and women, 15–75 yrs of age—occupational factors associated with NHL

TCDD, herbicidesRichardson et al., 2008

Chlorophenols

NHL—high-grade malignancy

  612.0 (1.3–2.9)

NHL—low-grade malignancy

  771.3 (1.0–1.8)

CLL

  440.9 (0.6–1.3)

Herbicides

NHL—high-grade malignancy

  562.2 (1.4–3.3)

NHL—low-grade malignancy

  791.4 (1.0–1.9)

CLL

  431.2 (0.8–1.7)

Irish farmers and farmworkers

HerbicidesDean, 1994

Other malignant neoplasms of lymphoid and histiocytic tissue (including some types of NHL) (ICD-9 202)

1641.8 (1.2–2.6)

Italian incident cases of malignancies of the hematolymphopoietic system in men and women (20–74 yrs of age) from agricultural and mixed use areas (HD cases = 258)

HerbicidesMiligi et al., 2006

Men, women

  731.0 (0.7–1.4)

Men

  490.8 (0.5–1.3)

Women

  241.3 (0.7–2.5)

NHL (men, women)

Phenoxy herbicides—ever

  321.1 (0.6–1.8)

Probability of use more than “low,” lack of protective equipment

  132.4 (0.9–7.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

2,4-D—ever

  170.9 (0.5–1.8)

Probability of use more than “low,” lack of protective equipment

    94.4 (1.1–29.1)

MCPA—ever

  180.9 (0.4–1.8)

Probability of use more than “low,” lack of protective equipment

    73.4 (0.8–23.2)

Italian residents of 11 areas (NHL other than lymphosarcoma and reticulosarcoma)—incidence

HerbicidesMiligi et al., 2003

Phenoxy acid herbicides exposure

Men

  181.0 (0.5–2.0)

Women

  111.3 (0.5–3.7)

2,4-D exposure

Men

    60.7 (0.3–1.9)

Women

    71.5 (0.4–5.7)

Italian farming and animal-breeding workers (men and women) (NHL other than lymphosarcoma and reticulosarcoma)—incidence

HerbicidesNanni et al., 1996

Exposure to herbicides

    31.4 (0.4–5.7)

Italian farming and animal-breeding workers (men and women)—incidence

HerbicidesAmadori et al., 1995

NHL, CLL combined

1641.8 (1.2–2.6)

Residents of selected Italian provinces

HerbicidesVineis et al., 1991

Male residents of contaminated areas

nr2.2 (1.4–3.5)

Residents of Milan, Italy, area (men and women)—incidence

HerbicidesLaVecchia et al., 1989

Agricultural occupations

nr2.1 (1.3–3.4)

New Zealand National Cancer Registry (1980–1984)—case-control study of 652 incident NHL cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

Aged 20–59

    42.0 (0.7–5.6)

Aged ≥ 60

    31.7 (0.5–5.4)

Sawmill workers (n = 139)

Herbicides, chlorophenols
    41.2 (0.4–3.2)

New Zealand National Cancer Registry (1977–1981) (< 70 yrs of age)—incidence (1977–1981) (ICD-9 200 and 202)

HerbicidesPearce et al., 1987

Farming occupations

  331.0 (0.7–1.5)

Fencing work

  681.4 (1.0–2.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

New Zealand National Cancer Registry (1977–1981) (< 70 yrs of age)—incidence (1977–1981) (ICD-9 202 only)

Phenoxy herbicidesPearce et al., 1986

Agricultural sprayers

  191.5 (0.7–3.3)

New Zealand National Cancer Registry (1977–1981) (≥ 20 yrs of age) with agricultural occupations—incidence (ICD-9 200 and 202)

HerbicidesPearce et al., 1985
nr1.4 (0.9–2.0)

Sweden—male, female subjects (18–74 yrs of age) with NHL living in Sweden between December 1, 1999 and April 30, 2002 vs controls from national population registry

Pesticides, herbicidesEriksson et al., 2008

Herbicides, total

  741.7 (1.2–2.5)

≤ 20 days

  361.6 (1.0–2.7)

> 20 days

  381.9 (1.1–3.2)

Phenoxyacetic acids

  472.0 (1.2–3.4)

≤ 45 days

  322.8 (1.5–5.5)

> 45 days

  151.3 (0.6–2.7)

MCPA

  212.8 (1.3–6.2)

≤ 32 days

  153.8 (1.4–10.5)

> 32 days

    61.7 (0.5–6.0)

2,4,5-T, 2,4-D

  331.6 (0.9–3.0)

≤ 29 days

  212.1 (1.0–4.4)

> 29 days

  121.3 (0.6–3.1)

Sweden—male and female patients (18–74 yrs of age) diagnosed December 1999–April 2002

Pesticides, herbicidesHardell et al., 2002

Chlorophenols

NHL—high grade malignancy

  612.0 (1.3–2.9)

Sweden—pooled analysis of case-control NHL, hairy cell leukemia studies

HerbicidesHardell et al., 2002

Herbicide exposure

  771.8 (1.3–2.4)

Phenoxyacetic acids

  641.7 (1.2–2.3)

MCPA

  212.6 (1.4–4.9)

2,4-D, 2,4,5-T

  481.5 (1.0–2.2)

Other

  152.9 (1.3–6.4)

Substantial exposure

    51.8 (0.4–7.4)

Sweden—adipose tissue from 33 NHL patients and 39 surgical controls from Örebro-Uppsala medical region (1994–1997)

Dioxin, dibenzofuransHardell et al., 2001

TEQ > 27.8, EA > 80

    82.8 (0.5–18.0)

Umea (Sweden) Hospital patients—incidence

Phenoxy herbicides, chlorophenolsHardell et al., 1994

Exposed to phenoxy herbicides

  255.5 (2.7–11.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Exposed to chlorophenols

  354.8 (2.7–8.8)

Swedish Regional Cancer Registry—NHL patients

Phenoxy herbicidesPersson et al., 1993

Exposed to phenoxy herbicides

  102.3 (0.7–7.2)

Exposed to chlorophenols

    96.0 (1.1–31.0)

Örebro (Sweden) Hospital (men and women)—incidence

Phenoxy herbicides, chlorophenolsPersson et al., 1989

Exposed to phenoxy acids

    64.9 (1.0–27.0)

Lund (Sweden) Hospital patients—incidence

HerbicidesOlsson and Brandt, 1988

Exposed to herbicides

nr1.3 (0.8–2.1)

Exposed to chlorophenols

nr1.2 (0.7–2.0)

Swedish patients (1970–1977)

Phenoxy acids, chlorophenolsHardell, 1981

Exposed to phenoxy herbicides

  414.8 (2.9–8.1)

Exposed to chlorophenols

  504.3 (2.7–6.9)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; ACC, Army Chemical Corps; CA, California; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CLL, chronic lymphocytic leukemia; COI, chemical of interest; dl, dioxin-like; HD, Hodgkin disease; HR, hazard ratio; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; ICDA, International Classification of Diseases, Adapted for Use in the United States; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupation specialty; NCI, National Cancer Institute; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; NKTCL, NK/T-cell lymphoma; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; SEA, Southeast Asia; SEER, Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio; SMR, standardized mortality rate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; TEQ, toxicity equivalent; USDA, United States Department of Agriculture; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cLymphopoietic cancers comprise all of forms of lymphoma (including Hodgkin disease and non-Hodgkin lymphoma) and leukemia (ALL, AML, CLL, CML).

dCommittee computed total SMR and SIR by dividing sum of observed values by sum of expected values over all years; 95% CIs on these total ratios were computed with exact methods.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-43 Selected Epidemiologic Studies—Chronic Lymphocytic Leukemia (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
International Vietnam-Veteran Study

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  581.2 (0.7–1.7)ADVA, 2005a

Navy

  121.5 (0.8–2.6)

Army

  421.7 (1.2–2.2)

Air Force

    40.9 (0.2–2.2)
OCCUPATIONAL—HERBICIDE-USING WORKERS (not related to IARC sprayer cohorts)

CANADA

Sawmill Workers in British Columbia—23,829 workers for ≥ 1 year at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDD

Incidence—all leukemias (1969–1989)

  471.2 (0.9–1.5)Hertzman et al., 1997

ALL

    21.0 (0.2–3.1)

CLL

  241.7 (1.2–2.4)

AML

    50.8 (0.3–1.7)

CML

    71.1 (0.5–2.0)

Other, unspecified

    50.5 (0.2–1.0)

DENMARK

Danish gardeners—incidence from 3,156 male and 859 female gardeners

HerbicidesHansen et al., 2007

10-year followup (1975–1984) of Danish gardeners

Hansen et al., 1992

All gardeners

    62.5 (0.9–5.5)

Male gardeners

    62.8 (1.0–6.0)

UNITED STATES

White Male Residents of Iowa—chronic lymphocytic leukemia on death certificate, usual occupation: farmers vs not

Herbicides

> 30 yrs old when died 1964–1978—case-control (1,675 leukemia deaths, 1968–1978)

Burmeister et al., 1982

Farmer usual occupation on death certificate

1.2 (p < 0.05))

CLL

1321.7 (1.2–2.4)

Lived in counties with highest herbicide use

nr1.9 (1.2–3.1)

White Male Residents of Iowa and Minnesota— > 30 yrs old diagnosed 1981–1983 in Iowa or 1980–1982 in Minnesota—case-control

Herbicides
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

> 30 yrs old diagnosed 1981–1983 in Iowa or 1980–1982 in Minnesota—case-control (ever farmer)

Brown et al., 1990

Ever farmed

1561.4 (1.1–1.9)

Any herbicide used

  741.4 (1.0–2.0)

Ever used 2,4,5-T

  101.6 (0.7–3.4)

Use at least 20 yrs before interview

    73.3 (1.2–8.7)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women (lymphatic leukemia, ICD-9 204)

Zone A

    12.8 (0.4–19.9)Pesatori et al., 2009

Zone B

    0nr

Zone R

  130.8 (0.5–1.5)

Mortality

25-yr followup to 2001—men and women (lymphatic leukemia, ICD-9 204)

Consonni et al., 2008

Zone A

    0nr

Zone B

    31.3 (0.4–4.1)

Zone R

  231.4 (0.9–2.2)

20-yr followup to 1996 (lymphatic leukemia)

Bertazzi et al., 2001

Zones A, B—men

    21.6 (0.4–6.8)

Zones A, B—women

    0nr
Other International Environmental Studies

NEW ZEALAND

Residents of New Plymouth Territorial Authority, New Zealand, near plant manufacturing 2,4,5-T in 1962–1987

2,4,5-TRead et al., 2007

Incidence

1041.3 (1.1–1.6)c

1970–1974

  162.5 (1.4–4.1)

1975–1979

    70.9 (0.4–1.8)

1980–1984

  212.6 (1.6–3.9)

1985–1989

  161.4 (0.8–2.3)

1990–1994

  130.9 (0.5–1.6)

1995–1999

  190.9 (0.5–1.4)

2000–2001

  121.1 (0.6–1.9)

Mortality

  401.3 (0.9–1.8)c

1970–1974

    71.7 (0.7–3.5)

1975–1979

    71.8 (0.7–3.6)

1980–1984

    61.4 (0.5–3.0)

1985–1989

    40.8 (0.2–2.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

1990–1994

    61.1 (0.4–2.5)

1995–1999

    81.3 (0.6–2.6)

2000–2001

    20.8 (0.1–2.8)
CASE-CONTROL STUDIES

US Case-Control Studies

Tecumseh, Michigan, residents participating in longitudinal study (1959–1987)

  10Herbicides 1.8 (0.8–3.2)Waterhouse et al., 1996

Nebraska—1,084 leukemia deaths in 1957–1974; farmers–usual occupation on death certificate

Herbicides, pesticidesBlair and White, 1985
nr1.3 (p < 0.05)

248 CLL cases

nr1.7 (p < 0.05)

International Case-Control Studies

France hospital-based case-control study

HerbicidesOrsi et al., 2009

Occupational use of herbicides

    50.5 (0.2–1.3)

Phenoxy herbicides

    30.4 (0.1–1.7)

German population-based study (1986–1998), men and women, 15–75 yrs of age—occupational factors associated with CLL

TCDD, herbicidesRichardson et al., 2008

Chlorophenols

  440.9 (0.6–1.3)

Lowest tertile cumulative exposure

  120.9 (0.4–1.8)

Middle tertile

  150.9 (0.5–1.8)

Highest tertile

  170.9 (0.5–1.6)
p-trend = 0.770

Herbicides

  431.2 (0.8–1.7)

Lowest tertile cumulative exposure

  131.3 (0.7–2.7)

Middle tertile

  151.3 (0.7–2.5)

Highest tertile

  151.0 (0.5–1.9)
p-trend = 0.755

Italian farming and animal-breeding workers (men and women)—incidence

  15Herbicides 2.3 (0.9–5.8)Amadori et al., 1995

Farming workers only

    51.6 (0.5–5.2)

Breeding workers only

  103.1 (1.1–8.3)

NOTE: 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; COI, chemical of interest; ICD, International Classification of Diseases; nr, not reported; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cThe total SMR/SIR were computed by dividing sum of observed values by sum of expected values over all years; 95% CIs on these total ratios were computed with exact methods.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. Use of the estimated TCDD concentrations of the workers in both factories showed a significant increase in death due to NHL in association with TCDD exposure (HR = 1.36, 95% CI 1.06–1.74). Dose–response modeling applied only to the workers in factory A estimated an increased risk of NHL mortality that neared significance (HR = 1.27, 95% CI 0.95–1.71), whereas an increase in risk had not been evident (HR = 0.98, 95% CI 0.19–4.47) in the qualitative exposure analysis by Boers et al. (2010).

Manuwald et al. (2012) reported mortality in 1,191 men and 398 women who had been employed for at least 3 months during 1952–1984 in a chemical plant in Hamburg (a subcohort of the IARC phenoxy-herbicide cohort). During that period, the plant produced insecticides and herbicides, including 2,4,5-T, so cohort members had the possibility of exposure to TCDD. Subjects entered the cohort on the date of their first employment in the plant, and vital status was sought through 2007. SMRs that were calculated relative to the population of Hamburg showed that mortality from NHL was not increased in men (five deaths, SMR = 1.56, 95% CI 0.50–3.65) or in women (two deaths, SMR = 1.67, 95% CI 0.19–6.02), but for the entire cohort the increase in risk was significant (SMR = 1.59, 95% CI 0.64–3.28).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, deaths from NHL were significantly increased in the entire cohort (17 deaths, SMR = 1.77, 95% CI 1.03–2.84) and in the PCP-plus-TCDD group (eight deaths, SMR = 2.50, 95% CI 1.08–4.93) but not in the PCP-only group (nine deaths, SMR = 1.41, 95% CI 0.64–2.67).

Koutros et al. (2010a) and Waggoner et al. (2011) assessed cancer incidence and mortality, respectively, in private applicators, commercial applicators, and their spouses in the AHS cohort vs the general population of Iowa and North Carolina. Koutros et al. (2010a) updated their previously reported incidence study through December 31, 2006, and found no association between pesticide exposure and NHL incidence in private applicators (195 cases, SIR = 0.99, 95% CI 0.86–1.14), commercial applicators (9 cases, SIR = 0.82, 95% CI 0.38–1.56) and their spouses (86 cases, SIR = 0.99, 95% CI 0.79–1.22). Waggoner et al. (2011) reported similar findings in applicators (90 cases, SMR = 0.84, 95% CI 0.67–1.03) and in their spouses (42 cases, SMR = 1.11, 95% CI 0.80–1.50). The AHS has been generating valuable information on the COIs for a number of

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies Using information assembled in the Cross-Canada Study of Pesticides and Health, Hohenadel et al. (2011) tested for interaction effects on the risk of NHL when exposures involved various combinations of pesticides. Men who had NHL (513) were compared with the studywide control group (1,506) to assess NHL risk associated with exposure to multiple pesticides. When exposure to multiple herbicides (144 cases exposed to any herbicide) was considered, there was a trend (p = 0.02) in those who had been exposed to more herbicides to have a higher risk of NHL. When the analysis was limited to phenoxy-herbicide exposures (129 cases exposed to any phenoxy herbicide), the trend was a bit stronger (p = 0.01). When 36 combinations of differing types of pesticides were assessed, five pairs (all including the insecticide malathion) showed higher risk when exposure was to both, but none of the interaction terms was statistically significant; two of the combinations with malathion involved the phenoxy herbicides 2,4-D and Mecoprop. That is consistent with results on associations between NHL and individual pesticides published previously (McDuffie et al., 2001), in which exposure to the two phenoxy herbicides individually increased the risk of NHL significantly, whereas this was not the case for the two other phenoxy herbicides considered (MCP and diclofop-methyl). For the subsets of those exposed to the particular phenoxy herbicide, but not to malathion, the risk remained significant for Mecoprop (23 cases exposed only to phenoxy herbicide, OR = 2.09, 95% CI 1.23–3.54) but not for 2,4-D (49 cases exposed only to phenoxy herbicide, OR = 0.94, 95% CI 0.67–1.3).

Bräuner et al. (2012) measured the concentrations of 10 PCBs and eight organochlorine pesticides in adipose tissues and examined their relationship with NHL risk. There were no associations between PCBs and other organochlorine pesticides tested except DDT, which was associated with an increased NHL risk.

Viel et al. (2011) found a strong and consistent association between serum concentrations of PCDDs, PCDFs, and dioxin-like PCBs and NHL risk in people who lived in the vicinity of a municipal solid-waste incinerator that had high dioxin emission concentrations (Viel et al., 2011).

The literature search for the present update identified two additional case-control studies in which the exposures considered were not sufficiently specific for this review’s COIs. In an Iranian hospital-based case-control study of exposure to pesticides, Zakerinia et al. (2012) found a significant increase in NHL incidence in people who were exposed (OR = 3.9, 95% CI 2.2–6.8). Similarly, a case-control study in the Shanghai Health Watch project reported statistically significant increases in NHL risks in agriculture and farmworkers and in workers who were exposed to general herbicides (OR = 1.77, 95% CI 1.02–3.05) (Wong et al., 2010).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Biologic Plausibility

The diagnosis of NHL encompasses a wide variety of lymphoma subtypes. In humans, about 85% are of B-cell origin and 15% of T-cell origin. In commonly used laboratory mice, the lifetime incidence of spontaneous B-cell lymphomas is about 30% in females and about 10% in males. Although researchers seldom note the subtypes of B-cell lymphomas observed, lymphoblastic, lymphocytic, follicular, and plasma-cell lymphomas are seen in mice and are similar to types of NHL seen in humans. Laboratory rats, however, are less prone to develop lymphomas, but Fisher 344 rats do have an increased incidence of spontaneous mononuclearcell leukemia of nonspecific origin. The lifetime incidence of leukemia is about 50% in male rats and about 20% in female rats. Neither mice nor rats develop T-cell lymphomas spontaneously at a predictable incidence, but T-cell–derived tumors can be induced by exposure to some carcinogens.

Several long-term feeding studies of various strains of mice and rats have been conducted over the last 30 years to determine the effects of TCDD on cancer incidence. Few of them have shown effects of TCDD on lymphoma or leukemia incidence. The NTP (1982a) reported no increase in overall incidence of lymphoma in female B6C3F1 mice exposed to TCDD at 0.04, 0.2, or 2.0 μg/kg per week for 104 weeks but found that histiocytic lymphomas (now considered to be equivalent to large B-cell lymphomas) were more common in the high-dose group. No effects on lymphoma incidence were seen in Osborne–Mendel rats treated with TCDD at 0.01, 0.05, or 0.5 μg/kg per week. Sprague–Dawley rats treated with TCDD at 0.003, 0.010, 0.022, 0.046, or 0.100 μg/kg per day showed no change in incidence of malignant lymphomas. Long-term exposure to phenoxy herbicides or cacodylic acid also has not resulted in an increased incidence of lymphomas in laboratory animals. Thus, few laboratory animal data support the biologic plausibility of promotion of NHL by TCDD or other COIs, but it should be noted that standard rodent models are not particularly sensitive for detection of chemicals that cause lymphohematopoietic cancers.

In contrast, more recent studies at the cellular level indicate that activation of the AHR by TCDD inhibits apoptosis, a mechanism of cell death that controls the growth of cancer cells. Vogel et al. (2007) studied human cancer cells in tissue culture and showed that addition of TCDD inhibited apoptosis in histiocytic-lymphoma cells, Burkitt-lymphoma cells, and NHL cell lines. The reduction in apoptosis was associated with an increase in the expression of Cox-2, C/EBP β, and Bcl-xL mRNA in the cells. Those genes code for proteins that protect cells from apoptosis. The effects of TCDD on apoptosis were blocked when an AHR antagonist or a Cox-2 inhibitor was added to the culture; this demonstrated the underlying AHR-dependent mechanism of the effects. More important, when C57Bl/10J mice were given multiple doses of TCDD over a period of 140 days, premalignant lymphoproliferation of B cells was induced before the appearance of any spontaneous lymphomas in the control mice. When the B cells were

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

examined, they were found to manifest changes in gene expression similar to those induced by TCDD in the human cell lines, which provided support for this mechanism of lymphoma promotion by TCDD.

Recent evidence has shown that AHR activation by TCDD in human breast and endocervical cell lines induces sustained high concentrations of the interleukin-6 (IL-6) cytokine, which has tumor-promoting effects in numerous tissues (Hollingshead et al., 2008). IL-6 plays a roll in B-cell maturation and induces a transcriptional inflammatory response. It is known to be increased in B-cell neoplasms, including MM and various lymphomas, especially diffuse large B-cell lymphomas (Hussein et al., 2002; Kato et al., 1998; Kovacs, 2006).

An alternative link that could help to explain the association between TCDD and NHL has been explored in human studies. Chromosomal rearrangements, with consequent dysregulation of expression of various genes, are prevalent in B-cell lymphomas, and the t(14;18) reciprocal translocation, which juxtaposes the BCL2 with the locus of the immunoglobin heavy chain, is found in tumor cells in most cases of follicular lymphoma. Roulland et al. (2004) investigated the prevalence of the t(14;18) translocation that is characteristic of most cases of follicular lymphoma in 53 never-smoking and pesticide-using men in a cohort of French farmers whose pesticide exposures and confounding information had previously been well characterized; blood samples had been gathered from 21 during periods of high pesticide use and samples from the other 32 during a period of low pesticide use. The authors found a higher prevalence of cells carrying the translocation in the farmers whose blood had been drawn during a period of high pesticide use than in those whose blood had been drawn during a low-use period. Baccarelli et al. (2006) reported an increase in t(14;18) chromosomal translocation in lymphocytes from humans who were exposed to TCDD in the Seveso accident. In most cases of follicular lymphoma, tumor cells carry the t(14;18) chromosomal translocation, and there is evidence that an increased frequency of lymphocytes from the peripheral blood carrying this tumor marker may be a necessary but not sufficient step toward development of follicular lymphoma (Roulland et al., 2006).

Synthesis

The first VAO committee found the evidence to be sufficient to support an association between exposure to at least one of the COIs and NHL. The evidence was drawn from occupational and other studies in which subjects were exposed to a variety of herbicides and herbicide components. As has generally been the case in previous updates, the new studies were largely concordant with the conclusion that there is an association with the COIs. Of the seven studies newly evaluated for this update that investigated the association between NHL and adequately specified exposures to the COIs, three found statistically significant positive associations (Boers et al., 2012; Ruder and Yiin, 2011; Viel et al., 2011).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Individual findings on CLL are fairly few compared with the considerable number of studies supporting an association between exposure to the COIs and NHL. Results of some high-quality studies show that exposure to 2,4-D and 2,4,5-T appears to be associated with CLL, including the incidence study of Australian veterans (ADVA, 2005a); the case-control study by Hertzman et al. (1997) of British Columbia sawmill workers who were exposed to chlorophenates; the Danish-gardener study (Hansen et al., 1992); and the population-based case-control study in two US states by Brown et al. (1990) that showed increased risks associated with any herbicide use and specifically use of 2,4,5-T for at least 20 years before the subjects were interviewed. Other studies that showed positive associations but do not contribute greatly to the overall conclusion include the population-based case-control study by Amadori et al. (1995) that used occupational titles but did not include specific assessments of exposure to the chemicals; the cancer-incidence study in Tecumseh County, Michigan, in which no exposure assessments were available (Waterhouse et al., 1996); and proportionate-mortality studies by Blair and White (1985) and Burmeister et al. (1982).

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is sufficient evidence of an association between exposure to at least one of the COIs and NHL.

Multiple Myeloma

MM (ICD-9 203.0) is characterized by proliferation of bone-marrow stem cells that results in an excess of neoplastic plasma cells and in the production of excess abnormal proteins, usually fragments of immunoglobulins. MM is sometimes grouped with other immunoproliferative neoplasms (ICD-9 203.8). ACS estimated that 12,190 men and 9,510 women would receive diagnoses of MM in the United States in 2012 and that 6,020 men and 4,690 women would die from it (Siegel et al., 2012). The average annual incidence of MM is shown in Table 8-44.

TABLE 8-44 Average Annual Incidence (per 100,000) of Multiple Myeloma in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
Men11.610.525.018.816.647.228.727.061.7
Women8.67.717.113.111.530.718.515.746.9

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The incidence of MM is highly age-dependent and is relatively low in people under 40 years old. The incidence is slightly higher in men than in women, and the difference becomes more pronounced with age.

An increased incidence of MM has been observed in several occupational groups, including farmers and other agricultural workers and those with workplace exposure to rubber, leather, paint, and petroleum (Riedel et al., 1991). People who have high exposure to ionizing radiation and those who suffer from other plasma-cell diseases, such as monoclonal gammopathy of unknown significance or solitary plasmacytoma, are also at greater risk.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was limited or suggestive evidence of an association between exposure to the COIs and MM. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

Table 8-45 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran and Environmental Studies No Vietnam-veteran studies or environmental studies of exposure to the COIs and MM have been published since Update 2010.

Occupational Studies Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With two cases observed, the incidence of MM in the most restrictively defined cohort was not increased (SIR = 0.79, 95% CI 0.09–2.87), as was the case for the two successively more inclusive, but potentially more biased, cohorts.

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. In the total cohort, seven deaths attributed to MM were identified, which was consistent with the mortality experience of the US population (SMR = 1.50, 95% CI 0.60–3.10). The results were similar for the 1,402 workers in the PCP-only group (six deaths, SMR = 1.84, 95% CI

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-45 Selected Epidemiologic Studies—Multiple Myeloma

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—White subjects vs national rates

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  100.9 (0.4–1.5)

With tours between 1966–1970

    70.7 (0.3–1.4)

SEA comparison veterans (n = 1,776)

    90.6 (0.3–1.0)

With tours between 1966–1970

    40.3 (0.1–0.8)

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

Boehmer et al., 2004

1965–2000

    10.4 (nr)

US VA Proportionate Mortality Study—sample of deceased male Vietnam-era Army and Marine veterans who served 7/4/1965–3/1/1973

All COIs

1965–1988

Watanabe and Kang, 1996

Army, deployed (n = 27,596) vs nondeployed (n = 31,757)

  360.9 (nr)

Marine Corps, deployed (n = 6,237) vs nondeployed (n = 5,040)

    40.6 (nr)

1965–1982

Breslin et al., 1988

Army, deployed (n = 19,708) vs nondeployed (n = 22,904)

  180.8 (0.2–2.5)

Marine Corps, deployed (n = 4,527) vs nondeployed (n = 3,781)

    20.5 (0.0–17.1)

US VA Cohort of Female Vietnam Veterans

All COIs

Mortality, through 2004

  180.7 (0.4–1.3)Cypel and Kang, 2008

Vietnam-veteran nurses only

  140.7 (0.3–1.3)
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

  310.7 (0.4–0.9)ADVA, 2005a

Navy

    40.4 (0.1–1.0)

Army

  210.7 (0.4–1.0)

Air Force

    61.1 (0.4–2.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Mortality

All branches, return–2001

  240.9 (0.5–1.2)ADVA, 2005b

Navy

    30.5 (0.1–1.5)

Army

  150.8 (0.4–1.3)

Air Force

    61.7 (0.6–3.6)

1980–1994

    60.6 (0.2–1.3)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs

Incidence

1982–2000

    82.1 (0.7–6.0)ADVA, 2005c

Mortality

1966–2001

    50.9 (0.2–3.4)ADVA, 2005c

1982–1994

    0nrCDVA, 1997b
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  171.3 (0.8–2.1)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

    91.2 (0.6–2.3)

7,553 not exposed to highly chlorinated

    81.6 (0.7–3.1)

PCDDs

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

    40.7 (0.2–1.8)Saracci et al., 1991

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Incidence 1943–1987 (men only)

    0nrLynge, 1993

Dutch production workers in Plant A (549 men exposed during production 1955–1985; 594 unexposed) (in IARC cohort)

Dioxins, 2,4,5-T, 2,4,5-TCP

Mortality 1955–1991

    00.0 (nr)Hooiveld et al., 1998

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0nrBecher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1965–1989

    0nrBecher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4-DP; 2,4,5-T; MCPA; MCPP

Mortality 1956–1989

    0nrBecher et al., 1996

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,5-DCP; 2,4,5-T; 2,4,5-TCP

Mortality 1952–1989

    35.4 (1.1–15.9)Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004

McBride et al., 2009a

Ever-exposed workers

    22.2 (0.2–8.1)

Never-exposed workers

    00.0 (0.0–12.2)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

’t Mannetje et al., 2005

Mortality 1969–2000

    35.5 (1.1–16.1)

Sprayers (697 men and 2 women on register of New Zealand applicators, 1973–1984)

Mortality 1973–2000

    00.0 (0.0–5.3)

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  102.1 (1.0–3.8)Steenland et al., 1999

Through 1987

    51.6 (0.5–3.9)Fingerhut et al., 1991

≥ 1-year exposure, ≥ 20-year latency

    32.6 (0.5–7.7)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    71.5 (0.6–3.1)

PCP and TCP (n = 720)

    10.7 (0.0–4.0)

PCP (no TCP) (n = 1,402)

    61.8 (0.7–4.0)

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan) (subset of all TCP-exposed workers)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) Cohort 3)

    20.8 (0.1–2.9)Burns et al., 2011

Through 1994 (n = 1,517)

    10.8 (0.0–4.5)Burns et al., 2001
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine compounds

Never

  210.8 (0.5–1.3)

Ever

  201.1 (0.7–1.7)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from MM June 1971–December 1987

Farmers from Canadian prairie provinces

1600.8 (0.7–1.0)Semenciw et al., 1994

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

    21.5 (0.2–5.2)Asp et al.,

Mortality 1972–1989

    32.6 (0.5–7.7)1994

Except for lung cancer, numbers too small for reporting mortality 1972–1980

Expected number of exposed casesRiihimaki et al., 1982
    10.2 (nr)

ITALIAN Licensed Pesticide Users—male

farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401)

    50.4 (0.1–1.0)Torchio et al., 1994
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Italian rice growers with documented phenoxy use (n = 1,487)

Phenoxy herbicidesGambini et al., 1997
    0nr

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of incident multiple myeloma cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134)

    10.5 (0.1–3.7)

SWEDISH lumberjacks—used phenoxys 1954–1967, incidence (1958–1992)

Thörn et al., 2000

Exposed (n = 154)

Foremen (n = 15)

    0

Lumberjacks (n = 139)

    0

Unexposed lumberjacks (n = 241)

    11.5 (0.0–8.6)

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341

certified before 1980

Through 2000

    32.1 (0.4–6.1)Swaen et al., 2004

Through 1987

    38.2 (1.6–23.8)Swaen et al., 1992

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

4131.2 (1.0–1.3)

Nonwhites (n = 11,446)

  510.9 (0.7–1.2)

Women

Whites (n = 2,400)

  141.8 (0.97–3.0)

Nonwhites (n = 2,066)

  111.1 (0.6–2.0)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

  711.2 (0.9–1.5)

Commercial applicators

    1nr

Spouses

  210.9 (0.6–1.4)

Nested case-control study of MGUS among male private and commercial applicators

Landgren et al., 2009
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

2,4-D

  331.8 (0.7–4.8)

Dicamba

  170.9 (0.5–1.8)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  431.3 (1.0–1.8)

Spouses of private applicators (> 99% women)

  131.1 (0.6–1.9)

Commercial applicators

    00.0 (0.0–2.7)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641)

  521.0 (0.8–1.3)

Spouses (n = 676)

  100.6 (0.3–1.0)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women)

  110.6 (0.3–1.2)

Spouses of private applicators (> 99% women)

    50.9 (0.3–2.1)

US Department of Agriculture Workers—nested case-control study of white men dying

Herbicides

1970–1979 of MM

Forest conservationists

1.3nr (p-trend = 0.35)Alavanja et al., 1989

Soil conservationists

1.3nr (p-trend = 0.32)

White Male Residents of Iowa—MM on death certificate, usual occupation: farmers vs not

Herbicides

> 30 yrs old diagnosed 1981–1984—case-control (ever farmer) > 30 yrs old when died 1964–1978—case-control

1111.2 (0.8–1.7)Brown et al., 1993 Burmeister et al., 1983

H0: only for “modern methods” → born after 1900

Born 1980–1900

nr2.7 (p < 0.05)

Born after 1900

nr2.4 (p < 0.05)
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence

20-yr followup to 1996—men and women

Zone A

    12.9 (0.4–20.7)Pesatori et al., 2009

Zone B

    62.8 (1.2–6.3)

Zone R

  181.2 (0.7–1.9)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone B

    23.2 (0.8–13.3)

Zone R

    10.2 (0.0–1.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone B

    25.3 (1.2–22.6)

Zone R

    20.6 (0.2–2.8)

Mortality

25-yr followup to 2001—men and women

Consonni et al., 2008

Zone A

    24.3 (1.1–17.5)

Zone B

    51.7 (0.7–4.1)

Zone R

  241.1 (0.7–1.7)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A, B—men

    10.6 (0.1–4.3)

Zones A, B—women

    43.2 (1.2–8.8)

15-yr followup to 1991—men

Bertazzi et al., 1997

Zone B

    11.1 (0.0–6.2)

Zone R

    50.8 (0.3–1.9)

15-yr followup to 1991—women

Bertazzi et al., 1997

Zone B

    46.6 (1.8–16.8)

Zone R

    51.0 (0.3–2.3)
CASE-CONTROL STUDIES

US Case-Control Studies

ACS Prevention Study II subjects, MM on death certificate (128 MM cases vs 154 controls)

Herbicides, pesticidesBoffetta et al., 1989
122.1 (1.0–4.2)

Farmers using herbicides, pesticides

    84.3 (1.7–10.9)

Residents of four SEER program areas, 698 cases (< 80 yrs of age) vs 1,683 controls (July 1977–June 1981)

PesticidesMorris et al., 1986
nr2.9 (1.5–5.5)

Nebraska herbicide and pesticide use by Nebraska residents

HerbicidesZahm et al., 1992

Eastern Nebraska users of herbicides

Men

    80.6 (0.2–1.7)

Women

  102.3 (0.8–7.0)

Eastern Nebraska users of insecticides

Men

  110.6 (0.2–1.4)

Women

  212.8 (1.1–7.3)

Wisconsin mortality listings (1968–1976)—farmers (30–39 yrs of age) in counties with highest herbicide use

HerbicidesCantor and Blair, 1984
nr1.4 (0.8–2.3)

International Case-Control Studies

Canadian multicenter population-based study (September 1991–December 1994), male MM patients (n = 342) and controls (n = 1,506) and non-trivial exposure to pesticides

Phenoxy herbicidesPahwa et al., 2012

Expose to any phenoxy herbicide

  871.3 (1.0–1.8)

2,4-D

  801.3 (0.9–1.8)

Mecoprop

  270.9 (1.2–3.1)

MCPA

    80.7 (0.3–1.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Canadian residents

Phenoxy herbicidesPahwa et al., 2006

Any phenoxy herbicide

  621.2 (0.8–1.8)

2,4-D

  591.3 (0.9–1.9)

Mecoprop

  161.2 (0.7–2.8)

MCPA

    70.5 (0.2–1.2)

France hospital-based case-control study

HerbicidesOrsi et al., 2009

Occupational use of herbicides

  122.9 (1.3–6.5)

Phenoxy herbicides

    72.6 (0.9–7.0)

Domestic use of herbicides

  221.0 (0.6–2.0)

Irish farmers and farm workers

HerbicidesDean, 1994

Other malignant neoplasms of lymphoid and histiocytic tissue (including some types of NHL) (ICD-9 202)

1711.0 (nr)

Italian residents of 11 areas (NHL other than lymphosarcoma and reticulosarcoma)—incidence

HerbicidesMiligi et al., 2003

Herbicide exposure

  111.6 (0.8–3.5)

Men

    81.4 (0.6–3.5)

Women

    33.2 (0.7–14.7)

Residents of Milan, Italy, area (men and women)—incidence

HerbicidesLaVecchia et al., 1989

Agricultural occupations

nr2.0 (1.1–3.5)

New Zealand National Cancer Registry (1977–1981)—agricultural workers (< 70 yrs of age) (76 MM cases vs 315 controls)—incidence

Phenoxy herbicides, chlorophenolsPearce et al., 1986

Use of agricultural spray

  161.3 (0.7–2.5)

Likely sprayed 2,4,5-T

  141.6 (0.8–3.1)

Swedish residents from 4 counties diagnosed with MM (n = 275) vs 275 controls from population registry (July 1982–June 1986)

Phenoxy herbicidesEriksson and Karlsson,
90% CI

Exposed to phenoxy herbicides

  202.2 (1.2–4.7)1992

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxy-acetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COI, chemical of interest; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy)butanoic acid; MCPP, methylchlorophenoxypropionic acid; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; SEA, Southeast Asia; SEER, Surveillance, Epidemiology, and End Results; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; TEQ, toxicity equivalent; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

0.68–4.00). Only one of the deaths occurred in the PCP-plus-TCDD group (SMR = 0.72, 95% CI 0.02–3.99).

Koutros et al. (2010a) and Waggoner et al. (2011) assessed cancer incidence and mortality, respectively, in private and commercial pesticide applicators and their spouses in the AHS cohort vs the general population of Iowa and North Carolina. Koutros et al. (2010a) updated their previously reported incidence study through December 31, 2006, and found nonsignificant associations for MM in private pesticide applicators (71 cases, SIR = 1.2, 95% CI 0.93–1.51) and their spouses (21 cases, SIR = 0.94, 95% CI 0.58–1.44). Similarly, in an analysis of MM mortality in agricultural applicators and their spouses in 1993–2007 in this AHS cohort, Waggoner et al. (2011) reported a nonsignificant SMR in applicators (52 cases, SMR = 1.01, 95% CI 0.76–1.33) and their spouses (10 cases, SMR = 0.56, 95% CI 0.27–1.04). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

Case-Control Studies The Cross-Canada Study of Pesticides and Health is a population-based case-control study of several rare cancers conducted in men who lived in six Canadian provinces. Pahwa et al. (2012) assessed the effect of exposure to several specific phenoxy herbicides on 342 MM cases in comparison with the study’s standard set of 1,506 controls with adjustment for age, province of residence, and several aspects of personal and family history. Mecoprop was found to be positively associated with the risk of MM (OR = 1.89, 95% CI 1.15–3.12), whereas this was not the case for 2,4-D (OR = 1.23, 95% CI 0.93–1.76) or for the less frequently used phenoxy herbicides MCPA (OR = 0.68, 95% CI 0.30–1.53) and diclofop-methyl (OR = 1.49, 95% CI 0.60–3.72).

Additional studies identified in the literature search for the present update presented results on MM in association with exposures that were not sufficiently specific with respect to the COIs in the VAO reviews. Perrotta et al. (2012) published findings from the EPILYMPH study, which applied a detailed occupational exposure-assessment approach to a large multicenter case-control study conducted in six European countries. The study included 227 MM cases and four age-matched controls per case, and ORs and 95% CIs were calculated for MM risk associated with level of education, individual occupations, and specific exposures. An increased risk was observed in general farmers (OR = 1.77, 95% CI 1.05–2.99) after adjustment for level of education. Pesticide exposure over a period of 10 years or more increased MM risk (OR = 1.62, 95% CI 1.01–2.58). In an Iranian hospital-based case-control study of exposure to pesticides, Zakerinia et al. (2012) found a significant increase in MM incidence (OR = 2.48, 95% CI 1.16–5.20).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Biologic Plausibility

No animal studies have reported an association between exposure to the COIs and MM. Thus, there are no specific animal data to support the biologic plausibility of such an association between the COIs and MM.

Recent evidence has shown that AHR activation by TCDD in human breast and endocervical cell lines induces sustained high concentrations of the IL-6 cytokine, which has tumor-promoting effects in numerous tissues (Hollingshead et al., 2008). IL-6 plays a roll in B-cell maturation and induces a transcriptional inflammatory response. It is known to be increased in B-cell neoplasms, including MM and various lymphomas (Hussein et al., 2002; Kovacs, 2006).

In comparing the frequency of specific variants of several metabolic genes between MM cases and controls, Gold et al. (2009) found some indication of differences, particularly in CYP1B1 and AHR alleles, that might reflect increased suspectibility to MM after exposure to particular chemicals. A biochemical link to the COIs, however, is far from being established.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

Previous VAO reports found limited or suggestive evidence of an association between exposure to at least one of the COIs and MM. MM is a type of lymphohematopoietic malignancy that is derived from antibody-secreting plasma cells from the B-cell lineage. The evidence of an association between the COIs and lymphomas (NHL, HL, and CLL/HCL) has been classified as sufficient. Most of these cancers also arise from B cells, so the committee hypothesized that it would be etiologically plausible for the association with MM to belong with the lymphomas in the sufficient category. Although many studies of exposure to pesticides in general and MM found strong or at least positive associations, review of studies that addressed an association between the specific COIs and MM found that the results were considerably weaker than those for the other B-cell neoplasms and did not justify advancing MM out of the limited or suggestive category.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is limited or suggestive evidence of an association between exposure to at least one of the COIs and MM.

AL Amyloidosis

The committee responsible for Update 2006 moved the discussion of AL amyloidosis from the chapter on miscellaneous nonneoplastic health conditions

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

to the cancer chapter to put it closer to related neoplastic conditions, such as MM and some types of B-cell lymphoma. The conditions share several biologic features, notably clonal hyperproliferation of B-cell–derived plasma cells and production of abnormal amounts of immunoglobulins.

The primary feature of amyloidosis (ICD-9 277.3) is the accumulation and deposition in various tissues of insoluble proteins that were historically denoted by the generic term amyloid. Amyloid protein accumulates in the extracellular spaces of various tissues. The pattern of organ involvement depends on the nature of the protein; some amyloid proteins are more fibrillogenic than are others. Amyloidosis is classified according to the biochemical properties of the fibril-forming protein. Excessive amyloid protein can have modest clinical consequences or can produce severe, rapidly progressive multiple–organ-system dysfunction. The annual incidence is estimated at 1/100,000; there are about 2,000 new cases each year in the United States (http://www.cancer.net/cancer-types/amyloidosis/statistics, as of June 13, 2013). Amyloidosis occurs mainly in people 50–70 years old and occurs more often in males than in females.

AL amyloidosis is the most common form of systemic amyloidosis; the A stands for amyloid, and the L indicates that the amyloid protein is derived from immunoglobin light chains. That links AL amyloidosis with other B-cell disorders that involve overproduction of immunoglobin, such as MM and some types of B-cell lymphomas. AL amyloidosis results from the overproduction of immunoglobulin light-chain protein from a monoclonal population of plasma cells. Clinical findings can include excessive AL protein or immunoglobulin fragments in the urine or serum, renal failure with nephrotic syndrome, liver failure with hepatomegaly, heart failure with cardiomegaly, marcroglossia, carpal tunnel syndrome, and peripheral neuropathy. Bone marrow biopsies commonly show an increased density of plasma cells, which suggests a premalignant state. Historically, that test emphasized routine histochemical analysis, but modern immunocytochemistry and flow cytometry now commonly identify monoclonal populations of plasma cells with molecular techniques. AL amyloidosis can progress rapidly and is often far advanced by the time it is diagnosed (Buxbaum, 2004).

Conclusions from VAO and Previous Updates

VA identified AL amyloidoisis as of concern after the publication of Update 1998. The committees responsible for Update 2000, Update 2002, and Update 2004 concluded that there was inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and AL amyloidosis. Although there are few epidemiologic data specifically on AL amyloidosis, the committee responsible for Update 2006 changed the categorization to limited or suggestive evidence of an association on the basis of commonalities in its cellular lineage with MM and B-cell lymphomas. Later committees have not changed that categorization.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Update of the Epidemiologic Literature

No studies of exposure to the COIs and amyloidosis of any sort have been published since Update 2010.

Biologic Plausibility

A 1979 study reported the dose-dependent development of a “generalized lethal amyloidosis” in Swiss mice that were treated with TCDD for 1 year (Toth et al., 1979). That finding has not been validated in 2-year carcinogenicity studies of TCDD in mice or rats. Thus, few animal data support an association between TCDD exposure and AL amyloidosis in humans, and no animal data support an association between the other COIs and AL amyloidosis.

It is known, however, that AL amyloidosis is associated with B-cell diseases, and 15–20% of cases of AL amyloidosis occur with MM. Other diagnoses associated with AL amyloidosis include B-cell lymphoma (Cohen et al., 2004), monoclonal gammopathy, and agammaglobulinemia (Rajkumar et al., 2006).

Synthesis

AL amyloidosis is very rare, and it is not likely that population-based epidemiology will ever provide substantial direct evidence regarding its causation. However, the biologic and pathophysiologic features linking AL amyloidosis, MM, and some types of B-cell lymphoma—especially clonal hyperproliferation of plasma cells and abnormal immunoglobulin production—indicate that AL amyloidosis is pathophysiologically related to these conditions.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is limited or suggestive evidence of an association between exposure to the COIs and AL amyloidosis.

Leukemia

Leukemias (ICD-9 202.4, 203.1, 204.0–204.9, 205.0–205.9, 206.0–206.9, 207.0–207.2, 207.8, 208.0–208.9) have traditionally been divided into four primary types: acute and chronic lymphocytic leukemia and acute and chronic myeloid leukemia. There are numerous subtypes of AML (ICD-9 205), which is also called acute myelogenous leukemia, granulocytic leukemia, or acute non-lymphocytic leukemia.

ACS estimated that 26,380 men and 20,320 women would receive diagnoses of some form of leukemia in the United States in 2012 and that 13,500 men and

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

10,040 women would die from it (Siegel et al., 2012). Collectively, leukemia was expected to account for 2.9% of all new diagnoses of cancer and 4.1% of deaths from cancer in 2012. The different forms of leukemia have different patterns of incidence and in some cases different risk factors. The incidences of the various forms of leukemia are presented in Table 8-46.

Myeloid Leukemias

In adults, acute leukemia is nearly always in the form of AML (ICD-9 205.0, 207.0, 207.2). ACS estimated that about 7,350 men and 6,430 women would receive new diagnoses of AML in the United States in 2012 and that 5,790 men and 4,410 women would die from it (Siegel et al., 2012). In the age groups that include most Vietnam veterans, AML makes up roughly one-fourth of cases of leukemia in men and one-third in women. Overall, AML is slightly more common in men than in women. Risk factors associated with AML include high doses of ionizing radiation, occupational exposure to benzene, and exposure to some medications used in cancer chemotherapy (such as melphalan). Fanconi anemia

TABLE 8-46 Average Annual Incidence (per 100,000) of Leukemias in the United Statesa

55–59 Years Old60–64 Years Old65–69 Years Old
All RacesWhiteBlackAll RacesWhiteBlackAll RacesWhiteBlack
All leukemias:
     Men20.922.214.531.833.631.147.250.831.7
     Women12.813.510.418.920.014.827.428.923.4
Acute lymphocytic leukemia:
     Men1.01.10.31.21.21.11.41.41.1
     Women0.70.80.61.11.10.61.31.12.6
Acute myeloid leukemia:
     Men4.95.13.76.86.88.210.511.07.8
     Women4.34.53.95.05.13.68.18.55.5
Chronic lymphocytic leukemia:
     Men10.111.05.516.117.713.525.528.215.0
     Women4.95.32.89.110.25.312.313.58.5
Chronic myeloid leukemia:
     Men2.62.63.23.83.84.55.35.53.3
     Women1.61.71.22.12.03.62.83.12.1
All other leukemiab
     Men0.60.60.81.41.22.61.71.81.7
     Women0.50.41.00.70.51.51.21.22.6

aSurveillance, Epidemiology, and End Results program, nine standard registries, crude age-specific rates, 2005–2009 (NCI, 2013).

bIncludes leukemic reticuloendotheliosis (hairy cell leukemia), plasma-cell leukemia, monocytic leukemia, and acute and chronic erythremia and erythroleukemia.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

and Down syndrome are associated with an increased risk of AML, and tobacco use is thought to account for about 20% of AML cases.

Vietnam veterans have expressed concern about whether myelodysplastic syndromes, most often precursors to AML, are associated with Agent Orange exposure. However, no results on those conditions in conjunction with the COIs have been found in VAO literature searches. Epidemiologic research on those hematologic disorders has been undertaken fairly recently; for instance, the LATIN case-control study (Maluf et al., 2009) has undertaken investigation of aplastic anemia in South America, but the reported exposures have been only as specific as “herbicides” and “agricultural pesticides.”

The incidence of CML increases steadily with age in people over 30 years old. Its lifetime incidence is roughly equal in whites and blacks and is slightly higher in men than in women. CML accounts for about one-fifth of cases of leukemia in people in the age groups that include most Vietnam veterans. It is associated with an acquired chromosomal abnormality known as the Philadelphia chromosome, for which exposure to high doses of ionizing radiation is a known risk factor.

Lymphoid Leukemias

ALL is a disease of young children (peak incidence at the age of 2–5 years) and of people over 70 years old. It is relatively uncommon in the age groups that include most Vietnam veterans. The lifetime incidence of ALL is slightly higher in whites than in blacks and higher in men than in women. Exposure to high doses of ionizing radiation is a known risk factor for ALL, but there is little consistent evidence on other factors.

CLL shares many traits with lymphomas (such as immunohistochemistry, B-cell origin, and progression to an acute, aggressive form of NHL), so the committee now considers it in the section above on NHL, as classified in the WHO system.

Conclusions from VAO and Previous Updates

The committee responsible for VAO concluded that there was inadequate or insufficient information to determine whether there is an association between exposure to the COIs and all types of leukemia. Additional information available to the committees responsible for Update 1996, Update 1998, Update 2000, Update 2002, Update 2004, Update 2006, Update 2008, and Update 2010 did not change that conclusion.

The committee responsible for Update 2002, however, considered CLL separately and judged that there was sufficient evidence of an association with the herbicides used in Vietnam and CLL alone, and Update 2008 noted that HCL is closely related to CLL.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

The committee responsible for Update 2006 considered AML individually but did not find evidence to suggest that its occurrence is associated with exposure to the COIs, and there is still not sufficient evidence to support such an association, so AML has been retained with other non-CLL leukemias in the category of inadequate and insufficient evidence.

Table 8-47 summarizes the results of the relevant studies.

Update of the Epidemiologic Literature

Vietnam-Veteran, Environmental, and Case-Control Studies No Vietnam-veteran studies, environmental studies, or case-control studies of exposure to the COIs and leukemia have been published since Update 2010.

Occupational Studies Burns et al. (2011) updated cancer incidence through 2007 in workers who were alive on January 1, 1985, and had been employed at any time from 1945 to 1994 in 2,4-D production by the Dow Chemical Company in Midland, Michigan. They found no evidence of significantly increased rates of cancer overall. With five cases observed, the incidence of leukemia in the most restrictively defined cohort was not increased (SIR = 0.86, 95% CI 0.28–2.02), as was the case for the two successively more inclusive, but potentially more biased, cohorts.

Boers et al. (2012) provided a quantified, TCDD-based analysis of mortality updated through 2006 in male workers in two Dutch phenoxy-herbicide factories, which were considered in Update 2010 (Boers et al., 2010). The 1,020 workers in factory A had been involved in production of 2,4,5-T with its associated TCDD contamination, whereas the 1,036 working in factory B had produced only phenoxy herbicides that would not have had TCDD contamination. Contemporary TCDD concentrations measured in a subsample of 187 workers were used to derive a model incorporating job history to estimate serum TCDD concentrations of all the men at the end of their employment. The estimated TCDD concentrations in the workers in both factories did not indicate an increased risk of leukemia mortality in association with TCDD (HR = 0.90, 95% CI 0.59–1.37). The dose–response modeling, applied only to the workers in factory A, also did not find an increased risk of death from leukemia (HR = 0.74, 95% CI 0.38–1.42), whereas the qualitative exposure analysis in Boers et al. (2010) had found an HR of 0.28 (95% CI 0.03–2.61).

Ruder and Yiin (2011) reported mortality in 1940–2005 in the NIOSH PCP cohort of 2,122 workers in the four US plants that had been involved in PCP production. PCP production entailed exposure to PCDDs and PCDFs but not to the most toxic 2,3,7,8 dioxin congener. A subcohort of 720 workers (all men, the PCP-plus-TCDD group) had also been employed in TCP production and so had also been exposed to TCDD. Relative to US referent rates, deaths from leukemia were not substantially altered in the entire cohort (nine deaths, SMR =

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

TABLE 8-47 Selected Epidemiologic Studies—Leukemia (Shaded Entries Are New Information for This Update)

Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
VIETNAM VETERANS
US Vietnam Veterans

US Air Force Health Study—Ranch Hand veterans vs SEA veterans (unless otherwise noted)

All COIs

Incidence

Through 1999—White subjects vs national rates (lymphopoietic cancerc)

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

  100.9 (0.4–1.5)

With tours between 1966–1970

    70.7 (0.3–1.4)

SEA comparison veterans (n = 1,776)

    90.6 (0.3–1.0)

With tours between 1966–1970

    40.3 (0.1–0.8)

Mortality

Through 1999—White subjects vs national rates (lymphopoietic cancerc)

Akhtar et al., 2004

Ranch Hand veterans (n = 1,189)

    61.0 (0.4–2.0)

SEA comparison veterans (n = 1,776)

    50.6 (0.2–1.2)

US VA Cohort of Army Chemical Corps—Expanded as of 1997 to include all Army men with chemical MOS (2,872 deployed vs 2,737 nondeployed) serving during Vietnam era (7/1/1965–3/28/1973)

All COIs

Mortality—Through 2005

Cypel and Kang, 2010

All lymphopoietic

Deployed vs nondeployed

6 vs 61.1 (0.4–2.5)

ACC veterans vs US men

Vietnam cohort

    60.5 (0.2–1.0)

Non-Vietnam cohort

    60.6 (0.2–1.4)

Leukemia

Deployed vs nondeployed

2 vs 40.6 (0.1–3.2)

ACC veterans vs US men

Vietnam cohort

    20.4 (0.1–1.5)

Non-Vietnam cohort

    41.2 (0.3–3.0)

Mortality—Through 2001

1.0 (0.1–3.8)Dalager and Kang, 1997

US CDC Vietnam Experience Study—Cross-sectional study, with medical examinations, of Army veterans: 9,324 deployed vs 8,989 nondeployed

All COIs

Mortality

1965–2000

    81.0 (0.4–2.5)Boehmer et al., 2004

US VA Cohort of Female Vietnam Veterans
Mortality

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Through 2004 (lymphopoietic cancersc)

  180.7 (0.4–1.3)Cypel and Kang, 2008

Vietnam–veteran nurses

  140.7 (0.3–1.3)
State Studies of US Vietnam Veterans

Michigan Vietnam-era veterans, PM study of deaths (1974–1989)—deployed vs nondeployed

  301.0 (0.7–1.5)Visintainer et al., 1995
International Vietnam-Veteran Studies

Australian Vietnam Veterans—58,077 men and 153 women served on land or in Vietnamese waters during 5/23/1962–7/1/1973 vs Australian population

All COIs

Incidence

All branches, 1982–2000

1301.1 (1.0–1.4)ADVA, 2005a

Lymphocytic leukemia

  721.4 (1.1–1.7)

Myeloid leukemia

  541.0 (0.8–1.3)

Navy

  351.5 (1.0–2.0)

Lymphocytic leukemia

  141.3 (0.7–2.1)

Myeloid leukemia

  191.7 (1.0–2.6)

Army

  801.1 (0.8–1.3)

Lymphocytic leukemia

  501.4 (1.0–1.8)

Myeloid leukemia

  280.8 (0.5–1.1)

Air Force

  151.2 (0.7–2.0)

Lymphocytic leukemia

    81.4 (0.6–2.7)

Myeloid leukemia

    71.3 (0.5–2.6)

Validation Study

Expected number of exposed casesAIHW, 1999
  2726 (16–36)

Men

  6426 (16–36CDVA, 1998a

Women

    10 (0–4)CDVA, 1998b

Mortality

All branches, return–2001

  841.0 (0.8–1.3)ADVA, 2005b

Lymphocytic leukemia

  241.2 (0.7–1.7)

Myeloid leukemia

  551.1 (0.8–1.3)

Army

  480.1 (0.7–1.2)

Lymphocytic leukemia

  171.3 (0.7–2.0)

Myeloid leukemia

  300.8 (0.5–1.1)

Air Force

  141.6 (0.8–2.6)

Lymphocytic leukemia

    62.7 (1.0–5.8)

Myeloid leukemia

    81.3 (0.5–2.5)

1980–1994

  331.3 (0.8–1.7)CDVA, 1997a

Australian Conscripted Army National Service (18,940 deployed vs 24,642 nondeployed)

All COIs
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Incidence—1982–2000

  160.6 (0.3–1.1)ADVA, 2005c

Lymphocytic leukemia

    90.8 (0.3–2.0)

Myeloid leukemia

    70.5 (0.2–1.3)

Mortality—1966–2001

  110.6 (0.3–1.3)ADVA, 2005c

Lymphocytic leukemia

    20.4 (0.0–2.4)

Myeloid leukemia

    80.7 (0.3–1.7)
OCCUPATIONAL—INDUSTRIAL
IARC Phenoxy Herbicide Cohort—Workers exposed to any phenoxy herbicide or chlorophenol (production or spraying) vs respective national mortality rates

Mortality 1939–1992

  341.0 (0.7–1.4)Kogevinas et al., 1997

13,831 exposed to highly chlorinated PCDDs

  160.7 (0.4–1.2)

7,553 not exposed to highly chlorinated

  171.4 (0.8–2.3)

PCDDs

Mortality 1955–1988 of 12,492 production workers and 5,898 sprayers exposed—13,482 in exposed subcohort

  181.2 (0.7–1.9)Saracci et al., 1991

Mortality, incidence of women in production (n = 699) and spraying (n = 2) compared to national death rates and cancer incidence rates (myeloid leukemia)

    1TCDD 2.0 (0.2–7.1)Kogevinas et al., 1993

Danish Production Workers (3,390 men and 1,069 women involved in production of phenoxy herbicides unlikely to contain TCDD at 2 plants in 1947–1987) (in IARC cohort)

Dioxins, but TCDD unlikely; 2,4-D, 2,4-DP, MCPA, MCPP

Mortality 1955–2006

    90.9 (0.6–1.4)Boers et al., 2012

Dutch production workers in Plant A (549

Dioxins, 2,4,5-T,

men exposed during production 1955–1985; 594

2,4,5-TCP

unexposed) (in IARC cohort)

Mortality 1955–2006 (hazard ratios for lagged TCDD plasma levels)

    50.7 (0.4–1.4)Boers et al., 2012

Mortality 1955–2006

Boers et al., 2010

LHC

11 vs 70.9 (0.3–2.6)

Leukemia

2 vs 30.3 (0.0–2.6)

Mortality 1955–1991

    11.0 (0.0–5.7)Hooiveld et al., 1998

Mortality 1955–1985

Bueno de Mesquita et al., 1993

Leukemia, aleukemia (ICD-9 204–207)

    11.5 (0.0–8.2)

Myeloid leukemia (ICD-8 205)

    12.9 (0.0–15.9)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Dutch production workers in Plant B (414 men exposed during production 1965–1986; 723 unexposed) (in IARC cohort)

2,4-D; MCPA; MCPP; highly chlorinated dioxins unlikely

Mortality 1965–2006

Boers et al., 2010

LHC

3 vs 31.5 (0.3–7.5)

Leukemia

2 vs 21.5 (0.2–10.8)

Mortality 1965–1986

Bueno de Mesquita et al., 1993

Leukemia, aleukemia (ICD-9 204–207)

    14.4 (0.1–24.2)

Myeloid leukemia (ICD-8 205)

    17.7 (0.2–42.9)

German Production Workers—2,479 workers at 4 plants (in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

BASF Cleanup Workers from 1953 accident (n = 247); 114 with chloracne, 13 more with erythema; serum TCDD levels (not part of IARC)

Focus on TCDD

Mortality

Through 1987

90% CIZober et al., 1990

All cohorts (n = 247)

    11.7 (nr)

Cohort 3

    15.2 (0.4–63.1)

German Production Workers at Bayer Plant in Uerdingen (135 men working > 1 month in 1951–1976) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4,5-TCP

Mortality 1951–1992

    0Becher et al., 1996

German Production Workers at Bayer Plant in Dormagen (520 men working > 1 month in 1965–1989) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1965–1989

    0Becher et al., 1996

German Production Workers at BASF Ludwigshafen Plant (680 men working > 1 month in 1957–1987) (in IARC cohort as of 1997) and women—no results

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPP; 2,4-DP

Mortality 1956–1989

    0Becher et al., 1996
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

German Production Workers at Boehringer–Ingelheim Plant in Hamburg (1,144 men working > 1 month in 1952–1984; generation of TCDD reduced after chloracne outbreak in 1954) and women—no results (some additions to observed cancers over Manz et al., 1991) (in IARC cohort as of 1997)

Dioxins; 2,4,5-T; 2,5-DCP; 2,4,5-TCP

Mortality 1952–1989

    41.8 (0.5–4.7)Becher et al., 1996

New Zealand Phenoxy Herbicide Production Workers and Sprayers (1,599 men and women working any time in 1969–1988 at Dow plant in New Plymouth) (in IARC cohort)

Dioxins; 2,4-D; 2,4,5-T; MCPA; MCPB; 2,4,5-TCP; Picloram

Mortality 1969–2004 (leukemia, aleukemia)

McBride et al., 2009a

Ever-exposed workers

    10.6 (0.0–3.1)

Never-exposed workers

    00.0 (0.0–6.0)

Production Workers (713 men and 100 women worked > 1 month in 1969–1984)

Mortality 1969–2000

    00.0 (0.0–5.3)’t Mannetje et al., 2005

Sprayers (697 men and 2 women registered any time 1973–1984)

Mortality 1973–2000

    11.2 (0.0–6.4)’t Mannetje et al., 2005

NIOSH Mortality Cohort (12 US plants, 5,172 male production and maintenance workers 1942–1984) (included in IARC cohort as of 1997)

Dioxins, phenoxy herbicides

Through 1993

  100.8 (0.4–1.5)Steenland et al., 1999

Through 1987

    60.7 (0.2–1.5)Fingerhut et al., 1991

All Dow TCP-Exposed Workers (TCP production 1942–1979 or 2,4,5-T production 1948–1982 in Midland, Michigan) (in IARC and NIOSH cohorts)

2,4,5-T; 2,4,5-TCP

1942–2003 (n = 1,615) (leukemia, aleukemia)

  131.9 (1.0–3.2)Collins et al., 2009a

Excluding subset with PCP exposure

    21.9 (1.0–3.4)

1942–2003 (n = 1,615) (other lymphopoietic)

    20.6 (0.1–2.3)

Excluding subset with PCP exposure

    20.7 (0.1–2.6)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All Dow PCP-Exposed Workers—all workers from the two plants that only made PCP (in Tacoma, Washington, and Wichita, Kansas) and workers who made PCP and TCP at two additional plants (in Midland, Michigan, and Sauget, Illinois)

2,4,5-T; 2,4,5-TCPRuder and Yiin, 2011

1940–2005 (n = 2,122)

    90.9 (0.4–1.7)

PCP and TCP (n = 720)

    20.6 (0.1–2.2)

PCP (no TCP) (n = 1,402)

    71.0 (0.4–2.1)

Dow PCP Production Workers (1937–1989 in Midland, Michigan) (not in IARC and NIOSH cohorts)

Low chlorinated dioxins, 2,4-D

Mortality 1940–2004 (n = 577, excluding 196 also having exposure to TCP)

Collins et al., 2009b

1942–2003 (n = 773) (leukemia, aleukemia)

    20.6 (0.1–2.0)

Excluding subset with TCP exposure

    10.4 (0.0–2.0)

1942–2003 (n = 773) (other lymphopoietic)

    21.3 (0.2–4.6)

Excluding subset with TCP exposure

    21.7 (0.2–6.0)

Mortality 1940–1989 (n = 770)

Ramlow et al., 1996

0-yr latency

    21.0 (0.1–3.6)

15-yr latency

    1nr

Dow 2,4-D Production Workers (1945–1982 in Midland, Michigan)

2,4-D, lower chlorinated dioxins

Cancer incidence through 2007 in Dow workers (n = 1,256) vs comparisons from state cancer registries (n = 23,354) (Cohort 3)

    50.9 (0.3–2.0)Burns et al., 2011

Through 1994 (n = 1,517)—lymphopoietic mortality in workers with high 2,4-D exposure Through 1982 (n = 878)

Burns et al., 2001 Bond et al., 1988
41.3 (0.4–3.3)
23.6 (0.4–13.2)
OCCUPATIONAL—PAPER AND PULPTCDD
WORKERS

IARC cohort of pulp and paper workers—60,468 workers from 11 countries, TCDD among 27 agents assessed by JEM

McLean et al., 2006

Exposure to nonvolatile organochlorine

compounds

Never

  491.0 (0.7–1.3)

Ever

  350.9 (0.6–1.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Danish paper workers

Rix et al., 1998

Men

  200.8 (0.5–1.2)

Women

    71.3 (0.5–2.7)
OCCUPATIONAL—HERBICIDE-USING
WORKERS (not related to IARC sprayer cohorts)

CANADA

Canadian Farm Operator Study—156,242 men farming in Manitoba, Saskatchewan, and Alberta in 1971; mortality from leukemia June 1971–December 1987

Herbicides

Farm operators ≥ 35 yrs of age (June 1971–December 1987)

3570.9 (0.8–1.0)Semenciw et al., 1994

Lymphatic

1320.9 (0.8–1.1)

Myeloid

1270.8 (0.7–0.9)

Farm operators ≥ 35 yrs of age during study period (June 1971–December 1985)

Wigle et al., 1990
1380.9 (0.7–1.0)

Sawmill workers in British Columbia—23,829 workers for ≥ 1 yr at 11 mills using chlorophenates 1940–1985

Chlorophenates, not TCDDHertzman et al., 1997

All leukemias—incidence

  471.2 (0.9–1.5)

ALL

    21.0 (0.2–3.1)

CLL

  241.7 (1.2–2.4)

AML

    50.8 (0.3–1.7)

CML

    71.1 (0.5–2.0)

Other, unspecified

    50.5 (0.2–1.0)

DENMARK

Danish gardeners—incidence from 3,156 male and 859 female gardeners

HerbicidesHansen et al., 2007

25-year followup (1975–2001)

  421.1 (0.8–1.4)

Leukemia (ICD-7 204)

  221.4 (0.9–2.1)

Born before 1915 (high exposure)

  161.4 (0.9–2.3)

Leukemia (ICD-7 204)

  122.3 (1.3–4.1)

Born 1915–1934 (medium exposure)

  251.2 (0.8–1.8)

Leukemia (ICD-7 204)

    91.0 (0.5–2.0)

Born after 1934 (low exposure)

    10.2 (0.0–1.0)

Leukemia (ICD-7 204)

    10.5 (0.0–3.4)

10-year followup (1975–1984) reported in

Hansen et al. (1992)

  151.4 (0.8–2.4)

NHL (ICD-7 200, 202, 205)

    61.7 (0.6–3.8)

HD (ICD-7 201)

    0nr

Multiple myeloma (ICD-7 203)

    0nr

CLL (ICD-7 204.0)

    62.8 (1.0–6.0)

Other leukemia (ICD-7 204.1–204.4)

    31.4 (0.3–4.2)

10-year followup (1975–1984) of male gardeners

Hansen et al., 1992

All gardeners—CLL

    62.5 (0.9–5.5)

Men

    62.8 (1.0–6.0)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

All gardeners—all other types of leukemia

    31.2 (0.3–3.6)

Men

    31.4 (0.3–4.2)

Danish Farmers—incidence from linking farmers on 1970 census with national cancer registry (1970–1980)

HerbicidesRonco et al., 1992

Men

Self-employed

1450.9 (nr)

Employee

  331.0 (nr)

Women

Self-employed

    82.2 (p < 0.05)

Employee

    31.3 (nr)

Family worker

  270.9 (nr)

FINNISH Phenoxy Herbicide Sprayers (1,909 men working 1955–1971 ≥ 2 wks) not IARC

Phenoxy herbicides

Incidence

Asp et al., 1994

Lymphatic

    31.0 (0.2–3.0)

Mortality

    2nr

Lymphatic

    10.9 (0.0–5.1)

Myeloid

    10.7 (0.0–3.7)

ITALIAN Licensed Pesticide Users—male farmers in southern Piedmont licensed 1970–1974

Mortality 1970–1986 (n = 23,401) (ICD-8 202.0–202.9)

  270.8 (0.5–1.1)Torchio et al., 1994

Italian rice growers with documented phenoxy use (n = 1,487)

    4Phenoxy herbicidesGambini et al., 1997
0.6 (0.2–1.6)

NEW ZEALAND National Cancer Registry (1980–1984)—case-control study of 571 incident pancreatic cancer cases vs remainder of 19,904 men with any incident cancer

HerbicidesReif et al., 1989

Forestry workers (n = 134) (leukemia)

    41.0 (0.4–2.6)

Aged 20–59 (AML)

    22.8 (0.7–11.0)

Aged ≥ 60 (AML)

    11.6 (0.2–11.5)

Sawmill workers (n = 139)

Herbicides, chlorophenols

Leukemia (ICD-7 204–248)

    20.5 (0.1–2.1)

AML (ICD-7 205.0)

    10.9 (0.1–6.4)

SWEDEN

Swedish lumberjacks—used phenoxys 1954–1967, Incidence 1958–1992

Thörn et al., 2000
0nr

THE NETHERLANDS

Dutch Licensed Herbicide Sprayers—1,341 certified before 1980

Through 2000

    31.3 (0.3–3.7)Swaen et al., 2004
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

UNITED STATES

US farmers—usual occupation of farmer and industry of agriculture on death certificates 1984–1988 from 23 states

Herbicides PCMRsBlair et al., 1993

Men

Whites (n = 119,648)

1,0721.3 (1.2–1.4)

Nonwhites (n = 11,446)

  550.9 (0.7–1.3)

Women

Whites (n = 2,400)

  241.5 (0.9–2.2)

Nonwhites (n = 2,066)

    80.9 (0.4–1.9)

US Agricultural Health Study—prospective study of licensed pesticide sprayers in Iowa and North Carolina: commercial (n = 4,916), private/farmers (n = 52,395, 97.4% men), and spouses of private sprayers (n = 32,347, 0.007% men), enrolled 1993–1997; followups with CATIs 1999–2003 and 2005–2010

Phenoxy herbicides

Incidence

Enrollment through 2006—SIRs for participants

Koutros et al., 2010a

Private applicators

1331.0 (0.8–1.1)

Commercial applicators

    70.9 (0.4–1.9)

Spouses

  370.8 (0.6–1.1)

Enrollment through 2002

Alavanja et al., 2005

Private applicators

  700.9 (0.7–1.2)

Spouses of private applicators (> 99% women)

  170.7 (0.4–1.2)

Commercial applicators

    40.9 (0.3–2.4)

Mortality

Enrollment through 2007, vs state rates

Waggoner et al., 2011

Applicators (n = 1,641) Spouses (n = 676)

91 330.9 (0.7–1.0) 1.1 (0.8–1.5)

Enrollment through 2000, vs state rates

Blair et al., 2005a

Private applicators (men and women) Spouses of private applicators (> 99% women)

  270.8 (0.5–1.1)
141.4 (0.8–2.4)

California United Farm Workers of America

Nested case-control analysis of Hispanic workers in cohort of 139,000 CA United Farm Workers

Mills et al., 2005

Ever used 2,4-D—total leukemia

nr1.0 (0.4–2.6)

Lymphocytic leukemia

nr1.5 (0.3–6.6)

Granulocytic (myeloid) leukemia

nr1.3 (0.3–5.4)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

US Department of Agriculture Workers—nested case-control study of white men dying 1970–1979 of NHL

Herbicides

Agricultural extension agents

  231.9 (1.0–3.5)Alavanja et al., 1988

Lymphatic

nr2.1 (0.7–6.4)

Trend over years worked

(p < 0.01)

Myeloid

nr2.8 (1.1–7.2)

Trend over years worked

(p < 0.01)

White Male Residents of Iowa—leukemia

Herbicides

cancer on death certificate, usual occupation:

farmers vs not

> 30 yrs old when died 1964–1978—case-control

1.2 (p < 0.05)Burmeister et al., 1983

ALL

  280.7 (0.4–1.2)

CLL

1321.7 (1.2–2.4)

Lived in one of 33 counties with highest herbicide use

nr1.9 (1.2–3.1)

Unspecified lymphatic

  641.7 (1.0–2.7)

AML

  861.0 (0.8–1.5)

CML

  461.0 (0.7–1.7)

Unspecified myeloid

  360.8 (0.5–1.4)

Acute monocytic

  101.1 (0.4–2.6)

Unspecified leukemia

  311.1 (0.6–2.0)

White Male Residents of Iowa and Minnesota— > 30 yrs old diagnosed 1981–1983 in Iowa or 1980–1982 in Minnesota (ever farmer, used herbicides)

HerbicidesBrown et al., 1990
578

Ever farmed

3351.2 (1.0–1.5)

AML

  811.2 (0.8–1.8)

CML

  271.1 (0.6–2.0)

CLL

1561.4 (1.1–1.9)

ALL

    70.9 (0.3–2.5)

Myelodysplasias

  320.8 (0.5–1.4)

Any herbicide use

1571.2 (0.9–1.6)

AML

  391.3 (0.8–2.0)

CML

  161.3 (0.7–2.6)

CLL

  741.4 (1.0–2.0)

ALL

    20.5 (0.1–2.2)

Myelodysplasias

  100.7 (0.3–1.5)

Phenoxy acid use

1201.2 (0.9–1.6)

2,4-D use

  981.2 (0.9–1.6)

2,4,5-T use

  221.3 (0.7–2.2)

First use > 20 yrs before

  111.8 (0.8–4.0)

MCPA

  111.9 (0.8–4.3)

First use > 20 yrs before

    52.4 (0.7–8.2)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference
ENVIRONMENTAL
Seveso, Italy Residential Cohort—Industrial accident July 10, 1976 (723 residents Zone A; 4,821 Zone B; 31,643 Zone R; 181,574 local reference group) (ICD-9 171)TCDD

Incidence—20-yr followup to 1996—men and women

Leukemia (ICD-9 204–208)

Pesatori et al., 2009

Zone A

    22.2 (0.5–8.8)

Zone B

    81.4 (0.7–2.7)

Zone R

  310.8 (0.5–2.1)

Lymphatic leukemia (ICD-9 204)

Zone A

    12.8 (0.4–19.9)

Zone B

    0nr

Zone R

  130.8 (0.5–1.5)

Myeloid leukemia (ICD-9 205)

Zone A

    12.2 (0.3–16.0)

Zone B

    72.4 (1.1–5.2)

Zone R

  150.8 (0.4–1.3)

Leukemia, unspecified (ICD-9 208)

Zone A

    0nr

Zone B

    12.2 (0.3–16.1)

Zone R

    20.6 (0.1–2.6)

10-yr followup to 1991—men

Bertazzi et al., 1993

Zone B

    21.6 (0.4–6.5)

Myeloid leukemia (ICD-9 205)

    12.0 (0.3–14.6)

Zone R

    80.9 (0.4–1.9)

Myeloid leukemia (ICD-9 205)

    51.4 (0.5–3.8)

10-yr followup to 1991—women

Bertazzi et al., 1993

Zone B

    21.8 (0.4–7.3)

Myeloid leukemia (ICD-9 205)

    23.7 (0.9–15.7)

Zone R

    30.4 (0.1–1.2)

Myeloid leukemia (ICD-9 205)

    20.5 (0.1–2.1)

Mortality—25-yr followup to 2001 (men and women)

Leukemia (ICD-9 204–208)

Consonni et al., 2008

Zone A

    10.9 (0.1–6.3)

Zone B

  131.7 (1.0–3.0)

Zone R

  511.0 (0.7–1.3)

Lymphatic leukemia (ICD-9 204)

Zone A

    0nr

Zone B

    31.3 (0.4–4.1)

Zone R

  231.4 (0.9–2.2)

Myeloid leukemia (ICD-9 205)

Zone A

    12.1 (0.3–15.2)

Zone B

    62.0 (0.9–4.5)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

Zone R

  160.7 (0.4–1.2)

Monocytic leukemia (ICD-9 206)

    0nr

Leukemia, unspecified (ICD-9 208)

Zone A

    0nr

Zone B

    42.4 (0.9–6.5)

Zone R

  100.8 (0.4–1.6)

20-yr followup to 1996

Bertazzi et al., 2001

Zones A, B—men

    92.1 (1.1–4.1)

Zones A, B—women

    31.0 (0.3–3.0)

15-yr followup to 1991—men

Bertazzi et al., 1998

Zone B

    73.1 (1.4–6.7)

Zone R

  120.8 (0.4–1.5)

15-yr followup to 1991—women

Bertazzi et al., 1998

Zone B

    10.6 (0.1–4.0)

Zone R

  120.9 (0.5–1.6)
Chapaevsk, Russia Residential CohortDioxinRevich et al., 2001

Incidence—Crude incidence rate in 1998 vs

Men

Regional (Samara)

nr14.6 (nr)

National (Russia)

nr15.2 (nr)

Women

Regional (Samara)

nr13.9 (nr)

National (Russia)

nr10.7 (nr)

Mortality—1995–1998 (SMR vs regional rates)

Men

  111.5 (0.8–2.7)

Women

  151.5 (0.8–2.4)
Other International Environmental Studies

SWEDEN

Swedish fishermen (high consumption of fish with persistent organochlorines)

Organochlorine compoundsSvensson et al., 1995

Incidence

Lymphocytic

East coast (higher serum TEQs)

    41.2 (0.3–3.3)

West coast (lower serum TEQs)

  161.3 (0.8–2.2)

Myeloid

East coast (higher serum TEQs)

    20.9 (0.1–3.1)

West coast (lower serum TEQs)

    60.5 (0.2–1.1)

Mortality—all leukemias

East coast (higher serum TEQs)

    51.4 (0.5–3.2)

West coast (lower serum TEQs)

  241.0 (0.6–1.5)
CASE-CONTROL STUDIES

US Case-Control Studies

1,084 leukemia deaths in Nebraska in 1957–1974; farmers–usual occupation on death certificate

Herbicides, pesticides 1.3 (p < 0.05)Blair and White, 1985

99 ALL cases

nr1.3 (nr)
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Study PopulationaExposed CasesbExposure of Interest/Estimated Relative Risk (95% CI)bReference

248 CLL cases

nr1.7 (p < 0.05)

105 unspecified lymphatic cases

nr0.9 (nr)

235 AML cases

nr1.2 (nr)

96 CML cases

nr1.1 (nr)

39 unspecified myeloid cases

nr1.0 (nr)

39 acute monocytic cases

nr1.9 (nr)

52 acute unspecified leukemia cases

nr2.4 (nr)

65 unspecified leukemia cases

nr1.2 (nr)

Tecumseh, Michigan, residents participating in longitudinal study (1959–1987)

HerbicidesWaterhouse et al., 1996

All leukemias

Men

  421.4 (1.0–1.9)

Women

  321.2 (0.9–1.8)

CLL

  101.4 (1.0–1.9)

International Case-Control Studies

Italian residents of 11 areas (incidence of leukemia excluding CLL)

HerbicidesMiligi et al., 2003

Exposure to phenoxy herbicides

    62.1 (0.7–6.2)

Italian farming and animal-breeding workers (men and women)—incidence (CLL)

HerbicidesAmadori et al., 1995
152.3 (0.9–5.8)

Farmers

    51.6 (0.5–5.2)

Breeders

  103.1 (1.1–8.3)

NOTE: 2,4-D, 2,4-dichlorophenoxyacetic acid; 2,4-DP, dichlorprop; 2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; 2,4,5-TCP, 2,4,5-trichlorophenol; 2,5-DCP, 2,5-dichlorophenol; ACC, Army Chemical Corps; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CA, California; CATI, computer-assisted telephone interviewing; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; COI, chemical of interest; HD, Hodgkin disease; IARC, International Agency for Research on Cancer; ICD, International Classification of Diseases; JEM, job-exposure matrix; LHC, lymphohematopoietic cancers; MCPA, 2-methyl-4-chlorophenoxyacetic acid; MCPB, 4-(4-chloro-2-methylphenoxy) butanoic acid; MCPP, methylchlorophenoxypropionic acid; MOS, military occupation specialty; NHL, non-Hodgkin lymphoma; NIOSH, National Institute for Occupational Safety and Health; nr, not reported; PCDD, polychlorinated dibenzo-p-dioxin (highly chlorinated, if four or more chlorines); PCMR, proportionate cancer mortality ratios; PCP, pentachlorophenol; PM, proportionate mortality; SEA, Southeast Asia; SIR, standardized incidence ratio; SMR, standardized mortality rate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, trichlorophenol; TEQ, toxicity equivalent; VA, US Department of Veterans Affairs.

aSubjects are male and outcome is mortality unless otherwise noted.

bGiven when available; results other than estimated risk explained individually.

cLymphopoietic cancers comprise all forms of lymphoma (including Hodgkin lymphoma and non-Hodgkin lymphoma) and leukemia (ALL, AML, CLL, CML).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

0.89, 95% CI 0.41–1.68), the PCP-only group (seven deaths, SMR = 1.03, 95% CI 0.41–2.12), or the PCP-plus-TCDD group (two deaths, SMR = 0.60, 95% CI 0.07–2.16). Of the nine leukemia deaths, four occurred in the small group of 277 nonwhite males and resulted in a significant increase in SMR (4.57, 95% CI 1.25–11.7).

Koutros et al. (2010a) updated cancer incidence data in the AHS through 2006 and found nonsignificant associations with leukemia in the private pesticide applicators (133 cases, SIR = 0.96, 95% CI 0.81–1.14) and their spouses (37 cases, SIR = 0.83, 95% CI 0.58–1.14). Similarly, in an analysis of leukemia mortality in agricultural pesticide applicators and their spouses (1993–2007), Waggoner et al. (2011) reported no increased risk of leukemia in applicators (91 deaths, SMR = 0.85, 95% CI 0.68–1.04) or in their spouses (33 deaths, SMR = 1.09, 95% CI 0.75–1.53). The AHS has been generating valuable information on the COIs for a number of years, but these results are not herbicide-specific and so are not regarded as being fully informative for the committee’s task.

In the British PUHS cohort of 62,960 subjects, neither leukemia incidence nor leukemia mortality was significantly increased by pesticide exposure in men or women (Frost et al., 2011).

Biologic Plausibility

Leukemia is a relatively rare spontaneous neoplasm in mice, but it is less rare in some strains of rats. A small study reported that five of 10 male rats fed TCDD at 1 ng/kg per week for 78 weeks showed an increased incidence of various cancers, one of which was lymphocytic leukemia (Van Miller et al., 1977). Later studies of TCDD’s carcinogenicity have not shown an increased incidence of lymphocytic leukemia in mice or rats.

Two studies that used cells in tissue culture suggested that TCDD exposure does not promote leukemia. Proliferation of cultured human bone marrow stem cells (the source of leukemic cells) was not influenced by addition of TCDD to the culture medium (van Grevenynghe et al., 2005). Likewise, Mulero-Navarro et al. (2006) reported that the AHR promoter is silenced in ALL—an effect that could lead to reduced expression of the receptor, which binds TCDD and mediates its toxicity. No reports of animal studies have noted an increased incidence of leukemia after exposure to the phenoxy herbicides or other COIs.

The biologic plausibility of the carcinogenicity of the COIs is discussed in general at the beginning of this chapter.

Synthesis

The new findings from three cohorts of production workers (Boers et al., 2012; Burns et al., 2011; Ruder and Yiin, 2011) provide no evidence to support

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

an association between exposure to the COIs and the occurrence of leukemia. The committee has some concern about misclassification of leukemia types and finds the correspondence between intensity of exposure and magnitude of risk for leukemias (other than CLL) to be erratic.

Conclusion

On the basis of the evidence reviewed here and in previous VAO reports, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and leukemias in general. An exception is the specific leukemia subtypes of chronic B-cell hematoproliferative diseases, including CLL and HCL, which are more appropriately grouped with lymphomas.

Nonmalignant Myeloid Diseases

The myelodysplastic syndromes (MDSs) are a collection of proliferative diseases (ICD-9 238.7, ICD-10 D46) that involve myeloid dysplasia. Patients often develop anemia and cytopenia caused by progressive bone marrow failure. MDSs are not malignancies, nor are they necessarily fatal, but aggressive cases of MDS frequently progress to AML. On the basis of Surveillance, Epidemiology, and End Results program data collected from 2001 to 2003, the age-adjusted incidence of MDS in the United States was estimated to be 3.4 per 100,000 people per year, which means about 10,000 new cases per year (Sekeres, 2011). Various factors determine prognosis, and several scoring systems are used. Most involve the number of cytopenias, dependence on transfusion, cytogenetic abnormalities, and the number of blasts in the marrow. For low-risk disease, the median survival is about 7 years; for high risk, it is less than 1 year. MDS does not always progress to AML, and the incidence of progression varies with risk category. Of cases with high-risk MDS, around 25–35% progress to AML. More people die from complications of infection or bleeding than through transformation to AML. Myeloproliferative neoplasms (ICD-9 205.1, 238.4, 289.89, 289.9; ICD-10 D47.1) are generally less serious clonal diseases of the myeloid lineage, but they may progress into MDS or AML.

Aplastic anemia (AA) (ICD-9 284, ICD-10 D60-D61) is another disease of the bone marrow in which stem cells are damaged in such a way that there are simultaneous decreases in red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia)—pancytopenia. Exposures to radiation, a number of drugs, and some industrial chemicals (such as benzene) are recognized as risk factors for this condition, but it may also arise from an autoimmune disease.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Update of the Epidemiologic Literature

No Vietnam-veteran, occupational, or environmental studies of MDS with adequate specification of exposure to the COIs have been published since Update 2010, but two hospital-based case-control studies have investigated possible association between herbicides and MDS, and another has addressed pesticides and AA.

Case-Control Studies In a study comprising 403 newly diagnosed MDS patients and 806 sex- and age-matched patient controls in 27 major hospitals in Shanghai, China, Lv et al. (2011) examined the relation of lifestyle, environmental, and occupational factors to risk of MDS. Exposure to herbicides was associated with an increased risk of MDS (OR = 5.33, 95% CI 1.41–20.10) and with the MDS subtype refractory cytopenia with multilineage dysplasia (OR = 12, 95% CI 1.44–99.67).

Shorter constitutive telomeres in proliferative mononuclear cells has been associated with MDS and is thus a plausible mechanism by which associated exposures could induce MDS. Rollison et al. (2011) measured telomere length (TL) in peripheral blood leukocytes of MDS cases identified in a hospital-based case-control study in Florida, with (n = 8) and without (n = 47) self-reported herbicide exposure (Rollison et al., 2011). Telomere length was significantly reduced (p = 0.05) in the exposed people, with a mean ± SD of 2.52 ± 0.95 compared with that in unexposed people (4.23 ± 2.44).

AA is a severe disease of bone marrow failure involving stem cells from different lineages. It has a fatality rate of 34% 1 year after diagnosis. Its causes are unknown, but may be associated with pesticide exposure. Risk of AA from occupational exposures to pesticides in the preceding 6 months was assessed in a hospital-based case-control study in Thailand with 541 cases and 2,261 controls (Prihartono et al., 2011). The time frame of AA does not correspond to the situation of concern in the present review. An increased risk of AA was found to be associated with exposure to several classes of pesticides measured by either self-report or expert assessment (organophosphates, carbamates, organochlorines, and paraquat), but there was no indication that exposures to phenoxy herbicides, picloram, or cacodylic acid were assessed.

Synthesis

There are no data with which to assess the role that specific COIs may play in the occurrence of the various nonmalignant bone-marrow–derived diseases.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Conclusion

On the basis of the available tangential information, the committee concludes that there is inadequate or insufficient evidence to determine whether there is an association between exposure to the COIs and nonmalignant myeloid diseases.

REFERENCES1

ACS (American Cancer Society). 2011. Skin cancer: Basal and squamous cell. Atlanta, GA. American Cancer Society.

ACS. 2012a. Laryngeal and hypopharyngeal cancer. Atlanta, GA: American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003108-pdf.pdf (accessed May 15, 2013).

ACS. 2012b. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society.

ACS.2012c. Brain and spinal cord tumors in adults. Atlanta, GA: American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003088-pdf.pdf (accessed May 15, 2013).

ACS. 2013a. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index (accessed May 15, 2013).

ACS. 2013b. Skin cancer: Basal and squamous cell overview. Atlanta, GA: American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003075-pdf.pdf (accessed May 15, 2013).

ADVA (Australia Department of Veterans’ Affairs). 2005a. Cancer Incidence in Australian Vietnam Veteran Study 2005. Canberra, Australia: Department of Veterans’ Affairs.

ADVA. 2005b. The Third Australian Vietnam Veterans Mortality Study 2005. Canberra, Australia: Department of Veterans’ Affairs.

ADVA. 2005c. Australian National Service Vietnam Veterans: Mortality and Cancer Incidence 2005. Canberra, Australia: Department of Veterans’ Affairs.

AFHS (Air Force Health Study). 1996. An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides. Mortality Update 1996. Brooks AFB, TX: Epidemiologic Research Division. Armstrong Laboratory. AL/AO-TR-1996-0068. 31 pps.

AFHS. 2000. An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides. 1997 Follow-up Examination Results. Brooks AFB, TX: Epidemiologic Research Division, Armstrong Laboratory. AFRL-HE-BR-TR-2000-02.

AIHW (Australian Institute of Health and Welfare). 1999. Morbidity of Vietnam Veterans: A Study of the Health of Australia’s Vietnam Veteran Community, Volume 3: Validation Study. Canberra, Australia.

Akhtar FZ, Garabrant DH, Ketchum NS, Michalek JE. 2004. Cancer in US Air Force veterans of the Vietnam War. Journal of Occupational and Environmental Medicine 46(2):123–136.

Alavanja MC, Blair A, Merkle S, Teske J, Eaton B. 1988. Mortality among agricultural extension agents. American Journal of Industrial Medicine 14(2):167–176.

Alavanja MC, Blair A, Merkle S, Teske J, Eaton B, Reed B. 1989. Mortality among forest and soil conservationists. Archives of Environmental Health 44:94–101.

__________________

1Throughout this report, the same alphabetic indicator after year of publication is used consistently for a given reference when there are multiple citations by the same first author in a given year. The convention of assigning the alphabetic indicators in order of citation in a given chapter is not followed.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, Knott C, Thomas K, Hoppin JA, Barker J, Coble J, Sandler DP, Blair A. 2003. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. American Journal of Epidemiology 157(9):800–814.

Alavanja MCR, Sandler DP, Lynch CF, Knott C, Lubin JH, Tarone R, Thomas K, Dosemeci M, Barker J, Hoppin JA, Blair A. 2005. Cancer incidence in the Agricultural Health Study. Scandinavian Journal of Work, Environment and Health 31(Suppl 1):39–45.

Allan LL, Sherr DH. 2010. Disruption of human plasma cell differentiation by an environmental polycyclic aromatic hydrocarbon: A mechanistic immunotoxicological study. Environmental Health 9:15.

Allen JR, Barsotti DA, Van Miller JP, Abrahamson LJ, Lalich JJ. 1977. Morphological changes in monkeys consuming a diet containing low levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Food and Cosmetics Toxicology 15:401–410.

Amadori D, Nanni O, Falcini F, Saragoni A, Tison V, Callea A, Scarpi E, Ricci M, Riva N, Buiatti E. 1995. Chronic lymphocytic leukaemias and non-Hodgkin’s lymphomas by histological type in farming-animal breeding workers: A population case-control study based on job titles. Occupational and Environmental Medicine 52(6):374–379.

Ambolet-Camoit A, Bui L, Pierre S, Chevallier A, Marchand A, Coumoul X, Garlatti M, Andreau K, Barouki R, Aggerbeck M. 2010. 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker AGR2 in the hepatocarcinoma cell line HepG2. Toxicological Sciences 115(2):501–512.

Anderson HA, Hanrahan LP, Jensen M, Laurin D, Yick WY, Wiegman P. 1986. Wisconsin Vietnam Veteran Mortality Study: Final Report. Madison: Wisconsin Division of Health.

Andersson P, McGuire J, Rubioi C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A, Poellinger L. 2002a. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proceedings of the National Academy of Sciences of the United States 99(15):9990–9995.

Andersson P, Rubio C, Poellinger L, Hanberg A. 2005. Gastric hamartomatous tumours in a transgenic mouse model expressing an activated dioxin/Ah receptor. Anticancer Research 25(2A):903–911.

Andreotti G, Freeman LE, Hou L, Coble J, Rusiecki J, Hoppin JA, Silverman DT, Alavanja MC. 2009. Agricultural pesticide use and pancreatic cancer risk in the Agricultural Health Study cohort. International Journal of Cancer 124(10):2495–2500.

Andreotti G, Hou L, Beane Freeman LE, Mahajan R, Koutros S, Coble J, Lubin J, Blair A, Hoppin JA, Alavanja M. 2010. Body mass index, agricultural pesticide use, and cancer incidence in the Agricultural Health Study cohort. Cancer Causes and Control 21(11):1759–1775.

Andreotti G, Silverman DT. 2012. Occupational risk factors and pancreatic cancer: A review of recent findings. Molecular Carcinogenesis 51(1):98–108.

Androutsopoulos VP, Tsatsakis AM, Spandidos DA. 2009. Cytochrome P450 CYP1A1: Wider roles in cancer progression and prevention. BMC Cancer 9:187.

Arnold LL, Eldan M, Nyska A, van Gemert M, Cohen SM. 2006. Dimethylarsinic acid: Results of chronic toxicity/oncogenicity studies in F344 rats and in B6C3F1 mice. Toxicology 223(1-2):82–100.

Asp S, Riihimaki V, Hernberg S, Pukkala E. 1994. Mortality and cancer morbidity of Finnish chlorophenoxy herbicide applicators: An 18-year prospective follow-up. American Journal of Industrial Medicine 26(2):243–253.

Aussem A, de Morais SR, Corbex M. 2012. Analysis of nasopharyngeal carcinoma risk factors with Bayesian networks. Artificial Intelligence in Medicine 54(1):53–62.

Axelson O, Sundell L, Andersson K, Edling C, Hogstedt C, Kling H. 1980. Herbicide exposure and tumor mortality. An updated epidemiologic investigation on Swedish railroad workers. Scandinavian Journal of Work, Environment, and Health 6(1):73–79.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens—Part F: Chemical agents and related occupations. Lancet Oncology 10(12):1143–1144.

Baccarelli A, Hirt C, Pesatori AC, Consonni D, Patterson DG Jr, Bertazzi PA, Dolken G, Landi MT. 2006. t(14;18) translocations in lymphocytes of healthy dioxin-exposed individuals from Seveso, Italy. Carcinogenesis 27(10):2001–2007.

Bagga D, Anders KH, Wang HJ, Roberts E, Glaspy JA. 2000. Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects. Journal of the National Cancer Institute 92(9):750–753.

Balarajan R, Acheson ED. 1984. Soft tissue sarcomas in agriculture and forestry workers. Journal of Epidemiology and Community Health 38(2):113–116.

Band PR, Abanto Z, Bert J, Lang B, Fang R, Gallagher RP, Le ND. 2011. Prostate cancer risk and exposure to pesticides in British Columbia farmers. The Prostate 71:168–183.

Barhoover MA, Hall JM, Greenlee WF, Thomas RS. 2010. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Molecular Pharmacology 77(2):195–201.

Barouki R, Coumoul X. 2010. Cell migration and metastasis markers as targets of environmental pollutants and the aryl hydrocarbon receptor. Cell Adhesion and Migration 4(1):72–76.

Barry KH, Koutros S, Berndt SI, Andreotti G, Hoppin JA, Sandler DP, Burdette LA, Yeager M, Freeman LE, Lubin JH, Ma X, Zheng T, Alavanja MC. 2011. Genetic variation in base excision repair pathway genes, pesticide exposure, and prostate cancer risk. Environmental Health Perspectives 119(12):1726–1732.

Barry KH, Koutros S, Andreotti G, Sandler DP, Burdette LA, Yeager M, Beane Freeman LE, Lubin JH, Ma X, Zheng T, Alavanja MC, Berndt SI. 2012. Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk. Carcinogenesis 33(2):331–337.

Baumann JL, Cohen S, Evjen AN, Law JH, Vadivelu S, Attia A, Schindler JS, Chung CH, Wirth PS, Meijer CJ, Yarbrough WG, Slebos RJ. 2009. Human papillomavirus in early laryngeal carcinoma. Laryngoscope 119:1531–1537.

Becher H, Flesch-Janys D, Kauppinen T, Kogevinas M, Steindorf K, Manz A, Wahrendorf J. 1996. Cancer mortality in German male workers exposed to phenoxy herbicides and dioxins. Cancer Causes and Control 7(3):312–321.

Beebe LE, Fornwald LW, Diwan BA, Anver MR, Anderson LM. 1995. Promotion of N-nitroso-diethylamine-initiated hepatocellular tumors and hepatoblastomas by 2,3,7,8-tetrachloro-dibenzo-p-dioxin or Aroclor 1254 in C57BL/6, DBA/2, and B6D2F1 mice. Cancer Research 55(21):4875–4880.

Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan R, Gruber S, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; the Genes Environment and Melanoma (GEM) Study Group. 2005. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. Journal of the National Cancer Institute 97:1507–1515.

Behrens T, Lynge E, Cree I, Lutz JM, Eriksson M, Guenel P, Merletti F, Morales-Suarez-Varela M, Afonso N, Stengrevics A, Fevotte J, Sabroe S, Llopis-Gonzalez A, Gorini G, Hardell L, Stang A, Ahrens W. 2012. Pesticide exposure in farming and forestry and the risk of uveal melanoma. Cancer Causes and Control 23(1):141–151.

Bender AP, Parker DL, Johnson RA, Scharber WK, Williams AN, Marbury MC, Mandel JS. 1989. Minnesota highway maintenance worker study: Cancer mortality. American Journal of Industrial Medicine 15(5):545–556.

Bertazzi PA, Zocchetti C, Pesatori AC, Guercilena S, Sanarico M, Radice L. 1989a. Mortality in an area contaminated by TCDD following an industrial incident. Medicina Del Lavoro 80(4):316–329.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Bertazzi PA, Zocchetti C, Pesatori AC, Guercilena S, Sanarico M, Radice L. 1989b. Ten-year mortality study of the population involved in the Seveso incident in 1976. American Journal of Epidemiology 129(6):1187–1200.

Bertazzi A, Pesatori AC, Consonni D, Tironi A, Landi MT, Zocchetti C. 1993. Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-para-dioxin. Epidemiology 4(5):398–406.

Bertazzi PA, Zochetti C, Guercilena S, Consonni D, Tironi A, Landi MT, Pesatori AC. 1997. Dioxin exposure and cancer risk: A 15-year mortality study after the “Seveso accident." Epidemiology 8(6):646–652.

Bertazzi PA, Bernucci I, Brambilla G, Consonni D, Pesatori AC. 1998. The Seveso studies on early and long-term effects of dioxin exposure: A review. Environmental Health Perspectives 106(Suppl 2):625–633.

Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C, Pesatori AC. 2001. Health effects of dioxin exposure: A 20-year mortality study. American Journal of Epidemiology 153(11):1031–1044.

Bertrand KA, Spiegelman D, Aster JC, Altshul LM, Korrick SA, Rodig SJ, Zhang SM, Kurth T, Laden F. 2010. Plasma organochlorine levels and risk of non-Hodgkin lymphoma in a cohort of men. Epidemiology 21(2):172–180.

Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber S, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busan K, From L, Mujumdar U, Wilcox H, Begg CB; the GEM Study Group. 2006. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: An international population-based study. Cancer Epidemiology, Biomarkers and Prevention 15:1520–1525.

Birnbaum LS, Fenton SE. 2003. Cancer and developmental exposure to endocrine disruptors. Environmental Health Perspectives 111(4):389–394.

Bhat AR, Wani MA, Kirmani AR, Raina TH. 2010. Pesticides and brain cancer linked in orchard farmers of Kashmir. Indian Journal of Medical and Paediatric Oncology 31(4):110–120.

Black MB, Budinsky RA, Dombkowski A, Cukovic D, LeCluyse EL, Ferguson SS, Thomas RS, Rowlands JC. 2012. Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicological Sciences 127(1):199–215.

Blair A, White DW. 1985. Leukemia cell types and agricultural practices in Nebraska. Archives of Environmental Health 40(4):211–214.

Blair A, Grauman DJ, Lubin JH, Fraumeni JF Jr. 1983. Lung cancer and other causes of death among licensed pesticide applicators. Journal of the National Cancer Institute 71(1):31–37.

Blair A, Dosemeci M, Heineman EF. 1993. Cancer and other causes of death among male and female farmers from twenty-three states. American Journal of Industrial Medicine 23(5):729–742.

Blair A, Sandler DP, Tarone R, Lubin J, Thomas K, Hoppin JA, Samanic C, Coble J, Kamel F, Knott C, Dosemeci M, Zahm SH, Lynch CF, Rothman N, Alavanja MC. 2005a. Mortality among participants in the Agricultural Health Study. Annals of Epidemiology 15(4):279–285.

Blair A, Sandler D, Thomas K, Hoppin JA, Kamel F, Coble J, Lee WJ, Rusiecki J, Knott C, Dosemeci M, Lynch CF, Lubin J, Alavanja M. 2005b. Disease and injury among participants in the Agricultural Health Study. Journal of Agricultural Safety and Health 11(2):1410–150.

Bloemen LJ, Mandel JS, Bond GG, Pollock AF, Vitek RP, Cook RR. 1993. An update of mortality among chemical workers potentially exposed to the herbicide 2,4-dichlorophenoxyacetic acid and its derivatives. Journal of Occupational Medicine 35(12):1208–1212.

Blot WJ, McLaughlin JK. 1999. The changing epidemiology of esophageal cancer. Seminars in Oncology 26(5 Suppl 15):2–8.

Bodner KM, Collins JJ, Bloemen LJ, Carson ML. 2003. Cancer risk for chemical workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Occupational and Environmental Medicine 60(9):672–675.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Boehmer TK, Flanders WD, McGeehin MA, Boyle C, Barrett DH. 2004. Postservice mortality in Vietnam veterans: 30-year follow-up. Archives of Internal Medicine 164(17):1908–1916.

Boers D, Portengen L, Bueno de Mesquita HB, Heederik D, Vermeulen R. 2010. Cause-specific mortality of Dutch chlorophenoxy herbicide manufacturing workers. Occupational and Environmental Medicine 67(1):24–31.

Boers D, Portengen L, Turner WE, Bueno de Mesquita HB, Heederik D, Vermeulen R. 2012. Plasma dioxin levels and cause-specific mortality in an occupational cohort of workers exposed to chlorophenoxy herbicides, chlorophenols and contaminants. Occupational and Environmental Medicine 69(2):113–118.

Boffetta P, Stellman SD, Garfinkel L. 1989. A case-control study of multiple myeloma nested in the American Cancer Society prospective study. International Journal of Cancer 43(4):554–559.

Bond GG, Wetterstroem NH, Roush GJ, McLaren EA, Lipps TE, Cook RR. 1988. Cause specific mortality among employees engaged in the manufacture, formulation, or packaging of 2,4-dichlorophenoxyacetic acid and related salts. British Journal of Industrial Medicine 45(2):98–105.

Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, Ghisari M, Mulvad G, Kern P, Nzulumiki P, Dewailly E. 2011. Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: A case control study. Environmental Health: A Global Access Science Source 10(1):88.

Bonneterre V, Deschamps E, Persoons R, Bernardet C, Liaudy S, Maitre A, de Gaudemaris R. 2007. Sino-nasal cancer and exposure to leather dust. Occupational Medicine 57(6):438–443.

Borlak J, Jenke HS. 2008. Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation. Molecular Cancer Research 6(8):1326–1336.

Bosl GJ, Motzer RJ. 1997. Testicular germ-cell cancer. New England Journal of Medicine 337(4):242–253.

Boutros PC, Yan R, Moffat ID, Pohjanvirta R, Okey AB. 2008. Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: Comparison of rat and mouse. BMC Genomics 9:419.

Boutros PC, Bielefeld KA, Pohjanvirta R, Harper PA. 2009. Dioxin-dependent and dioxin-independent gene batteries: Comparison of liver and kidney in AHR-null mice. Toxicological Sciences 112(1):245–256.

Boyle C, Decoufle P, Delaney RJ, DeStefano F, Flock ML, Hunter MI, Joesoef MR, Karon JM, Kirk ML, Layde PM, McGee DL, Moyer LA, Pollock DA, Rhodes P, Scally MJ, Worth RM. 1987. Postservice Mortality Among Vietnam Veterans. Atlanta, GA: Centers for Disease Control. CEH 86–0076. 143 pps.

Bradlow H. 2008. Review: Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. In Vivo 22(4):441–445.

Brady PS. 2011. Not dead yet. The VVA Veteran (March/April). http://digitaledition.qwinc.com/display_article.php?id=675095 (accessed October 29, 2013).

Bräuner EV, Sørensen M, Gaudreau E, LeBlanc A, Eriksen KT, Tjønneland A, Overvad K, Raaschou-Nielsen O. 2012. A prospective study of organochlorines in adipose tissue and risk of non-Hodgkin lymphoma. Environmental Health Perspectives 120(1):105–111.

Bredhult C, Backlin BM, Olovsson M. 2007. Effects of some endocrine disruptors on the proliferation and viability of human endometrial endothelial cells in vitro. Reproductive Toxicology 23(4):550–559.

Brenner J, Rothenbacher D, Arndt V. 2009. Epidemiology of stomach cancer. Methods in Molecular Biology 472:467–477.

Breslin P, Lee Y, Kang H, Burt V, Shepard BM. 1986. A Preliminary Report: The Vietnam Veterans Mortality Study. Washington, DC: Veterans Administration, Office of Environmental Epidemiology.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Breslin P, Kang H, Lee Y, Burt V, Shepard BM. 1988. Proportionate mortality study of US Army and US Marine Corps veterans of the Vietnam War. Journal of Occupational Medicine 30(5):412–419.

Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM, Burmeister LF, Van Lier SF, Dick F. 1990. Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Research 50(20):6585–6591.

Brown LM, Burmeister LF, Everett GD, Blair A. 1993. Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes and Control 4(2):153–156.

Brunnberg S, Andersson P, Lindstam M, Paulson I, Poellinger L, Hanberg A. 2006. The constitutively active Ah receptor (CA-Ahr) mouse as a potential model for dioxin exposure—Effects in vital organs. Toxicology 224(3):191–201.

Bueno de Mesquita HB, Doornbos G, Van der Kuip DA, Kogevinas M, Winkelmann R. 1993. Occupational exposure to phenoxy herbicides and chlorophenols and cancer mortality in the Netherlands. American Journal of Industrial Medicine 23(2):289–300.

Bullman TA, Kang HK, Watanabe KK. 1990. Proportionate mortality among US Army Vietnam veterans who served in Military Region I. American Journal of Epidemiology 132(4):670–674.

Burmeister LF. 1981. Cancer mortality in Iowa farmers, 1971–1978. Journal of the National Cancer Institute 66(3):461–464.

Burmeister LF, Van Lier SF, Isacson P. 1982. Leukemia and farm practices in Iowa. American Journal of Epidemiology 115(5):720–728.

Burmeister LF, Everett GD, Van Lier SF, Isacson P. 1983. Selected cancer mortality and farm practices in Iowa. American Journal of Epidemiology 118(1):72–77.

Burns CJ, Beard KK, Cartmill JB. 2001. Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid (2,4-D) 1945–1994: An update. Occupational and Environmental Medicine 58(1):24–30.

Burns C, Bodner K, Swaen G, Collins J, Beard K, Lee M. 2011. Cancer incidence of 2,4-D production workers. International Journal of Environmental Research and Public Health 8(9):3579–3590.

Burt VL, Breslin PP, Kang HK, Lee Y. 1987. Non-Hodgkin’s Lymphoma in Vietnam Veterans. Washington, DC, Department of Medicine and Surgery, Veterans Administration. 33 pps.

Butler R, Inzunza J, Suzuki H, Fujii-Kuriyama Y, Warner M, Gustafsson JA. 2012. Uric acid stones in the urinary bladder of aryl hydrocarbon receptor (AhR) knockout mice. Proceedings of the National Academy of Sciences of the United States of America 109(4):1122–1126.

Buxbaum JN. 2004. The systemic amyloidoses. Current Opinion in Rheumatology 16(1):67–75.

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. 2008. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 117(19):5019–5032.

Cantor KP. 1982. Farming and mortality from non-Hodgkin’s lymphoma: A case-control study. International Journal of Cancer 29(3):239–247.

Cantor KP, Blair A. 1984. Farming and mortality from multiple myeloma: A case control study with the use of death certificates. Journal of the National Cancer Institute 72(2):251–255.

Cantor KP, Blair A, Everett G, Gibson R, Burmeister LF, Brown LM, Schuman L, Dick FR. 1992. Pesticides and other agricultural risk factors for non-Hodgkin’s lymphoma among men in Iowa and Minnesota. Cancer Research 52:2447–2455.

Caplan LS, Hall HI, Levine RS, Zhu K. 2000. Preventable risk factors for nasal cancer. Annals of Epidemiology 10(3):186–191.

Carlson E, McCulloch C, Koganti A, Goodwin S, Sutter T, Silkworth J. 2009. Divergent transcriptomic responses to aryl hydrocarbon receptor agonists between rat and human primary hepatocytes. Toxicological Sciences 112(1):257–272.

Carreon T, Butler MA, Ruder AM, Waters MA, Davis-King KE, Calvert GM, Schulte PA, Connally B, Ward EM, Sanderson WT, Heineman EF, Mandel JS, Morton RF, Reding DJ, Rosenman KD, Talaska G; Brain Cancer Collaborative Group. 2005. Gliomas and farm pesticide exposure in women: The Upper Midwest Health Study. Environmental Health Perspectives 113(5):546–551.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Casado FL, Singh KP, Gasiewicz TA. 2011. Aryl hydrocarbon receptor activation in hematopoietic stem/progenitor cells alters cell function and pathway-specific gene modulation reflecting changes in cellular trafficking and migration. Molecular Pharmacology 80(4):673–682.

CDC (Centers for Disease Control and Prevention). 1990a. The association of selected cancers with service in the US military in Vietnam. III. Hodgkin’s disease, nasal cancer, nasopharyngeal cancer, and primary liver cancer. The Selected Cancers Cooperative Study Group. Archives of Internal Medicine 150(12):2495–2505.

CDC. 1990b. The association of selected cancers with service in the US military in Vietnam. I. Non-Hodgkin’s lymphoma. Archives of Internal Medicine 150:2473–2483.

CDVA (Commonwealth Department of Veterans’ Affairs). 1997a. Mortality of Vietnam Veterans: The Veteran Cohort Study. A Report of the 1996 Retrospective Cohort Study of Australian Vietnam Veterans. Canberra, Australia: Department of Veterans’ Affairs.

CDVA. 1997b. Mortality of National Service Vietnam Veterans: A Report of the 1996 Retrospective Cohort Study of Australian Vietnam Veterans. Canberra, Australia: Department of Veterans’ Affairs.

CDVA. 1998a. Morbidity of Vietnam Veterans: A Study of the Health of Australia’s Vietnam Veteran Community. Volume 1: Male Vietnam Veterans Survey and Community Comparison Outcomes. Canberra, Australia: Department of Veterans’ Affairs.

CDVA. 1998b. Morbidity of Vietnam Veterans: A Study of the Health of Australia’s Vietnam Veteran Community. Volume 2: Female Vietnam Veterans Survey and Community Comparison Outcomes. Canberra, Australia: Department of Veterans’ Affairs.

Chamie K, de Vere White R, Volpp B, Lee D, Ok J, Ellison L. 2008. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer 113(9):2464–2470.

Charles JM, Bond DM, Jeffries TK, Yano BL, Stott WT, Johnson KA, Cunny HC, Wilson RD, Bus JS. 1996. Chronic dietary toxicity/oncogenicity studies on 2,4-dichlorophenoxyacetic acid in rodents. Fundamental and Applied Toxicology 33:166–172.

Charles LE, Burchfiel CM, Fekedulegn D, Gu JK, Petrovich H, Sanderson WT, Masaki K, Rodriguez BL, Ross GW. 2010. Occupational exposure to pesticides, metals, and solvents: The impact on mortality in the Honolulu Heart Program. Work 37:205–215.

Chen X, Ma SW, Ma XM, Xu YJ, Tang NJ. 2012. Changes in fibrinopeptide A peptides in the sera of rats chronically exposed to low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Environmental Toxicology and Pharmacology 33:191–196.

Chen YJ, Hung CM, Kay N, Chen CC, Kao YH, Yuan SS. 2012. Progesterone receptor is involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin-stimulated breast cancer cells proliferation. Cancer Letters 319(2):223–231.

Chiorazzi N, Rai KR, Ferrarini M. 2005. Mechanisms of disease: Chronic lymphocytic leukemia. The New England Journal of Medicine 352(8):804–815.

Chiu BC, Weisenburger DD, Zahm SH, Cantor KP, Gapstur SM, Holmes F, Burmeister LF, Blair A. 2004. Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. Cancer Epidemiology, Biomarkers and Prevention 13(4):525–531.

Chiu BC, Dave BJ, Blair A, Gapstur SM, Zahm SH, Weisenburger DD. 2006. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 108(4):1363–1369.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators. 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women’s Health Initiative Randomized Trial. Journal of the American Medical Association 289(24):3243–3253.

Chopra M, Dharmarajan AM, Meiss G, Schrenk D. 2009. Inhibition of UV-C light-induced apoptosis in liver cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicological Sciences 111(1):49–63.

Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, Chen YT, Hsueh YM. 2008. Urinary 8-hydroxy-deoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. Toxicology and Applied Pharmacology 226(1):14–21.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Clapp RW. 1997. Update of cancer surveillance of veterans in Massachusetts, USA. International Journal of Epidemiology 26(3):679–681.

Clapp RW, Cupples LA, Colton T, Ozonoff DM. 1991. Cancer surveillance of veterans in Massachusetts, 1982–1988. International Journal of Epidemiology 20(1):7–12.

Cocco P, Heineman EF, Dosemeci M. 1999. Occupational risk factors for cancer of the central nervous system (CNS) among US women. American Journal of Industrial Medicine 36(1):70–74.

Coggon D, Pannett B, Winter PD, Acheson ED, Bonsall J. 1986. Mortality of workers exposed to 2-methyl-4-chlorophenoxyacetic acid. Scandinavian Journal of Work, Environment, and Health 12(5):448–454.

Coggon D, Pannett B, Winter P. 1991. Mortality and incidence of cancer at four factories making phenoxy herbicides. British Journal of Industrial Medicine 48(3):173–178.

Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz MV, Dhodapkar J, Teruya-Feldstein D, Filippa D, Comenzo RL. 2004. Systemic AL amyloidosis due to non-Hodgkin’s lymphoma: An unusual clinicopathologic association. British Journal of Haematology 124:309–314.

Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD. 2006. Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Critical Reviews in Toxicology 36(2):99–133.

Collins JJ, Strauss ME, Levinskas GJ, Conner PR. 1993. The mortality experience of workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a trichlorophenol process accident. Epidemiology 4(1):7–13.

Collins JJ, Bodner K, Aylward LL, Wilken M, Bodner CM. 2009a. Mortality rates among trichlorophenol workers with exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. American Journal of Epidemiology 170(4):501–506.

Collins JJ, Bodner K, Aylward LL, Wilken M, Swaen G, Budinsky R, Rowlands C, Bodnar CM. 2009b. Mortality rates among workers exposed to dioxins in the manufacture of pentachlorophenol. Journal of Occupational and Environmental Medicine 51(10):1212–1219.

Comba P, Ascoli V, Belli S, Benedetti M, Gatti L, Ricci P, Tieghi A. 2003. Risk of soft tissue sarcomas and residence in the neighbourhood of an incinerator of industrial wastes. Occupational and Environmental Medicine 60(9):680–683.

Consonni D, Pesatori AC, Zocchetti C, Sindaco R, D’Oro LC, Rubagotti M, Bertazzi PA. 2008. Mortality in a population exposed to dioxin after the Seveso, Italy, accident in 1976: 25 Years of follow-up. American Journal of Epidemiology 167(7):847–858.

Cordier S, Poisson M, Gerin M, Varin J, Conso F, Hemon D. 1988. Gliomas and exposure to wood preservatives. British Journal of Industrial Medicine 45:705–709.

Cordier S, Le TB, Verger P, Bard D, Le CD, Larouze B, Dazza MC, Hoang TQ, Abenhaim L. 1993. Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. International Journal of Cancer 55(2):196–201.

Corrao G, Caller M, Carle F, Russo R, Bosia S, Piccioni P. 1989. Cancer risk in a cohort of licensed pesticide users. Scandinavian Journal of Work, Environment, and Health 15(3):203–209.

Costani G, Rabitti P, Mambrini A, Bai E, Berrino F. 2000. Soft tissue sarcomas in the general population living near a chemical plant in northern Italy. Tumori 86(5):381–383.

Cypel Y, Kang H. 2008. Mortality patterns among women Vietnam-era veterans: Results of a retrospective cohort study. Annals of Epidemiology 18(3):244–252.

Cypel Y, Kang H. 2010. Mortality patterns of Army Chemical Corps veterans who were occupationally exposed to herbicides in Vietnam. Annals of Epidemiology 20(5):339–346.

Dalager NA, Kang HK. 1997. Mortality among Army Chemical Corps Vietnam veterans. American Journal of Industrial Medicine 31(6):719–726.

Dalager NA, Kang HK, Burt VL, Weatherbee L. 1991. Non-Hodgkin’s lymphoma among Vietnam veterans. Journal of Occupational Medicine 33(7):774–779.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Dalager NA, Kang HK, Thomas TL. 1995. Cancer mortality patterns among women who served in the military: The Vietnam experience. Journal of Occupational and Environmental Medicine 37(3):298–305.

Davis BJ, McCurdy EA, Miller BD, Lucier GW, Tritscher AM. 2000. Ovarian tumors in rats induced by chronic 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. Cancer Research 60(19):5414–5419.

Dean G. 1994. Deaths from primary brain cancers, lymphatic and haematopoietic cancers in agricultural workers in the Republic of Ireland. Journal of Epidemiology and Community Health 48(4):364–368.

Degner SC, Papoutsis AJ, Selmin O, Romagnolo DF. 2009. Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3’-di-indolylmethane in breast cancer cells. Journal of Nutrition 139(1):26–32.

Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E. 2000. Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiology, Biomarkers and Prevention 9(2):161–166.

Dennis LK, Lynch CF, Sandler DP, Alavanja M. 2010. Pesticide use and cutaneous melanoma in pesticide applicators in the Agricultural Health Study. Environmental Health Perspectives 118(6):812–817.

Dere E, Boverhof DR, Burgoon LD, Zacharewski TR. 2006. In vivo-in vitro toxicogenomic comparison of TCDD-elicited gene expression in Hepa1c1c7 mouse hepatoma cells and C57BL/6 hepatic tissue. BMC Genomics 7:80.

d’Errico A, Pasian S, Baratti A, Zanelli R, Alfonzo S, Gilardi L, Beatrice F, Bena A, Costa G. 2009. A case-control study on occupational risk factors for sino-nasal cancer. Occupational and Environmental Medicine 66(7):448–455.

Desaulniers D, Leingartner K, Russo J, Perkins G, Chittim BG, Archer MC, Wade M, Yang J. 2001. Modulatory effects of neonatal exposure to TCDD or a mixture of PCBs, p,p’-DDT, and p-p’-DDE on methylnitrosourea-induced mammary tumor development in the rat. Environmental Health Perspectives 109:739–747.

Desaulniers D, Leingartner K, Musicki B, Cole J, Li M, Charboneau M, Tsang BK. 2004. Lack of effects of postnatal exposure to a mixture of aryl hydrocarbon-receptor agonists on the development of methylnitrosourea-induced mammary tumors in Sprague-Dawley rats. Journal of Toxicology and Environmental Health, Part A 67(18):1457–1475.

Dich J, Wiklund K. 1998. Prostate cancer in pesticide applicators in Swedish agriculture. Prostate 34(2):100–112.

Dietrich C, Kaina B. 2010. The aryl hydrocarbon receptor (AHR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31(8):1319–1328.

DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. 2010. Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. Journal of Biological Chemistry 285(32):24388–24397.

DiNatale BC, Schroeder JC, Perdew GH. 2011. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Molecular Carcinogenesis 50(3):173–183.

Donna A, Betta PG, Robutti F, Crosignani P, Berrino F, Bellingeri D. 1984. Ovarian mesothelial tumors and herbicides: A case-control study. Carcinogenesis 5(7):941–942.

Dopp E, Von Recklinghausen U, Hartmann LM, Stueckradt I, Pollok I, Rabieh S, Hao L, Nussler A, Katier C, Hirner AV, Rettenmeier AW. 2008. Subcellular distribution of inorganic and methylated arsenic compounds in human urothelial cells and human hepatocytes. Drug Metabolism and Disposition 36(5):971–979.

Dubrow R, Paulson JO, Indian RW. 1988. Farming and malignant lymphoma in Hancock County, Ohio. British Journal of Industrial Medicine 45(1):25–28.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Duell EJ, Millikan RC, Savitz DA, Newman B, Smith JC, Schell MJ, Sandler DP. 2000. A population-based case-control study of farming and breast cancer in North Carolina. Epidemiology 11(5):523–531.

Ekström AM, Eriksson M, Hansson LE, Lindgren A, Signorello LB, Nyrén O, Hardell L. 1999. Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Research 59:5932–5937.

Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, Dov A, Marcusson EG, Bennett CF, Chajut A, Cohen D, Yerushalmi N. 2010. Hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Research 70(20):8077–8087.

Engel LS, Hill DA, Hoppin JA, Lubin JH, Lynch CF, Pierce J, Samanic C, Sandler DP, Blair A, Alavanja MC. 2005. Pesticide use and breast cancer risk among farmers’ wives in the Agricultural Health Study. American Journal of Epidemiology 161(2):121–135.

Engel LS, Laden F, Andersen A, Strickland PT, Blair A, Needham LL, Barr DB, Wolff MS, Helzlsouer K, Hunter DJ, Lan Q, Cantor KP, Comstock GW, Brock, JW, Bush D, Hoover RN, Rothman N. 2007. Polychlorinated biphenyl levels in peripheral blood and non-Hodgkin’s lymphoma: A report from three cohorts. Cancer Research 67(11):5545–5552.

Eriksson M, Karlsson M. 1992. Occupational and other environmental factors and multiple myeloma: A population based case-control study. British Journal of Industrial Medicine 49(2):95–103.

Eriksson M, Hardell L, Berg NO, Moller T, Axelson O. 1979. Case-control study on malignant mesenchymal tumor of the soft tissue and exposure to chemical substances. Lakartidningen 76(44):3872–3875.

Eriksson M, Hardell L, Berg NO, Moller T, Axelson O. 1981. Soft-tissue sarcomas and exposure to chemical substances: A case-referent study. British Journal of Industrial Medicine 38(1):27–33.

Eriksson M, Hardell L, Adami HO. 1990. Exposure to dioxins as a risk factor for soft tissue sarcoma: A population-based case-control study. Journal of the National Cancer Institute 82:486–490.

Eriksson M, Hardell L, Malker H, Weiner J. 1992. Malignant lymphoproliferative diseases in occupations with potential exposure to phenoxyacetic acids or dioxins: A register-based study. American Journal of Industrial Medicine 22:305–312.

Eriksson M, Hardell L, Carlberg M, Akerman M. 2008. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. International Journal of Cancer 123(7):1657–1663.

Fenton SE. 2006. Endocrine-disrupting compounds and mammary gland development: Early exposure and later life consequences. Endocrinology 147(6):S18-S24.

Fenton SE. 2009. The mammary gland: A tissue sensitive to environmental exposures. Reviews on Environmental Health 24(4):319–325.

Feron VJ, Arts JH, Kuper CF, Slootweg PJ, Woutersen RA. 2001. Health risks associated with inhaled nasal toxicants. Critical Reviews in Toxicology 31(3):313–347.

Fett MJ, Nairn JR, Cobbin DM, Adena MA. 1987. Mortality among Australian conscripts of the Vietnam conflict era. II. Causes of death. American Journal of Epidemiology 125(15):878–884.

Fingerhut MA, Halperin WE, Marlow DA, Piacitelli LA, Honchar PA, Sweeney MH, Greife AL, Dill PA, Steenland K, Suruda AJ. 1991. Cancer mortality in workers exposed to 2,3,7,8-tetrachloro-dibenzo-p-dioxin. New England Journal of Medicine 324(4):212–218.

Fleming LE, Bean JA, Rudolph M, Hamilton K. 1999a. Mortality in a cohort of licensed pesticide applicators in Florida. Journal of Occupational and Environmental Medicine 56(1):14–21.

Fleming LE, Bean JA, Rudolph M, Hamilton K. 1999b. Cancer incidence in a cohort of licensed pesticide applicators in Florida. Journal of Occupational and Environmental Medicine 41(4):279–288.

Flesch-Janys D, Berger J, Gurn P, Manz A, Nagel S, Waltsgott H, Dwyer JH. 1995. Exposure to polychlorinated dioxins and furans (PCDD/F) and mortality in a cohort of workers from a herbicide-producing plant in Hamburg, Federal Republic of Germany. American Journal of Epidemiology 142(11):1165–1175.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Floret N, Mauny F, Challier B, Arveux P, Cahn JY, Viel JF. 2003. Dioxin emissions from a solid waste incinerator and risk of non-Hodgkin lymphoma. Epidemiology 14(4):392–398.

Fracchiolla NS, Todoerti K, Bertazzi PA, Servida F, Corradini P, Carniti C, Colombi A, Pesatori AC, Neri A, Deliliers GL. 2011. Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. Toxicology 283:18–23.

Fritschi L, Benke G, Hughes AM, Kricker A, Turner J, Vajdic CM, Grulich A, Milliken S, Kaldor J, Armstrong BK. 2005. Occupational exposure to pesticides and risk of non-Hodgkin’s lymphoma. American Journal of Epidemiology 162(9):849–857.

Fritz WA, Lin TM, Moore RW, Cooke PS, Peterson RE. 2005. In utero and lactational 2,3,7,8-tet-rachlorodibenzo-p-dioxin exposure: Effects on the prostate and its response to castration in senescent C57BL/6J mice. Toxicological Sciences 86(2):387–395.

Fritz WA, Lin TM, Peterson RE. 2008. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 29(5):1077–1082.

Frost G, Brown T, Harding AH. 2011. Mortality and cancer incidence among British agricultural pesticide users. Occupational Medicine 61(5):303–310.

Fukuda Y, Nakamura K, Takano T. 2003. Dioxins released from incineration plants and mortality from major diseases: An analysis of statistical data by municipalities. Journal of Medical and Dental Sciences 50(4):249–255.

Fukushima S, Morimura K, Wanibuchi H, Kinoshita A, Salim EI. 2005. Current and emerging challenges in toxicopathology: Carcinogenic threshold of phenobarbital and proof of arsenic carcinogenicity using rat medium-term bioassays for carcinogens. Toxicology and Applied Pharmacology 207(Suppl 2):225–229.

Gallagher RP, Bajdik CD, Fincham S, Hill GB, Keefe AR, Coldman A, McLean DI. 1996. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiology, Biomarkers and Prevention 5(6):419–424.

Gallagher RP, MacArthur AC, Lee TK, Weber JP, Leblanc A, Mark Elwood J, Borugian M, Abanto Z, Spinelli JJ. 2011. Plasma levels of polychlorinated biphenyls and risk of cutaneous malignant melanoma: A preliminary study. International Journal of Cancer 128(8):1872–1880.

Gambini GF, Mantovani C, Pira E, Piolatto PG, Negri E. 1997. Cancer mortality among rice growers in Novara Province, northern Italy. American Journal of Industrial Medicine 31(4):435–441.

Gann PH. 1997. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 8(2):117–120.

Garland FC, Gorham ED, Garland CF, Ferns JA. 1988. Non-Hodgkin’s lymphoma in US Navy personnel. Archives of Environmental Health 43(6):425–429.

Gelman A. 2013. How many Vietnam veterans are still alive? New York Times (March 25, 2013). http://www.nytimes.com/2013/03/26/science/how-many-vietnam-veterans-are-still-alive.html (accessed October 29, 2013).

Gillison ML, Shah KV. 2001. Human papillomavirus-associated head and neck squamous cell carcinoma: A mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Current Opinions in Oncology 13:183–188.

Gillison, ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsaque X. 2012. Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis. Vaccine 30(Suppl 5):F34-F54.

Giri VN, Cassidy AE, Beebe-Dimmer J, Smith DC, Bock CH, Cooney KA. 2004. Association between Agent Orange and prostate cancer: A pilot case-control study. Urology 63(4):757–760; discussion 760–761.

Gold LS, De Roos AJ, Brown EE, Lan Q, Milliken K, Davis S, Chanock SJ, Zhang Y, Severson R, Zahm SH, Zheng T, Rothman N, Baris D. 2009. Association of common varients in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiology 33:276–280.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Green LM. 1991. A cohort mortality study of forestry workers exposed to phenoxy acid herbicides. British Journal of Industrial Medicine 48(4):234–238.

Greenwald P, Kovasznay B, Collins DN, Therriault G. 1984. Sarcomas of soft tissues after Vietnam service. Journal of the National Cancer Institute 73(5):1107–1109.

Grimsrud TK, Peto J. 2006. Persisting risk of nickel related lung cancer and nasal cancer among Clydach refiners. Occupational and Environmental Medicine 63(5):365–366.

Gupta A, Ketchum N, Roehrborn CG, Schecter A, Aragaki CC, Michalek JE. 2006. Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: A prospective cohort study of Air Force veterans. Environmental Health Perspectives 114(11):1649–1654.

Hahn WC, Weinberg RA. 2002. Rules for making human tumor cells. New England Journal of Medicine 347(20):1593–1603.

Hallquist A, Hardell L, Degerman A, Boquist L. 1993. Occupational exposures and thyroid cancer: Results of a case-control study. European Journal of Cancer Prevention 2(4):345–349.

Halwachs S, Lakoma C, Gebhardt R, Schafer I, Seibel P, Honscha W. 2010. Dioxin mediates down-regulation of the reduced folate carrier transport activity via the arylhydrocarbon receptor signalling pathway. Toxicology and Applied Pharmacology 246(1–2):100–106.

Hansen ES, Hasle H, Lander F. 1992. A cohort study on cancer incidence among Danish gardeners. American Journal of Industrial Medicine 21(5):651–660.

Hansen ES, Lander F, Lauritsen JM. 2007. Time trends in cancer risk and pesticide exposure, a longterm follow-up of Danish gardeners. Scandinavian Journal of Work, Environment, and Health 33(6):465–469.

Hardell L. 1981. Relation of soft-tissue sarcoma, malignant lymphoma and colon cancer to phenoxy acids, chlorophenols and other agents. Scandinavian Journal of Work, Environment, and Health 7(2):119–130.

Hardell L, Sandström A. 1979. Case-control study: Soft-tissue sarcomas and exposure to phenoxyacetic acids or chlorophenols. British Journal of Cancer 39:711–717.

Hardell L, Bengtsson NO. 1983. Epidemiological study of socioeconomic factors and clinical findings in Hodgkin’s disease, and reanalysis of previous data regarding chemical exposure. British Journal of Cancer 48(2):217–225.

Hardell L, Eriksson M. 1988. The association between soft tissue sarcomas and exposure to phenoxyacetic acids: A new case-referent study. Cancer 62:652–656.

Hardell L, Eriksson M, Lenner P, Lundgren E. 1981. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: A case-control study. British Journal of Cancer 43:169–176.

Hardell L, Johansson B, Axelson O. 1982. Epidemiological study of nasal and nasopharyngeal cancer and their relation to phenoxy acid or chlorophenol exposure. American Journal of Industrial Medicine 3(3):247–257.

Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. 1984. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria: An epidemiological investigation. British Journal of Cancer 50(3):389–397.

Hardell L, Eriksson M, Degerman A. 1994. Exposure to phenoxyacetic acids, chlorophenols, or organic solvents in relation to histopathology, stage, and anatomical localization of non-Hodgkin’s lymphoma. Cancer Research 54(9):2386–2389.

Hardell L, Nasman A, Ohlson CG, Fredrikson M. 1998. Case-control study on risk factors for testicular cancer. International Journal of Oncology 13(6):1299–1303.

Hardell L, Lindström G, van Bavel B, Hardell K, Linde A, Carlberg M, Liljegren G. 2001. Adipose tissue concentrations of dioxins and dibenzofurans, titers of antibodies to Epstein-Barr virus early antigen and the risk for non-Hodgkin’s lymphoma. Environmental Research 87(2):99–107.

Hardell L, Eriksson M, Nordstrom M. 2002. Exposure to pesticides as risk factor for non-Hodgkin’s lymphoma and hairy cell leukemia: Pooled analysis of two Swedish case-control studies. Leukemia and Lymphoma 43(5):1043–1049.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Hartge P, Colt JS, Severson RK, Cerhan JR, Cozen W, Camann D, Zahm SH, Davis S. 2005. Residential herbicide use and risk of non-Hodgkin lymphoma. Cancer Epidemiology, Biomarkers and Prevention 14(4):934–937.

Hayashi H, Kanisawa M, Yamanaka K, Ito T, Udaka N, Ohji H, Okudela K, Okada S, Kitamura H. 1998. Dimethylarsinic acid, a main metabolite of inorganic arsenics, has tumorigenicity and progression effects in the pulmonary tumors of A/J mice. Cancer Letters 125(1–2):83–88.

Hebert CD, Harris MW, Elwell MR, Birnbaum LS. 1990. Relative toxicity and tumor-promoting ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2,3,4,7,8-pentachlorodibenzofuran (PCDF), and 1,2,3,4,7,8-hexachlorodibenzofuran (HCDF) in hairless mice. Toxicology and Applied Pharmacology 102(2):362–377.

Henneberger PK, Ferris BG Jr, Monson RR. 1989. Mortality among pulp and paper workers in Berlin, New Hampshire. British Journal of Industrial Medicine 46(9):658–664.

Hernández LG, van Steeg H, Luijten M, van Benthem J. 2009. Review: Mechanisms of nongenotoxic carcinogens and importance of a weight of evidence approach. Mutation Research 682:94–109.

Heron M, Hoyert D, Murphy S, Xu J, Kochanek K, Tejada-Vera B. 2009. Deaths: Final data for 2006. National Vital Statistics Reports 57(14):1–80.

Hertzman C, Teschke K, Ostry A, Hershler R, Dimich-Ward H, Kelly S, Spinelli JJ, Gallagher RP, McBride M, Marion SA. 1997. Mortality and cancer incidence among sawmill workers exposed to chlorophenate wood preservatives. American Journal of Public Health 87(1):71–79.

Hoar SK, Blair A, Holmes FF, Boysen CD, Robel RJ, Hoover R, Fraumeni JF. 1986. Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. Journal of the American Medical Association 256(9):1141–1147.

Hobbs CG, Birchall MA. 2004. Human papillomavirus infection in the etiology of laryngeal carcinoma. Current Opinion in Otolaryngology and Head and Neck Surgery 12(2):88–92.

Hoffman RE, Stehr-Green PA, Webb KB, Evans RG, Knutsen AP, Schramm WF, Staake JL, Gibson BB, Steinberg KK. 1986. Health effects of long term exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Journal of the American Medical Association 255(15):2031–2038.

Hohenadel K, Harris SA, McLaughlin JR, Spinelli JJ, Pahwa P, Dosman JA, Demers PA, Blair A. 2011. Exposure to multiple pesticides and risk of non-Hodgkin lymphoma in men from six Canadian provinces. International Journal of Environmental Research and Public Health 8:2320–2330.

Holcombe M, Safe S. 1994. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Letters 82(1):43–47.

Holford TR, Zheng T, Mayne ST, Zahm SH, Tessari JD, Boyle P. 2000. Joint effects of nine polychlorinated biphenyl (PCB) congeners on breast cancer risk. International Journal of Epidemiology 29(6):975–982.

Hollingshead BD, Beischlag TV, Dinatale BC, Ramadoss P, Perdew GH. 2008. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Research 68(10):3609–3617.

Holmes AP, Bailey C, Baron RC, Bosanac E, Brough J, Conroy C, Haddy L. 1986. West Virginia Department of Health Vietnam-Era Veterans Mortality Study: Preliminary Report. Charles Town, WV: West Virginia Health Department.

Hooiveld M, Heederik DJ, Kogevinas M, Boffetta P, Needham LL, Patterson DG Jr, Bueno de Mesquita HB. 1998. Second follow-up of a Dutch cohort occupationally exposed to phenoxy her bicides, chlorophenols, and contaminants. American Journal of Epidemiology 147(9):891–901.

Høyer AP, Jørgensen T, Brock JW, Grandjean P. 2000. Organochlorine exposure and breast cancer survival. Journal of Clinical Epidemiology 53(3):323–330.

Hruba E, Vondracek J, Libalova H, Topinka J, Bryja V, Soucek K, Machala M. 2011. Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands. Toxicology Letters 206(2):178–188.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Hsu EL, Yoon D, Choi HH, Wang F, Taylor RT, Chen N, Zhang R, Hankinson O. 2007. A proposed mechanism for the protective effect of dioxin against breast cancer. Toxicological Sciences 98(2):436–444.

Huang YK, Pu YS, Chung CJ, Shiue HS, Yang MH, Chen CJ, Hsueh YM. 2008. Plasma folate level, urinary arsenic methylation profiles, and urothelial carcinoma susceptibility. Food and Chemical Toxicology 46(3):929–938.

Hussein MA, Juturi JV, Lieberman I. 2002. Multiple myeloma: Present and future. Current Opinions in Oncology 14(1):31–35.

IARC (International Agency for Research on Cancer). 2001. Pathology and genetics of tumours of the haemopoietic and lymphoid tissues. In: Jaffe NL, Harris H, Stein, Vardiman JW, eds. World-Health Organization, IARC.

Ikuta T, Namiki T, Fujii-Kuriyama Y, Kawajiri K. 2009. AHR protein trafficking and function in the skin. Biochemical Pharmacology 77(4):588–596.

IOM (Institute of Medicine). 1994. Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam. Washington, DC: National Academy Press.

IOM. 1996. Veterans and Agent Orange: Update 1996. Washington, DC: National Academy Press.

IOM. 1999. Veterans and Agent Orange: Update 1998. Washington, DC: National Academy Press.

IOM. 2001. Veterans and Agent Orange: Update 2000. Washington, DC: National Academy Press.

IOM. 2003. Veterans and Agent Orange: Update 2002. Washington, DC: The National Academies Press.

IOM. 2005. Veterans and Agent Orange: Update 2004. Washington, DC: The National Academies Press.

IOM. 2006. Asbestos: Selected Cancers. Washington, DC: The National Academies Press.

IOM. 2007. Veterans and Agent Orange: Update 2006. Washington, DC: The National Academies Press.

IOM. 2009. Veterans and Agent Orange: Update 2008. Washington, DC: The National Academies Press.

IOM. 2011. Veterans and Agent Orange: Update 2010. Washington, DC: The National Academies Press.

Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, Mukai M, Okada Y, Oya M. 2010. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31(2):287–295.

Jaffe ES. 2009. The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology 1:523–531.

Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). 2001. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press. 352 pps.

Jaffe ES, Harris NL, Stein H, Isaacson PG. 2008. Classification of lymphoid neoplasms: The microscope as a tool for disease discovery. Blood 112(12):4384–4397.

Jenkins S, Rowell C, Wang J, Lamartiniere CA. 2007. Prenatal TCDD exposure predisposes for mammary cancer in rats. Reproductive Toxicology 23(3):391–396.

Johnstone SE, Baylin SB. 2010. Stress and the epigenetic landscape: A link to the pathobiology of human diseases? Nature Reviews Genetics 11(11):806–812.

Kalmes M, Hennen J, Clemens J, Blömeke B. 2011. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. Journal of Biological Chemistry 392:643–651.

Kang HK, Weatherbee L, Breslin PP, Lee Y, Shepard BM. 1986. Soft tissue sarcomas and military service in Vietnam: A case comparison group analysis of hospital patients. Journal of Occupational Medicine 28(12):1215–1218.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Kang HK, Mahan CM, Lee KY, Magee CA, Selvin S. 2000. Prevalence of gynecologic cancers among female Vietnam veterans. Journal of Occupational and Environmental Medicine 42(11):1121–1127.

Karunanayake CP, Spinelli JJ, McLaughlin JR, Dosman JA, Pahwa P, McDuffie HH. 2012. Hodgkin lymphoma and pesticides exposure in men: A Canadian case-control study. Journal of Agromedicine 17(1):30–39.

Kato H, Kinshita T, Suzuki S, Nagasaka T, Hatano S, Murate T, Saito H, Hotta T. 1998. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin’s lymphoma. Leukemia and Lymphoma 29(1–2):71–79.

Kato I, Watanabe-Meserve H, Koenig KL, Baptiste MS, Lillquist PP, Frizzera G, Burke JS, Moseson M, Shore RE. 2004. Pesticide product use and risk of non-Hodgkin lymphoma in women. Environmental Health Perspectives 112(13):1275–1281.

Keller-Byrne JE, Khuder SA, Schaub EA, McAfee O. 1997. A meta-analysis of non-Hodgkin’s lymphoma among farmers in the central United States. American Journal of Industrial Medicine 31(4):442–444.

Kenborg L, Lassen CF, Lander F, Olsen JH. 2012. Parkinson’s disease among gardeners exposed to pesticides—A Danish cohort study. Scandinavian Journal of Work, Environment and Health 38 (1):65–69.

Ketchum NS, Michalek JE, Burton JE. 1999. Serum dioxin and cancer in veterans of Operation Ranch Hand. American Journal of Epidemiology 149(7):630–639.

Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. 2004. Diet, nutrition and the prevention of cancer. Public Health Nutrition 7(1A):187–200.

Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR. 2009. Comparative analysis of AHR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicological Sciences 112(1):229–244.

Knerr S, Schrenk D. 2006. Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Molecular Nutrition and Food Research 50(10):897–907.

Kociba RJ, Keys DG, Beyer JE, Careon RM, Wade CE, Dittenber DA, Kalnins RP, Frauson LE, Park CN, Barnar SD, Hummel RA, Humiston CG. 1978. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicology and Applied Pharmacology 46:279–303.

Kogan MD, Clapp RW. 1988. Soft tissue sarcoma mortality among Vietnam veterans in Massachusetts, 1972 to 1983. International Journal of Epidemiology 17(1):39–43.

Kogevinas M, Saracci R, Bertazzi PA, Bueno de Mesquita BH, Coggon D, Green LM, Kauppinen T, Littorin M, Lynge E, Mathews JD, Neuberger M, Osman J, Pearce N, Winkelmann R. 1992. Cancer mortality from soft-tissue sarcoma and malignant lymphomas in an international cohort of workers exposed to chlorophenoxy herbicides and chlorophenols. Chemosphere 25:1071–1076.

Kogevinas M, Saracci R, Winkelmann R, Johnson ES, Bertazzi PA, Bueno de Mesquita BH, Kauppinen T, Littorin M, Lynge E, Neuberger M. 1993. Cancer incidence and mortality in women occupationally exposed to chlorophenoxy herbicides, chlorophenols, and dioxins. Cancer Causes and Control 4(6):547–553.

Kogevinas M, Kauppinen T, Winkelmann R, Becher H, Bertazzi PA, Bas B, Coggon D, Green L, Johnson E, Littorin M, Lynge E, Marlow DA, Mathews JD, Neuberger M, Benn T, Pannett B, Pearce N, Saracci R. 1995. Soft tissue sarcoma and non-Hodgkin’s lymphoma in workers exposed to phenoxy herbicides, chlorophenols and dioxins: Two nested case-control studies. Epidemiology 6(4):396–402.

Kogevinas M, Becher H, Benn T, Bertazzi PA, Boffetta P, Bueno de Mesquita HB, Coggon D, Colin D, Flesch-Janys D, Fingerhut M, Green L, Kauppinen T, Littorin M, Lynge E, Mathews JD, Neuberger M, Pearce N, Saracci R. 1997. Cancer mortality in workers exposed to phenoxy herbicides, chlorophenols, and dioxins. An expanded and updated international cohort study. American Journal of Epidemiology 145(12):1061–1075.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Köhle C, Bock KW. 2007. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochemical Pharmacology 73:1853–1862.

Köhle C, Schwarz M, Bock KW. 2008. Promotion of hepatocarcinogenesis in humans and animal models. Archives of Toxicology 82:623–631.

Kollara A, Brown TJ. 2009. Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2. International Journal of Biochemistry and Cell Biology 41(5):1182–1188.

Kollara A, Brown TJ. 2010. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. Journal of Steroid Biochemistry and Molecular Biology 118(1–2):51–58.

Korenaga T, Fukusato T, Ohta M, Asaoka K, Murata N, Arima A, Kubota S. 2007. Long-term effects of subcutaneously injected 2,3,7,8-tetrachlorodibenzo-p-dioxin on the liver of rhesus monkeys. Chemosphere 67(9):S399-S404.

Koutros S, Alavanja MCR, Lubin JH, Sandler DP, Hoppin JA, Lynch CF, Knott C, Blair A, Freeman LEB. 2010a. An update of cancer incidence in the Agricultural Health Study. Journal of Occupational and Environmental Medicine 52(11):1098–1105.

Koutros S, Beane Freeman LE, Berndt SI, Andreotti G, Lubin JH, Sandler DP, Hoppin JA, Yu K, Li Q, Burdette LA, Yuenger J, Yeager M, Alavanja MCR. 2010b. Pesticide use modifies the association between genetic variants on chromosome 8q24 and prostate cancer. Cancer Research 70(22):9224–9233.

Koutros S, Andreotti G, Berndt SI, Hughes Barry K, Lubin JH, Hoppin JA, Kamel F, Sandler DP, Burdette LA, Yuenger J, Yeager M, Alavanja MCR, Freeman LEB. 2011. Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer. Pharmacogenetics and Genomics 21(10):615–623.

Kovacs E. 2006. Multiple myeloma and B cell lymphoma: Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model. The Scientific World Journal 6:888–898.

Küppers R, Schwering I, Bräuninger A, Rajewsky K, Hansmann M. 2002. Biology of Hodgkin’s lymphoma. Annals of Oncology 13(Suppl 1):11–18.

La Rocca C, Alivernini S, Badiali M, Cornoldi A, Iacovella N, Silvestroni L, Spera G, Turrio-Baldassarri L. 2008. TEQ(S) and body burden for PCDDs, PCDFs, and dioxin-like PCBs in human adipose tissue. Chemosphere 73(1):92–96.

Labrecque MP, Takhar MK, Hollingshead BD, Prefontaine GG, Perdew GH, Beischlag TV. 2012. Distinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines. PLoS ONE 7(1):10 pps.

Laden F, Bertrand KA, Altshul L, Aster JC, Korrick SA, Sagiv SK. 2010. Plasma organochlorine levels and risk of non-Hodgkin lymphoma in the Nurses’ Health Study. Cancer Epidemiology and Biomarkers of Prevention 19(5):1381–1384.

Lampi P, Hakulinen T, Luostarinen T, Pukkala E, Teppo L. 1992. Cancer incidence following chlorophenol exposure in a community in southern Finland. Archives of Environmental Health 47(3):167–175.

Landgren O, Kyle RA, Hoppin JA, Freeman LEB, Cerhan JR, Katzmann JA, Rajkumar SV, Alavanja MC. 2009. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113(25):6386–6391.

LaVecchia C, Negri E, D’Avanzo B, Franceschi S. 1989. Occupation and lymphoid neoplasms. British Journal of Cancer 60(3):385–388.

Lawrence CE, Reilly AA, Quickenton P, Greenwald P, Page WF, Kuntz AJ. 1985. Mortality patterns of New York State Vietnam veterans. American Journal of Public Health 75(3):277–279.

Leavy J, Ambrosini G, Fritschi L. 2006. Vietnam military service history and prostate cancer. BMC Public Health 6:75.

Lee WJ, Lijinsky W, Heineman EF, Markin RS, Weisenburger DD, Ward MH. 2004a. Agricultural pesticide use and adenocarcinomas of the stomach and oesophagus. Occupational and Environmental Medicine 61(9):743–749.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Lee WJ, Cantor KP, Berzofsky JA, Zahm SH, Blair A. 2004b. Non-Hodgkin’s lymphoma among asthmatics exposed to pesticides. International Journal of Cancer 111(2):298–302.

Lee WJ, Colt JS, Heineman EF, McComb R, Weisenburger DD, Lijinsky W, Ward MH. 2005. Agricultural pesticide use and risk of glioma in Nebraska, United States. Occupational and Environmental Medicine 62(11):786–792.

Lee WJ, Sandler DP, Blair A, Samanic C, Cross AJ, Alavanja MC. 2007. Pesticide use and colorectal cancer risk in the Agricultural Health Study. International Journal of Cancer 121(2):339–346.

Lew BJ, Manickam R, Lawrence BP. 2011. Activation of the aryl hydrocarbon receptor during pregnancy in the mouse alters mammary development through direct effects on stromal and epithelial tissues. Biology of Reproduction 84(6):1094–1102.

Liao Y, Du X, Zou O. 2012. Extranodal natural killer/T-cell lymphoma, nasal type: Epidemiology study. Chinese-German Journal of Clinical Oncology 11(5):P290-P293.

Lin PH, Lin CH, Huang CC, Chuang MC, Lin P. 2007. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. Toxicology Letters 172(3):146–158.

Lin PH, Lin CH, Huang CC, Fang JP, Chuang MC. 2008. 2,3,7,8-tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression. Chemical Research in Toxicology 21(7):1337–1347.

Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. 2006. Follicular variant of papillary thyroid carcinoma: A clinicopathologic study of a problematic entity. Cancer 107:1255–1264.

Lo AC, Soliman AS, Khaled HM, Aboelyazid A, Greenson JK. 2010. Lifestyle, occupational, and reproductive factors and risk of colorectal cancer. Diseases of the Colon and Rectum 53(5):830–837.

Lu C, Wang Y, Sheng Z, Liu G, Fu Z, Zhao J, Zhao J, Yan XZ, Zhu B, Peng S. 2010. NMR-based metabonomic analysis of the hepatotoxicity induced by combined exposure to PCBs and TCDD in rats. Toxicology and Applied Pharmacology 248:178–184.

Lu H, Crawford RB, Suarez-Martinez JE, Kaplan BLF, Kaminski NE. 2010. Induction of the aryl hydrocarbon receptor-responsive genes and modulation of the immunoglobulin M response by 2,3,7,8-tetrachlorodibenzo-p-dioxin in primary human B cells. Toxicological Sciences 118(1):86–97.

Luecke S, Backlund M, Jux B, Esser C, Krutmann J, Rannug A. 2010. The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis. Pigment Cell and Melanoma Research 23:828–833.

Lv L, Lin G, Gao X, Wu C, Dai J, Yang Y, Zou H, Sun H, Gu M, Chen X, Fu H, Bao L. 2011. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. American Journal of Hematology 86:163–169.

Lynge E. 1985. A follow-up study of cancer incidence among workers in manufacture of phenoxy herbicides in Denmark. British Journal of Cancer 52(2):259–270.

Lynge E. 1993. Cancer in phenoxy herbicide manufacturing workers in Denmark, 1947–87—An update. Cancer Causes and Control 4(3):261–272.

Madak-Erdogan Z, Katzenellenbogen BS. 2012. Aryl hydrocarbon receptor modulation of estrogen receptor alpha-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. Toxicological Sciences 125(2):401–411.

Magnani C, Coggon D, Osmond C, Acheson ED. 1987. Occupation and five cancers: A case-control study using death certificates. British Journal of Industrial Medicine 44(11):769–776.

Mahan CM, Bullman TA, Kang HK, Selvin S. 1997. A case-control study of lung cancer among Vietnam veterans. Journal of Occupational and Environmental Medicine 39(8):740–747.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Maluf E, Hamerschlak N, Cavalcanti AB, Avezum Júnlor A, Eluf-Neto J, Passetto Falcao R, Lorand-Metze IG, Goldenberg D, Leite Santana C, De Oliveira Werneck Rodrigues D, Nascimento Da Motta Passos L, Mange Rosenfeld LG, Pitta M, Loggetto S, Feitosa Ribeiro AA, Velloso ED, Kondo AT, De Miranda Coelho EO, Tostes Pintao MC, Moraes De Souza H, Borbolla JR, Pasquini R. 2009. Incidence and risk factors of aplastic anemia in Latin American countries: The Latin case-control study. Haematologica 94(9):1220–1226.

Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436–444.

Manuwald U, Garrido MV, Berger J, Manz A, Baur X. 2012. Mortality study of chemical workers exposed to dioxins: Follow-up 23 years after chemical plant closure. Occupational and Environmental Medicine 69(9):636–642.

Manz A, Berger J, Dwyer JH, Flesch-Janys D, Nagel S, Waltsgott H. 1991. Cancer mortality among workers in chemical plant contaminated with dioxin. Lancet 338(8773):959–964.

Marlowe JL, Fan Y, Chang X, Peng L, Knudsen ES, Xia Y, Puga A. 2008. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Molecular Biology of the Cell 19:3263–3271.

Marur S, D’Souza G, Westra WH, Forastiere AA. 2010. HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncology 11:781–789.

McBride DI, Collins JJ, Humphry NF, Herbison P, Bodner KM, Aylward LL, Burns CJ, Wilken M. 2009a. Mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin at a trichlorophenol plant in New Zealand. Journal of Environmental Medicine 51(9):1049–1056.

McBride DI, Burns CJ, Herbison GP, Humphry NF, Bodner K, Collins JJ. 2009b. Mortality in employees at a New Zealand agrochemical manufacturing site. Occupational Medicine 59(4):255–263.

McDuffie HH, Klaassen DJ, Dosman JA. 1990. Is pesticide use related to the risk of primary lung cancer in Saskatchewan? Journal of Occupational Medicine 32(10):996–1002.

McDuffie HH, Pahwa P, McLaughlin JR, Spinelli JJ, Fincham S, Dosman JA, Robson D, Skinnider LF, Choi NW. 2001. Non-Hodgkin’s lymphoma and specific pesticide exposures in men: Cross-Canada study of pesticides and health. Cancer Epidemiology, Biomarkers and Prevention 10(11):1155–1163.

McGee SF, Lanigan F, Gilligan E, Groner B. 2006. Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression. EMBO Reports 7(11):1084–1088.

McLean D, Pearce N, Langseth H, Jappinen P, Szadkowska-Stanczyk I, Person B, Wild P, Kishi R, Lynge E, Henneberger P, Sala M, Teschke K, Kauppinen T, Colin D, Kogevinas M, Boffetta P. 2006. Cancer mortality in workers exposed to organochlorine compounds in the pulp and paper industry: An international collaborative study. Environmental Health Perspectives 114(7):1007–1012.

McNally RJQ, Blakey K, Parslow RC, James PW, Pozo BG, Stiller C, Vincent TJ, Norman P, McKinney PA, Murphy MF, Craft AW, Feltbower RG. 2012. Small-area analyses of bone cancer diagnosed in Great Britain provide clues to aetiology. BMC Cancer 12(1):270–279.

Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH. 1994. Occupational risk factors for renal-cell carcinoma in Denmark. Scandinavian Journal of Work, Environment, and Health 20(3):160–165.

Merletti F, Richiardi L, Bertoni F, Ahrens W, Buemi A, Costa-Santos C, Eriksson M, Guenel P, Kaerlev L, Jockel KH, Llopis-Gonzalez A, Merler E, Miranda A, Morales-Suarez-Varela MM, Olsson H, Fletcher T, Olsen J. 2005. Occupational factors and risk of adult bone sarcomas: A multicentric case-control study in Europe. International Journal of Cancer 118(3):721–727.

Meyer A, Alexandre PCB, de Rezende Chrisman J, Markowitz SB, Koifman RJ, Koifman S. 2011. Esophageal cancer among Brazilian agricultural workers: Case-control study based on death certificates. International Journal of Hygiene and Environmental Health 214(2):151–155.

Michalek JE, Pavuk M. 2008. Diabetes and cancer in Veterans of Operation Ranch Hand after adjustment for calendar period, days of sprayings, and time spent in Southeast Asia. Journal of Occupational and Environmental Medicine 50(3):330–340.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Michalek JE, Wolfe WH, Miner JC. 1990. Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. II. Mortality. Journal of the American Medical Association 264(14):1832–1836.

Miligi L, Costantini AS, Bolejack V, Veraldi A, Benvenuti A, Nanni O, Ramazzotti V, Tumino R, Stagnaro E, Rodella S, Fontana A, Vindigni C, Vineis P. 2003. Non-Hodgkin’s lymphoma, leukemia, and exposures in agriculture: Results from the Italian Multicenter Case-control Study. American Journal of Industrial Medicine 44:627–636.

Miligi L, Costantini AS, Veraldi A, Benvenuti A, WILL (Italian Working Group Leukemia Lymphomas), Vineis P. 2006. Cancer and pesticides: An overview and some results of the Italian Multicenter Case-control Study on hematolymphopoietic malignancies. Annals of the New York Academy of Sciences 1076:366–377.

Miller BA, Kolonel LN, Bernstein L, Young JL Jr, Swanson GM, West D, Key CR, Liff JM, Glover CS, Alexander GA, et al. (eds). 1996. Racial/Ethnic Patterns of Cancer in the United States 1988–1992. Bethesda, MD: National Cancer Institute. NIH Pub. No. 96–4104.

Mills PK, Yang R. 2005. Breast cancer risk in Hispanic agricultural workers in California. International Journal of Occupational and Environmental Health 11(2):123–131.

Mills PK, Yang RC. 2007. Agricultural exposures and gastric cancer risk in Hispanic farm workers in California. Environmental Research 104(2):282–289.

Mills PK, Yang R, Riordan D. 2005. Lymphohematopoietic cancers in the United Farm Workers of America (UFW), 1988–2001. Cancer Causes and Control 16(7):823–830.

Mitchell KA, Lockhart CA, Huang G, Elferink CJ. 2006. Sustained aryl hydrocarbon receptor activity attenuates liver regeneration. Molecular Pharmacology 70(1):163–170.

Morris PD, Koepsell TD, Daling JR, Taylor JW, Lyon JL, Swanson GM, Child M, Weiss NS. 1986. Toxic substance exposure and multiple myeloma: A case-control study. Journal of the National Cancer Institute 76(6):987–994.

Morrison H, Semenciw RM, Morison D, Magwood S, Mao Y. 1992. Brain cancer and farming in western Canada. Neuroepidemiology 11(4–6):267–276.

Morrison H, Savitz D, Semenciw RM, Hulka B, Mao Y, Morison D, Wigle D. 1993. Farming and prostate cancer mortality. American Journal of Epidemiology 137(3):270–280.

Morrison HI, Semenciw RM, Wilkins K, Mao Y, Wigle DT. 1994. Non-Hodgkin’s lymphoma and agricultural practices in the prairie provinces of Canada. Scandinavian Journal of Work, Environment, and Health 20(1):42–47.

Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Berstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Zahm SH, Chanock SJ, Cerhan JR, Hartge P. 2008. Etiology among non-Hodgkin lymphoma subtypes. Blood 112(13):5150–5160.

Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz M, Ballestar E, Fraga MF, Ropero S, Esteller M, Fernandez-Salguero PM. 2006. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 27(5):1099–1104.

Musicco M, Sant M, Molinari S, Filippini G, Gatta G, Berrino F. 1988. A case-control study of brain gliomas and occupational exposure to chemical carcinogens: The risks to farmers. American Journal of Epidemiology 128:778–785.

Nanni O, Amadori D, Lugaresi C, Falcini F, Scarpi E, Saragoni A, Buiatti E. 1996. Chronic lymphocytic leukaemias and non-Hodgkin’s lymphomas by histological type in farming-animal breeding workers: A population case-control study based on a priori exposure matrices. Occupational and Environmental Medicine 53(10):652–657.

NCI (National Cancer Institute). 2010. Surveillance, Epidemiology, and End Results (SEER) Incidence and US Mortality Statistics: SEER Incidence—Crude Rates for White/Black/Other 2004–2008. http://www.seer.cancer.gov/canques/incidence.html (accessed May 9, 2011).

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

NCI. 2013. Surveillance, Epidemiology, and End Results (SEER) Incidence and US Mortality Statistics: SEER Incidence—Crude Rates for White/Black/Other 2005–2009. http://www.seer.cancer.gov/canques/incidence.html (accessed April 2, 2013).

Nielsen GD, Wolkoff P. 2010. Cancer effects of formaldehyde: A proposal for an indoor air guideline value. Archives of Toxicology 84(6):423–446.

Nikiforov YE. 2011. Molecular analysis of thyroid tumors. Modern Pathology (Suppl 2):S34-S43.

Nordby KC, Andersen A, Kristensen P. 2004. Incidence of lip cancer in the male Norwegian agricultural population. Cancer Causes and Control 15(6):619–626.

NTP (National Toxicology Program). 1982a. Technical Report Series No. 209. Carcinogenesis Bio-assay of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (CAS No. 1746–01-6) in Osborne-Mendel Rats and B6c3F1 Mice (Gavage Study). NIH Publication No. 82–1765. 195 pps. National Toxicology Program, Research Triangle Park, NC, and Bethesda, MD.

NTP. 1982b. Technical Report Series No. 201. Carcinogenesis Bioassay of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (CAS No. 1746–01-6) in Swiss-Webster Mice (Dermal Study). National Toxicology Program, Research Triangle Park, NC, and Bethesda, MD.

NTP. 2006. NTP Technical Report on the Toxicology and Carcinogenesis Studies of 2,3,7,8-Tetra-chlorodibenzo-p-dioxin (TCDD) (CAS No. 1746–01-6) in Female Harlan Sprague-Dawley Rats (Gavage Studies). Issue 521:4–232. National Toxicology Program, Research Triangle Park, NC, and Bethesda, MD.

NTP. 2011. 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Report on Carcinogens, 12th ed. Pp. 396–398.

Nyska A, Jokinen MP, Brix AE, Sells DM, Wyde ME, Orzech D, Haseman JK, Flake G, Walker NJ. 2004. Exocrine pancreatic pathology in female Harlan Sprague-Dawley rats after chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds. Environmental Health Perspectives 112(8):903–909.

Nyska A, Yoshizawa K, Jokinen MP, Brix AE, Sells DM, Wyde ME, Orzech DP, Kissling GE, Walker NJ. 2005. Olfactory epithelial metaplasia and hyperplasia in female Harlan Sprague-Dawley rats following chronic treatment with polychlorinated biphenyls. Toxicologic Pathology 33(3):371–377.

O’Brien TR, Decoufle P, Boyle CA.1991. Non-Hodgkin’s lymphoma in a cohort of Vietnam veterans. American Journal of Public Health 81:758–760.

O’Donnell EF, Kopparapu PR, Koch DC, Jang HS, Phillips JL, Tanguay RL, Kerkvliet NI, Kollur SK. 2012. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS ONE 7(7):13 pps.

Olsson H, Brandt L. 1988. Risk of non-Hodgkin’s lymphoma among men occupationally exposed to organic solvents. Scandinavian Journal of Work, Environment, and Health 14:246–251.

Orsi L, Delabre L, Monnerau A, Delva P, Berthou C, Fenaux P, Marti G, Soubeyran P, Huguet F, Mipied N, Leporrier M, Hemon D, Troussard X, Clavel J. 2009. Occupational exposure to pesticides and lymphoid neoplasms among men: Results of a French case-control study. Occupational and Environmental Medicine 66(5):291–298.

O’Toole BI, Catts SV, Outram S, Pierse KR, Cockburn J. 2009. The physical and mental health of Australian Vietnam veterans 3 decades after the war and its relation to military service, combat, and post-traumatic stress disorder. American Journal of Epidemiology 170(3):318–330.

O’Toole BI, Catts SV, Outram S, Pierse KR, Cockburn J. 2010. Factors associated with civilian mortality in Australian Vietnam veterans three decades after the war. Military Medicine 175(2):88–95.

Ott MG, Zober A. 1996. Cause specific mortality and cancer incidence among employees exposed to 2,3,7,8-TCDD after a 1953 reactor accident. Occupational and Environmental Medicine 53:606–612.

Ovando BJ, Ellison CA, Vezina CM, Olson JR. 2010. Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: Identification of genomic biomarkers of exposure to AhR ligands. BMC Genomics 11:583.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Pahwa P, McDuffie HH, Dosman JA, Robson D, McLaughlin JR, Spinelli JJ, Fincham S. 2003. Exposure to animals and selected risk factors among Canadian farm residents with Hodgkin’s Disease, multiple myeloma, or soft tissue sarcoma. Journal of Occupational and Environmental Medicine 45(8):857–868.

Pahwa P, McDuffie HH, Dosman JA, McLaughlin JR, Spinelli JJ, Robson D, Fincham S. 2006. Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides. Journal of Occupational and Environmental Medicine 48(3):264–274.

Pahwa P, Karunanayake CP, Dosman JA, Spinelli JJ, McLaughlin JR. 2011. Soft-tissue sarcoma and pesticides exposure in men: Results of a Canadian case-control study. Journal of Occupational and Environmental Medicine 53(11):1279–1286.

Pahwa P, Karunanayake CP, Dosman JA, Spinelli JJ, McDuffie HH, McLaughlin JR. 2012. Multiple myeloma and exposure to pesticides: A Canadian case-control study. Journal of Agromedicine 17(1):40–50.

Park JY, Shigenaga MK, Ames BN. 1996. Induction of cytochrome P4501A1 by 2,3,7,8-tetrachloro-dibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proceedings of the National Academy of Sciences of the United States of America 93(6):2322–2327.

Pavuk M, Michalek JE, Schecter A, Ketchum NS, Akhtar FZ, Fox KA. 2005. Did TCDD exposure or service in Southeast Asia increase the risk of cancer in Air Force Vietnam veterans who did not spray Agent Orange? Journal of Occupational and Environmental Medicine 47(4):335–342.

Pavuk M, Michalek JE, Ketchum NS. 2006. Prostate cancer in US Air Force veterans of the Vietnam War. Journal of Exposure Science and Environmental Epidemiology 16(2):184–190.

Pearce NE, Smith AH, Fisher DO. 1985. Malignant lymphoma and multiple myeloma linked with agricultural occupations in a New Zealand cancer registry-based study. American Journal of Epidemiology 121:225–237.

Pearce NE, Smith AH, Howard JK, Sheppard RA, Giles HJ, Teague CA. 1986. Non-Hodgkin’s lymphoma and exposure to phenoxyherbicides, chlorophenols, fencing work, and meat works employment: A case-control study. British Journal of Industrial Medicine 43:75–83.

Pearce NE, Sheppard RA, Smith AH, Teague CA. 1987. Non-Hodgkin’s lymphoma and farming: An expanded case-control study. International Journal of Cancer 39:155–161.

Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH. 2009a. Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World Journal of Gastroenterology 15(14):1719–1729.

Peng TL, Chen J, Mao W, Song X, Chen MH. 2009b. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biology 10:27.

Percy C, Ries GL, Van Holten VD. 1990. The accuracy of liver cancer as the underlying cause of death on death certificates. Public Health Reports 105:361–368.

Perrotta C, Staines A, Codd M, Kleefeld S, Crowley D, T’Mannetje A, Becker N, Brennan P, De Sanjosé S, Foretova L, Maynadié M, Nieters A, Boffetta P, Cocco P. 2012. Multiple myeloma and lifetime occupation: Results from the EPILYMPH study. Journal of Occupational Medicine and Technology 7(1):25.

Persson B, Dahlander AM, Fredriksson M, Brage HN, Ohlson CG, Axelson O. 1989. Malignant lymphomas and occupational exposures. British Journal of Industrial Medicine 46:516–520.

Persson B, Fredriksson M, Olsen K, Boeryd B, Axelson O. 1993. Some occupational exposures as risk factors for malignant lymphomas. Cancer 72:1773–1778.

Pesatori AC, Consonni D, Tironi A, Landi MT, Zocchetti C, Bertazzi PA. 1992. Cancer morbidity in the Seveso area, 1976–1986. Chemosphere 25:209–212.

Pesatori AC, Baccarelli A, Consonni D, Lania A, Beck-Peccoz P, Bertazzi PA, Spada A. 2008. Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: A population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. European Journal of Endocrinology 159(6):699–703.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Pesatori AC, Consonni D, Rubagotti M, Grillo P, Bertazzi PA. 2009. Cancer incidence in the population exposed to dioxin after the “Seveso accident": Twenty years of follow-up. Environmental Health 8:1–11.

Piaggi S, Novelli M, Martino L, Masini M, Raggi C, Orciuolo E, Masiello P, Casini A, De Tata V. 2007. Cell death and impairment of glucose-stimulated insulin secretion induced by 2,3,7,8-tet-rachlorodibenzo-p-dioxin (TCDD) in the beta-cell line INS-1e. Toxicology and Applied Pharmacology 220(3):333–340.

Prihartono N, Kriebel D, Woskie S, Thetkhathuek A, Sripaung N, Padungtod C, Kaufman D. 2011. Risk of aplastic anemia and pesticide and other chemical exposures. Asia-Pacific Journal of Public Health 23(3):369–377.

Prochazka M, Feychting M, Ahlbom A, Edwards CG, Nise G, Plato N, Schwartzbaum JA, Forssen UM. 2010. Occupational exposures and risk of acoustic neuroma. Occupational and Environmental Medicine 67(11):766–771.

Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, Yang MH, Chen CJ, Hsueh YM. 2007. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicology and Applied Pharmacology 218(2):99–106.

Rajkumar SV, Dispenzieri A, Kyle RA. 2006. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: Diagnosis and treatment. Mayo Clinic Proceedings 81(5):693–703.

Ramlow JM, Spadacene NW, Hoag SR, Stafford BA, Cartmill JB, Lerner PJ. 1996. Mortality in a cohort of pentachlorophenol manufacturing workers, 1940–1989. American Journal of Industrial Medicine 30:180–194.

Rashid BA, Wani MA, Kirmani AR, Raina TH, Ramzan AU, Alam S, Dhar A, Arif S, Javed S. 2010. Malignant brain tumors (brain cancer) in orchard farmers of Kashmir linked to pesticides. Current Neurobiology 1(2):137–150.

Ray S, Swanson HI. 2009. Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: A tumor promoting event? Biochemical Pharmacology 77(4):681–688.

Read D, Wright C, Weinstein P, Borman B. 2007. Cancer incidence and mortality in a New Zealand community potentially exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin from 2,4,5-trichlo-rophenoxyacetic acid manufacture. Australian and New Zealand Journal of Public Health 31(1):13–18.

Reif JS, Pearce N, Fraser J. 1989. Occupational risks of brain cancer: A New Zealand cancer registry-based study. Journal of Occupational Medicine 31(10):863–867.

Revich B, Aksel E, Ushakova T, Ivanova I, Zhuchenko N, Klyuev N, Brodsky B, Sotskov Y. 2001. Dioxin exposure and public health in Chapaevsk, Russia. Chemosphere 43(4–7):951–966.

Reynolds P, Hurley SE, Petreas M, Goldberg DE, Smith D, Gilliss D, Mahoney ME, Jeffrey SS. 2005. Adipose levels of dioxins and risk of breast cancer. Cancer Causes and Control 16(5):525–535.

Richardson DB, Terschuren C, Hoffmann W. 2008. Occupational risk factors for non-Hodgkin’s lymphoma: A population-based case-control study in Northern Germany. American Journal of Industrial Medicine 51(4):258–268.

Riedel D, Pottern LM, Blattner WA. 1991. Etiology and epidemiology of multiple myeloma. In: Wiernick PH, Camellos G, Kyle RA, Schiffer CA, eds. Neoplastic Disease of the Blood and Blood Forming Organs. New York: Churchill Livingstone.

Riihimaki V, Asp S, Hernberg S. 1982. Mortality of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlo-rophenoxyacetic acid herbicide applicators in Finland: First report of an ongoing prospective cohort study. Scandinavian Journal of Work, Environment, and Health 8:37–42.

Rix BA, Villadsen E, Engholm G, Lynge E. 1998. Hodgkin’s disease, pharyngeal cancer, and soft tissue sarcomas in Danish paper mill workers. Journal of Occupational and Environmental Medicine 40(1):55–62.

Robinson CF, Waxweiler RJ, Fowler DP. 1986. Mortality among production workers in pulp and paper mills. Scandinavian Journal of Work, Environment, and Health 12:552–560.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Rollison DE, Epling-Burnette P, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. 2011. Telomere length in myelodysplastic syndromes. Leukemia and Lymphoma 52(8):1528–1536.

Ronco G, Costa G, Lynge E. 1992. Cancer risk among Danish and Italian farmers. British Journal of Industrial Medicine 49:220–225.

Roth MJ, Wei WQ, Baer J, Abnet CC, Wang GQ, Sternberg LR, Warner AC, Johnson LL, Lu N, Giffen CA, Dawsey SM, Qiao YL, Cherry J. 2009. Aryl hydrocarbon receptor expression is associated with a family history of upper gastrointestinal tract cancer in a high-risk population exposed to aromatic hydrocarbons. Cancer Epidemiology Biomarkers and Prevention 18(9):2391–2396.

Roulland S, Lebailly P, Lecluse Y, Briand M, Pottier D, Gauduchon P. 2004. Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides. Cancer Research 64(6):2264–2269.

Roulland S, Navarro JM, Grenot P, Milili M, Agopian J, Montpellier B, Gauduchon P, Lebailly P, Schiff C, Nadel B. 2006. Follicular lymphoma-like B cell in healthy individuals: A novel intermediate step in early lymphomagenesis. The Journal of Experimental Medicine 203(11):2425–2431.

Rowland RE, Edwards LA, Podd JV. 2007. Elevated sister chromatid exchange frequencies in New Zealand Vietnam War veterans. Cytogenetic and Genome Research 116(4):248–251.

Rudel RA, Fenton SE, Ackerman JM, Euling SY, Makris SL. 2011. Environmental exposures and mammary gland development: State of the science, public health implications, and research recommendations. Environmental Health Perspectives 119(8):1053–1061.

Ruder AM, Yiin JH. 2011. Mortality of US pentachlorophenol production workers through 2005. Chemosphere 83(6):851–861.

Ruder AM, Waters MA, Butler MA, Carreon T, Calvert GM, Davis-King KE, Schulte PA, Sanderson WT, Ward EM, Connally LB, Heineman EF, Mandel JS, Morton RF, Reding DJ, Rosenman KD, Talaska G. 2004. Gliomas and farm pesticide exposure in men: The Upper Midwest Health Study. Archives of Environmental Health 59(12):650–657.

Salehi F, Turner MC, Phillips KP, Wigle DT, Krewski D, Aronson KJ. 2008. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. Journal of Toxicology and Environmental Health—Part B: Critical Reviews 11(3–4):276–300.

Samanic C, Rusiecki J, Dosemeci M, Hou L, Hoppin JA, Sandler DP, Lubin J, Blair A, Alavanja MC. 2006. Cancer incidence among pesticide applicators exposed to dicamba in the Agricultural Health Study. Environmental Health Perspectives 114(10):1521–1526.

Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD. 2008. Occupational exposure to pesticides and risk of adult brain tumors. American Journal of Epidemiology 167(8):976–985.

Santibañez M, Alguacil J, de la Hera MG, Navarrete-Muñoz EM, Llorca J, Aragonés N, Kauppinen T, Vioque J; PANESOES Study Group. 2012. Occupational exposures and risk of stomach cancer by histological type. Occupational and Environmental Medicine 69(4):268–275.

Saracci R, Kogevinas M, Bertazzi PA, Bueno de Mesquita BH, Coggon D, Green LM, Kauppinen T, L’Abbe KA, Littorin M, Lynge E, Mathews JD, Neuberger M, Osman J, Pearce N, Winkelmann R. 1991. Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. Lancet 338:1027–1032.

Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH. 2006. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biological Chemistry 387(9):1175–1187.

Sekeres M. 2011. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. Journal of the National Comprehensive Cancer Network 9(1):57–63.

Semenciw RM, Morrison HI, Morison D, Mao Y. 1994. Leukemia mortality and farming in the prairie provinces of Canada. Canadian Journal of Public Health 85:208–211.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Senft AP, Dalton TP, Nebert DW, Genter MB, Puga A, Hutchinson RJ, Kerzee JK, Uno S, Shertzer HG. 2002. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radical Biology and Medicine 33(9):1268–1278.

Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris MK. 2009. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU International 103:1168–1172.

Shah I, Houck K, Judson RS, Kavlock RJ, Martin MT, Reif DM, Wambaugh J, Dix DJ. 2011. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 6(2):11 pps.

Sharma-Wagner S, Chokkalingam AP, Malker HS, Stone BJ, McLaughlin JK, Hsing AW. 2000. Occupation and prostate cancer risk in Sweden. Journal of Occupational and Environmental Medicine 42(5):517–525.

Shertzer HG, Dalton TP, Talaska G, Nebert DW. 2002. Decrease in 4-aminobiphenyl-induced methemoglobinemia in CYP1A2(-/-) knockout mice. Toxicology and Applied Pharmacology 181(1):32–37.

Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62(1):10–29.

Siemiatycki J, Wacholder S, Dewar R, Wald L, Bégin D, Richardson L, Rosenman K, Gérin M. 1988. Smoking and degree of occupational exposure: Are internal analyses in cohort studies likely to be confounded by smoking status? American Journal of Industrial Medicine 13(1):59–69.

Simanainen U, Haavisto T, Tuomisto JT, Paranko J, Toppari J, Tuomisto J, Peterson RE, Viluksela M. 2004. Pattern of male reproductive system effects after in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in three differentially TCDD-sensitive rat lines. Toxicological Sciences 80(1):101–108.

Singh NP, Nagarkatti M, Nagarkatti P. 2008. Primary peripheral T cells become susceptible to 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated apoptosis in vitro upon activation and in the presence of dendritic cells. Molecular Pharmacology 73(6):1722–1735.

Singh KP, Garrett RW, Casado FL, Gasiewicz TA. 2011. Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions. Stem Cells and Development 20(5):769–784.

Smith AH, Pearce NE. 1986. Update on soft tissue sarcoma and phenoxyherbicides in New Zealand. Chemosphere 15:1795–1798.

Smith AH, Fisher DO, Giles HJ, Pearce NE. 1983. The New Zealand soft tissue sarcoma case-control study: Interview findings concerning phenoxyacetic acid exposure. Chemosphere 12:565–571.

Smith AH, Pearce NE, Fisher DO, Giles HJ, Teague CA, Howard JK. 1984. Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. Journal of the National Cancer Institute 73:1111–1117.

Smith JG, Christophers AJ. 1992. Phenoxy herbicides and chlorophenols: A case control study on soft tissue sarcoma and malignant lymphoma. British Journal of Cancer 65:442–448.

Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ. 1998. Alcohol and breast cancer in women: A pooled analysis of cohort studies. Journal of the American Medical Association 279(7):535–540.

Solet D, Zoloth SR, Sullivan C, Jewett J, Michaels DM. 1989. Patterns of mortality in pulp and paper workers. Journal of Occupational Medicine 31:627–630.

Spinelli JJ, Ng CH, Weber JP, Connors JM, Gascoyne RD, Lai AS, Brooks-Wilson AR, Le ND, Berry BR, Gallagher RP. 2007. Organochlorines and risk of non-Hodgkin lymphoma. International Journal of Cancer 121(12):2767–2775.

Steenland K, Piacitelli L, Deddens J, Fingerhut M, Chang LI. 1999. Cancer, heart disease, and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Journal of the National Cancer Institute 91(9):779–786.

Stott WT, Johnson KA, Landry TD, Gorzinski SJ, Cieszlak FS. 1990. Chronic toxicity and oncogenicity of picloram in Fischer 344 rats. Journal of Toxicology and Environmental Health 30:91–104.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Svensson BG, Mikoczy Z, Stromberg U, Hagmar L. 1995. Mortality and cancer incidence among Swedish fishermen with a high dietary intake of persistent organochlorine compounds. Scandinavian Journal of Work, Environmental, and Health 21(2):106–115.

Swaen GM, van Vliet C, Slangen JJM, Sturmans F. 1992. Cancer mortality among licensed herbicide applicators. Scandinavian Journal of Work, Environment, and Health 18:201–204.

Swaen GM, van Amelsvoort LG, Slangen JJ, Mohren DC. 2004. Cancer mortality in a cohort of licensed herbicide applicators. International Archives of Occupational and Environmental Health 77(4):293–295.

Szentirmay Z, Polus K, Tamas L, Szentkuti G, Kurcsics J, Csernak E, Toth E, Kasler M. 2005. Human papilomavirus in head and neck cancer: Molecular biology and climicopathological correlations. Cancer Metastasis Review 24:19–34.

’t Mannetje A, McLean D, Cheng S, Boffetta P, Colin D, Pearce N. 2005. Mortality in New Zealand workers exposed to phenoxy herbicides and dioxins. Occupational and Environmental Medicine 62(1):34–40.

Takahashi N, Yoshida T, Ohnuma A, Horiuchi H, Ishitsuka K, Kashimoto Y, Kuwahara M, Nakashima N, Harada T. 2011. The enhancing effect of the antioxidant n-acetylcysteine on urinary bladder injury induced by dimethylarsinic acid. Toxicologic Pathology 39(7):1107–1114.

Tarone RE, Hayes HM, Hoover RN, Rosenthal JF, Brown LM, Pottern LM, Javadpour N, O’Connell KJ, Stutzman RE. 1991. Service in Vietnam and risk of testicular cancer. Journal of the National Cancer Institute 83:1497–1499.

Teitelbaum SL, Gammon MD, Britton JA, Neugut AI, Levin B, Stellman SD. 2007. Reported residential pesticide use and breast cancer risk on Long Island, New York. American Journal of Epidemiology 165(6):643–651.

Thiess AM, Frentzel-Beyme R, Link R. 1982. Mortality study of persons exposed to dioxin in a trichlorophenol-process accident that occurred in the BASF AG on November 17, 1953. American Journal of Industrial Medicine 3(2):179–189.

Thomas TL. 1987. Mortality among flavour and fragrance chemical plant workers in the United States. British Journal of Industrial Medicine 44:733–737.

Thomas TL, Kang HK. 1990. Mortality and morbidity among Army Chemical Corps Vietnam veterans: A preliminary report. American Journal of Industrial Medicine 18:665–673.

Thomas TL, Kang H, Dalager N. 1991. Mortality among women Vietnam veterans, 1973–1987. American Journal of Epidemiology 134:973–980.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. 2003. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 349(3):215–224.

Thörn Å, Gustavsson P, Sadigh J, Westerlund-Hännerstrand B, Hogstedt C. 2000. Mortality and cancer incidence among Swedish lumberjacks exposed to phenoxy herbicides. Occupational and Environmental Medicine 57:718–720.

Torchio P, Lepore AR, Corrao G, Comba P, Settimi L, Belli S, Magnani C, di Orio F. 1994. Mortality study on a cohort of Italian licensed pesticide users. The Science of the Total Environment 149(3):183–191.

Toth K, Somfai-Relle S, Sugar J, Bence J. 1979. Carcinogenicity testing of herbicide 2,4,5-trichlorophenoxyethanol containing dioxin and of pure dioxin in Swiss mice. Nature 278(5704):548–549.

Tritscher AM, Mahler J, Portier CJ, Lucier GW, Walker NJ. 2000. Induction of lung lesions in female rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicologic Pathology 28(6):761–769.

Tuomisto JT, Pekkanen J, Kiviranta H, Tukiainen E, Vartiainen T, Tuomisto J. 2004. Soft-tissue sarcoma and dioxin: A case-control study. International Journal of Cancer 108(6):893–900.

Turunen AW, Verkasalo PK, Kiviranta H, Pukkala E, Jula A, Mannisto S, Rasanen R, Marniemi J, Vartiainen T. 2008. Mortality in a cohort with high fish consumption. International Journal of Epidemiology 37(5):1008–1017.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Van den Berg M, Birnbaum LS, Denison M, De Vito M, Farland W, Feeley M, Fiedler H, Hakansson H, Hanberg A, Haws L, Rose M, Safe S, Schrenk D, Tohyama C, Tritscher A, Tuomisto J, Tysklind M, Walker N, Peterson RE. 2006. The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicological Sciences 93(2):223–241.

van Grevenynghe J, Bernard M, Langouet S, Le Berre C, Fest T, Fardel O. 2005. Human CD34-positive hematopoietic stem cells constitute targets for carcinogenic polycyclic aromatic hydrocarbons. Journal of Pharmacology and Experimental Therapeutics 314(2):693–702.

Van Miller JP, Lalich JJ, Allen JR. 1977. Increased incidence of neoplasms in rats exposed to low levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chemosphere 9:537–544.

Viel JF, Arveux P, Baverel J, Cahn JY. 2000. Soft-tissue sarcoma and non-Hodgkin’s lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels. American Journal of Epidemiology 152(1):13–19.

Viel JF, Clement MC, Hagi M, Grandjean S, Challier B, Danzon A. 2008. Dioxin emissions from a municipal solid waste incinerator and risk of invasive breast cancer: A population-based case-control study with GIS-derived exposure. International Journal of Health Geographics 7:4.

Viel JF, Floret N, Deconinck E, Focant JF, De Pauw E, Cahn JY. 2011. Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. Environment International 37:449–453.

Vineis P, Terracini B, Ciccone G, Cignetti A, Colombo E, Donna A, Maffi L, Pisa R, Ricci P, Zanini E, Comba P. 1986. Phenoxy herbicides and soft-tissue sarcomas in female rice weeders. A population-based case-referent study. Scandinavian Journal of Work, Environment, and Health 13:9–17.

Vineis P, Faggiano F, Tedeschi M, Ciccone G. 1991. Incidence rates of lymphomas and soft-tissue sarcomas and environmental measurements of phenoxy herbicides. Journal of the National Cancer Institute 83:362–363.

Visintainer PF, Barone M, McGee H, Peterson EL. 1995. Proportionate mortality study of Vietnam-era veterans of Michigan. Journal of Occupational and Environmental Medicine 37(4):423–428.

Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, Tuscano J, Matsumura F. 2007. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. American Journal of Pathology 171(5):1538–1548.

Vogel CFA, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y, Matsumura F. 2011. Interaction of aryl hydrocarbon receptor and NF-KB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Archives of Biochemistry and Biophysics 512 (1):78–86.

Vorderstrasse BA, Fenton SE, Bohn AA, Cundiff JA, Lawrence BP. 2004. A novel effect of dioxin: Exposure during pregnancy severely impairs mammary gland differentiation. Toxicological Sciences 78(2):248–257.

Waggoner JK, Kullman GJ, Henneberger PK, Umbach DM, Blair A, Alavanja MCR, Kamel F, Lynch CF, Knott C, London SJ, Hines CJ, Thomas KW, Sandler DP, Lubin JH, Beane Freeman LE, Hoppin JA. 2011. Mortality in the agricultural health study, 1993–2007. American Journal of Epidemiology 173(1):71–83.

Walker NJ, Wyde ME, Fischer LJ, Nyska A, Bucher JR. 2006. Comparison of chronic toxicity and carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 2-year bioassays in female Sprague-Dawley rats. Molecular Nutrition and Food Research 50(10):934–944.

Walker NJ, Yoshizawa K, Miller RA, Brix AE, Sells DM, Jokinen MP, Wyde ME, Easterling M, Nyska A. 2007. Pulmonary lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin-like compounds. Toxicologic Pathology 35(7):880–889.

Wang A, Kligerman AD, Holladay SD, Wolf DC, Robertson JL. 2009. Arsenate and dimethylarsinic acid in drinking water did not affect DNA damage repair in urinary bladder transitional cells or micronuclei in bone marrow. Environmental and Molecular Mutagenesis 50(9):760–770.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Wang SL, Chang YC, Chao HR, Li CM, Li LA, Lin LY, Papke O. 2006. Body burdens of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls and their relations to estrogen metabolism in pregnant women. Environmental Health Perspectives 114(5):740–745.

Wang SS, Nieters A. 2010. Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk. Expert Reviews in Anticancer Therapy 10(3):403–413.

Wang T, Wyrick KL, Meadows GG, Wills TB, Vorderstrasse BA. 2011. Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicological Sciences 124(2):291–298.

Wanibuchi H, Salim E, Kinoshita A, Shen J, Wei M, Morimura K, Yoshida K, Kuroda K, Endo G, Fukushima S. 2004. Understanding arsenic carcinogenicity by the use of animal models. Toxicology and Applied Pharmacology 198(3):366–376.

Warner M, Eskenazi B, Mocarelli P, Gerthoux PM, Samuels S, Needham L, Patterson D, Brambilla P. 2002. Serum dioxin concentrations and breast cancer risk in the Seveso Women’s Health Study. Environmental Health Perspectives 110(7):625–628.

Warner M, Mocarelli P, Samuels S, Needham L, Brambilla P, Eskenazi B. 2011. Dioxin exposure and cancer risk in the Seveso Women’s Health Study. Environmental Health Perspectives 119(12):1700–1705.

Watanabe KK, Kang HK. 1995. Military service in Vietnam and the risk of death from trauma and selected cancers. Annals of Epidemiology 5:407–412.

Watanabe KK, Kang HK. 1996. Mortality patterns among Vietnam veterans: A 24-year retrospective analysis. Journal of Occupational and Environmental Medicine 38(3):272–278.

Watanabe KK, Kang HK, Thomas TL. 1991. Mortality among Vietnam veterans: With methodological considerations. Journal of Occupational Medicine 33:780–785.

Waterhouse D, Carman WJ, Schottenfeld D, Gridley G, McLean S. 1996. Cancer incidence in the rural community of Tecumseh, Michigan: A pattern of increased lymphopoietic neoplasms. Cancer 77(4):763–770.

Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Nakae D, Fukushima S. 2002. Carcinogenicity of dimethylarsinic acid in make F344 rats and genetic alterations in incuded urinary bladder tumors. Carcinogenesis 23(8):1387–1397.

Weiderpass E, Adami HO, Baron JA, Wicklund-Glynn A, Aune M, Atuma S, Persson I. 2000. Organochlorines and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention 9:487–493.

Weinberg RA. 2008. Twisted epithelial-mesenchymal transition blocks senescence. Nature Cell Biology 10(9):1021–1023.

Weiss C, Faust D, Schreck I, Ruff A, Farwerck T, Melenberg A, Schneider S, Oesch-Bartlomowicz B, Zatloukalova J, Vondracek J, Oesch F, Dietrich C. 2008. TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene 27(15):2198–2207.

Wen S, Yang FX, Gong Y, Zhang XL, Hui Y, Li JG, Liu AIL, Wu YN, Lu WQ, Xu Y. 2008. Elevated levels of urinary 8-hydroxy-2’-deoxyguanosine in male electrical and electronic equipment dismantling workers exposed to high concentrations of polychlorinated dibenzo-p-dioxins and dibenzofurans, polybrominated diphenyl ethers, and polychlorinated biphenyls. Environmental Science and Technology 42(11):4202–4207.

WHO (World Health Organization). 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (4th edition). Lyon, France: World Health Organization.

Wigle DT, Semenciw RB, Wilkins K, Riedel D, Ritter L, Morrison HI, Mao Y. 1990. Mortality study of Canadian male farm operators: Non-Hodgkin’s lymphoma mortality and agricultural practices in Saskatchewan. Journal of the National Cancer Institute 82:575–582.

Wiklund K. 1983. Swedish agricultural workers: A group with a decreased risk of cancer. Cancer 51:566–568.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Wiklund K, Holm LE. 1986. Soft tissue sarcoma risk in Swedish agricultural and forestry workers. Journal of the National Cancer Institute 76(2):229–234.

Wiklund K, Lindefors BM, Holm LE. 1988. Risk of malignant lymphoma in Swedish agricultural and forestry workers. British Journal of Industrial Medicine 45:19–24.

Wiklund K, Dich J, Holm LE, Eklund G. 1989a. Risk of cancer in pesticide applicators in Swedish agriculture. British Journal of Industrial Medicine 46:809–814.

Wiklund K, Dich J, Holm LE. 1989b. Risk of soft tissue sarcoma, Hodgkin’s disease and non-Hodgkin’s lymphoma among Swedish licensed pesticide applicators. Chemosphere 18:395–400.

Wolfe WH, Michalek JE, Miner JC, Rahe A, Silva J, Thomas WF, Grubbs WD, Lustik MB, Karrison TG, Roegner RH, Williams DE. 1990. Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. Journal of the American Medical Association 264:1824–1831.

Wong O, Harris F, Armstrong TW, Hua F. 2010. A hospital-based case-control study of non-Hodgkin lymphoid neoplasms in Shanghai: Analysis of environmental and occupational risk factors by subtypes of the WHO classification. Chemico-Biological Interactions 184:129–146.

Woods JS, Polissar L, Severson RK, Heuser LS, Kulander BG. 1987. Soft tissue sarcoma and non-Hodgkin’s lymphoma in relation to phenoxy herbicide and chlorinated phenol exposure in western Washington. Journal of the National Cancer Institute 78:899–910.

Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. 2002. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncology 4(4):278–299.

Wyde ME, Braen AP, Hejtmancik M, Johnson JD, Toft JD, Blake JC, Cooper SD, Mahler J, Vallant M, Bucher JR, Walker NJ. 2004. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice. Toxicological Sciences 82(1):34–45.

Xie G, Peng Z, Raufman JP. 2012. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. American Journal of Physiology—Gastrointestinal and Liver Physiology 302(9):G1006-G1015.

Xu JX, Hoshida Y, Yang WI, Inohara H, Kubo T, Kim GE, Yoon JH, Kojya S, Bandoh N, Harabuchi Y, Tsutsumi K, Koizuka I, Jia XS, Kirihata M, Tsukuma H, Aozasa K. 2006. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: A case-control study in East Asia. International Journal of Cancer 120(2):406–410.

Yamamoto S, Konishi Y, Matsuda T, Murai T, Shibata MA, Matsui-Yuasa I, Otani S, Kuroda K, Endo G, Fukushima S. 1995. Cancer incidence by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carginogens. Cancer Research 55(6):1271–1276.

Yamanaka K, Ohtsubo K, Hasegawa A, Hayashi H, Ohji H, Kanisawa M, Okada S. 1996. Exposure to dimethylarsinic acid, a main metabolite of inorganic arsenics, strongly promotes tumorigenesis initiated by 4-nitroquinoline 1-oxide in the lungs of mice. Carcinogenesis 17(4):767–770.

Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH. 2008. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in premalignant and malignant mammary tissue. Journal of Cellular Biochemistry 104(2):402–417.

Yiin JH, Ruder AM, Stewart PA, Waters MA, Carreón T, Butler MA, Calvert GM, Davis-King KE, Schulte PA, Mandel JS, Morton RF, Reding DJ, Rosenman KD. 2012. The Upper Midwest Health Study: A case-control study of pesticide applicators and risk of glioma. Environmental Health: A Global Access Science Source 11:39.

Yoshizawa K, Walker NJ, Jokinen MP, Brix AE, Sells DM, Marsh T, Wyde ME, Orzech D, Haseman JK, Nyska A. 2005a. Gingival carcinogenicity in female Harlan Sprague-Dawley rats following two-year oral treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds. Toxicological Sciences 83(1):64–77. [erratum appears in Toxicological Sciences 2005; 83(2):405–406].

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.

Yoshizawa K, Marsh T, Foley JF, Cai B, Peddada S, Walker NJ, Nyska A. 2005b. Mechanisms of exocrine pancreatic toxicity induced by oral treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Harlan Sprague-Dawley rats. Toxicological Sciences 85(1):594–606.

Yoshizawa K, Heatherly A, Malarkey DE, Walker NJ, Nyska A. 2007. A critical comparison of murine pathology and epidemiological data of TCDD, PCB126, and PeCDF. Toxicologic Pathology 35(7):865–879.

Yoshizawa K, Brix AE, Sells DM, Jokinen MP, Wyde M, Orzech DP, Kissling GE, Walker NJ, Nyska A. 2009. Reproductive lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin and dioxin-like compounds. Toxicologic Pathology 37(7):921–937.

Yoshizawa K, Walker NJ, Nyska A, Kissling GE, Jokinen MP, Brix AE, Sells DM, Wyde ME. 2010. Thyroid follicular lesions induced by oral treatment for 2 years with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds in female Harlan Sprague-Dawley rats. Toxicologic Pathology 38:1037–1050.

Zack JA, Suskind RR. 1980. The mortality experience of workers exposed to tetrachlorodibenzodioxin in a trichlorophenol process accident. Journal of Occupational Medicine 22:11–14.

Zahm SH, Fraumeni JF Jr. 1997. The epidemiology of soft tissue sarcoma. Seminars in Oncology 24(5):504–514.

Zahm SH, Weisenburger DD, Babbitt PA, Saal RC, Vaught JB, Cantor KP, Blair A. 1990. A case-control study of non-Hodgkin’s lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. Epidemiology 1:349–356.

Zahm SH, Blair A, Weisenburger DD. 1992. Sex differences in the risk of multiple myeloma associated with agriculture. British Journal of Industrial Medicine 49:815–816.

Zahm SH, Weisenburger DD, Saal RC, Vaught JB, Babbitt PA, Blair A. 1993. The role of agricultural pesticide use in the development of non-Hodgkin’s lymphoma in women. Archives of Environmental Health 48:353–358.

Zakerinia M, Namdari M, Amirghofran S. 2012. The relationship between exposure to pesticides and the occurrence of lymphoid neoplasm. Iranian Red Crescent Medical Journal 14(6):337–344.

Zambon P, Ricci P, Bovo E, Casula A, Gattolin M, Fiore AR, Chiosi F, Guzzinati S. 2007. Sarcoma risk and dioxin emissions from incinerators and industrial plants: A population-based case-control study (Italy). Environmental Health: A Global Access Science Source 6:19.

Zhang J, Zong H, Li S, Zhang D, Zhang L, Xia Q. 2012. Activation of aryl hydrocarbon receptor suppresses invasion of esophageal squamous cell carcinoma cell lines. Tumori 98(1):152–157.

Zhong Y, Rafnsson V. 1996. Cancer incidence among Icelandic pesticide users. International Journal of Epidemiology 25(6):1117–1124.

Zober A, Messerer P, Huber P. 1990. Thirty-four-year mortality follow-up of BASF employees exposed to 2,3,7,8-TCDD after the 1953 accident. International Archives of Occupational and Environmental Health 62:139–157.

Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 299
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 300
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 301
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 302
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 303
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 304
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 305
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 306
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 307
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 308
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 309
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 310
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 311
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 312
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 313
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 314
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 315
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 316
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 317
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 318
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 319
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 320
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 321
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 322
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 323
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 324
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 325
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 326
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 327
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 328
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 329
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 330
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 331
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 332
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 333
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 334
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 335
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 336
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 337
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 338
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 339
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 340
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 341
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 342
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 343
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 344
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 345
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 346
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 347
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 348
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 349
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 350
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 351
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 352
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 353
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 354
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 355
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 356
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 357
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 358
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 359
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 360
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 361
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 362
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 363
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 364
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 365
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 366
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 367
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 368
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 369
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 370
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 371
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 372
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 373
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 374
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 375
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 376
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 377
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 378
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 379
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 380
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 381
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 382
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 383
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 384
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 385
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 386
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 387
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 388
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 389
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 390
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 391
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 392
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 393
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 394
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 395
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 396
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 397
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 398
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 399
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 400
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 401
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 402
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 403
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 404
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 405
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 406
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 407
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 408
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 409
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 410
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 411
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 412
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 413
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 414
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 415
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 416
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 417
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 418
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 419
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 420
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 421
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 422
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 423
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 424
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 425
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 426
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 427
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 428
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 429
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 430
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 431
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 432
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 433
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 434
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 435
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 436
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 437
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 438
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 439
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 440
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 441
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 442
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 443
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 444
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 445
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 446
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 447
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 448
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 449
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 450
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 451
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 452
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 453
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 454
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 455
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 456
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 457
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 458
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 459
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 460
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 461
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 462
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 463
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 464
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 465
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 466
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 467
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 468
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 469
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 470
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 471
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 472
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 473
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 474
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 475
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 476
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 477
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 478
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 479
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 480
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 481
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 482
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 483
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 484
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 485
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 486
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 487
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 488
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 489
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 490
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 491
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 492
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 493
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 494
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 495
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 496
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 497
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 498
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 499
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 500
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 501
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 502
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 503
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 504
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 505
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 506
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 507
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 508
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 509
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 510
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 511
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 512
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 513
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 514
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 515
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 516
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 517
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 518
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 519
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 520
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 521
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 522
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 523
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 524
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 525
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 526
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 527
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 528
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 529
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 530
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 531
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 532
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 533
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 534
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 535
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 536
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 537
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 538
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 539
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 540
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 541
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 542
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 543
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 544
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 545
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 546
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 547
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 548
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 549
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 550
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 551
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 552
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 553
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 554
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 555
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 556
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 557
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 558
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 559
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 560
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 561
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 562
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 563
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 564
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 565
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 566
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 567
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 568
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 569
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 570
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 571
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 572
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 573
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 574
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 575
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 576
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 577
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 578
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 579
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 580
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 581
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 582
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 583
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 584
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 585
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 586
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 587
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 588
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 589
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 590
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 591
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 592
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 593
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 594
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 595
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 596
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 597
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 598
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 599
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 600
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 601
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 602
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 603
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 604
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 605
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 606
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 607
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 608
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 609
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 610
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 611
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 612
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 613
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 614
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 615
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 616
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 617
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 618
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 619
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 620
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 621
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 622
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 623
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 624
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 625
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 626
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 627
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 628
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 629
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 630
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 631
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 632
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 633
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 634
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 635
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 636
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 637
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 638
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 639
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 640
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 641
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 642
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 643
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 644
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 645
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 646
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 647
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 648
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 649
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 650
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 651
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 652
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 653
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 654
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 655
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 656
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 657
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 658
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 659
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 660
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 661
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 662
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 663
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 664
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 665
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 666
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 667
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 668
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 669
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 670
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 671
Suggested Citation: "8 Cancer." Institute of Medicine. 2014. Veterans and Agent Orange: Update 2012. Washington, DC: The National Academies Press. doi: 10.17226/18395.
Page 672
Next Chapter: 9 Fertility and Gestational Outcomes
Subscribe to Emails from the National Academies
Stay up to date on activities, publications, and events by subscribing to email updates.